alendronate has been researched along with Osteoporosis in 1065 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
Osteoporosis: Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this randomized, controlled trial, sequential therapy with once-weekly subcutaneous injection of teriparatide for 72 weeks, followed by alendronate for 48 weeks resulted in a significantly lower incidence of morphometric vertebral fracture than monotherapy with alendronate for 120 weeks in women with osteoporosis at high risk of fracture." | 9.69 | Sequential therapy with once-weekly teriparatide injection followed by alendronate versus monotherapy with alendronate alone in patients at high risk of osteoporotic fracture: final results of the Japanese Osteoporosis Intervention Trial-05. ( Hagino, H; Mitomo, Y; Mori, S; Nakamura, T; Soen, S; Sone, T; Sugimoto, T; Takahashi, K; Tanaka, S, 2023) |
| "The efficacy of generic teriparatide in improving BMD at lumbar spine in patients with osteoporosis was similar to that of alendronate." | 9.51 | Efficacy of generic teriparatide and alendronate in Chinese postmenopausal women with osteoporosis: a prospective study. ( Chao, A; Cheng, Q; Dong, J; Gao, X; Hu, J; Jin, X; Li, M; Li, P; Li, Q; Lin, H; Shen, L; Shi, R; Tang, H; Xia, W; Xiong, X; Xue, Q; You, L; Yu, W; Zhang, Y; Zhang, Z; Zheng, S, 2022) |
| "This systematic review and meta-analysis aimed to reveal the efficacy and safety of zoledronic acid compared with alendronate in patients with primary osteoporosis." | 9.41 | Efficacy and Safety of Annual Infusion of Zoledronic Acid and Weekly Oral Alendronate in the Treatment of Primary Osteoporosis: A Meta-Analysis. ( Ai, W; Wang, Q; Yu, Q; Zeng, P, 2023) |
| "In this randomized, controlled trial, treatment with once-weekly subcutaneous injection of teriparatide for 72 weeks was found to be associated with a significant reduction in the incidence of morphometric vertebral fractures compared with alendronate in women with primary osteoporosis who were at high risk of fracture." | 9.41 | A randomized, controlled trial of once-weekly teriparatide injection versus alendronate in patients at high risk of osteoporotic fracture: primary results of the Japanese Osteoporosis Intervention Trial-05. ( Hagino, H; Mori, S; Nakamura, T; Sasaki, K; Soen, S; Sone, T; Sugimoto, T; Tanaka, S, 2021) |
| "This article reports the design and rationale for the Japanese Osteoporosis Intervention Trial-05 (JOINT-05), a randomized, controlled trial that compares the efficacy and safety of teriparatide followed by alendronate with alendronate monotherapy for severe osteoporosis." | 9.34 | Design of a randomized trial of teriparatide followed by alendronate: Japanese Osteoporosis Intervention Trial-05 (JOINT-05). ( Hagino, H; Mori, S; Sugimoto, T; Tanaka, S, 2020) |
| "To study and compare the clinical effects of Rehmannia Decoction and alendronate sodium for the treatment of primary osteoporosis." | 9.30 | [Comparison of the clinical effects between Dihuang Decoction and alendronate sodium in the treatment of primary osteoporosis]. ( Huang, K; Wan, JM; Zhang, JF; Zhang, PL; Zhu, SY, 2019) |
| "Osteoporosis patients in Thailand were recruited to a multicenter, open-label, 6-month trial of oral alendronate sodium 70 mg/vitamin D3 5600 IU." | 9.27 | Open-label study of treatment with alendronate sodium plus vitamin D in men and women with osteoporosis in Thailand. ( Luevitoonvechkij, S; Ongphiphadhanakul, B; Robert, CS; Robert, L; Rojanasthien, S; Santora, AC; Songpatanasilp, T; Sugkraroek, P, 2018) |
| "A total of 140 postmenopausal women or men aged older than 50 years who met the indications for osteoporosis treatment were randomized to receive either generic (Bonmax®) or brand alendronate (Fosamax®) 70 mg/week over a 12-month period during the May 2014 to June 2015 study period." | 9.24 | Randomized clinical trial comparing efficacy and safety of brand versus generic alendronate (Bonmax®) for osteoporosis treatment. ( Jarusriwanna, A; Songcharoen, P; Unnanuntana, A, 2017) |
| "Denosumab and alendronate showed similar clinical efficacy in the therapy of ADT-related osteoporosis in men with prostate carcinoma; both drugs provided significant improvements in back pain and general health conditions." | 9.24 | Treatment of osteoporosis secondary to hypogonadism in prostate cancer patients: a prospective randomized multicenter international study with denosumab vs. alendronate. ( Balsano, M; Doria, C; Maestretti, G; Mosele, GR; Scarpa, RM; Solla, F, 2017) |
| " The aim of this study was to perform a meta-analysis of the effects of alendronate combined with atorvastatin compared with alendronate alone in the treatment of osteoporosis in diabetes mellitus." | 9.22 | Meta-Analysis of the Efficacy and Safety of Alendronate Combined with Atorvastatin in the Treatment of Osteoporosis in Diabetes Mellitus. ( Shu, L; Tang, X; Xiong, Z; Yi, P; Zhang, C, 2022) |
| "Glucocorticoid-induced osteoporosis (GIOP) is the most common secondary osteoporosis, alendronate (ALE) and teriparatide (TPTD) are widely used in the treatment of GIOP." | 9.22 | The efficiency and safety of alendronate versus teriparatide for treatment glucocorticoid-induced osteoporosis: A meta-analysis and systematic review of randomized controlled trials. ( Guan, XQ; Liu, ZM; Shen, ZB; Yin, F; Zhang, D; Zhang, M; Zong, Y, 2022) |
| "To determine the effect of alendronate (ALN) and teriparatide on trabecular bone score (TBS) in patients with glucocorticoid-induced osteoporosis." | 9.22 | Trabecular Bone Score in Patients With Chronic Glucocorticoid Therapy-Induced Osteoporosis Treated With Alendronate or Teriparatide. ( Agnusdei, D; Alam, J; Hans, D; Kohlmeier, LA; Krohn, KD; Leib, ES; MacLaughlin, EJ; Marcus, R; Saag, KG; Simonelli, C; Taylor, KA, 2016) |
| "This is the first prospective follow-up study to describe the effects of oral alendronate medication on neurofibromatosis 1 (NF1)-related osteoporosis." | 9.19 | Follow-up of six patients with neurofibromatosis 1-related osteoporosis treated with alendronate for 23 months. ( Heervä, E; Huilaja, L; Leinonen, P; Peltonen, J; Peltonen, S, 2014) |
| " Bisphosphonates such as alendronate potently inhibit bone resorption and are effective against osteoporosis." | 9.16 | Effect of alendronate on HIV-associated osteoporosis: a randomized, double-blind, placebo-controlled, 96-week trial (ANRS 120). ( Bentata, M; Costagliola, D; Darasteanu, I; Kolta, S; Lanoy, E; Missy, P; Roux, C; Rozenberg, S; Valantin, MA; Viard, JP, 2012) |
| "To evaluate the efficacy and safety of alendronate for the treatment of osteoporosis/osteopenia secondary to hyperthyroidism." | 9.16 | [Clinical application of alendronate for osteoporosis/osteopenia secondary to hyperthyroidism]. ( Shen, FX; Yang, LJ; Zhang, HL; Zheng, JC, 2012) |
| "The effects of teriparatide versus alendronate were compared by gender and menopausal status in patients with glucocorticoid-induced osteoporosis." | 9.14 | Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status. ( Dobnig, H; Krohn, K; Langdahl, BL; Maricic, M; Marin, F; See, K; Shane, E; Warner, MR; Zanchetta, JR, 2009) |
| "In order to study the benefit of adding recombinant human growth hormone (rhGH) to antiresorptive therapy, six patients with idiopathic osteoporosis (IO) receiving alendronate plus calcium and vitamin D were started on daily subcutaneous injections of rhGH 2." | 9.14 | Additional beneficial effects of recombinant growth hormone in alendronate-treated patients with idiopathic osteoporosis. ( Coeli, CM; de Farias, ML; Lopes, RF; Vaisman, M, 2009) |
| "To determine the effect of alendronate on glucocorticoid-induced osteoporosis(GIO)." | 9.14 | [Effect of alendronate on glucocorticoid-induced osteoporosis]. ( Li, Q; Shi, C; Zou, X, 2009) |
| "The comparative effects of alendronate and alfacalcidol on bone mineral density (BMD) and bone turnover have already been established in postmenopausal women with osteoporosis." | 9.14 | Comparison of the effects of alendronate and alfacalcidol on hip bone mineral density and bone turnover in Japanese men having osteoporosis or osteopenia with clinical risk factors for fractures. ( Iwamoto, J; Matsumoto, H; Sato, Y; Takeda, T; Uzawa, M, 2009) |
| " The OPTAMISE (Open-label Study to Determine How Prior Therapy with Alendronate or Risedronate in Postmenopausal Women with Osteoporosis Influences the Clinical Effectiveness of Teriparatide) study reported greater increases in biochemical markers of bone turnover and volumetric bone mineral density (BMD) when 12 months of teriparatide treatment was preceded by 2 years or more of risedronate versus alendronate treatment." | 9.14 | Biomechanical effects of teriparatide in women with osteoporosis treated previously with alendronate and risedronate: results from quantitative computed tomography-based finite element analysis of the vertebral body. ( Borah, B; Chevalier, Y; Gross, G; Lang, T; Quek, E; Stewart, J; Zysset, P, 2010) |
| "Osteoporosis represents a significant side effect of glucocorticoid therapy, and alendronate has been reported to prevent this glucocorticoid-induced osteoporosis." | 9.14 | Effects of alendronate on bone metabolism in glucocorticoid-induced osteoporosis measured by 18F-fluoride PET: a prospective study. ( Baba, H; Fujibayashi, Y; Kawahara, H; Kobayashi, S; Miyazaki, T; Nakajima, H; Okazawa, H; Tsuchida, T; Uchida, K; Yayama, T, 2009) |
| "To compare the bone anabolic drug teriparatide (20 microg/day) with the antiresorptive drug alendronate (10 mg/day) for treating glucocorticoid-induced osteoporosis (OP)." | 9.14 | Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. ( Adler, RA; Devogelaer, JP; Eastell, R; Krege, JH; Krohn, K; Saag, KG; See, K; Warner, MR; Zanchetta, JR, 2009) |
| "This post-hoc analysis studied the effect of baseline glucocorticoid dose on the 18-month bone mineral density (BMD) response to teriparatide 20 microg/day or alendronate 10 mg/day in 387 patients with glucocorticoid-induced osteoporosis (GIO) from a randomized, double-blind trial." | 9.14 | Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis. ( Adler, RA; Devogelaer, JP; Krohn, K; Recknor, C; See, K; Warner, MR; Wong, M, 2010) |
| "The aim of this study was to evaluate the efficacy, safety, and tolerability of weekly alendronate administration on male osteoporosis in Taiwan." | 9.14 | The effects of weekly alendronate therapy in Taiwanese males with osteoporosis. ( Chen, JF; Ho, C; Huang, YY; Hwang, JS; Lin, JD; Liou, MJ; Tsai, KS; Wang, CJ, 2010) |
| "The purpose of this post hoc analysis was to determine whether baseline concentrations or early changes in serum bone turnover markers were correlated with changes in bone mineral density (BMD) at 18 months in patients with glucocorticoid-induced osteoporosis (GIO) treated with teriparatide (n=80; 20 mug/day) or alendronate (n=77; 10 mg/day)." | 9.14 | Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate. ( Burshell, AL; Chen, P; Correa-Rotter, R; Dalsky, GP; Krege, JH; Möricke, R; Taylor, KA; Warner, MR, 2010) |
| "Zoledronic acid (ZOL) has shown beneficial effects on bone turnover and bone mineral density (BMD) in postmenopausal osteoporosis." | 9.14 | Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. ( Adachi, JD; Adler, RA; Brown, J; Bucci-Rechtweg, C; Kendler, D; Mesenbrink, P; Miller, PD; Orwoll, ES; Readie, A; Weinstein, RS, 2010) |
| "To investigate the effects of alendronate (Alen) on the prevention of systemic glucocorticoid-induced osteoporosis in patients with rheumatic diseases." | 9.13 | [Alendronate prevents steroid-induced osteoporosis in patients with rheumatic diseases]. ( Huang, YL; Wang, QH; Wen, LH; Wu, HX; Xue, J; Yang, XY; Zhu, L, 2008) |
| "To compare the effects of alendronate and raloxifene on lumbar bone mineral density (BMD), bone turnover, and lipid metabolism in elderly women with osteoporosis." | 9.13 | Comparison of effects of alendronate and raloxifene on lumbar bone mineral density, bone turnover, and lipid metabolism in elderly women with osteoporosis. ( Iwamoto, J; Matsumoto, H; Sato, Y; Takeda, T; Uzawa, M, 2008) |
| "The use of buffered soluble alendronate 70 mg effervescent tablet, a convenient dosing regimen for bisphosphonate therapy, seems a cost-effective strategy compared with relevant alternative treatments for postmenopausal women with osteoporosis aged 60 years and over in Italy." | 9.12 | Cost-effectiveness of buffered soluble alendronate 70 mg effervescent tablet for the treatment of postmenopausal women with osteoporosis in Italy. ( Hiligsmann, M; Maggi, S; Reginster, JY; Sartori, L; Veronese, N, 2021) |
| "To evaluate the efficacy and safety of oral alendronate on bone mineral density (BMD) in children and adolescents with osteoporosis." | 9.12 | Efficacy and safety of oral alendronate treatment in children and adolescents with osteoporosis. ( Abaci, A; Bober, E; Büyükgebiz, A; Unal, E, 2006) |
| "During this 18-month trial in patients with rheumatic diseases, alendronate was more effective in the prevention of glucocorticoid-induced bone loss than was alfacalcidol." | 9.12 | Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. ( Algra, A; Bijlsma, JW; Bruyn, GA; Buskens, E; de Laet, CE; de Nijs, RN; Dijkmans, BA; Geusens, PP; Huisman, AM; Jacobs, JW; Laan, RF; Lems, WF; Oostveen, AC, 2006) |
| "In osteoporosis patients who avoided sunlight and vitamin D supplements, this once-weekly tablet containing alendronate and cholecalciferol provided equivalent antiresorptive efficacy, reduced the risk of low serum 25OHD, improved vitamin D status over 15 weeks, and was not associated with hypercalcemia, hypercalciuria or other adverse findings, versus alendronate alone." | 9.12 | Alendronate with and without cholecalciferol for osteoporosis: results of a 15-week randomized controlled trial. ( Benhamou, L; Delmas, PD; Emkey, R; Felsenberg, D; Hawkins, F; He, W; Lippuner, K; Lips, P; Recker, R; Rosen, C; Salzmann, G; Santora, AC, 2006) |
| "In an 18-month randomized, double-blind, controlled trial, we compared teriparatide with alendronate in 428 women and men with osteoporosis (ages, 22 to 89 years) who had received glucocorticoids for at least 3 months (prednisone equivalent, 5 mg daily or more)." | 9.12 | Teriparatide or alendronate in glucocorticoid-induced osteoporosis. ( Boonen, S; Dalsky, GP; Donley, DW; Marcus, R; Marín, F; Saag, KG; Shane, E; Taylor, KA, 2007) |
| "Our trial was a 3-year, open-label, prospective, comparative, clinical study comparing the effects of oral alendronate (ALN), 10 mg daily, and alfacalcidol (AC), 1 microg daily, on bone mineral density (BMD), fracture events, height, back pain, safety and tolerability in 134 men with established primary osteoporosis." | 9.11 | Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study. ( Dorst, A; Faber, H; Ibach, K; Ringe, JD, 2004) |
| "Alendronate 70 mg administered once weekly to women and men with osteoporosis has an upper GI and overall tolerability profile similar to that of placebo." | 9.11 | Upper gastrointestinal and overall tolerability of alendronate once weekly in patients with osteoporosis: results of a randomized, double-blind, placebo-controlled study. ( Eisman, JA; Gaines, KA; Lipschitz, S; Melton, ME; Rizzoli, R; Roman-Ivorra, J; Verbruggen, N, 2004) |
| "To assess efficacy and safety of alendronate sodium treatment in osteoporosis patients with hip fracture." | 9.11 | [Clinic effect of alendronate sodium treatment in osteoporosis patients with hip fracture]. ( Jin, J; Lin, J; Luo, XZ; Qiu, GX; Shen, JX; Tang, H; Tian, Y; Wang, YP; Weng, XS; Wu, ZH; Yang, XY; Zhang, JG; Zhao, H, 2004) |
| "The current study was undertaken to investigate the effect of alendronate on bone mineral density (BMD), bone metabolism markers, and serum bone-resorbing cytokines in patients with chronic idiopathic neutropenia (CIN)-associated osteopenia/osteoporosis." | 9.11 | Alendronate reduces serum TNFalpha and IL-1beta, increases neutrophil counts, and improves bone mineral density and bone metabolism indices in patients with chronic idiopathic neutropenia (CIN)-associated osteopenia/osteoporosis. ( Christoforidou, A; Eliopoulos, GD; Malliaraki, N; Margioris, AN; Miliaki, M; Papadaki, HA; Pontikoglou, C; Psyllaki, M; Tsatsanis, C, 2004) |
| "The FACT study (Fosamax Actonel Comparison Trial) was a 1-year-head-to-head trial comparing the efficacy and tolerability of once weekly (DW) alendronate 70 mg and OW risedronate 35 mg for the treatment of postmenopausal osteoporosis." | 9.11 | Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis. ( Bonnick, SL; Chen, E; de Papp, AE; Kagan, R; Sebba, AI; Skalky, CS; Thompson, DE, 2004) |
| "HIV-1-infected patients with osteoporosis were randomly assigned to alendronate 70 mg once-weekly plus dietary counselling (n = 11) or diet counselling alone (n = 14)." | 9.11 | Reversal of HIV-1-associated osteoporosis with once-weekly alendronate. ( Clotet, B; del Rio, L; Gel, S; Holgado, S; Martínez-López, E; Negredo, E; Paredes, R; Pérez-Alvarez, N; Rey-Joly, C; Rosales, J; Tena, X, 2005) |
| "Alendronate, vitamin D, and calcium are safe and potentially useful in the treatment of osteopenia/osteoporosis associated with HIV infection." | 9.11 | Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection. ( Claxton, SA; Hoffmann, ME; Mondy, K; Powderly, WG; Royal, M; Stoneman, JS; Tebas, P; Yarasheski, KH, 2005) |
| "To compare the effects on back pain of teriparatide versus alendronate, we analyzed the reporting of back pain in a head to head comparator trial and a followup study." | 9.11 | Longterm reduction of back pain risk in women with osteoporosis treated with teriparatide compared with alendronate. ( Body, JJ; Chen, P; Krege, JH; Miller, PD; Rohe, ME; Shergy, WJ, 2005) |
| "The efficacy and safety of treatment with oral alendronate (ALN) 35 mg once weekly for 52 weeks were compared with those of ALN 5 mg once daily in a double-blind, randomized, multicenter study of Japanese patients with involutional osteoporosis." | 9.11 | Therapeutic effects of alendronate 35 mg once weekly and 5 mg once daily in Japanese patients with osteoporosis: a double-blind, randomized study. ( Arizono, H; Fukunaga, M; Kakikawa, T; Nagata, K; Nakamura, T; Ohashi, Y; Okaniwa, M; Okuyama, K; Santora, AC; Shimizu, T; Shiraki, M; Taniguchi, T; Tomomitsu, T; Uchida, S, 2005) |
| " The study enrolled 450 postmenopausal women and men with osteoporosis (224 took alendronate, 226 took placebo) who were ambulatory and community dwelling at 48 outpatient study centers in the United States." | 9.10 | Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study. ( de Papp, AE; Field-Munves, E; Greenspan, S; Palmisano, J; Petruschke, R; Smith, M; Tonino, R; Wang, L; Yates, J, 2002) |
| "To determine the efficacy of an anti-osteoporosis regimen that combined a bisphosphonate agent (alendronate sodium) with the osteogenic stimulus of mechanical loading, 25 HTRs were randomly assigned either to a group that received alendronate (10 mg/day) for 6 months (ALEN; n = 8), a group that received alendronate (10 mg/day) and performed specific resistance exercises for 6 months (ALEN + TRN; n = 8) or to a non-intervention control group (CONTR; n = 9)." | 9.10 | Resistance exercise training and alendronate reverse glucocorticoid-induced osteoporosis in heart transplant recipients. ( Aranda, J; Braith, RW; Fulton, MN; Hill, JA; Magyari, PM; Walker, T, 2003) |
| "The aim of this open prospective randomized study was to evaluate the effect of a 6-month treatment with alendronate on the bone mineral density (BMD) at lumbar spine in patients with central diabetes insipidus." | 9.09 | Effect of a short-term treatment with alendronate on bone density and bone markers in patients with central diabetes insipidus. ( Colao, A; Di Somma, C; Faggiano, A; Filippella, M; Klain, M; Lombardi, G; Pivonello, R; Salvatore, M, 1999) |
| "To evaluate the efficacy and safety of alendronate, a double-masked, active (alfacalcidol) controlled comparative study for 48 weeks was carried out in a total of 210 Japanese patients with osteoporosis." | 9.09 | A double-masked multicenter comparative study between alendronate and alfacalcidol in Japanese patients with osteoporosis. The Alendronate Phase III Osteoporosis Treatment Research Group. ( Fukunaga, M; Inoue, T; Kaneda, K; Kishimoto, H; Kushida, K; Minaguchi, H; Morii, H; Nagata, Y; Nakamura, T; Nakashima, M; Orimo, H; Shiraki, M; Taga, M; Tomita, A; Yamamoto, K, 1999) |
| "Alendronate has been reported to increase bone mineral density (BMD) and reduce fracture risk in women with osteoporosis." | 9.09 | Effects of alendronate on bone density in men with primary and secondary osteoporosis. ( Frauman, AG; Ho, YV; Seeman, E; Thomson, W, 2000) |
| "In a two-year double-blind trial, we studied the effect of 10 mg of alendronate or placebo, given daily, on bone mineral density in 241 men (age, 31 to 87 years; mean, 63) with osteoporosis." | 9.09 | Alendronate for the treatment of osteoporosis in men. ( Adami, S; Ettinger, M; Graham, J; Kendler, D; Lombardi, A; Lorenc, R; Miller, P; Orwoll, E; Pietschmann, P; Vandormael, K; Weber, K; Weiss, S, 2000) |
| " In this preliminary study, we evaluated the effect of an oral bisphosphonate (alendronate) on bone mass in children with diffuse connective tissue diseases." | 9.09 | Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children: a prospective multicenter study. ( Bardare, M; Bianchi, ML; Boncompagni, A; Brandi, ML; Cimaz, R; Corona, F; Falcini, F; Galbiati, E; Giuntini, D; Lepore, L; Luisetto, G; Picco, P; Zulian, F, 2000) |
| " Eighteen GHD patients with osteoporosis were randomized to continue their rhGH maintenance dose or to receive combination therapy with rhGH and alendronate for 12 months." | 9.09 | Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial. ( Biermasz, NR; Hamdy, NA; Janssen, YJ; Roelfsema, F, 2001) |
| "Treatment effects on bone quality and remodeling was assessed in postmenopausal women with osteoporosis treated with oral alendronate." | 9.08 | Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. ( Arlot, ME; Chavassieux, PM; Meunier, PJ; Reda, C; Wei, L; Yates, AJ, 1997) |
| "Alendronate has been used to prevent or treat glucocorticoid-induced osteoporosis (GIO), data regarding its efficacy are inconsistent." | 8.98 | Effects of alendronate for treatment of glucocorticoid-induced osteoporosis: A meta-analysis of randomized controlled trials. ( Guo, JB; Luo, ZJ; Ma, T; Qin, SQ; Wang, X; Wang, YK; Zhang, YM; Zhu, C, 2018) |
| "Cohort studies reporting association between alendronate or bisphosphonate therapy including alendronate in patients with osteoporosis and risk of cancer were selected by two authors." | 8.91 | The carcinogenicity of alendronate in patients with osteoporosis: evidence from cohort studies. ( Chen, LX; Cheng, L; Feng, SQ; Li, YL; Ning, GZ; Wu, QL; Zhang, D; Zhang, TS; Zhou, ZR, 2015) |
| "To assess the efficiency and safety of alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis (GIOP)." | 8.89 | [A Meta-analysis of alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis]. ( He, ZY; Tang, XL; Tian, JH; Yang, KH; Yang, L, 2013) |
| "To explore the incidence of atrial fibrillation (AF) and other cardiovascular endpoints in clinical trials of alendronate." | 8.88 | Alendronate and atrial fibrillation: a meta-analysis of randomized placebo-controlled clinical trials. ( Barrett-Connor, E; Bone, HG; de Papp, A; Hustad, CM; Liberman, UA; Papapoulos, S; Santora, AC; Swern, AS; Wang, H, 2012) |
| "Alendronate is commonly used in the treatment of osteoporosis and other bone diseases." | 8.88 | Laryngeal ulceration and hemoptysis secondary to inadvertent alendronate overdose: case report and review of the literature. ( Bee, J; Hanna, J; Sataloff, RT, 2012) |
| "The purpose of this paper is to discuss the effects of antifracture drugs on postmenopausal, male and glucocorticoid-induced osteoporosis, focussing on the efficacy and safety of alendronate and risedronate." | 8.84 | Effects of antifracture drugs in postmenopausal, male and glucocorticoid-induced osteoporosis--usefulness of alendronate and risedronate. ( Iwamoto, J; Sato, Y; Takeda, T, 2007) |
| "To investigate alendronate for treating osteoporosis in men." | 8.84 | Alendronate for the treatment of osteoporosis in men. ( Davison, KS; Olszynski, WP, 2008) |
| "In osteoporosis, both the bisphosphonate alendronate and parathyroid hormone (1-34) (PTH (1-34) ) have been shown to reduce the incidence of fractures." | 8.82 | Does the combination of alendronate and parathyroid hormone give a greater benefit than either agent alone in osteoporosis? ( Doggrell, SA, 2004) |
| "Alendronate and risedronate, the two oral bisphosphonates approved in the United States for preventing and treating osteoporosis, have never been compared in direct head-to-head trials, but they appear to have similar pharmacokinetics, drug interactions, adverse effect profiles, and efficacy." | 8.81 | Role of alendronate and risedronate in preventing and treating osteoporosis. ( Leonard, M; Licata, AA; Peters, ML, 2001) |
| "From January 2018 to January 2020, we recruited 165 female osteoporosis patients after percutaneous vertebroplasty who were assigned into sequential treatment of teriparatide followed by alendronate group (TPTD + ALN group) and alendronate alone group (ALN group)." | 8.31 | Sequential treatment of teriparatide and alendronate versus alendronate alone for elevation of bone mineral density and prevention of refracture after percutaneous vertebroplasty in osteoporosis: a prospective study. ( Han, W; Huang, K; Long, Y; Tan, J; Wang, M; Yang, D; Yi, W; Zeng, S; Zhu, S, 2023) |
| "A total of 82 postmenopausal women with primary osteoporosis receiving alendronate (70 mg administered orally per week) for one year were observed." | 8.31 | Influence of the Osteogenomic Profile in Response to Alendronate Therapy in Postmenopausal Women with Osteoporosis: A Retrospective Cohort Study. ( Gámez Nava, JI; Nuño Arana, I; Pérez Romero, M; Ruiz González, F; Trujillo Rangel, WÁ; Villagómez Vega, A, 2023) |
| "The study results indicate that women with osteoporosis initiated on gastro-resistant risedronate have a lower risk of fracture than those initiated on immediate release risedronate or alendronate." | 8.31 | Fracture risk in women with osteoporosis initiated on gastro-resistant risedronate versus immediate release risedronate or alendronate: a claims data analysis in the USA. ( Boolell, M; Cortet, B; Eisman, JA; Heroux, J; Ionescu-Ittu, R; Thomasius, F; Vekeman, F, 2023) |
| "Alendronate and estradiol are potential molecules for the treatment of osteoporosis but their use is limited by lower skin permeation and first-pass metabolism respectively." | 8.31 | Novel iontophoretic drug delivery of estradiol with alendronate for osteoporosis treatment. ( Chang, J; Li, S, 2023) |
| "Both teriparatide and alendronate were used in the treatment of osteoporosis after renal transplantation." | 8.02 | Analysis of the Efficacy and Safety of Teriparatide and Alendronate in the Treatment of Osteoporosis After Renal Transplantation. ( Deng, J; Lin, C; Qiu, Z; Wu, M; Zhang, Y, 2021) |
| " Icariin (ICA), one of the main flavonoids from plants of the Epimedium genus, has been shown to ameliorate osteoporosis and improve bone health in preclinical studies." | 8.02 | Icariin reduces bone loss in a Rankl-induced transgenic medaka (Oryzias latipes) model for osteoporosis. ( Ha, TTM; Lai, TT; Nguyen, HVM; Pham, CV; Pham, TT; Phuong, TT; To, TT; Tran, LD; Trinh, DC; Winkler, C, 2021) |
| "After 5 years of alendronate treatment, younger postmenopausal women (ages 50-70) with osteoporosis would likely benefit from a drug holiday, whereas older women (age 80) are likely to benefit from treatment for 10 years before a drug holiday." | 7.96 | Cost-effectiveness of five versus ten years of alendronate treatment prior to drug holiday for women with osteoporosis. ( Greenspan, SL; Nayak, S, 2020) |
| "The present study aimed to investigate the effects of phosphatidylserine liposomes (PSLs) and phosphatidylserine liposomes containing alendronate (AL-PSLs) on the improvement of methylprednisolone (MP) induced osteoporosis in a rat model." | 7.96 | Phosphatidylserine nanoliposomes inhibit glucocorticoid-induced osteoporosis: A potential combination therapy with alendronate. ( Alaeddini, M; Dehpour, AR; Doustimotlagh, AH; Eskandarynasab, M; Etemad-Moghadam, S; Goudarzi, R; Partoazar, A; Takzaree, N, 2020) |
| "Alendronate and raloxifene are among the most popular anti-osteoporosis medications." | 7.96 | Comparative safety and effectiveness of alendronate versus raloxifene in women with osteoporosis. ( Duke, J; Hripcsak, G; Huser, V; Jin, P; Kim, Y; Lambert, CG; Madigan, D; Park, H; Park, RW; Reich, C; Rijnbeek, PR; Ryan, PB; Schuemie, MJ; Shah, NH; Suchard, MA; Tian, Y; Van Zandt, M; Vashisht, R; Wu, Y; Yang, J; You, SC, 2020) |
| "e risedronate and alendronate in the treatment of osteoporosis." | 7.91 | Novel combinatorial transdermal drug delivery of alendronate with risedronate for the treatment of osteoporosis. ( Cui, P; Jia, B; Kong, F; Wang, D, 2019) |
| "This study evaluated the preventative effects of metformin (Met) on glucocorticoid (GC)-induced osteoporosis in a rat model, compared with alendronate (Aln)." | 7.91 | Preventative effects of metformin on glucocorticoid-induced osteoporosis in rats. ( Li, Q; Li, Y; Meng, Y; Shi, D; Zhang, H; Zhao, J; Zuo, L, 2019) |
| "The anti-catabolic bisphosphonate alendronate is considered as the first-line medical treatment in post-menopausal osteoporosis; but several side effects, including gastric mucosal injury, are associated with its use." | 7.91 | Melatonin supports alendronate in preserving bone matrix and prevents gastric inflammation in ovariectomized rats. ( Akkiprik, M; Çilingir-Kaya, ÖT; Ercan, F; Gürler, EB; Peker Eyüboglu, I; Reiter, RJ; Yegen, BÇ, 2019) |
| "The aim of this study was to assess changes in bone mineral density (BMD) and cadmium (Cd) levels in blood and urine in individuals living in a Cd-contaminated area according to the type of osteoporosis medication over a three-year period." | 7.88 | Changes in blood and urinary cadmium levels and bone mineral density according to osteoporosis medication in individuals with an increased cadmium body burden. ( Choi, BS; Eom, SY; Hong, SM; Kim, GB; Kim, H; Kim, YD; Park, CH; Park, JD; Yim, DH; Yu, SD, 2018) |
| "There are many challenges facing the use of alendronate sodium for the treatment of osteoporosis such as low bioavailability of 0." | 7.88 | Quality by design approach to optimize the formulation variables influencing the characteristics of biodegradable intramuscular in-situ gel loaded with alendronate sodium for osteoporosis. ( Hosny, KM; Rizg, WY, 2018) |
| "We performed a cross-sectional study to clarify the factors associated with the development of glucocorticoid-induced bone loss and osteoporosis in patients with childhood-onset rheumatic disease and to investigate the impact of the early use of alendronate." | 7.88 | Early use of alendronate as a protective factor against the development of glucocorticoid-induced bone loss in childhood-onset rheumatic diseases: a cross-sectional study. ( Arima, T; Chiba, K; Inoue, Y; Kohno, Y; Mitsunaga, K; Morita, Y; Nakano, T; Shimojo, N; Suzuki, S; Tomiita, M; Yamaguchi, KI; Yamaide, A; Yamaide, F; Yamamoto, T, 2018) |
| "Alendronate (ALD) is clinically indicated for the treatment of osteoporosis, but its therapeutic use has been marred by severe GIT adverse effects affecting quality of life in patients." | 7.88 | Positive effect of alendronate on bone turnover in ovariectomised rats' osteoporosis: comparison of transdermal lipid-based delivery with conventional oral administration. ( Boche, M; Pokharkar, V, 2018) |
| "Alendronate regulates the activity of osteoclasts and healing of osteoporosis." | 7.85 | Effects of alendronate on osteoporosis treatment and levels of related cytokines. ( Gao, GC; Liu, CT; Yuan, XJ, 2017) |
| " Our aims were to evaluate if the risk of surgically treated ONJ increases with longer or more compliant treatment with alendronate for osteoporosis and to identify risk factors for surgically treated ONJ." | 7.85 | Surgically treated osteonecrosis and osteomyelitis of the jaw and oral cavity in patients highly adherent to alendronate treatment: a nationwide user-only cohort study including over 60,000 alendronate users. ( Abrahamsen, B; Eastell, R; Eiken, PA; Prieto-Alhambra, D, 2017) |
| "By using an experimental model of dexamethasone-induced osteoporosis we investigated the effects of different therapeutic schemes combining sodium alendronate (SA) and simvastatin on bone mineral and protein composition, microstructural and mechanical remodeling." | 7.85 | Low Doses of Simvastatin Potentiate the Effect of Sodium Alendronate in Inhibiting Bone Resorption and Restore Microstructural and Mechanical Bone Properties in Glucocorticoid-Induced Osteoporosis. ( Gonçalves, RV; Maldonado, IRSC; Novaes, RD; Oliveira, MGA; Oliveira, TT; Pinto, AS; Sequetto, PL, 2017) |
| "Alendronate (ALN) is a key therapeutic used to treat glucocorticoid-induced osteoporosis (GIOP), but may induce severe side effects." | 7.85 | Promotion effect of extracts from plastrum testudinis on alendronate against glucocorticoid-induced osteoporosis in rat spine. ( Huang, J; Jiang, X; Qiu, T; Ren, H; Shen, G; Tang, J; Yang, Z; Yao, Z; Yu, X; Zhang, Z; Zhao, W, 2017) |
| "Intravenous alendronate is an effective treatment for osteoporosis in SMID patients." | 7.85 | [The efficacy of intravenous alendronate for osteoporosis in patients with severe motor intellectual disabilities]. ( Aihara, M; Ishii, S; Kaga, Y; Kamiya, Y; Kanemura, H; Kuroda, I; Nakamura, K; Sugita, K, 2017) |
| "A retrospective study was performed to evaluate the outcome of alendronate treatment for 7 years among Japanese men with osteoporosis or osteopenia and clinical risk factors for fractures." | 7.83 | Experience with alendronate treatment for 7 years among Japanese men with osteoporosis or osteopenia and clinical risk factors for fractures. ( Iwamoto, J; Uzawa, M, 2016) |
| "639 Chinese postmenopausal women with osteoporosis or osteopenia received alendronate treatment." | 7.81 | SOST polymorphisms and response to alendronate treatment in postmenopausal Chinese women with osteoporosis. ( Chen, DC; Jiang, Y; Li, M; Liao, EY; Liu, J; Wang, O; Wu, W; Xia, WB; Xing, XP; Xu, L; Xu, XJ; Zhang, ZL; Zhou, PR, 2015) |
| "This study provides evidence that zoledronate is more effective than alendronate in treating patients with osteoporosis and with no gastrointestinal (GI) serious side effects." | 7.81 | Favorable therapeutic response of osteoporosis patients to treatment with intravenous zoledronate compared with oral alendronate. ( Akanle, OA; Al-Adhoubi, NK; Al-Bogami, MM; Alkhorayef, MA; Bystrom, J; Jawad, AS; Mageed, RA, 2015) |
| "Six hundred and thirty nine Chinese postmenopausal women with osteopenia or osteoporosis were included and received alendronate treatment." | 7.80 | LRP5 polymorphisms and response to alendronate treatment in Chinese postmenopausal women with osteoporosis. ( Chen, DC; Li, M; Liao, EY; Liu, HJ; Liu, J; Wu, W; Xia, WB; Xing, XP; Xu, L; Zhang, ZL; Zhou, PR, 2014) |
| "Alendronate sodium (ALS) is the most common drug used for the treatment of osteoporosis." | 7.79 | Enteric-coated alendronate sodium nanoliposomes: a novel formula to overcome barriers for the treatment of osteoporosis. ( Ahmed, OA; Al-Abdali, RT; Hosny, KM, 2013) |
| "To explore the compliance in elderly male with osteoporosis treated with oral alendronate and analyze the factors which affect the therapeutic compliance." | 7.79 | [The compliance in elderly male with osteoporosis treated with oral alendronate]. ( Fang, FS; Hou, HR; Jiang, Y; Li, CL; Liu, MY; Pei, Y; Pi, HY; Yan, YF, 2013) |
| " We used health registers to identify predictors of new major osteoporotic fractures in patients adhering to alendronate." | 7.79 | Characteristics of patients who suffer major osteoporotic fractures despite adhering to alendronate treatment: a National Prescription registry study. ( Abrahamsen, B; Eastell, R; Eiken, PA; Rubin, KH, 2013) |
| "Alendronate is a widely used bisphosphonate in the treatment of osteoporosis." | 7.78 | Nephrotic syndrome after oral bisphosphonate (alendronate) administration in a patient with osteoporosis. ( Kara, E; Ozagari, A; Taninmis, H; Unsal, A; Yilmaz, M, 2012) |
| "Base-case analysis results showed that at annual alendronate costs of $200 or less, osteoporosis screening followed by treatment was cost-saving, resulting in lower total costs than no screening as well as more QALYs (10." | 7.78 | Impact of generic alendronate cost on the cost-effectiveness of osteoporosis screening and treatment. ( Greenspan, SL; Nayak, S; Roberts, MS, 2012) |
| "The objective of this study was to analyze the comparative gastrointestinal tolerability of proprietary versus generic alendronate in patients treated for primary osteoporosis." | 7.78 | The comparative gastrointestinal tolerability of proprietary versus generic alendronate in patients treated for primary osteoporosis. ( Landfeldt, E; Ström, O, 2012) |
| "Controversy still exists regarding whether alendronate (ALN) use increases the risk of esophageal cancer or breast cancer." | 7.78 | A higher dosage of oral alendronate will increase the subsequent cancer risk of osteoporosis patients in Taiwan: a population-based cohort study. ( Chang, SN; Kao, CH; Lee, WY; Liang, JA; Lin, MC; Muo, CH; Sun, LM; Sung, FC, 2012) |
| "Efficacy and safety of a new combination package containing 4 or 12 self-explanatory one-week blisters, each with one tablet of 70 mg alendronate (CAS 260055-05-8) and 7 capsules of 1 microg alfacalcidol (CAS 41294-56-8) (Tevabone) on muscle power, muscle function, balance and back pain was investigated in an open, multi-centered, uncontrolled, prospective study on a cohort of elderly patients with a high risk of falls and fractures." | 7.77 | Risk reduction of falls and fractures, reduction of back pain and safety in elderly high risk patients receiving combined therapy with alfacalcidol and alendronate: a prospective study. ( Ringe, JD; Schacht, E, 2011) |
| "To describe the distribution of serum 25-hydroxyvitamin D (25-[OH] D) in Canadian men and postmenopausal women with osteoporosis taking 400 IU or less of vitamin D daily and to evaluate the safety, tolerability, and impact of vitamin D(3) supplementation 400 IU daily taken concurrently with alendronate sodium 70 mg weekly." | 7.77 | Vitamin D status and response to daily 400 IU vitamin D3 and weekly alendronate 70 mg in men and women with osteoporosis. ( Chouha, F; Djandji, M; Hanley, DA; Karaplis, AC; Sampalis, JS, 2011) |
| "We determined serum ionic fluoride (SIF) concentrations before and after treatment of osteoporosis with alendronate to clarify whether SIF concentrations directly reflect a change in bone metabolism." | 7.77 | Serum ionic fluoride concentrations are significantly decreased after treatment with alendronate in patients with osteoporosis. ( Itai, K; Muro-oka, G; Sato, H; Tanno, K, 2011) |
| "We aimed to investigate the risk of AF, stroke, or acute myocardial infarction (AMI) associated with the use of the bisphosphonates alendronate and raloxifene in patients with osteoporosis." | 7.77 | Alendronate and raloxifene use related to cardiovascular diseases: differentiation by different dosing regimens of alendronate. ( Hsieh, CF; Huang, WF; Lu, PY; Tsai, YW, 2011) |
| "The aim of this study was to evaluate a possible role of microcracks in the pathogenesis of bisphosphonate-related osteonecrosis of the jaw (ONJ) and to discuss an etiological model." | 7.76 | Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings. ( Eufinger, H; Hoefert, S; Schmitz, I; Tannapfel, A, 2010) |
| "A pre-existing model of osteoporosis was used to predict numbers of fractures, quality-adjusted life-years (QALYs), and costs associated with risedronate or alendronate treatment in post-menopausal (PMO) women aged > or =65 years with a previous vertebral fracture, within the Italian National Health System (NHS)." | 7.76 | Risedronate versus alendronate in older patients with osteoporosis at high risk of fracture: an Italian cost-effectiveness analysis. ( Berto, P; Lopatriello, S; Maggi, S; Noale, M, 2010) |
| "A paradoxical association between long-term alendronate therapy and low-energy subtrochanteric femoral fractures has been recently recognized." | 7.76 | Subtrochanteric femoral fractures in patients receiving long-term alendronate therapy: imaging features. ( Capeci, C; Chan, K; Chan, SS; Rosenberg, ZS, 2010) |
| "In premenopausal women with MDD, reduced daily adiponectin production may increase the risk of diabetes mellitus, and elevated leptin may contribute to osteoporosis." | 7.76 | Low 24-hour adiponectin and high nocturnal leptin concentrations in a case-control study of community-dwelling premenopausal women with major depressive disorder: the Premenopausal, Osteopenia/Osteoporosis, Women, Alendronate, Depression (POWER) study. ( Ahima, RS; Blackman, MR; Cizza, G; Duan, Z; Eskandari, F; Nguyen, VT; Reynolds, JC; Wright, EC, 2010) |
| "This population-based study aimed to compare direct health care costs related to the pharmacological treatment of osteoporosis and to the management of osteoporotic fractures among compliant and noncompliant users of alendronate and risedronate." | 7.75 | Comparison of direct health care costs related to the pharmacological treatment of osteoporosis and to the management of osteoporotic fractures among compliant and noncompliant users of alendronate and risedronate: a population-based study. ( Blouin, J; Dragomir, A; Fernandes, JC; Fredette, M; Perreault, S; Ste-Marie, LG, 2009) |
| "Several recent medical articles have described multiple cases of unusual low-impact subtrochanteric stress fractures or completed fractures of the femur in patients who have been on the bisphosphonate alendronate for several years for osteoporosis or osteopenia." | 7.75 | Bisphosphonates and low-impact femoral fractures: current evidence on alendronate-fracture risk. ( Schneider, JP, 2009) |
| " At the end of the osteoporosis development period, MP rats were randomized to receive: vehicle (n= 7), genistein aglycone (5 mg x kg(-1) s." | 7.75 | Genistein aglycone reverses glucocorticoid-induced osteoporosis and increases bone breaking strength in rats: a comparative study with alendronate. ( Altavilla, D; Armbruster, MA; Bitto, A; Burnett, BP; Di Stefano, V; Irrera, N; Levy, RM; Marini, H; Minutoli, L; Polito, F; Squadrito, F, 2009) |
| "Treatment with once-weekly 70 mg alendronate significantly improved the BMD at the lumbar spine and femoral neck in patients with prostate cancer with severe osteopenia or osteoporosis and on ADT, and significantly decreased the risk of femoral neck fracture." | 7.75 | Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis. ( Cecchini, L; Encabo, G; Morote, J; Orsola, A; Placer, J; Planas, J; Raventós, C; Salvador, C; Trilla, E, 2009) |
| "We studied the therapeutic effects of one-year alendronate treatment in three cases (two males and one female) of osteoporosis with parietal thinning of skull." | 7.74 | Therapeutic effects of one-year alendronate treatment in three cases of osteoporosis with parietal thinning of skull. ( Hayashi, F; Takao, S; Takata, S; Yasui, N; Yoshida, S, 2008) |
| "Three boys with muscular dystrophy with known osteoporosis were each treated for 1 yr with weekly alendronate and daily calcium and vitamin D." | 7.74 | Use of weekly alendronate to treat osteoporosis in boys with muscular dystrophy. ( Apkon, S; Coll, J, 2008) |
| "To evaluate the cost-effectiveness of a fixed dose combination of alendronate 70 mg and cholecalciferol 2800 IU (alendronate/vitamin D3; Fosavance) versus no treatment, alendronate with dietary vitamin D supplements and ibandronate in the treatment of osteoporosis in the UK and Netherlands." | 7.74 | Cost-effectiveness of a fixed dose combination of alendronate and cholecalciferol in the treatment and prevention of osteoporosis in the United Kingdom and The Netherlands. ( Bergman, G; Gaugris, S; Jansen, JP; Sen, SS, 2008) |
| "Our objective was to investigate the efficacy of intravenous alendronate for the treatment of glucocorticoid-induced osteoporosis (GIOP) in children with autoimmune diseases." | 7.74 | Efficacy of intravenous alendronate for the treatment of glucocorticoid-induced osteoporosis in children with autoimmune diseases. ( Arima, T; Inoue, Y; Kohno, Y; Minagawa, M; Shimojo, N; Suzuki, S; Tomiita, M, 2008) |
| "Intravenous pamidronate is frequently used for the treatment of osteoporosis in patients who cannot tolerate oral bisphosphonates." | 7.73 | The effect of intravenous pamidronate versus oral alendronate on bone mineral density in patients with osteoporosis. ( Bultink, IE; Dijkmans, BA; Lems, WF; Vis, M, 2005) |
| "Osteoporosis in men was not recognized as a major health problem until recently, and increased research in this area resulted in the approval of alendronate for the treatment of osteoporosis in men at the beginning of this decade." | 7.73 | Effect of alendronate on bone mineral density in Puerto Rican males with osteoporosis. ( Guzmán, J; Martinó, A; Ramírez, M; Rosa, J, 2005) |
| " The aim of this study was to investigate the action of alendronate on the IGF-I-deficient bones of adult patients with LS and osteoporosis, as determined by dual X-ray absorptiometry ." | 7.73 | Effect of alendronate on bone mineral density in adult patients with Laron syndrome (primary growth hormone insensitivity). ( Benbassat, CA; Eshed, V; Laron, Z, 2006) |
| "Alendronate derivatives were evaluated as potential prodrugs for the osteoporosis drug alendronate sodium in an attempt to enhance the systemic exposure after oral administration." | 7.73 | Synthesis and study of alendronate derivatives as potential prodrugs of alendronate sodium for the treatment of low bone density and osteoporosis. ( Alani, LL; Algayer, K; Ghosh, S; Hale, JJ; Kesisoglou, F; Lu, Z; MacCoss, M; Manser, K; Mills, SG; Streckfuss, EC; Vachal, P; Yin, DH, 2006) |
| "The aim of our study was to evaluate the upper gastrointestinal (GI) tract side effect profile in 759 female patients that had taken alendronate (10 mg/day), for at least 6 months, for the treatment of osteoporosis, in relation to the safety of alendronate and the compliance of patients to its absorption rules." | 7.72 | Gastrointestinal side effect profile due to the use of alendronate in the treatment of osteoporosis. ( Akarirmak, U; Aki, S; Akyüz, G; Alper, S; Arpacioğlu, O; Atalay, F; Eryavuz, M; Eskiyurt, N; Kavuncu, V; Kokino, S; Kuru, O; Nas, K; Ozerbil, O; Savaş, G; Sendur, OF; Soy, D; Tüzün, F, 2003) |
| "To investigate the cost effectiveness of alendronate for male osteoporosis in Sweden by assuming the same relative risk reduction of fractures in men as for women, based on the FIT trial." | 7.72 | Cost effectiveness of alendronate for the treatment of male osteoporosis in Sweden. ( Borgström, F; Johnell, O; Jönsson, B; Sen, SS; Zethraeus, N, 2004) |
| "A 79-year-old Caucasian woman who had been taking alendronate 10 mg/day for over 2 years to prevent osteoporosis reported hearing "voices in her head" along with red-colored visual disturbances." | 7.72 | Alendronate-induced auditory hallucinations and visual disturbances. ( Coleman, CI; Lewis, A; Perkerson, KA, 2004) |
| "We investigated the effect of alendronate on calcium, PTH, and bone mineral density in 27 female and 5 male patients with primary hyperparathyroidism." | 7.71 | Alendronate in the treatment of primary hyperparathyroid-related osteoporosis: a 2-year study. ( Blackwell, PJ; Fairbairn, KJ; Hosking, DJ; Parker, CR, 2002) |
| " The objective of this study was to determine whether the osteoporosis treatment agent alendronate accelerates the rate of CAC." | 7.71 | Progression of coronary artery calcification in patients taking alendronate for osteoporosis. ( Adams, JS; Aziz, D; Emerick, AM; Gjertson, D; Goldin, JG; Greaser, LD; Hill, JA; Khorrami, S; Yoon, HC, 2002) |
| "To evaluate the anti-osteoporosis effect of alendronate on bone in rat model." | 7.71 | [The treatment of osteoporosis and bone resorption of alveoli with alendronate in rat model]. ( Wang, X; Yang, Z; Yu, S, 2001) |
| "About 1 in 3 women taking alendronate for osteoporosis report gastrointestinal symptoms, a rate much higher than that found during clinical trials." | 7.70 | Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis. ( Ettinger, B; Pressman, A; Schein, J, 1998) |
| "The authors report the case of a 54-year-old man suffering from steroid-induced osteoporosis, who presented with severe oral ulcerations due to sucking alendronate tablets instead of swallowing them." | 7.70 | Severe oral ulcerations induced by alendronate. ( Bolla, G; Demerjian, N; Spreux, A, 1999) |
| " However, ALN is characterized by restricted oral absorption and bioavailability and simultaneously its administration has serious side-effects (jaw osteonecrosis, irritation of the gastrointestinal system, nausea, musculoskeletal pain, and cardiovascular risks)." | 6.82 | How Efficient are Alendronate-Nano/Biomaterial Combinations for Anti-Osteoporosis Therapy? An Evidence-Based Review of the Literature. ( Klara, J; Lewandowska-Łańcucka, J, 2022) |
| "Minodronate is a potent nitrogen-containing bisphosphonate that can be administered according to a monthly (every 4 weeks) dosing regimen." | 6.82 | Patient preference for monthly bisphosphonate versus weekly bisphosphonate in a cluster-randomized, open-label, crossover trial: Minodroate Alendronate/Risedronate Trial in Osteoporosis (MARTO). ( Furuya, T; Hasegawa, M; Hirabayashi, H; Iwamoto, J; Kumakubo, T; Makita, K; Okano, H; Urano, T, 2016) |
| "Thirty-nine patients with ulcerative colitis and treated with glucocorticoids were randomized to receive alendronate (5 mg/day) or alfacalcidol (1 microg/day) daily for 12 months." | 6.74 | Clinical trial: comparison of alendronate and alfacalcidol in glucocorticoid-associated osteoporosis in patients with ulcerative colitis. ( Harada, K; Kitazaki, S; Kuwaki, K; Masuda, J; Mitsuyama, K; Sata, M; Sugiyama, G; Takedatsu, H; Tsuruta, O; Yamasaki, H, 2009) |
| "Alendronate therapy was well tolerated and produced a significantly greater increase in BMD over 12 months compared with placebo." | 6.73 | Alendronate once weekly for the prevention and treatment of bone loss in Canadian adult cystic fibrosis patients (CFOS trial). ( Adachi, JD; Berthiaume, Y; Freitag, A; Ioannidis, G; Jeanneret, A; Kennedy, CC; Matouk, E; Nixon, M; O'Neill, J; Papaioannou, A; Paterson, N; Pui, M; Rabin, HR; Villeneuve, J; Webber, C, 2008) |
| "Alendronate was initiated at 7 days after Tx." | 6.73 | Comparison of alendronate vs alendronate plus mechanical loading as prophylaxis for osteoporosis in lung transplant recipients: a pilot study. ( Baz, MA; Braith, RW; Casey, DP; Conner, JA; Fulton, MN; Howe, KS; Lisor, CF, 2007) |
| "Osteoporosis is a frequent complication after renal transplantation." | 6.71 | Alendronate for treatment of renal transplant patients with osteoporosis. ( Gutierrez, A; Moreno, A; Oppenheimer, F; Torregrosa, JV; Vidal, S, 2003) |
| "Alendronate therapy was given for 30 months; parathyroid hormone therapy was begun at month 6." | 6.71 | The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. ( Finkelstein, JS; Hayes, A; Hunzelman, JL; Lee, H; Neer, RM; Wyland, JJ, 2003) |
| "The alendronate-treated patients gained (mean +/- SD) 4." | 6.71 | Efficacy of alendronate in adults with cystic fibrosis with low bone density. ( Aris, RM; Blackwood, AD; Brown, SA; Caminiti, M; Chalermskulrat, W; Guillen, U; Hecker, TM; Hensler, M; Lark, RK; Lester, GE; Neuringer, IP; Ontjes, DA; Renner, JB, 2004) |
| "Alendronate treatment had significantly increased lumbar spine BMD by 4." | 6.71 | Alendronate treatment in men with primary osteoporosis: a three-year longitudinal study. ( Breschi, M; Bruni, D; Caffarelli, C; Cepollaro, C; Gennari, C; Gennari, L; Gonnelli, S; Montagnani, A; Nuti, R, 2003) |
| " Our results support the long-term administration of alendronate along with testosterone replacement to men with hypogonadism-induced osteoporosis." | 6.71 | Alendronate for osteoporosis in men with androgen-repleted hypogonadism. ( Doolman, R; Eshed, V; Karasik, A; Sela, BA; Shimon, I; Vered, I, 2005) |
| "Men with osteoporosis have been neglected in the past, and only a few therapeutic trials have been performed in men." | 6.70 | Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study. ( Dorst, A; Faber, H; Ringe, JD, 2001) |
| "Alendronate is an aminobisphosphonate that is able to increase bone mass mainly by inhibiting bone resorption." | 6.69 | Effectiveness of chronic treatment with alendronate in the osteoporosis of Cushing's disease. ( Colao, A; Di Somma, C; Faggiano, A; Klain, M; Lombardi, G; Merola, B; Pivonello, R; Salvatore, M; Tripodi, FS, 1998) |
| "Osteoporosis is a common complication of long-term glucocorticoid therapy for which there is no well-proved preventive or restorative treatment." | 6.69 | Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. ( Brown, JP; Czachur, M; Daifotis, AG; Delmas, PD; Emkey, R; Goemaere, S; Hawkins, F; Liberman, UA; Malice, MP; Saag, KG; Schnitzer, TJ; Thamsborg, G, 1998) |
| "The treatment with alendronate resulted in a significant and progressive increase in BMD of the lumbar spine and femoral neck." | 6.69 | Comparison of biochemical markers of bone remodelling in the assessment of the effects of alendronate on bone in postmenopausal osteoporosis. ( Stĕpán, JJ; Vokrouhlická, J, 1999) |
| "Osteoporosis is a frequent complication of rheumatoid arthritis (RA)." | 6.69 | Evaluation of bone turnover and osteoclastic cytokines in early rheumatoid arthritis treated with alendronate. ( Acquista, CA; Cantatore, FP; Pipitone, V, 1999) |
| "Alendronate treatment was not associated with any qualitative abnormalities." | 6.69 | Effects of alendronate on bone quality and remodeling in glucocorticoid-induced osteoporosis: a histomorphometric analysis of transiliac biopsies. ( Arlot, ME; Chavassieux, PM; Daifotis, A; Freedholm, D; Hamdy, NA; Malice, MP; Meunier, PJ; Portero, N; Roux, JP; Yates, AJ, 2000) |
| "Alendronate was not able to reduce the incidence of vertebral fractures (RR = 0." | 6.53 | Alendronate prevents glucocorticoid-induced osteoporosis in patients with rheumatic diseases: A meta-analysis. ( Ai, J; Feng, SQ; Kan, SL; Li, Y; Sun, JC; Xu, H; Yuan, ZF, 2016) |
| " Subgroup analysis revealed that among the patients in the combination therapy group, greater increases in the spine BMD were observed when the PTH was administered with a dosage of 20 μg (WMD = 2." | 6.52 | Parathyroid Hormone Plus Alendronate in Osteoporosis: A Meta-Analysis of Randomized Controlled Trials. ( Chen, J; Fan, J; Gu, M; Li, B; Wang, C; Zhang, G, 2015) |
| " This new formulation provides an alternative so that patients may select a method of dosing tailored to their preferences." | 6.49 | Alendronate sodium hydrate (oral jelly) for the treatment of osteoporosis: review of a novel, easy to swallow formulation. ( Imai, K, 2013) |
| "Overactive bone resorption and limited bone formation lead to unstable combination between bone tissue and scaffolds." | 6.44 | An osteoporosis bone defect regeneration strategy via three-dimension short fibers loaded with alendronate modified hydroxyapatite. ( Cheng, Z; Dai, Z; Jia, W; Jiang, X; Jiao, K; Liu, G; Liu, L; Liu, Y; Luo, Y; Sun, M; Wang, H; Wang, S; Yang, T; Yang, Y, 2024) |
| " A subsequent clinical trial reported that the once-weekly dosing regimen is therapeutically equivalent to the daily regimen." | 6.41 | Update on alendronate for osteoporosis: once-weekly dosing. ( Schnitzer, TJ, 2001) |
| "Alendronate has demonstrated its ability to increase bone mass significantly above the placebo values at any studied skeletal site in a wide variety of patient subgroups regardless of age, race, baseline rate of bone turnover or baseline bone mineral density." | 6.40 | A risk-benefit assessment of alendronate in the treatment of involutional osteoporosis. ( Devogelaer, JP, 1998) |
| "Postmenopausal women compliance to alendronate therapy is suboptimal due to the complex dosing requirements." | 5.72 | Knowledge and compliance towards alendronate therapy among postmenopausal women with osteoporosis in Palestine. ( Elaraj, J; Fatayer, D; Hamad, A; Jarar, B; Johar, A; Radwan, A; Shraim, N; Zriqah, A, 2022) |
| "In this randomized, controlled trial, sequential therapy with once-weekly subcutaneous injection of teriparatide for 72 weeks, followed by alendronate for 48 weeks resulted in a significantly lower incidence of morphometric vertebral fracture than monotherapy with alendronate for 120 weeks in women with osteoporosis at high risk of fracture." | 5.69 | Sequential therapy with once-weekly teriparatide injection followed by alendronate versus monotherapy with alendronate alone in patients at high risk of osteoporotic fracture: final results of the Japanese Osteoporosis Intervention Trial-05. ( Hagino, H; Mitomo, Y; Mori, S; Nakamura, T; Soen, S; Sone, T; Sugimoto, T; Takahashi, K; Tanaka, S, 2023) |
| " However, the use of Alen has been limited due to its low bioavailability and gastrointestinal side effects." | 5.62 | Alendronate-Decorated Nanoparticles as Bone-Targeted Alendronate Carriers for Potential Osteoporosis Treatment. ( Chen, S; Jing, C; Li, B; Liang, H; Liu, C; Na, H; Tan, H; Zhang, C; Zhao, L, 2021) |
| " Nearly six-time enhancement of bioavailability was observed when alendronate was used in the nanoparticulate form in transdermal patches used with sonophoresis." | 5.56 | Ultrasound-assisted transdermal delivery of alendronate for the treatment of osteoporosis. ( Huang, G; Li, B; Ma, Z; Qin, S, 2020) |
| "The efficacy of generic teriparatide in improving BMD at lumbar spine in patients with osteoporosis was similar to that of alendronate." | 5.51 | Efficacy of generic teriparatide and alendronate in Chinese postmenopausal women with osteoporosis: a prospective study. ( Chao, A; Cheng, Q; Dong, J; Gao, X; Hu, J; Jin, X; Li, M; Li, P; Li, Q; Lin, H; Shen, L; Shi, R; Tang, H; Xia, W; Xiong, X; Xue, Q; You, L; Yu, W; Zhang, Y; Zhang, Z; Zheng, S, 2022) |
| "Alendronate (ALN) is a BCS III bone resorption inhibitor, with very poor oral bioavailability." | 5.48 | Alendronate-loaded, biodegradable smart hydrogel: a promising injectable depot formulation for osteoporosis. ( Boraie, N; Nafee, N; Zewail, M, 2018) |
| "Alendronate is a widely used drug for osteoporosis in the elderly and postmenopausal women." | 5.48 | Preventing muscle wasting by osteoporosis drug alendronate in vitro and in myopathy models via sirtuin-3 down-regulation. ( Chan, DC; Chiang, CK; Chiu, CY; Chiu, HC; Liu, SH; Yang, RS, 2018) |
| "Chronic back pain is one of the most important complications of postmenopausal osteoporosis." | 5.46 | Alendronate inhibits hyperalgesia and suppresses neuropeptide markers of pain in a mouse model of osteoporosis. ( Iino, T; Kato, S; Naito, Y; Nakagawa, T; Sudo, A; Wakabayashi, H, 2017) |
| "This systematic review and meta-analysis aimed to reveal the efficacy and safety of zoledronic acid compared with alendronate in patients with primary osteoporosis." | 5.41 | Efficacy and Safety of Annual Infusion of Zoledronic Acid and Weekly Oral Alendronate in the Treatment of Primary Osteoporosis: A Meta-Analysis. ( Ai, W; Wang, Q; Yu, Q; Zeng, P, 2023) |
| "Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab, followed by alendronate, reduce clinical fractures in postmenopausal females with osteoporosis." | 5.41 | Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis: A Living Systematic Review and Network Meta-analysis for the American College of Physicians. ( Ayers, C; Fu, R; Harrod, C; Kansagara, D; Kwon, A; Lazur, B, 2023) |
| "This study assessed the effectiveness and safety of denosumab (Prolia®) compared to bisphosphonates (alendronate, ibandronate, risedronate, zoledronate), selective estrogen receptor modulators (SERMs) (bazedoxifene, raloxifene) and placebo for the treatment of osteoporosis in hormone-sensitive cancer patients receiving endocrine therapy (men with prostate cancer [MPC] on hormone ablation therapy [HAT], and women with breast cancer [WBC] on adjuvant aromatase inhibitor therapy [AAIT])." | 5.41 | The clinical effectiveness of denosumab (Prolia®) in patients with hormone-sensitive cancer receiving endocrine therapy, compared to bisphosphonates, selective estrogen receptor modulators (SERM), and placebo: a systematic review and network meta-analysis ( Jenal, M; Ma, N; Moshi, MR; Nicolopoulos, K; Stringer, D; Vreugdenburg, T, 2023) |
| " The primary measures of romosozumab efficacy used in this study were vertebral, non-vertebral, and clinical fracture events, and secondary outcomes were bone mineral density (BMD) changes at the lumbar spine, total hip, and femoral neck and the incidence of adverse events (AEs), RESULTS: Nine RCTs including 12 796 participants were included in the analysis, and romosozumab was compared with placebo, alendronate, and teriparatide in the treatment of osteoporosis in postmenopausal women." | 5.41 | Evaluation of the efficacy and safety of romosozumab (evenity) for the treatment of osteoporotic vertebral compression fracture in postmenopausal women: A systematic review and meta-analysis of randomized controlled trials (CDM-J). ( Guo, S; Huang, W; Nagao, M; Nishizaki, Y; Tanigawa, T; Yonemoto, N, 2023) |
| "To assess the effectiveness and safety of denosumab (Prolia®) compared to bisphosphonates (alendronate, ibandronate, risedronate, zoledronate), selective estrogen receptor modulators (SERMs; bazedoxifene, raloxifene) or placebo, for the treatment of osteoporosis in postmenopausal women (PMW)." | 5.41 | The Clinical Effectiveness of Denosumab (Prolia®) for the Treatment of Osteoporosis in Postmenopausal Women, Compared to Bisphosphonates, Selective Estrogen Receptor Modulators (SERM), and Placebo: A Systematic Review and Network Meta-Analysis. ( Jenal, M; Ma, N; Moshi, MR; Nicolopoulos, K; Stringer, D; Vreugdenburg, T, 2023) |
| "In this randomized, controlled trial, treatment with once-weekly subcutaneous injection of teriparatide for 72 weeks was found to be associated with a significant reduction in the incidence of morphometric vertebral fractures compared with alendronate in women with primary osteoporosis who were at high risk of fracture." | 5.41 | A randomized, controlled trial of once-weekly teriparatide injection versus alendronate in patients at high risk of osteoporotic fracture: primary results of the Japanese Osteoporosis Intervention Trial-05. ( Hagino, H; Mori, S; Nakamura, T; Sasaki, K; Soen, S; Sone, T; Sugimoto, T; Tanaka, S, 2021) |
| "Zoledronic acid is a third-generation nitrogen-containing BP." | 5.40 | Pentoxifylline and tocopherol in the treatment of yearly zoledronic acid-related osteonecrosis of the jaw in a corticosteroid-induced osteoporosis. ( Magremanne, M; Reychler, H, 2014) |
| "Methionine treatment could be beneficial for the treatment of postmenopausal osteoporosis." | 5.40 | Methionine down-regulates TLR4/MyD88/NF-κB signalling in osteoclast precursors to reduce bone loss during osteoporosis. ( Gupta, S; Khandelwal, M; Manglani, K; Surolia, A; Vijayan, V, 2014) |
| "Alendronate was stopped, and he was started on intravenous ibandronate injections given every 3 months." | 5.40 | Exacerbation of myasthenia gravis by alendronate. ( Alay, S; Güzelküçük, U; Kesikburun, S; Tan, AK; Yavuz, F, 2014) |
| "We term this strategy as the "local treatment of osteoporosis"." | 5.40 | Local treatment of osteoporosis with alendronate-loaded calcium phosphate cement. ( Li, G; Tang, H; Wang, J; Zhao, J, 2014) |
| "Alendronate (ALN) can increase bone mass and improve the microstructure of osteoporotic vertebrae, which might be helpful in preserving disc morphology and mechanical properties." | 5.39 | Alendronate retards the progression of lumbar intervertebral disc degeneration in ovariectomized rats. ( Hu, QF; Luo, Y; Song, HP; Su, YL; Wang, WY; Zhang, L; Zhang, YZ, 2013) |
| " The present study was carried out to compare the effect of a novel agent glucosamine alendronate (GA) alone and is combination with dihydroquercetin (DHQ) against the effect of a known drug alendronate (ALN) in the senescence-accelerated OXYS rats as model of osteoporosis." | 5.38 | Efficacy of glucosamine alendronate alone & in combination with dihydroquercetin for treatment of osteoporosis in animal model. ( Kolosova, NG; Muraleva, NA; Ofitserov, EN; Tikhonov, VP, 2012) |
| "Oral alendronate produces an increase in BMD in these patients, with good tolerance and no need for hospitalization, and so improves quality of life and reduces health care costs." | 5.37 | [Alendronate treatment of osteoporosis secondary to Duchenne muscular dystrophy]. ( Ballester Herrera, MJ; Carmona Vilchez, RM; Márquez de La Plata, MA; Medina Cano, E; Palomo Atance, E, 2011) |
| " Among patients with osteoporosis in Taiwan who had experienced a fracture and had started alendronate therapy, compliance with the dosage regimen was suboptimal." | 5.37 | Alendronate adherence and its impact on hip-fracture risk in patients with established osteoporosis in Taiwan. ( Lin, SJ; Lin, TC; Yang, CY; Yang, YH, 2011) |
| "Rosiglitazone (RSG) is an insulin-sensitizing drug used to treat type 2 diabetes mellitus." | 5.37 | Effect of rosiglitazone on bone quality in a rat model of insulin resistance and osteoporosis. ( Fantus, IG; Grynpas, MD; Renlund, R; Sardone, LD; Willett, TL, 2011) |
| "Osteoporosis is accompanied by predominantly metaphyseal fractures with a delayed and qualitatively reduced healing process." | 5.36 | Do estrogen and alendronate improve metaphyseal fracture healing when applied as osteoporosis prophylaxis? ( Hoerster, AK; Kolios, L; Malcherek, MC; Rack, T; Sehmisch, S; Seidlova-Wuttke, D; Stuermer, EK; Stuermer, KM; Tezval, M; Wuttke, W, 2010) |
| "Male osteoporosis is not the epidemic problem that female osteoporosis is; however, the National Osteoporosis Foundation estimates that over 14 million American men have osteoporosis or low bone mass, and approximately 25% to 30% of all hip fractures occur in male individuals who incur greater morbidity and mortality than their female counterparts." | 5.36 | Intravenous zoledronic acid: what are the indications for male osteoporosis? ( Maricic, M, 2010) |
| " The bioavailability (BA) of alendronate in rats was approximately 8." | 5.36 | Development of a novel transdermal patch of alendronate, a nitrogen-containing bisphosphonate, for the treatment of osteoporosis. ( Abe, M; Hayashi, R; Hirai, Y; Kamiyama, F; Katsumi, H; Kusamori, K; Quan, YS; Sakai, R; Sakane, T; Ueda, A; Yamamoto, A, 2010) |
| "Pamidronate 30 mg was administered on 26 osteoporotic patients; and acute phase reactants, inflammatory cytokines and bone biomarkers were measured." | 5.36 | Acute effects of intravenous administration of pamidronate in patients with osteoporosis. ( Kwon, SR; Lim, MJ; Park, SG; Park, W, 2010) |
| "Osteoporosis is associated with the pathogenesis and risk of urolithiasis, which is higher among postmenopausal women (as opposed to premenopausal)." | 5.35 | Alendronate reduces the excretion of risk factors for calcium phosphate stone formation in postmenopausal women with osteoporosis. ( Hamamoto, S; Hirose, M; Itoh, Y; Kobayashi, T; Kohri, K; Okada, A; Tozawa, K; Yasui, T, 2009) |
| "This article reports the design and rationale for the Japanese Osteoporosis Intervention Trial-05 (JOINT-05), a randomized, controlled trial that compares the efficacy and safety of teriparatide followed by alendronate with alendronate monotherapy for severe osteoporosis." | 5.34 | Design of a randomized trial of teriparatide followed by alendronate: Japanese Osteoporosis Intervention Trial-05 (JOINT-05). ( Hagino, H; Mori, S; Sugimoto, T; Tanaka, S, 2020) |
| "Granulomatous interstitial nephritis is a rare but characteristic hallmark of certain diseases such as sarcoidosis and tuberculosis." | 5.33 | Acute granulomatous interstitial nephritis secondary to bisphosphonate alendronate sodium. ( Fervenza, FC; Habermann, T; Lager, D; Leung, N; Peña de la Vega, L, 2005) |
| "Osteoporosis is a metabolic bone disease characterized by reduced bone mass and deterioration of bone microarchitecture." | 5.33 | Evaluation of modal damping factor as a diagnostic tool for osteoporosis and its relation with serum osteocalcin and collagen I N-telopeptide for monitoring the efficacy of alendronate in ovariectomized rats. ( Anastassopoulos, G; Christopoulou, GE; Karamanos, NK; Panagiotopoulos, E; Panteliou, SD; Papadaki, E; Stavropoulou, A, 2006) |
| "Alendronate is a bisphosphonate compound used to treat diseases of pathologic bone resorption." | 5.32 | Superficial gyrate erythema as a cutaneous reaction to alendronate for osteoporosis. ( Cockerell, CJ; Cohen, JB; High, WA; Wetherington, W, 2003) |
| "Subjects were patients that were treated for osteoporosis at Department for physical medicine and rehabilitation in Clinical hospital Dubrava." | 5.32 | [Weekly and daily intake of alendronate: comparison of tolerance in osteoporosis treatment]. ( Badovinac, O; Delija, A; Sakić, D; Sakić, VA, 2004) |
| "Treatment with alendronate 10 mg/day improved bone density and back pain." | 5.31 | Male osteoporosis associated with longterm cyproterone treatment. ( Swinson, DR; Vasireddy, S, 2001) |
| "To study and compare the clinical effects of Rehmannia Decoction and alendronate sodium for the treatment of primary osteoporosis." | 5.30 | [Comparison of the clinical effects between Dihuang Decoction and alendronate sodium in the treatment of primary osteoporosis]. ( Huang, K; Wan, JM; Zhang, JF; Zhang, PL; Zhu, SY, 2019) |
| "The randomized, clinical trial demonstrated that switching to monthly minodronate from weekly alendronate and risedronate provides greater increases in patients' satisfaction and bone mineral density and more substantial decreases in a bone resorption marker than continuing weekly alendronate and risedronate in patients with systemic rheumatic diseases on glucocorticoid therapy." | 5.27 | Patient satisfaction and efficacy of switching from weekly bisphosphonates to monthly minodronate for treatment and prevention of glucocorticoid-induced osteoporosis in Japanese patients with systemic rheumatic diseases: a randomized, clinical trial. ( Hayami, Y; Iwagaitsu, S; Maeda, S; Naniwa, T; Ohmura, SI; Sasaki, K; Tamechika, SY, 2018) |
| "Osteoporosis patients in Thailand were recruited to a multicenter, open-label, 6-month trial of oral alendronate sodium 70 mg/vitamin D3 5600 IU." | 5.27 | Open-label study of treatment with alendronate sodium plus vitamin D in men and women with osteoporosis in Thailand. ( Luevitoonvechkij, S; Ongphiphadhanakul, B; Robert, CS; Robert, L; Rojanasthien, S; Santora, AC; Songpatanasilp, T; Sugkraroek, P, 2018) |
| "A total of 140 postmenopausal women or men aged older than 50 years who met the indications for osteoporosis treatment were randomized to receive either generic (Bonmax®) or brand alendronate (Fosamax®) 70 mg/week over a 12-month period during the May 2014 to June 2015 study period." | 5.24 | Randomized clinical trial comparing efficacy and safety of brand versus generic alendronate (Bonmax®) for osteoporosis treatment. ( Jarusriwanna, A; Songcharoen, P; Unnanuntana, A, 2017) |
| "Denosumab and alendronate showed similar clinical efficacy in the therapy of ADT-related osteoporosis in men with prostate carcinoma; both drugs provided significant improvements in back pain and general health conditions." | 5.24 | Treatment of osteoporosis secondary to hypogonadism in prostate cancer patients: a prospective randomized multicenter international study with denosumab vs. alendronate. ( Balsano, M; Doria, C; Maestretti, G; Mosele, GR; Scarpa, RM; Solla, F, 2017) |
| "Osteoporosis is found to have high prevalence after gastrectomy and therefore, it is important to prevent this condition by means of effective medication, such as alendronate sodium hydrate." | 5.24 | A Comparative Study of Intravenous Injection Form and Oral Jelly Form of Alendronate Sodium Hydrate for Bone Mineral Disorder after Gastrectomy. ( Akiyama, H; Endo, I; Izumisawa, Y; Kosaka, T; Kunisaki, C; Miyamoto, H; Sato, K; Sato, S; Suematsu, H; Taguri, M; Tanaka, Y; Yamanaka, T; Yukawa, N, 2017) |
| "A 10% increased risk of acute myocardial infarction was found in users of other bisphosphonates as compared to alendronate users within CPRD." | 5.22 | Comparative risk of acute myocardial infarction for anti-osteoporosis drugs in primary care: a meta-analysis of propensity-matched cohort findings from the UK Clinical Practice Research Database and the Catalan SIDIAP Database. ( Abrahamsen, B; Arden, N; Calderon-Larranaga, S; Cooper, C; Hawley, S; Javaid, MK; Judge, A; Khalid, S; Prieto-Alhambra, D; Sami, A; Van Staa, TP, 2022) |
| " The aim of this study was to perform a meta-analysis of the effects of alendronate combined with atorvastatin compared with alendronate alone in the treatment of osteoporosis in diabetes mellitus." | 5.22 | Meta-Analysis of the Efficacy and Safety of Alendronate Combined with Atorvastatin in the Treatment of Osteoporosis in Diabetes Mellitus. ( Shu, L; Tang, X; Xiong, Z; Yi, P; Zhang, C, 2022) |
| "Glucocorticoid-induced osteoporosis (GIOP) is the most common secondary osteoporosis, alendronate (ALE) and teriparatide (TPTD) are widely used in the treatment of GIOP." | 5.22 | The efficiency and safety of alendronate versus teriparatide for treatment glucocorticoid-induced osteoporosis: A meta-analysis and systematic review of randomized controlled trials. ( Guan, XQ; Liu, ZM; Shen, ZB; Yin, F; Zhang, D; Zhang, M; Zong, Y, 2022) |
| "To determine the effect of alendronate (ALN) and teriparatide on trabecular bone score (TBS) in patients with glucocorticoid-induced osteoporosis." | 5.22 | Trabecular Bone Score in Patients With Chronic Glucocorticoid Therapy-Induced Osteoporosis Treated With Alendronate or Teriparatide. ( Agnusdei, D; Alam, J; Hans, D; Kohlmeier, LA; Krohn, KD; Leib, ES; MacLaughlin, EJ; Marcus, R; Saag, KG; Simonelli, C; Taylor, KA, 2016) |
| "This study aims to evaluate patient perceptions of subcutaneous denosumab or oral alendronate in postmenopausal women with or at risk for osteoporosis and how these perceptions influence adherence." | 5.19 | Influence of patient perceptions and preferences for osteoporosis medication on adherence behavior in the Denosumab Adherence Preference Satisfaction study. ( Horne, R; Huang, J; Kaur, P; Kendler, DL; Lillestol, MJ; Macarios, D; Moffett, A; Satram-Hoang, S; Tang, ET; Wagman, RB, 2014) |
| "This is the first prospective follow-up study to describe the effects of oral alendronate medication on neurofibromatosis 1 (NF1)-related osteoporosis." | 5.19 | Follow-up of six patients with neurofibromatosis 1-related osteoporosis treated with alendronate for 23 months. ( Heervä, E; Huilaja, L; Leinonen, P; Peltonen, J; Peltonen, S, 2014) |
| "The fracture intervention trial is a large randomized, placebo-controlled trial of alendronate treatment for osteoporosis." | 5.17 | Natural history and risk factors for adjacent vertebral fractures in the fracture intervention trial. ( Bauer, DC; Frankel, B; Krishna, V; Nicholas, J; Vandergrift, A, 2013) |
| " Bisphosphonates such as alendronate potently inhibit bone resorption and are effective against osteoporosis." | 5.16 | Effect of alendronate on HIV-associated osteoporosis: a randomized, double-blind, placebo-controlled, 96-week trial (ANRS 120). ( Bentata, M; Costagliola, D; Darasteanu, I; Kolta, S; Lanoy, E; Missy, P; Roux, C; Rozenberg, S; Valantin, MA; Viard, JP, 2012) |
| "To evaluate the efficacy and safety of alendronate for the treatment of osteoporosis/osteopenia secondary to hyperthyroidism." | 5.16 | [Clinical application of alendronate for osteoporosis/osteopenia secondary to hyperthyroidism]. ( Shen, FX; Yang, LJ; Zhang, HL; Zheng, JC, 2012) |
| "The effects of teriparatide versus alendronate were compared by gender and menopausal status in patients with glucocorticoid-induced osteoporosis." | 5.14 | Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status. ( Dobnig, H; Krohn, K; Langdahl, BL; Maricic, M; Marin, F; See, K; Shane, E; Warner, MR; Zanchetta, JR, 2009) |
| "In order to study the benefit of adding recombinant human growth hormone (rhGH) to antiresorptive therapy, six patients with idiopathic osteoporosis (IO) receiving alendronate plus calcium and vitamin D were started on daily subcutaneous injections of rhGH 2." | 5.14 | Additional beneficial effects of recombinant growth hormone in alendronate-treated patients with idiopathic osteoporosis. ( Coeli, CM; de Farias, ML; Lopes, RF; Vaisman, M, 2009) |
| "To determine the effect of alendronate on glucocorticoid-induced osteoporosis(GIO)." | 5.14 | [Effect of alendronate on glucocorticoid-induced osteoporosis]. ( Li, Q; Shi, C; Zou, X, 2009) |
| "Alendronate decreases the urinary levels of cross-linked N-terminal telopeptides of type I collagen (NTX; about 45% at 3 months) and serum levels of alkaline phosphatase (ALP; about 27% at 24 months), leading to an increase in lumbar spine bone mineral density (BMD; about 9% at 24 months) in postmenopausal Japanese women with osteoporosis." | 5.14 | Effect of alendronate on bone mineral density and bone turnover markers in post-gastrectomy osteoporotic patients. ( Iwamoto, J; Matsumoto, H; Sato, Y; Takeda, T; Uzawa, M, 2010) |
| "The comparative effects of alendronate and alfacalcidol on bone mineral density (BMD) and bone turnover have already been established in postmenopausal women with osteoporosis." | 5.14 | Comparison of the effects of alendronate and alfacalcidol on hip bone mineral density and bone turnover in Japanese men having osteoporosis or osteopenia with clinical risk factors for fractures. ( Iwamoto, J; Matsumoto, H; Sato, Y; Takeda, T; Uzawa, M, 2009) |
| " The OPTAMISE (Open-label Study to Determine How Prior Therapy with Alendronate or Risedronate in Postmenopausal Women with Osteoporosis Influences the Clinical Effectiveness of Teriparatide) study reported greater increases in biochemical markers of bone turnover and volumetric bone mineral density (BMD) when 12 months of teriparatide treatment was preceded by 2 years or more of risedronate versus alendronate treatment." | 5.14 | Biomechanical effects of teriparatide in women with osteoporosis treated previously with alendronate and risedronate: results from quantitative computed tomography-based finite element analysis of the vertebral body. ( Borah, B; Chevalier, Y; Gross, G; Lang, T; Quek, E; Stewart, J; Zysset, P, 2010) |
| "Osteoporosis represents a significant side effect of glucocorticoid therapy, and alendronate has been reported to prevent this glucocorticoid-induced osteoporosis." | 5.14 | Effects of alendronate on bone metabolism in glucocorticoid-induced osteoporosis measured by 18F-fluoride PET: a prospective study. ( Baba, H; Fujibayashi, Y; Kawahara, H; Kobayashi, S; Miyazaki, T; Nakajima, H; Okazawa, H; Tsuchida, T; Uchida, K; Yayama, T, 2009) |
| "To compare the bone anabolic drug teriparatide (20 microg/day) with the antiresorptive drug alendronate (10 mg/day) for treating glucocorticoid-induced osteoporosis (OP)." | 5.14 | Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. ( Adler, RA; Devogelaer, JP; Eastell, R; Krege, JH; Krohn, K; Saag, KG; See, K; Warner, MR; Zanchetta, JR, 2009) |
| "This post-hoc analysis studied the effect of baseline glucocorticoid dose on the 18-month bone mineral density (BMD) response to teriparatide 20 microg/day or alendronate 10 mg/day in 387 patients with glucocorticoid-induced osteoporosis (GIO) from a randomized, double-blind trial." | 5.14 | Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis. ( Adler, RA; Devogelaer, JP; Krohn, K; Recknor, C; See, K; Warner, MR; Wong, M, 2010) |
| "The aim of this study was to evaluate the efficacy, safety, and tolerability of weekly alendronate administration on male osteoporosis in Taiwan." | 5.14 | The effects of weekly alendronate therapy in Taiwanese males with osteoporosis. ( Chen, JF; Ho, C; Huang, YY; Hwang, JS; Lin, JD; Liou, MJ; Tsai, KS; Wang, CJ, 2010) |
| "The purpose of this post hoc analysis was to determine whether baseline concentrations or early changes in serum bone turnover markers were correlated with changes in bone mineral density (BMD) at 18 months in patients with glucocorticoid-induced osteoporosis (GIO) treated with teriparatide (n=80; 20 mug/day) or alendronate (n=77; 10 mg/day)." | 5.14 | Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate. ( Burshell, AL; Chen, P; Correa-Rotter, R; Dalsky, GP; Krege, JH; Möricke, R; Taylor, KA; Warner, MR, 2010) |
| "Zoledronic acid (ZOL) has shown beneficial effects on bone turnover and bone mineral density (BMD) in postmenopausal osteoporosis." | 5.14 | Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. ( Adachi, JD; Adler, RA; Brown, J; Bucci-Rechtweg, C; Kendler, D; Mesenbrink, P; Miller, PD; Orwoll, ES; Readie, A; Weinstein, RS, 2010) |
| "In an open-label, prospective, controlled, 12-month study the effects of strontium ranelate (SR, CAS 135459-87-9) or alendronate (CAS 129318-43-0) on bone mineral density (BMD) were compared in 152 men with primary osteoporosis." | 5.14 | Efficacy of strontium ranelate on bone mineral density in men with osteoporosis. ( Dorst, A; Farahmand, P; Ringe, JD, 2010) |
| " Subjects had just developed systemic autoimmune diseases and were randomized to be treated with 1 mg/kg/day prednisolone and alfacalcidol 1 microg/day alone (alfacalcidol group; n = 22), or prednisolone and alfacalcidol 1 microg/day with alendronate 5 mg/day (alendronate group; n = 25), each for 18 months." | 5.13 | Alendronate protects premenopausal women from bone loss and fracture associated with high-dose glucocorticoid therapy. ( Nakayamada, S; Nawata, M; Okada, Y; Saito, K; Tanaka, Y, 2008) |
| "To investigate the effects of alendronate (Alen) on the prevention of systemic glucocorticoid-induced osteoporosis in patients with rheumatic diseases." | 5.13 | [Alendronate prevents steroid-induced osteoporosis in patients with rheumatic diseases]. ( Huang, YL; Wang, QH; Wen, LH; Wu, HX; Xue, J; Yang, XY; Zhu, L, 2008) |
| "To compare the effects of alendronate and raloxifene on lumbar bone mineral density (BMD), bone turnover, and lipid metabolism in elderly women with osteoporosis." | 5.13 | Comparison of effects of alendronate and raloxifene on lumbar bone mineral density, bone turnover, and lipid metabolism in elderly women with osteoporosis. ( Iwamoto, J; Matsumoto, H; Sato, Y; Takeda, T; Uzawa, M, 2008) |
| "The use of buffered soluble alendronate 70 mg effervescent tablet, a convenient dosing regimen for bisphosphonate therapy, seems a cost-effective strategy compared with relevant alternative treatments for postmenopausal women with osteoporosis aged 60 years and over in Italy." | 5.12 | Cost-effectiveness of buffered soluble alendronate 70 mg effervescent tablet for the treatment of postmenopausal women with osteoporosis in Italy. ( Hiligsmann, M; Maggi, S; Reginster, JY; Sartori, L; Veronese, N, 2021) |
| "In a prospective, randomized controlled trial of previously untreated postmenopausal women with osteoporosis, oral BP therapy (daily doses of either 10 mg alendronate or 5 mg risedronate) in combination with calcium/vitamin D was compared to calcium/vitamin D treatment alone (control group)." | 5.12 | Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients. ( Dobnig, H; Fahrleitner-Pammer, A; Hofbauer, LC; Obermayer-Pietsch, B; Viereck, V, 2006) |
| "To evaluate the efficacy and safety of oral alendronate on bone mineral density (BMD) in children and adolescents with osteoporosis." | 5.12 | Efficacy and safety of oral alendronate treatment in children and adolescents with osteoporosis. ( Abaci, A; Bober, E; Büyükgebiz, A; Unal, E, 2006) |
| "During this 18-month trial in patients with rheumatic diseases, alendronate was more effective in the prevention of glucocorticoid-induced bone loss than was alfacalcidol." | 5.12 | Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. ( Algra, A; Bijlsma, JW; Bruyn, GA; Buskens, E; de Laet, CE; de Nijs, RN; Dijkmans, BA; Geusens, PP; Huisman, AM; Jacobs, JW; Laan, RF; Lems, WF; Oostveen, AC, 2006) |
| "In osteoporosis patients who avoided sunlight and vitamin D supplements, this once-weekly tablet containing alendronate and cholecalciferol provided equivalent antiresorptive efficacy, reduced the risk of low serum 25OHD, improved vitamin D status over 15 weeks, and was not associated with hypercalcemia, hypercalciuria or other adverse findings, versus alendronate alone." | 5.12 | Alendronate with and without cholecalciferol for osteoporosis: results of a 15-week randomized controlled trial. ( Benhamou, L; Delmas, PD; Emkey, R; Felsenberg, D; Hawkins, F; He, W; Lippuner, K; Lips, P; Recker, R; Rosen, C; Salzmann, G; Santora, AC, 2006) |
| "These data show that weekly systemic administration of alendronate improves pin fixation in cancellous bone in elderly female patients with osteoporosis." | 5.12 | Alendronate improves screw fixation in osteoporotic bone. ( Faldini, C; Giannini, S; Hoang-Kim, A; Moroni, A; Pegreffi, F, 2007) |
| "In an 18-month randomized, double-blind, controlled trial, we compared teriparatide with alendronate in 428 women and men with osteoporosis (ages, 22 to 89 years) who had received glucocorticoids for at least 3 months (prednisone equivalent, 5 mg daily or more)." | 5.12 | Teriparatide or alendronate in glucocorticoid-induced osteoporosis. ( Boonen, S; Dalsky, GP; Donley, DW; Marcus, R; Marín, F; Saag, KG; Shane, E; Taylor, KA, 2007) |
| "46 men with osteoporosis were randomly allocated to three groups: 15 patients in the first group received daily 10 mg alendronate and calcium (1000 mg/day), 14 patients in the second group used every other day 10 mg alendronate and calcium and 17 patients in the third group were given intranasal salmon calcitonin and calcium." | 5.12 | The effects of daily alendronate, daily calcitonin and alendronate every other day on bone mineral density in osteoporotic men. ( Akyuz, G; Guven, Z; Karadag-Saygi, E; Unlu-Ozkan, F, 2007) |
| "Our trial was a 3-year, open-label, prospective, comparative, clinical study comparing the effects of oral alendronate (ALN), 10 mg daily, and alfacalcidol (AC), 1 microg daily, on bone mineral density (BMD), fracture events, height, back pain, safety and tolerability in 134 men with established primary osteoporosis." | 5.11 | Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study. ( Dorst, A; Faber, H; Ibach, K; Ringe, JD, 2004) |
| "Alendronate 70 mg administered once weekly to women and men with osteoporosis has an upper GI and overall tolerability profile similar to that of placebo." | 5.11 | Upper gastrointestinal and overall tolerability of alendronate once weekly in patients with osteoporosis: results of a randomized, double-blind, placebo-controlled study. ( Eisman, JA; Gaines, KA; Lipschitz, S; Melton, ME; Rizzoli, R; Roman-Ivorra, J; Verbruggen, N, 2004) |
| "To assess efficacy and safety of alendronate sodium treatment in osteoporosis patients with hip fracture." | 5.11 | [Clinic effect of alendronate sodium treatment in osteoporosis patients with hip fracture]. ( Jin, J; Lin, J; Luo, XZ; Qiu, GX; Shen, JX; Tang, H; Tian, Y; Wang, YP; Weng, XS; Wu, ZH; Yang, XY; Zhang, JG; Zhao, H, 2004) |
| "The current study was undertaken to investigate the effect of alendronate on bone mineral density (BMD), bone metabolism markers, and serum bone-resorbing cytokines in patients with chronic idiopathic neutropenia (CIN)-associated osteopenia/osteoporosis." | 5.11 | Alendronate reduces serum TNFalpha and IL-1beta, increases neutrophil counts, and improves bone mineral density and bone metabolism indices in patients with chronic idiopathic neutropenia (CIN)-associated osteopenia/osteoporosis. ( Christoforidou, A; Eliopoulos, GD; Malliaraki, N; Margioris, AN; Miliaki, M; Papadaki, HA; Pontikoglou, C; Psyllaki, M; Tsatsanis, C, 2004) |
| "The use of alendronate had a positive effect on bone mineral density in SCI patients and therefore represents a potential tool for prevention and treatment of osteoporosis in this population." | 5.11 | Effect of alendronate on bone mineral density in spinal cord injury patients: a pilot study. ( Battistella, LR; Moran de Brito, CM; Saito, ET; Sakamoto, H, 2005) |
| "The FACT study (Fosamax Actonel Comparison Trial) was a 1-year-head-to-head trial comparing the efficacy and tolerability of once weekly (DW) alendronate 70 mg and OW risedronate 35 mg for the treatment of postmenopausal osteoporosis." | 5.11 | Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis. ( Bonnick, SL; Chen, E; de Papp, AE; Kagan, R; Sebba, AI; Skalky, CS; Thompson, DE, 2004) |
| "HIV-1-infected patients with osteoporosis were randomly assigned to alendronate 70 mg once-weekly plus dietary counselling (n = 11) or diet counselling alone (n = 14)." | 5.11 | Reversal of HIV-1-associated osteoporosis with once-weekly alendronate. ( Clotet, B; del Rio, L; Gel, S; Holgado, S; Martínez-López, E; Negredo, E; Paredes, R; Pérez-Alvarez, N; Rey-Joly, C; Rosales, J; Tena, X, 2005) |
| " A total of 450 (224 alendronate; 226 placebo) postmenopausal women and men with osteoporosis were randomized." | 5.11 | Upper gastrointestinal tolerability of once weekly alendronate 70 mg with concomitant non-steroidal anti-inflammatory drug use. ( Chen, E; Cryer, B; Geba, GP; Miller, P; Papp, AE; Petruschke, RA, 2005) |
| "Alendronate, vitamin D, and calcium are safe and potentially useful in the treatment of osteopenia/osteoporosis associated with HIV infection." | 5.11 | Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection. ( Claxton, SA; Hoffmann, ME; Mondy, K; Powderly, WG; Royal, M; Stoneman, JS; Tebas, P; Yarasheski, KH, 2005) |
| " All patients received vitamin D and calcium supplementation before and after LT, those with osteopenia or osteoporosis prior to LT were additionally treated with alendronate following LT." | 5.11 | Alendronate in combination with calcium and vitamin D prevents bone loss after orthotopic liver transplantation: a prospective single-center study. ( Eichler, D; Finkenstedt, G; Graziadei, IW; Koenigsrainer, A; Margreiter, R; Millonig, G; Muehllechner, P; Pfeiffer, KP; Vogel, W, 2005) |
| "To compare the effects on back pain of teriparatide versus alendronate, we analyzed the reporting of back pain in a head to head comparator trial and a followup study." | 5.11 | Longterm reduction of back pain risk in women with osteoporosis treated with teriparatide compared with alendronate. ( Body, JJ; Chen, P; Krege, JH; Miller, PD; Rohe, ME; Shergy, WJ, 2005) |
| "The efficacy and safety of treatment with oral alendronate (ALN) 35 mg once weekly for 52 weeks were compared with those of ALN 5 mg once daily in a double-blind, randomized, multicenter study of Japanese patients with involutional osteoporosis." | 5.11 | Therapeutic effects of alendronate 35 mg once weekly and 5 mg once daily in Japanese patients with osteoporosis: a double-blind, randomized study. ( Arizono, H; Fukunaga, M; Kakikawa, T; Nagata, K; Nakamura, T; Ohashi, Y; Okaniwa, M; Okuyama, K; Santora, AC; Shimizu, T; Shiraki, M; Taniguchi, T; Tomomitsu, T; Uchida, S, 2005) |
| " The study enrolled 450 postmenopausal women and men with osteoporosis (224 took alendronate, 226 took placebo) who were ambulatory and community dwelling at 48 outpatient study centers in the United States." | 5.10 | Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study. ( de Papp, AE; Field-Munves, E; Greenspan, S; Palmisano, J; Petruschke, R; Smith, M; Tonino, R; Wang, L; Yates, J, 2002) |
| "To determine the efficacy of an anti-osteoporosis regimen that combined a bisphosphonate agent (alendronate sodium) with the osteogenic stimulus of mechanical loading, 25 HTRs were randomly assigned either to a group that received alendronate (10 mg/day) for 6 months (ALEN; n = 8), a group that received alendronate (10 mg/day) and performed specific resistance exercises for 6 months (ALEN + TRN; n = 8) or to a non-intervention control group (CONTR; n = 9)." | 5.10 | Resistance exercise training and alendronate reverse glucocorticoid-induced osteoporosis in heart transplant recipients. ( Aranda, J; Braith, RW; Fulton, MN; Hill, JA; Magyari, PM; Walker, T, 2003) |
| "Alendronate (10 mg daily) has been shown in long term clinical trials to be an effective treatment for postmenopausal osteoporosis." | 5.10 | The upper GI safety and tolerability of oral alendronate at a dose of 70 milligrams once weekly: a placebo-controlled endoscopy study. ( Daifotis, A; Lanza, F; Leung, A; Musliner, T; Quan, H; Reyes, R; Sahba, B; Schwartz, H; Torosis, J; Winograd, S, 2002) |
| "The aim of this open prospective randomized study was to evaluate the effect of a 6-month treatment with alendronate on the bone mineral density (BMD) at lumbar spine in patients with central diabetes insipidus." | 5.09 | Effect of a short-term treatment with alendronate on bone density and bone markers in patients with central diabetes insipidus. ( Colao, A; Di Somma, C; Faggiano, A; Filippella, M; Klain, M; Lombardi, G; Pivonello, R; Salvatore, M, 1999) |
| "To evaluate the efficacy and safety of alendronate, a double-masked, active (alfacalcidol) controlled comparative study for 48 weeks was carried out in a total of 210 Japanese patients with osteoporosis." | 5.09 | A double-masked multicenter comparative study between alendronate and alfacalcidol in Japanese patients with osteoporosis. The Alendronate Phase III Osteoporosis Treatment Research Group. ( Fukunaga, M; Inoue, T; Kaneda, K; Kishimoto, H; Kushida, K; Minaguchi, H; Morii, H; Nagata, Y; Nakamura, T; Nakashima, M; Orimo, H; Shiraki, M; Taga, M; Tomita, A; Yamamoto, K, 1999) |
| "Alendronate has been reported to increase bone mineral density (BMD) and reduce fracture risk in women with osteoporosis." | 5.09 | Effects of alendronate on bone density in men with primary and secondary osteoporosis. ( Frauman, AG; Ho, YV; Seeman, E; Thomson, W, 2000) |
| "In a two-year double-blind trial, we studied the effect of 10 mg of alendronate or placebo, given daily, on bone mineral density in 241 men (age, 31 to 87 years; mean, 63) with osteoporosis." | 5.09 | Alendronate for the treatment of osteoporosis in men. ( Adami, S; Ettinger, M; Graham, J; Kendler, D; Lombardi, A; Lorenc, R; Miller, P; Orwoll, E; Pietschmann, P; Vandormael, K; Weber, K; Weiss, S, 2000) |
| " In this preliminary study, we evaluated the effect of an oral bisphosphonate (alendronate) on bone mass in children with diffuse connective tissue diseases." | 5.09 | Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children: a prospective multicenter study. ( Bardare, M; Bianchi, ML; Boncompagni, A; Brandi, ML; Cimaz, R; Corona, F; Falcini, F; Galbiati, E; Giuntini, D; Lepore, L; Luisetto, G; Picco, P; Zulian, F, 2000) |
| " Gastric ulcers developed in five out of 26 subjects given ASA, two out of 25 given alendronate, and none of 25 given placebo." | 5.09 | A randomized controlled trial to assess alendronate-associated injury of the upper gastrointestinal tract. ( Hunt, RH; James, C; Marshall, JK; Rainsford, KD, 2000) |
| "This was a multicenter, double-blind trial in which postmenopausal women with osteoporosis who had previously discontinued alendronate therapy because of a UGI adverse experience were randomized to daily treatment with either alendronate 10 mg or matching placebo (1:1 ratio) for 8 weeks." | 5.09 | Rechallenge of patients who had discontinued alendronate therapy because of upper gastrointestinal symptoms. ( Ettinger, MP; Licata, AA; Mako, B; Melton, ME; Miller, PD; Palmisano, JJ; Smith, ME; Wang, L; Woodson, G; Yates, SJ, 2000) |
| " Eighteen GHD patients with osteoporosis were randomized to continue their rhGH maintenance dose or to receive combination therapy with rhGH and alendronate for 12 months." | 5.09 | Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial. ( Biermasz, NR; Hamdy, NA; Janssen, YJ; Roelfsema, F, 2001) |
| "Treatment effects on bone quality and remodeling was assessed in postmenopausal women with osteoporosis treated with oral alendronate." | 5.08 | Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. ( Arlot, ME; Chavassieux, PM; Meunier, PJ; Reda, C; Wei, L; Yates, AJ, 1997) |
| "We have evaluated two commercial assays for serum bone specific alkaline phosphatase (bALP) as a marker of bone turnover in a group of 35 postmenopausal women with osteoporosis during their first year of treatment with the anti-resorptive drug, alendronate." | 5.08 | Clinical usefulness of bone alkaline phosphatase in osteoporosis. ( Fairney, A; Kerkhoff, F; Kyd, PA; Thomas, E; Vooght, KD, 1998) |
| "Minodronate has better clinical efficacy in the treatment of osteoporosis than other drugs (alendronate, risedronate, raloxifene, or eldecalcitol)." | 5.05 | Minodronate in the treatment of osteoporosis: A systematic review and meta-analysis. ( Chen, D; Huang, X; Jin, Z; Liu, Q; Ma, T; Ye, Z, 2020) |
| " The fractures were associated with 6 years of oral alendronate treatment immediately followed by subcutaneous denosumab therapy and later teriparatide therapy for osteoporosis." | 5.01 | Antiresorptive-associated spontaneous fractures of both tibiae, followed by an atypical femur fracture during the sequential treatment with alendronate, denosumab then teriparatide. ( Poole, K; Sano, H; Tan, J, 2019) |
| "Alendronate has been used to prevent or treat glucocorticoid-induced osteoporosis (GIO), data regarding its efficacy are inconsistent." | 4.98 | Effects of alendronate for treatment of glucocorticoid-induced osteoporosis: A meta-analysis of randomized controlled trials. ( Guo, JB; Luo, ZJ; Ma, T; Qin, SQ; Wang, X; Wang, YK; Zhang, YM; Zhu, C, 2018) |
| "Cohort studies reporting association between alendronate or bisphosphonate therapy including alendronate in patients with osteoporosis and risk of cancer were selected by two authors." | 4.91 | The carcinogenicity of alendronate in patients with osteoporosis: evidence from cohort studies. ( Chen, LX; Cheng, L; Feng, SQ; Li, YL; Ning, GZ; Wu, QL; Zhang, D; Zhang, TS; Zhou, ZR, 2015) |
| "Of the eight patients, who sustained atypical femoral fractures, six were on alendronate and two were on zoledronate therapy before the fractures." | 4.90 | Predictors of atypical femoral fractures during long term bisphosphonate therapy: a case series & review of literature. ( Bhadada, SK; Bhansali, A; Dhiman, V; Mithal, A; Muthukrishnan, J; Sharma, DC; Sridhar, S, 2014) |
| "Alendronate is a second generation bisphosphonate which has been widely used in medical practice for two decades to treat osteoporosis and prevent fragility fractures both in elderly people and in younger patients." | 4.90 | Alendronate: new formulations of an old and effective drug to improve adherence avoiding upper gastrointestinal side effects. ( Auriemma, R; Migliore, A; Neglia, C; Piscitelli, P, 2014) |
| "To assess the efficiency and safety of alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis (GIOP)." | 4.89 | [A Meta-analysis of alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis]. ( He, ZY; Tang, XL; Tian, JH; Yang, KH; Yang, L, 2013) |
| "To explore the incidence of atrial fibrillation (AF) and other cardiovascular endpoints in clinical trials of alendronate." | 4.88 | Alendronate and atrial fibrillation: a meta-analysis of randomized placebo-controlled clinical trials. ( Barrett-Connor, E; Bone, HG; de Papp, A; Hustad, CM; Liberman, UA; Papapoulos, S; Santora, AC; Swern, AS; Wang, H, 2012) |
| " The effects of 36 months' treatment with teriparatide and alendronate in women and men with glucocorticoid-induced osteoporosis were examined in an active-comparator randomized, double-blind, controlled trial." | 4.88 | [Efficacy of teriparatide in treatment of glucocorticoid-induced osteoporosis]. ( Soen, S, 2012) |
| "We have found 11 cases of BRONJ in our hospital: 4 women taking oral alendronate or risendronate for osteoporosis and 7 cancer patients treated with intravenous zolendronic acid." | 4.88 | [Bisphosphonate related osteonecrosis of the jaw and infection with Actinomyces]. ( Arranz Caso, JA; Dominguez-Mompello, JL; Flores Ballester, E; López Pizarro, V; Ngo Pombe, S; Restoy Lozano, A, 2012) |
| "Alendronate is commonly used in the treatment of osteoporosis and other bone diseases." | 4.88 | Laryngeal ulceration and hemoptysis secondary to inadvertent alendronate overdose: case report and review of the literature. ( Bee, J; Hanna, J; Sataloff, RT, 2012) |
| "Alendronate and risedronate have been the standard regimens in the pharmacological intervention of osteoporosis based on their accumulated evidences of fracture prevention." | 4.85 | [New development in bisphosphonate treatment. Fracture prevention by bisphosphonates]. ( Hosoi, T, 2009) |
| " In Japan, at present, only weekly alendronate and risedronate, both oral, have been approved for osteoporosis." | 4.85 | [New development in bisphosphonate treatment. Characteristics and effectiveness of intermittent bisphophonates]. ( Okazaki, R, 2009) |
| " We performed additional analyses of phase III clinical trial and compared the effect of minodronic acid hydrate on bone turnover markers with those of alendronate in primary osteoporosis." | 4.85 | [New development in bisphosphonate treatment. Review of effect on bone metabolism by minodronic acid in primary osteoporosis]. ( Fukunaga, M, 2009) |
| " Alendronate effects were also prospectively assessed using CT/FEM in 33 patients with postmenopausal osteoporosis who were treated with alendronate at a dose of 5 mg/day for 1 year." | 4.85 | [Prediction of vertebral strength using a CT based finite element method--clinical application in evaluation of the efficacy of alendronate]. ( Ohnishi, I, 2009) |
| "Three completed randomised-controlled studies examined the role of alendronate in patients with HIV and osteopenia or osteoporosis." | 4.84 | Interventions for the treatment of decreased bone mineral density associated with HIV infection. ( Lin, D; Rieder, MJ, 2007) |
| "The purpose of this paper is to discuss the effects of antifracture drugs on postmenopausal, male and glucocorticoid-induced osteoporosis, focussing on the efficacy and safety of alendronate and risedronate." | 4.84 | Effects of antifracture drugs in postmenopausal, male and glucocorticoid-induced osteoporosis--usefulness of alendronate and risedronate. ( Iwamoto, J; Sato, Y; Takeda, T, 2007) |
| "To investigate alendronate for treating osteoporosis in men." | 4.84 | Alendronate for the treatment of osteoporosis in men. ( Davison, KS; Olszynski, WP, 2008) |
| " Alendronate and risedronate are the two most widely used compounds in the treatment of postmenopausal osteoporosis." | 4.83 | Bisphosphonates. ( Botsis, D; Christodoulakos, G; Lambrinoudaki, I, 2006) |
| "For this literature review, published trials of antiresorptive therapy with the bisphosphonates risedronate and alendronate, the selective estrogen receptor modulator raloxifene and calcitonin were reviewed; hormone replacement therapy was not included as this modality is not indicated for treatment of osteoporosis." | 4.82 | Risk of fracture and treatment to prevent osteoporosis-related fracture in postmenopausal women. A review. ( Martens, MG, 2003) |
| "Alendronate, a bisphosphonate that potently inhibits bone resorption, has been shown in long-term clinical trials to be an effective treatment for osteoporosis, increasing bone mineral density and substantially reducing the incidence of both vertebral and nonvertebral fractures, including hip fractures, mostly using a daily dosage regimen." | 4.82 | Once weekly alendronate. ( Sambrook, P, 2003) |
| " We studied 1588 patients over the age of 50 yr who were started on cyclic etidronate (1119) or alendronate (469) in the CANDOO (Canadian Database for Osteoporosis and Osteopenia Patients) Study." | 4.82 | What predicts early fracture or bone loss on bisphosphonate therapy? ( Adachi, JD; Brown, JP; Goldsmith, CH; Hanley, DA; Ioannidis, G; Josse, R; Murray, T; Olszynski, WP; Papaioannou, A; Petrie, A; Sawka, AM; Sebaldt, RJ; Tenenhouse, A, 2003) |
| "In osteoporosis, both the bisphosphonate alendronate and parathyroid hormone (1-34) (PTH (1-34) ) have been shown to reduce the incidence of fractures." | 4.82 | Does the combination of alendronate and parathyroid hormone give a greater benefit than either agent alone in osteoporosis? ( Doggrell, SA, 2004) |
| "Alendronate/colecalciferol 70 mg/2800 IU, a once-weekly tablet containing the bisphosphonate alendronate and colecalciferol (the precursor of the biologically active form of vitamin D), has been approved for the treatment of osteoporosis in women and for increasing bone mass in men with osteoporosis." | 4.82 | Alendronate/colecalciferol. ( Curran, MP; Reynolds, NA, 2005) |
| "Alendronate and risedronate, the two oral bisphosphonates approved in the United States for preventing and treating osteoporosis, have never been compared in direct head-to-head trials, but they appear to have similar pharmacokinetics, drug interactions, adverse effect profiles, and efficacy." | 4.81 | Role of alendronate and risedronate in preventing and treating osteoporosis. ( Leonard, M; Licata, AA; Peters, ML, 2001) |
| "Alendronate has been approved as a first antiresorptive drug for treatment of osteoporosis in men." | 4.81 | Treatment of osteoporosis in men with fluoride alone or in combination with bisphosphonates. ( Ringe, JD; Rovati, LC, 2001) |
| " Four drugs, calcium, calcitonin, estrogen, and alendronate have been approved for marketing by the Food and Drug Administration for the treatment of osteoporosis." | 4.80 | Medical management of osteoporosis. Fracture prevention. ( Brunelli, MP; Einhorn, TA, 1998) |
| " The parent compound, etidronate, was first used in multicentered trials for the treatment of primary osteoporosis and showed some success in increasing bone density and perhaps controlling fracture rates." | 4.79 | Bisphosphonate therapy. ( Licata, AA, 1997) |
| " ISCRs for atrial fibrillation (AF), angina pectoris, arteriosclerosis coronary artery (ACA), cardiac arrhythmias, coronary artery disease (CAD), thromboembolic events (TE), ischaemic heart disease (IHD), torsade de pointes/QT prolongation (TDP) associated with alendronate, zoledronic acid and teriparatide use were extracted." | 4.31 | Cardiac adverse events in bisphosphonate and teriparatide users: An international pharmacovigilance study. ( Ebeling, PR; Nerlekar, N; Rodríguez, AJ, 2023) |
| "From January 2018 to January 2020, we recruited 165 female osteoporosis patients after percutaneous vertebroplasty who were assigned into sequential treatment of teriparatide followed by alendronate group (TPTD + ALN group) and alendronate alone group (ALN group)." | 4.31 | Sequential treatment of teriparatide and alendronate versus alendronate alone for elevation of bone mineral density and prevention of refracture after percutaneous vertebroplasty in osteoporosis: a prospective study. ( Han, W; Huang, K; Long, Y; Tan, J; Wang, M; Yang, D; Yi, W; Zeng, S; Zhu, S, 2023) |
| "A total of 82 postmenopausal women with primary osteoporosis receiving alendronate (70 mg administered orally per week) for one year were observed." | 4.31 | Influence of the Osteogenomic Profile in Response to Alendronate Therapy in Postmenopausal Women with Osteoporosis: A Retrospective Cohort Study. ( Gámez Nava, JI; Nuño Arana, I; Pérez Romero, M; Ruiz González, F; Trujillo Rangel, WÁ; Villagómez Vega, A, 2023) |
| "The study results indicate that women with osteoporosis initiated on gastro-resistant risedronate have a lower risk of fracture than those initiated on immediate release risedronate or alendronate." | 4.31 | Fracture risk in women with osteoporosis initiated on gastro-resistant risedronate versus immediate release risedronate or alendronate: a claims data analysis in the USA. ( Boolell, M; Cortet, B; Eisman, JA; Heroux, J; Ionescu-Ittu, R; Thomasius, F; Vekeman, F, 2023) |
| "A 66-year-old woman treated by alendronate for her osteoporosis was investigated." | 4.31 | Orbital myositis induced by alendronate: A case report. ( Biver, E; Caruso, A; Fayolle, D; Lefeuvre, L, 2023) |
| "Abaloparatide (ABL) significantly increases bone mineral density in men with osteoporosis similar to what was reported in postmenopausal women with osteoporosis." | 4.31 | Cost-Effectiveness of Sequential Abaloparatide/Alendronate in Men at High Risk of Fractures in the United States. ( Caminis, J; Hiligsmann, M; Mathew, J; Pearman, L; Reginster, JY; Silverman, SS; Singer, AJ; Wang, Y, 2023) |
| " This retrospective study assessed the comparability of postmenopausal women, treated with osteoporosis medications with various mechanisms of action such as denosumab (receptor activator of nuclear factor κB ligand [RANKL] inhibitor), zoledronic acid (bisphosphonate derivative), or oral bisphosphonates including alendronate." | 4.31 | Comparability of Osteoporosis Treatment Groups Among Female Medicare Beneficiaries in the United States. ( Arora, T; Balasubramanian, A; Bradbury, BD; Curtis, JR; Kim, M; Lin, TC; O'Kelly, J; Spangler, L; Stad, RK; Zhao, H, 2023) |
| "Atypical femur fracture (AFF) is a rare but catastrophic adverse event first reported in the long-term use of alendronate, one of the most commonly used drugs for osteoporosis currently." | 4.31 | Atypical femur fracture associated with common anti-osteoporosis drugs in FDA adverse event reporting system. ( Chen, Y; Huang, Y; Xiao, Y, 2023) |
| "To evaluate the cost-effectiveness of four anti-osteoporosis medications (denosumab, zoledronate, teriparatide, and alendronate) for postmenopausal osteoporotic women in mainland China, using a stratified treatment strategy recommended by the American Association of Clinical Endocrinologists and the American College of Endocrinology (AACE/ACE)." | 4.31 | Economic evaluation of four treatment strategies for postmenopausal patients with osteoporosis and a recent fracture in mainland China: a cost-effectiveness analysis. ( Li, YF; Luo, C; Qu, XL; Sheng, ZF; Tian, L; Wang, QY; Xu, LL; Yang, YY; Yue, C, 2023) |
| "Alendronate and estradiol are potential molecules for the treatment of osteoporosis but their use is limited by lower skin permeation and first-pass metabolism respectively." | 4.31 | Novel iontophoretic drug delivery of estradiol with alendronate for osteoporosis treatment. ( Chang, J; Li, S, 2023) |
| "Bisphosphonate medications, including alendronate, ibandronate and risedronate administered orally and zoledronate, administered intravenously, are commonly prescribed for the treatment of osteoporosis based on evidence that, correctly taken, bisphosphonates can improve bone strength and lead to a reduction in the risk of fragility fractures." | 4.31 | Clinicians' views of prescribing oral and intravenous bisphosphonates for osteoporosis: a qualitative study. ( Bastounis, A; Bishop, S; Corp, N; Gittoes, N; Griffin, J; Langley, T; Leonardi-Bee, J; Narayanasamy, MJ; Paskins, Z; Sahota, O, 2023) |
| " In this study, a novel nano-carrier with bone targeting was prepared by modifying mPEG-PLGA with alendronate (AL) before incorporation into astragaloside nano-micelles (AS-AL-mPEG-PLGA) to enhance the oral bioavailability, bone targeting and anti-osteoporosis effect of AS." | 4.12 | Alendronate modified mPEG-PLGA nano-micelle drug delivery system loaded with astragaloside has anti-osteoporotic effect in rats. ( He, H; Ma, L; Pan, W; Shi, C; Wang, W; Xi, Y; Xu, G; Xu, N, 2022) |
| "To investigate the changes to soft tissue biomechanics and insertional structure secondary to osteoporosis with and without an osteogenic therapy carrier (ie, modified alendronate)." | 4.12 | Modified Alendronate Mitigates Mechanical Degradation of the Rotator Cuff in an Osteoporotic Ovine Model. ( Bisazza, K; Easley, J; Gadomski, B; Johnson, JW; McGilvray, K; Nelson, B; Regan, D; Troyer, K; von Stade, D; Zhou, T, 2022) |
| "Our results showed that a combination of olive oil and Lepidium sativum had a beneficial therapeutic effect in the treatment of osteoporosis as compared to alendronate therapy." | 4.12 | The combination of olive oil and Lepidium sativum improves the deleterious effects resulting from dexamethasone-induced osteoporosis in rats. ( Abd Elmageed, ZY; Abdelraheim, MH; Badary, DM; Farrag, MMY; Galal, HA; Mohamed, NM; Sedeek, MI, 2022) |
| " Bisphosphonates are first-line treatment of osteoporosis, and we aimed to investigate whether the risk of developing type 2 diabetes was associated with prior use of alendronate." | 4.02 | Alendronate Use and Risk of Type 2 Diabetes: A Nationwide Danish Nested Case-Control Study. ( Al-Mashhadi, Z; Starup-Linde, J; Vestergaard, P; Viggers, R, 2021) |
| "Both teriparatide and alendronate were used in the treatment of osteoporosis after renal transplantation." | 4.02 | Analysis of the Efficacy and Safety of Teriparatide and Alendronate in the Treatment of Osteoporosis After Renal Transplantation. ( Deng, J; Lin, C; Qiu, Z; Wu, M; Zhang, Y, 2021) |
| " Icariin (ICA), one of the main flavonoids from plants of the Epimedium genus, has been shown to ameliorate osteoporosis and improve bone health in preclinical studies." | 4.02 | Icariin reduces bone loss in a Rankl-induced transgenic medaka (Oryzias latipes) model for osteoporosis. ( Ha, TTM; Lai, TT; Nguyen, HVM; Pham, CV; Pham, TT; Phuong, TT; To, TT; Tran, LD; Trinh, DC; Winkler, C, 2021) |
| "This study examined the effect of once-weekly parathyroid hormone (PTH) combined with alendronate upon osteoporotic fracture healing after long-term alendronate anti-osteoporosis therapy." | 4.02 | Once-weekly parathyroid hormone combined with ongoing long-term alendronate treatment promotes osteoporotic fracture healing in ovariectomized rats. ( Guan, Z; Jia, J; Leng, H; Song, C; Sun, T; Wang, H; Yuan, W; Zhang, C; Zhang, W; Zhu, J, 2021) |
| " This health economic analysis indicates that sequential romosozumab-to-alendronate can be a cost-effective treatment option for postmenopausal women with severe osteoporosis at high risk of fracture." | 4.02 | Cost-effectiveness of romosozumab for the treatment of postmenopausal women with severe osteoporosis at high risk of fracture in Sweden. ( Åkesson, KE; Berling, P; Borgström, F; Kanis, JA; Lindberg, I; Lorentzon, M; Söreskog, E; Ström, O; Willems, D, 2021) |
| "40 rats were randomly divided into 4 groups: control, untreated atherosclerosis group, atherosclerotic rats treated with carvedilol (10mg/kg/d) and atherosclerotic rats treated with alendronate sodium (10mg/kg/d)." | 4.02 | Matrix metalloproteinase 9 a potential major player connecting atherosclerosis and osteoporosis in high fat diet fed rats. ( Abdelgwad, M; Estaphan, S; Kamar, S; Mostafa, S; Rashed, L; Sabry, M, 2021) |
| "We believe that the continuous use of alendronate and risedronate for 10 years could be an option for the treatment of postmenopausal osteoporosis patients." | 3.96 | Effect of continuous long-term treatment for 10 years with bisphosphonate on Japanese osteoporosis patients. ( Iba, K; Sonoda, T; Takada, J; Yamashita, T, 2020) |
| "Alendronate sodium is used to reduce the risk of bone fracture in aged osteoporosis patients." | 3.96 | Transient increase in international normalized ratio (INR) and bleeding risk following Alendronate sodium in elderly patients on warfarin: Two case reports. ( Bian, P; Qian, S; Shi, L; Zhou, J, 2020) |
| "After 5 years of alendronate treatment, younger postmenopausal women (ages 50-70) with osteoporosis would likely benefit from a drug holiday, whereas older women (age 80) are likely to benefit from treatment for 10 years before a drug holiday." | 3.96 | Cost-effectiveness of five versus ten years of alendronate treatment prior to drug holiday for women with osteoporosis. ( Greenspan, SL; Nayak, S, 2020) |
| " Conservative treatment was conducted using a soft lumbosacral orthosis plus osteoporosis drugs, either weekly alendronate (bisphosphonate) or daily teriparatide." | 3.96 | Is Bone Nonunion, Vertebral Deformity, or Spinopelvic Malalignment the Best Therapeutic Target for Amelioration of Low Back Pain After Osteoporotic Vertebral Fracture? ( Hashimoto, T; Iwasaki, N; Iwata, A; Kanayama, M; Oha, F; Shimamura, Y; Takahata, M, 2020) |
| "The present study aimed to investigate the effects of phosphatidylserine liposomes (PSLs) and phosphatidylserine liposomes containing alendronate (AL-PSLs) on the improvement of methylprednisolone (MP) induced osteoporosis in a rat model." | 3.96 | Phosphatidylserine nanoliposomes inhibit glucocorticoid-induced osteoporosis: A potential combination therapy with alendronate. ( Alaeddini, M; Dehpour, AR; Doustimotlagh, AH; Eskandarynasab, M; Etemad-Moghadam, S; Goudarzi, R; Partoazar, A; Takzaree, N, 2020) |
| "Alendronate and raloxifene are among the most popular anti-osteoporosis medications." | 3.96 | Comparative safety and effectiveness of alendronate versus raloxifene in women with osteoporosis. ( Duke, J; Hripcsak, G; Huser, V; Jin, P; Kim, Y; Lambert, CG; Madigan, D; Park, H; Park, RW; Reich, C; Rijnbeek, PR; Ryan, PB; Schuemie, MJ; Shah, NH; Suchard, MA; Tian, Y; Van Zandt, M; Vashisht, R; Wu, Y; Yang, J; You, SC, 2020) |
| "A 76-year-old woman was treated with oral bisphosphonate, alendronate, for osteoporosis in an outpatient clinic." | 3.96 | Severe hypophosphataemia following oral bisphosphonate treatment in a patient with osteoporosis. ( Bagger, LW; Hansen, PKD; Nielsen, BR; Schwarz, P, 2020) |
| "e risedronate and alendronate in the treatment of osteoporosis." | 3.91 | Novel combinatorial transdermal drug delivery of alendronate with risedronate for the treatment of osteoporosis. ( Cui, P; Jia, B; Kong, F; Wang, D, 2019) |
| "This study evaluated the preventative effects of metformin (Met) on glucocorticoid (GC)-induced osteoporosis in a rat model, compared with alendronate (Aln)." | 3.91 | Preventative effects of metformin on glucocorticoid-induced osteoporosis in rats. ( Li, Q; Li, Y; Meng, Y; Shi, D; Zhang, H; Zhao, J; Zuo, L, 2019) |
| "The anti-catabolic bisphosphonate alendronate is considered as the first-line medical treatment in post-menopausal osteoporosis; but several side effects, including gastric mucosal injury, are associated with its use." | 3.91 | Melatonin supports alendronate in preserving bone matrix and prevents gastric inflammation in ovariectomized rats. ( Akkiprik, M; Çilingir-Kaya, ÖT; Ercan, F; Gürler, EB; Peker Eyüboglu, I; Reiter, RJ; Yegen, BÇ, 2019) |
| " Cohorts consisted of 92 355 individuals 50 years or older who were new users of denosumab (n = 4624) or alendronate (n = 87 731) from May 2010 to December 2017 after at least 1 year without an antiosteoporosis medication dispensing." | 3.91 | Comparison of Risk of Osteoporotic Fracture in Denosumab vs Alendronate Treatment Within 3 Years of Initiation. ( Ehrenstein, V; Heide-Jørgensen, U; Pedersen, AB; Prieto-Alhambra, D; Sørensen, HT, 2019) |
| "The aim of this study was to explore the effects of bone marrow mesenchymal stem cells (BMMSCs) and alendronate sodium (ALN) intervention on osteoporosis (OP)." | 3.91 | Comparison of bone biomechanical properties after bone marrow mesenchymal stem cell or alendronate treatment in an osteoporotic animal model. ( Ding, J; Kong, D; Li, Z; Piao, C, 2019) |
| "Alendronate and raloxifene, a bisphosphonate and a selective estrogen modulator, respectively, are established osteoporosis therapies." | 3.88 | Raloxifene but not alendronate can compensate the impaired osseointegration in osteoporotic rats. ( Faverani, LP; Freire, AR; Gruber, R; Hassumi, JS; Luvizuto, ER; Momesso, GAC; Okamoto, R; Polo, TOB; Prado, FB; Ramalho-Ferreira, G; Rossi, AC, 2018) |
| "The aim of this study was to assess changes in bone mineral density (BMD) and cadmium (Cd) levels in blood and urine in individuals living in a Cd-contaminated area according to the type of osteoporosis medication over a three-year period." | 3.88 | Changes in blood and urinary cadmium levels and bone mineral density according to osteoporosis medication in individuals with an increased cadmium body burden. ( Choi, BS; Eom, SY; Hong, SM; Kim, GB; Kim, H; Kim, YD; Park, CH; Park, JD; Yim, DH; Yu, SD, 2018) |
| "Nitrogen-containing bisphosphonates including alendronate (ALN) are the current first line antiresorptive drug in treating osteoporosis." | 3.88 | Alendronate induces osteoclast precursor apoptosis via peroxisomal dysfunction mediated ER stress. ( Bai, Y; Cheng, P; Ding, N; Dou, C; Gao, X; Li, J; Li, Z; Liu, C; Luo, F; Luo, K; Ma, Q; Mei, T; Xing, J; Xu, J; Yao, L, 2018) |
| "There are many challenges facing the use of alendronate sodium for the treatment of osteoporosis such as low bioavailability of 0." | 3.88 | Quality by design approach to optimize the formulation variables influencing the characteristics of biodegradable intramuscular in-situ gel loaded with alendronate sodium for osteoporosis. ( Hosny, KM; Rizg, WY, 2018) |
| "We performed a cross-sectional study to clarify the factors associated with the development of glucocorticoid-induced bone loss and osteoporosis in patients with childhood-onset rheumatic disease and to investigate the impact of the early use of alendronate." | 3.88 | Early use of alendronate as a protective factor against the development of glucocorticoid-induced bone loss in childhood-onset rheumatic diseases: a cross-sectional study. ( Arima, T; Chiba, K; Inoue, Y; Kohno, Y; Mitsunaga, K; Morita, Y; Nakano, T; Shimojo, N; Suzuki, S; Tomiita, M; Yamaguchi, KI; Yamaide, A; Yamaide, F; Yamamoto, T, 2018) |
| "Alendronate (ALD) is clinically indicated for the treatment of osteoporosis, but its therapeutic use has been marred by severe GIT adverse effects affecting quality of life in patients." | 3.88 | Positive effect of alendronate on bone turnover in ovariectomised rats' osteoporosis: comparison of transdermal lipid-based delivery with conventional oral administration. ( Boche, M; Pokharkar, V, 2018) |
| "Alendronate regulates the activity of osteoclasts and healing of osteoporosis." | 3.85 | Effects of alendronate on osteoporosis treatment and levels of related cytokines. ( Gao, GC; Liu, CT; Yuan, XJ, 2017) |
| " Our aims were to evaluate if the risk of surgically treated ONJ increases with longer or more compliant treatment with alendronate for osteoporosis and to identify risk factors for surgically treated ONJ." | 3.85 | Surgically treated osteonecrosis and osteomyelitis of the jaw and oral cavity in patients highly adherent to alendronate treatment: a nationwide user-only cohort study including over 60,000 alendronate users. ( Abrahamsen, B; Eastell, R; Eiken, PA; Prieto-Alhambra, D, 2017) |
| "By using an experimental model of dexamethasone-induced osteoporosis we investigated the effects of different therapeutic schemes combining sodium alendronate (SA) and simvastatin on bone mineral and protein composition, microstructural and mechanical remodeling." | 3.85 | Low Doses of Simvastatin Potentiate the Effect of Sodium Alendronate in Inhibiting Bone Resorption and Restore Microstructural and Mechanical Bone Properties in Glucocorticoid-Induced Osteoporosis. ( Gonçalves, RV; Maldonado, IRSC; Novaes, RD; Oliveira, MGA; Oliveira, TT; Pinto, AS; Sequetto, PL, 2017) |
| " Alendronate treatment increases bone mass and reduces the risk of fractures in patients with osteoporosis by suppressing bone resorption." | 3.85 | Risk of long-term infection-related death in clinical osteoporotic vertebral fractures: A hospital-based analysis. ( Chen, YC; Lin, WC, 2017) |
| "Alendronate (ALN) is a key therapeutic used to treat glucocorticoid-induced osteoporosis (GIOP), but may induce severe side effects." | 3.85 | Promotion effect of extracts from plastrum testudinis on alendronate against glucocorticoid-induced osteoporosis in rat spine. ( Huang, J; Jiang, X; Qiu, T; Ren, H; Shen, G; Tang, J; Yang, Z; Yao, Z; Yu, X; Zhang, Z; Zhao, W, 2017) |
| "Intravenous alendronate is an effective treatment for osteoporosis in SMID patients." | 3.85 | [The efficacy of intravenous alendronate for osteoporosis in patients with severe motor intellectual disabilities]. ( Aihara, M; Ishii, S; Kaga, Y; Kamiya, Y; Kanemura, H; Kuroda, I; Nakamura, K; Sugita, K, 2017) |
| "Using previous data from Taiwan and literature, we determined cost-effectiveness thresholds for prevention of osteoporotic fractures by alendronate with a Markov model, as well as using two other translational approaches." | 3.85 | Establishing and evaluating FRAX ( Chan, DC; Chang, CB; Lim, LC; Lin, KP; McCloskey, EV; Tsai, KS; Yang, RS, 2017) |
| " In the present study, we aimed to examine the efficacy and safety of alendronate (ALN) and teriparatide (TPD) for treating bone disorder in late-stage CKD with pre-existing secondary hyperparathyroidism using a rat model of CKD." | 3.85 | Efficacy and safety of osteoporosis medications in a rat model of late-stage chronic kidney disease accompanied by secondary hyperparathyroidism and hyperphosphatemia. ( Hamano, H; Hiratsuka, S; Iwasaki, N; Kameda, Y; Kanehira, Y; Kimura-Suda, H; Ota, M; Sato, D; Shimizu, T; Takahata, M, 2017) |
| "Combined therapy with BJD and alendronate can act synergistically against osteoporosis, which was possibly related to a reduced bone conversion rate through inhibiting bone resorption." | 3.85 | Mechanism of Bushen Jianpi decoction in preventing and treating osteoporosis caused by aromatase inhibitors in breast cancer treatment. ( Guo, W; Huang, XH; Liang, RH; Su, L; Wang, CJ, 2017) |
| "We conducted a retrospective study in our facility for comparing the pharmacological effects of teriparatide and alendronate on 32 NOFH patients diagnosed with osteoporosis." | 3.85 | Efficacy of teriparatide in the treatment of nontraumatic osteonecrosis of the femoral head: a retrospective comparative study with alendronate. ( Arai, R; Asano, T; Inoue, M; Irie, T; Iwasaki, N; Kondo, E; Konno, T; Onodera, T; Takahashi, D; Terkawi, MA, 2017) |
| "A retrospective study was performed to evaluate the outcome of alendronate treatment for 7 years among Japanese men with osteoporosis or osteopenia and clinical risk factors for fractures." | 3.83 | Experience with alendronate treatment for 7 years among Japanese men with osteoporosis or osteopenia and clinical risk factors for fractures. ( Iwamoto, J; Uzawa, M, 2016) |
| "Retrospective single-center cohort study of osteoporosis patients treated with alendronate or risedronate for at least 2 years and then discontinued their bisphosphonate for a drug holiday." | 3.83 | Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday. ( Adams-Huet, B; Maalouf, NM; Poindexter, JR; Xu, LH, 2016) |
| " The patient had been followed-up for 15 years because of osteoporosis and administrated alendronate and ibandronate treatment for 10 years." | 3.83 | Atypical femoral fracture following zoledronic acid treatment. ( Ataoğlu, B; Berkay, AF; Eren, TK; Kaptan, AY; Yapar, AE, 2016) |
| " Assuming a willingness to pay (WTP) of €32,000 per quality-adjusted life years (QALYs), treatment with generic alendronate is cost effective for men and women aged 50 years or more, with 10-year probabilities for major osteoporotic fractures and hip above 8." | 3.83 | Cost-Effectiveness of Intervention Thresholds for the Treatment of Osteoporosis Based on FRAX(®) in Portugal. ( Borgström, F; da Silva, JA; Kanis, JA; Lourenço, Ó; Marques, A; Ortsäter, G, 2016) |
| "Treatment of osteoporosis with alendronate sodium has several challenges." | 3.83 | Alendronate Sodium as Enteric Coated Solid Lipid Nanoparticles; Preparation, Optimization, and In Vivo Evaluation to Enhance Its Oral Bioavailability. ( Hosny, KM, 2016) |
| " To determine the skeletal safety and efficacy of long term (≥10 years) alendronate use in patients with osteoporosis." | 3.83 | Risk of hip, subtrochanteric, and femoral shaft fractures among mid and long term users of alendronate: nationwide cohort and nested case-control study. ( Abrahamsen, B; Eastell, R; Eiken, P; Prieto-Alhambra, D, 2016) |
| " We report on a 35-year-old female who was diagnosed with TRAPS, after finding the V95M mutation on the TNFRSF1A gene; who was treated in order with etanercept, anakinra, and canakinumab (150 mg/every 8 weeks by subcutaneous injection, then increased to 150 mg every 4 weeks); and who started therapy with oral alendronate (70 mg/weekly) to control her osteoporosis." | 3.81 | Tumor necrosis factor receptor-associated periodic syndrome managed with the couple canakinumab-alendronate. ( Cantarini, L; Frediani, B; Iannone, F; Lopalco, G; Rigante, D; Vitale, A, 2015) |
| "Until definite evidence is available, alendronate treatment in patients with osteoporosis is not now prohibited by the healthcare authorities, probably because its beneficial influence outweighs the adverse effects." | 3.81 | Low-energy femoral shaft fractures after long-term alendronate therapy: report of seven cases. ( Ballas, EG; Karamanis, E; Kokkalis, ZT; Koulalis, D; Mastrokalos, D; Mavrogenis, AF; Mitsiokapa, E; Papagelopoulos, PJ, 2015) |
| " We retrospectively reviewed the medical records of 45 consecutive AFFs in 34 Japanese patients who had received oral bisphosphonates (alendronate or risedronate) for osteoporosis before AFF and had been followed for ≥12 months (range, 12-90 months)." | 3.81 | Healing of bisphosphonate-associated atypical femoral fractures in patients with osteoporosis: a comparison between treatment with and without teriparatide. ( Aizawa, T; Ando, S; Aonuma, H; Kasukawa, Y; Maekawa, S; Miyakoshi, N; Sasaki, H; Sasaki, S; Shimada, Y; Tsuchie, H, 2015) |
| "In an effort to elucidate the effect of high-frequency (HF) loading on bone and to optimize its potential for treatment osteoporosis, this study aimed to investigate the effect of HF loading via whole body vibration (WBV), alone or in association with bisphosphonate treatment (alendronate--ALN), on the micro-architecture of ovariectomy (OVX)-induced compromised bone." | 3.81 | Single and combined effect of high-frequency loading and bisphosphonate treatment on the bone micro-architecture of ovariectomized rats. ( Camargos, GV; Chatterjee, M; Duyck, J; Faot, F; Hatori, K; Sasaki, K; Vandamme, K, 2015) |
| "Little is known of the effect of alendronate and risedronate on osteoporotic fractures after discontinuation of therapy." | 3.81 | Residual effect after oral bisphosphonate treatment and healthy adherer effects--the Swedish Adherence Register Analysis (SARA). ( Garellick, G; Landfeldt, E; Ström, O, 2015) |
| " Alendronate, risedronate, zoledronate and denosumab have been shown to prevent spine, nonspine and hip fractures; in addition, teriparatide and strontium ranelate prevent both spine and nonspine fractures, and raloxifene and ibandronate prevent spine fractures." | 3.81 | Efficacy, effectiveness and side effects of medications used to prevent fractures. ( Reid, IR, 2015) |
| "639 Chinese postmenopausal women with osteoporosis or osteopenia received alendronate treatment." | 3.81 | SOST polymorphisms and response to alendronate treatment in postmenopausal Chinese women with osteoporosis. ( Chen, DC; Jiang, Y; Li, M; Liao, EY; Liu, J; Wang, O; Wu, W; Xia, WB; Xing, XP; Xu, L; Xu, XJ; Zhang, ZL; Zhou, PR, 2015) |
| "This study provides evidence that zoledronate is more effective than alendronate in treating patients with osteoporosis and with no gastrointestinal (GI) serious side effects." | 3.81 | Favorable therapeutic response of osteoporosis patients to treatment with intravenous zoledronate compared with oral alendronate. ( Akanle, OA; Al-Adhoubi, NK; Al-Bogami, MM; Alkhorayef, MA; Bystrom, J; Jawad, AS; Mageed, RA, 2015) |
| "to describe the efficacy and safety of the off-label use of alendronate in the treatment of osteoporosis in children and adolescents." | 3.81 | Efficacy and safety of alendronic acid in the treatment of osteoporosis in children. ( Áreas Del Águila, VL; Encinas Barrios, C; Fernández Marchante, AI; Franco Sereno, MT; Martín Siguero, A; Pérez Serrano, R, 2015) |
| "To provide information on ONJ in Asian populations, this study compares the incidence and risk of ONJ between patients receiving alendronate and those receiving non-bisphosphonate osteoporosis medications in Taiwan." | 3.80 | Incidence and risk of osteonecrosis of the jaw among the Taiwan osteoporosis population. ( Kao Yang, YH; Lin, SJ; Lin, TC; Yang, CY, 2014) |
| "Alendronate, a nitrogen-containing bisphosphonate, is well established as a treatment for osteoporosis through regulation of osteoclast activity." | 3.80 | Differential impact of the bisphosphonate alendronate on undifferentiated and terminally differentiated human myogenic cells. ( Harada, A; Hashimoto, N; Kiyono, T; Nagata, Y; Shiomi, K, 2014) |
| "Patients receiving alendronate for osteoporosis carry a significantly higher risk of developing upper gastrointestinal bleeding (GIB) and lower GIB (hazard ratio 1." | 3.80 | Alendronate, a bisphosphonate, increased upper and lower gastrointestinal bleeding: risk factor analysis from a nationwide population-based study. ( Hou, MC; Hu, HY; Lee, FY; Lin, HC; Luo, JC; Peng, YL, 2014) |
| "This retrospective analysis found that the incidence of VTE in Taiwanese patients with osteoporosis was low, and the risk of VTE was similar across alendronate, raloxifene, and calcitonin recipients in patients with osteoporotic fractures who were new to osteoporosis therapy." | 3.80 | Incidence and risk of venous thromboembolism among Taiwan osteoporotic fracture population under osteoporosis pharmacological treatments. ( Lee, CH; Lin, SJ; Lin, TC; Yang, CY; Yang, YH, 2014) |
| "This study aimed to explore the possible association between osteonecrosis of the jaws (ONJ) and oral alendronate or raloxifene used for osteoporosis and to estimate its absolute and attributable risks in the Taiwanese population." | 3.80 | The risk of osteonecrosis of the jaws in Taiwanese osteoporotic patients treated with oral alendronate or raloxifene. ( Chien, JY; Chiu, WY; Juang, JM; Lee, JJ; Tsai, KS; Yang, WS, 2014) |
| "Six hundred and thirty nine Chinese postmenopausal women with osteopenia or osteoporosis were included and received alendronate treatment." | 3.80 | LRP5 polymorphisms and response to alendronate treatment in Chinese postmenopausal women with osteoporosis. ( Chen, DC; Li, M; Liao, EY; Liu, HJ; Liu, J; Wu, W; Xia, WB; Xing, XP; Xu, L; Zhang, ZL; Zhou, PR, 2014) |
| " We document one case of BRONJ associated with oral administration of methotrexate, a known immunosuppressive drug used to treat rheumatoid arthritis." | 3.80 | Bisphosphonate-associated osteonecrosis of jaw reoccurrence after methotrexate therapy: a case report. ( Adams, L; Alsalleeh, F; Bavitz, B; Keippel, J, 2014) |
| "Alendronate sodium (Fosamax) is most widely used for the prevention and treatment of osteoporosis." | 3.80 | An NMR metabolomic study on the effect of alendronate in ovariectomized mice. ( Chen, SY; Chiang, SS; Kao, JP; Mau, JL; Mishchuk, DO; Slupsky, CM; Yang, CC; Yu, HT, 2014) |
| "The patient was a 72-year-old woman with osteoporosis who had received 35 mg alendronate sodium hydrate once every week for 6 years." | 3.80 | Bisphosphonate-related osteonecrosis of the palatal torus. ( Kaneko, K; Takahashi, H, 2014) |
| "For alendronate, the adjusted risk of major osteoporotic fractures was significantly reduced (OR 0." | 3.79 | Association between refill compliance to oral bisphosphonate treatment, incident fractures, and health care costs--an analysis using national health databases. ( Abrahamsen, B; Hansen, C; Olsen, KR, 2013) |
| "Alendronate sodium (ALS) is the most common drug used for the treatment of osteoporosis." | 3.79 | Enteric-coated alendronate sodium nanoliposomes: a novel formula to overcome barriers for the treatment of osteoporosis. ( Ahmed, OA; Al-Abdali, RT; Hosny, KM, 2013) |
| "To explore the compliance in elderly male with osteoporosis treated with oral alendronate and analyze the factors which affect the therapeutic compliance." | 3.79 | [The compliance in elderly male with osteoporosis treated with oral alendronate]. ( Fang, FS; Hou, HR; Jiang, Y; Li, CL; Liu, MY; Pei, Y; Pi, HY; Yan, YF, 2013) |
| " We used health registers to identify predictors of new major osteoporotic fractures in patients adhering to alendronate." | 3.79 | Characteristics of patients who suffer major osteoporotic fractures despite adhering to alendronate treatment: a National Prescription registry study. ( Abrahamsen, B; Eastell, R; Eiken, PA; Rubin, KH, 2013) |
| " The objective of this study was to investigate the association between AGS and persistence with alendronate treatment of primary osteoporosis in Sweden." | 3.78 | The association between automatic generic substitution and treatment persistence with oral bisphosphonates. ( Landfeldt, E; Ström, O, 2012) |
| "Alendronate is a widely used bisphosphonate in the treatment of osteoporosis." | 3.78 | Nephrotic syndrome after oral bisphosphonate (alendronate) administration in a patient with osteoporosis. ( Kara, E; Ozagari, A; Taninmis, H; Unsal, A; Yilmaz, M, 2012) |
| "Base-case analysis results showed that at annual alendronate costs of $200 or less, osteoporosis screening followed by treatment was cost-saving, resulting in lower total costs than no screening as well as more QALYs (10." | 3.78 | Impact of generic alendronate cost on the cost-effectiveness of osteoporosis screening and treatment. ( Greenspan, SL; Nayak, S; Roberts, MS, 2012) |
| "Alendronate is a nitrogen-containing bisphosphonate that is widely used for the treatment of osteoporosis." | 3.78 | Development of a novel self-dissolving microneedle array of alendronate, a nitrogen-containing bisphosphonate: evaluation of transdermal absorption, safety, and pharmacological effects after application in rats. ( Hayashi, R; Hirai, Y; Hitomi, K; Kamiyama, F; Katsumi, H; Kusamori, K; Liu, S; Quan, YS; Sakane, T; Tanaka, Y; Yamamoto, A, 2012) |
| "The objective of this study was to analyze the comparative gastrointestinal tolerability of proprietary versus generic alendronate in patients treated for primary osteoporosis." | 3.78 | The comparative gastrointestinal tolerability of proprietary versus generic alendronate in patients treated for primary osteoporosis. ( Landfeldt, E; Ström, O, 2012) |
| " The patient suffered from osteoporosis and had been treated with oral alendronate sodium in the past." | 3.78 | The importance of a thorough medical and pharmacological history before dental implant placement. ( Abu-Tair, J; Elad, S; Yarom, N; Zadik, Y; Zaharia, B, 2012) |
| "Controversy still exists regarding whether alendronate (ALN) use increases the risk of esophageal cancer or breast cancer." | 3.78 | A higher dosage of oral alendronate will increase the subsequent cancer risk of osteoporosis patients in Taiwan: a population-based cohort study. ( Chang, SN; Kao, CH; Lee, WY; Liang, JA; Lin, MC; Muo, CH; Sun, LM; Sung, FC, 2012) |
| "Before the drugs were started, patients later initiating alendronate or raloxifene had fewer strokes than the controls." | 3.77 | Stroke in relation to use of raloxifene and other drugs against osteoporosis. ( Mosekilde, L; Pinholt, EM; Rejnmark, L; Schwartz, K; Vestergaard, P, 2011) |
| "twenty-three ONJ patients had taken alendronate for osteoporosis treatment, and the s-CTX testing results were low levels of 10-192 pg/ml (mean: 93." | 3.77 | Retrospective study of two biochemical markers for the risk assessment of oral bisphosphonate-related osteonecrosis of the jaws: can they be utilized as risk markers? ( Chung, DJ; Kim, DY; Kwon, YD; Ohe, JY; Park, YD, 2011) |
| "Efficacy and safety of a new combination package containing 4 or 12 self-explanatory one-week blisters, each with one tablet of 70 mg alendronate (CAS 260055-05-8) and 7 capsules of 1 microg alfacalcidol (CAS 41294-56-8) (Tevabone) on muscle power, muscle function, balance and back pain was investigated in an open, multi-centered, uncontrolled, prospective study on a cohort of elderly patients with a high risk of falls and fractures." | 3.77 | Risk reduction of falls and fractures, reduction of back pain and safety in elderly high risk patients receiving combined therapy with alfacalcidol and alendronate: a prospective study. ( Ringe, JD; Schacht, E, 2011) |
| "To describe the distribution of serum 25-hydroxyvitamin D (25-[OH] D) in Canadian men and postmenopausal women with osteoporosis taking 400 IU or less of vitamin D daily and to evaluate the safety, tolerability, and impact of vitamin D(3) supplementation 400 IU daily taken concurrently with alendronate sodium 70 mg weekly." | 3.77 | Vitamin D status and response to daily 400 IU vitamin D3 and weekly alendronate 70 mg in men and women with osteoporosis. ( Chouha, F; Djandji, M; Hanley, DA; Karaplis, AC; Sampalis, JS, 2011) |
| "Bisphosphonates (BP), especially alendronate and risedronate, are the drugs most commonly used for osteoporosis treatment, being incorporated into the skeleton where they inhibit bone resorption and are thereafter slowly released during bone turnover." | 3.77 | Prolonged bisphosphonate release after treatment in women with osteoporosis. Relationship with bone turnover. ( Guañabens, N; Martínez-Ferrer, A; Monegal, A; Olivares, V; Peris, P; Reyes, R; Torra, M, 2011) |
| "Systemic application of Alendronate sodium in osteoporosis rabbits can improve the bone-implant osseointegration significantly." | 3.77 | [Effect of alendronate sodium on torque-out testing on implant-bone interfaces in estrogen-deficient rabbits with alendronate systemic administration]. ( Fu, L; Gong, L; Li, CY; Li, YQ; Wang, L; Zhou, YM, 2011) |
| "The purpose of this research was to study the effect of Alendronate on bone mineral density (BMD) and markers of bone turnover in male and female Wistar rats and senescence-accelerated OXYS rats with early development of osteoporosis." | 3.77 | [Effect of alendronate on bone tissue status of senescence-accelerated OXYS rats]. ( Kolosova, NG; Muraleva, NA; Sadovoĭ, MA, 2011) |
| "We determined serum ionic fluoride (SIF) concentrations before and after treatment of osteoporosis with alendronate to clarify whether SIF concentrations directly reflect a change in bone metabolism." | 3.77 | Serum ionic fluoride concentrations are significantly decreased after treatment with alendronate in patients with osteoporosis. ( Itai, K; Muro-oka, G; Sato, H; Tanno, K, 2011) |
| "We aimed to investigate the risk of AF, stroke, or acute myocardial infarction (AMI) associated with the use of the bisphosphonates alendronate and raloxifene in patients with osteoporosis." | 3.77 | Alendronate and raloxifene use related to cardiovascular diseases: differentiation by different dosing regimens of alendronate. ( Hsieh, CF; Huang, WF; Lu, PY; Tsai, YW, 2011) |
| "The goal of this study was to evaluate the benefits of alendronate in preventing rehospitalization due to hip fractures and whether its use increases risk of hospitalization for atypical diaphyseal femoral fractures in Taiwan." | 3.77 | Hip and subtrochanteric or diaphyseal femoral fractures in alendronate users: a 10-year, nationwide retrospective cohort study in Taiwanese women. ( Chen, LK; Chen, YM; Hsiao, FY; Huang, WF; Kao, YH; Tsai, YW; Wen, YW, 2011) |
| "One of the patients was treated with alendronate therapy in concern of her risk factors for osteoporosis (her previous a hysterectomy with bilateral oophorectomy) with unsubstantiated evidence of her pretreatment, bone-mineral-density measurements (BMD), for a 10-year prior episode of left prodromal thigh pain and an insufficiency fracture at 8 days post experiencing the pain." | 3.77 | Unusual subtrochanteric femoral insufficiency fractures associated with the prolonged use of alendronate and risedronate: a report of two cases. ( Angthong, C; Angthong, W, 2011) |
| "The aim of this study was to evaluate a possible role of microcracks in the pathogenesis of bisphosphonate-related osteonecrosis of the jaw (ONJ) and to discuss an etiological model." | 3.76 | Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings. ( Eufinger, H; Hoefert, S; Schmitz, I; Tannapfel, A, 2010) |
| " Six-month-old Sprague-Dawley OVX rats (n=60; 12/group) were administered vehicle, risedronate, alendronate, or zoledronate at doses used clinically for treatment of post-menopausal osteoporosis." | 3.76 | Bisphosphonates do not inhibit periosteal bone formation in estrogen deficient animals and allow enhanced bone modeling in response to mechanical loading. ( Allen, MR; Burr, DB; Feher, A; Fuchs, RK; Koivunemi, A; Koivunemi, M; Phipps, RJ; Reinwald, S, 2010) |
| "A pre-existing model of osteoporosis was used to predict numbers of fractures, quality-adjusted life-years (QALYs), and costs associated with risedronate or alendronate treatment in post-menopausal (PMO) women aged > or =65 years with a previous vertebral fracture, within the Italian National Health System (NHS)." | 3.76 | Risedronate versus alendronate in older patients with osteoporosis at high risk of fracture: an Italian cost-effectiveness analysis. ( Berto, P; Lopatriello, S; Maggi, S; Noale, M, 2010) |
| "No BMD test or alendronate therapy, a BMD test followed by selective alendronate therapy for patients with osteoporosis, or universal alendronate therapy without a BMD test." | 3.76 | Cost-effectiveness of fracture prevention in men who receive androgen deprivation therapy for localized prostate cancer. ( Elkin, EB; Girotra, M; Ito, K; Morris, MJ, 2010) |
| "A paradoxical association between long-term alendronate therapy and low-energy subtrochanteric femoral fractures has been recently recognized." | 3.76 | Subtrochanteric femoral fractures in patients receiving long-term alendronate therapy: imaging features. ( Capeci, C; Chan, K; Chan, SS; Rosenberg, ZS, 2010) |
| "In premenopausal women with MDD, reduced daily adiponectin production may increase the risk of diabetes mellitus, and elevated leptin may contribute to osteoporosis." | 3.76 | Low 24-hour adiponectin and high nocturnal leptin concentrations in a case-control study of community-dwelling premenopausal women with major depressive disorder: the Premenopausal, Osteopenia/Osteoporosis, Women, Alendronate, Depression (POWER) study. ( Ahima, RS; Blackman, MR; Cizza, G; Duan, Z; Eskandari, F; Nguyen, VT; Reynolds, JC; Wright, EC, 2010) |
| "Alendronate is a well-established treatment for osteoporosis and suppresses bone resorption by a direct effect on osteoclasts and their precursors." | 3.76 | The effect of the alendronate on OPG/RANKL system in differentiated primary human osteoblasts. ( Álvarez, L; Combalia, A; Enjuanes, A; Guañabens, N; Martínez de Osaba, MJ; Monegal, A; Ozalla, D; Pares, A; Peris, P; Ruiz-Gaspà, S, 2010) |
| "This population-based study aimed to compare direct health care costs related to the pharmacological treatment of osteoporosis and to the management of osteoporotic fractures among compliant and noncompliant users of alendronate and risedronate." | 3.75 | Comparison of direct health care costs related to the pharmacological treatment of osteoporosis and to the management of osteoporotic fractures among compliant and noncompliant users of alendronate and risedronate: a population-based study. ( Blouin, J; Dragomir, A; Fernandes, JC; Fredette, M; Perreault, S; Ste-Marie, LG, 2009) |
| "Five years of alendronate therapy for those diagnosed with osteoporosis." | 3.75 | Using the osteoporosis self-assessment tool for referring older men for bone densitometry: a decision analysis. ( Charlson, ME; Hollenberg, JP; Ito, K, 2009) |
| "Several recent medical articles have described multiple cases of unusual low-impact subtrochanteric stress fractures or completed fractures of the femur in patients who have been on the bisphosphonate alendronate for several years for osteoporosis or osteopenia." | 3.75 | Bisphosphonates and low-impact femoral fractures: current evidence on alendronate-fracture risk. ( Schneider, JP, 2009) |
| " At the end of the osteoporosis development period, MP rats were randomized to receive: vehicle (n= 7), genistein aglycone (5 mg x kg(-1) s." | 3.75 | Genistein aglycone reverses glucocorticoid-induced osteoporosis and increases bone breaking strength in rats: a comparative study with alendronate. ( Altavilla, D; Armbruster, MA; Bitto, A; Burnett, BP; Di Stefano, V; Irrera, N; Levy, RM; Marini, H; Minutoli, L; Polito, F; Squadrito, F, 2009) |
| "Treatment with once-weekly 70 mg alendronate significantly improved the BMD at the lumbar spine and femoral neck in patients with prostate cancer with severe osteopenia or osteoporosis and on ADT, and significantly decreased the risk of femoral neck fracture." | 3.75 | Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis. ( Cecchini, L; Encabo, G; Morote, J; Orsola, A; Placer, J; Planas, J; Raventós, C; Salvador, C; Trilla, E, 2009) |
| " Then 5 rats were confirmed cases of osteoporosis and the remaining 60 were randomly divided into 4 groups 15 each: (1) control group with NS 8 ml x kg(-1) x w(-1); (2) alendronate group with alendronate 40 mg x kg(-1) x w(-1); (3) qianggu group with qianggu capsules 90 mg x kg(-1) x d(-1); (4) co-medicated group with alendronate 40 mg x kg(-1) x w(-1) and qianggu capsules 90 mg x kg(-1) x d(-1)." | 3.75 | [Skeletal biomechanical effectiveness of retinoic acid on induction of osteoporotic rats treated by alendronate and qianggu capsules]. ( Chen, H; Chen, L; Chen, LW; Guo, XS; Qi, DS; Xu, HZ; Zhang, GY, 2009) |
| " To clarify this, we investigated the effects of genistein compared with alendronate, raloxifene and oestradiol in an animal model of established osteoporosis." | 3.74 | Effects of genistein aglycone in osteoporotic, ovariectomized rats: a comparison with alendronate, raloxifene and oestradiol. ( Altavilla, D; Antoci, S; Armbruster, MA; Bitto, A; Burnett, BP; Di Stefano, V; Granese, R; Irrera, N; Levy, RM; Marini, H; Minutoli, L; Polito, F; Squadrito, F, 2008) |
| "We studied the therapeutic effects of one-year alendronate treatment in three cases (two males and one female) of osteoporosis with parietal thinning of skull." | 3.74 | Therapeutic effects of one-year alendronate treatment in three cases of osteoporosis with parietal thinning of skull. ( Hayashi, F; Takao, S; Takata, S; Yasui, N; Yoshida, S, 2008) |
| "We studied 26,636 new users of an osteoporosis medication (alendronate, calcitonin, estrogen, raloxifene, or risedronate) who were age 65 or older and had an extended lapse in refill compliance, defined as a period of at least 60 days after the completion of one prescription in which no refill for any osteoporosis medication was obtained." | 3.74 | Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance. ( Arnold, M; Avorn, J; Brookhart, MA; Finkelstein, JS; Katz, JN; Mogun, H; Patrick, AR; Polinski, JM; Solmon, DH, 2007) |
| "A simulation model adopting a health system perspective showed population-based screening with DXA, followed by alendronate treatment of persons with osteoporosis, or with anamnestic fracture and osteopenia, to be cost-effective in Swiss postmenopausal women from age 70, but not in men." | 3.74 | Simulation-based cost-utility analysis of population screening-based alendronate use in Switzerland. ( Lippuner, K; Schwenkglenks, M, 2007) |
| "Three boys with muscular dystrophy with known osteoporosis were each treated for 1 yr with weekly alendronate and daily calcium and vitamin D." | 3.74 | Use of weekly alendronate to treat osteoporosis in boys with muscular dystrophy. ( Apkon, S; Coll, J, 2008) |
| "To evaluate the cost-effectiveness of a fixed dose combination of alendronate 70 mg and cholecalciferol 2800 IU (alendronate/vitamin D3; Fosavance) versus no treatment, alendronate with dietary vitamin D supplements and ibandronate in the treatment of osteoporosis in the UK and Netherlands." | 3.74 | Cost-effectiveness of a fixed dose combination of alendronate and cholecalciferol in the treatment and prevention of osteoporosis in the United Kingdom and The Netherlands. ( Bergman, G; Gaugris, S; Jansen, JP; Sen, SS, 2008) |
| "Our objective was to investigate the efficacy of intravenous alendronate for the treatment of glucocorticoid-induced osteoporosis (GIOP) in children with autoimmune diseases." | 3.74 | Efficacy of intravenous alendronate for the treatment of glucocorticoid-induced osteoporosis in children with autoimmune diseases. ( Arima, T; Inoue, Y; Kohno, Y; Minagawa, M; Shimojo, N; Suzuki, S; Tomiita, M, 2008) |
| "Patients were eligible for inclusion if they had osteoporosis or osteopenia and demonstrated a decline in BMD during the preceding year while taking stable doses of alendronate or risedronate, plus supplemental calcium and vitamin D." | 3.74 | Increase in bone mass after correction of vitamin D insufficiency in bisphosphonate-treated patients. ( Adams, JS; Geller, JL; Hu, B; Mirocha, J; Reed, S, 2008) |
| "Alendronate, an inhibitor of bone resorption, is widely used in osteoporosis treatment." | 3.73 | Severely suppressed bone turnover: a potential complication of alendronate therapy. ( Gottschalk, FA; Maalouf, N; Odvina, CV; Pak, CY; Rao, DS; Zerwekh, JE, 2005) |
| "Intravenous pamidronate is frequently used for the treatment of osteoporosis in patients who cannot tolerate oral bisphosphonates." | 3.73 | The effect of intravenous pamidronate versus oral alendronate on bone mineral density in patients with osteoporosis. ( Bultink, IE; Dijkmans, BA; Lems, WF; Vis, M, 2005) |
| " The question arises whether the absorption of alendronate, and thus its bioavailability, is further altered by the local inflammatory process in patients with Crohn's disease, thereby potentially affecting clinical outcome when used in the treatment of osteoporosis." | 3.73 | Absorption of the oral bisphosphonate alendronate in osteoporotic patients with Crohn's disease. ( Bänffer, D; Cremers, SC; den Hartigh, J; Hamdy, NA; Papapoulos, SE; van Hogezand, R; Vermeij, P, 2005) |
| "Alendronate and calcitonin are antiresorptive drugs that were used for the treatment of postmenopausal osteoporosis and were shown to increase bone mineral density (BMD)." | 3.73 | Effects of alendronate and calcitonin on bone mineral density in postmenopausal osteoporotic women. An observational study. ( Hejdova, M; Kucera, Z; Palicka, V; Vlcek, J, 2005) |
| "Osteoporosis in men was not recognized as a major health problem until recently, and increased research in this area resulted in the approval of alendronate for the treatment of osteoporosis in men at the beginning of this decade." | 3.73 | Effect of alendronate on bone mineral density in Puerto Rican males with osteoporosis. ( Guzmán, J; Martinó, A; Ramírez, M; Rosa, J, 2005) |
| "Treatment with alendronate was associated with significantly greater improvements in lumbar spine BMD within one year in breast cancer survivors when compared with treatment with cyclic etidronate or calcium and vitamin D." | 3.73 | Are oral bisphosphonates effective in improving lumbar bone mineral density in breast cancer survivors with osteopenia or osteoporosis? ( Adachi, JD; Boulos, P; Brown, JP; Goldsmith, CH; Hanley, DA; Ioannidis, G; Josse, RG; Kouroukis, T; Murray, TM; Olszynski, WP; Papaioannou, A; Petrie, A; Sawka, AM; Sebaldt, RJ; Tenenhouse, A; Thabane, L, 2005) |
| " The aim of this study was to investigate the action of alendronate on the IGF-I-deficient bones of adult patients with LS and osteoporosis, as determined by dual X-ray absorptiometry ." | 3.73 | Effect of alendronate on bone mineral density in adult patients with Laron syndrome (primary growth hormone insensitivity). ( Benbassat, CA; Eshed, V; Laron, Z, 2006) |
| "Alendronate derivatives were evaluated as potential prodrugs for the osteoporosis drug alendronate sodium in an attempt to enhance the systemic exposure after oral administration." | 3.73 | Synthesis and study of alendronate derivatives as potential prodrugs of alendronate sodium for the treatment of low bone density and osteoporosis. ( Alani, LL; Algayer, K; Ghosh, S; Hale, JJ; Kesisoglou, F; Lu, Z; MacCoss, M; Manser, K; Mills, SG; Streckfuss, EC; Vachal, P; Yin, DH, 2006) |
| "Investigators identified a continuously benefit-eligible cohort of women from a large, geographically diverse, national managed care plan who were newly diagnosed and treated for osteoporosis with alendronate, risedronate, or raloxifene." | 3.73 | Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting. ( Boccuzzi, SJ; Downey, TW; Foltz, SH; Kahler, KH; Omar, MA, 2006) |
| " Etidronate and alendronate are most cost effective in women with borderline osteoporosis (t scores of -1." | 3.72 | A cost effectiveness analysis of calcium and vitamin D supplementation, etidronate, and alendronate in the prevention of vertebral fractures in women treated with glucocorticoids. ( Buckley, LM; Hillner, BE, 2003) |
| "Alendronate sodium is an aminobiphosphonate, an analog of inorganic pyrophosphate, indicated for the treatment of osteoporosis in post-menopausal women." | 3.72 | Pharmacovigilance study of alendronate in England. ( Biswas, PN; Shakir, SA; Wilton, LV, 2003) |
| "We report a case of transient osteoporosis of the navicular bone of the foot in a 20-year-old, female, top-level track athlete (400 m sprinter) treated with alendronate, and a review of the literature." | 3.72 | Transient osteoporosis of the navicular bone in a runner. ( Miltner, O; Niedhart, C; Piroth, W; Siebert, CH; Weber, M, 2003) |
| "Three simple, accurate and sensitive spectrophotometric methods are developed for the determination of some new drugs for the treatment of osteoporosis: risedronate sodium (I), alendronate sodium (II) and etidronate disodium (III)." | 3.72 | Spectrophotometric determination of some drugs for osteoporosis. ( Taha, EA; Youssef, NF, 2003) |
| "The aim of our study was to evaluate the upper gastrointestinal (GI) tract side effect profile in 759 female patients that had taken alendronate (10 mg/day), for at least 6 months, for the treatment of osteoporosis, in relation to the safety of alendronate and the compliance of patients to its absorption rules." | 3.72 | Gastrointestinal side effect profile due to the use of alendronate in the treatment of osteoporosis. ( Akarirmak, U; Aki, S; Akyüz, G; Alper, S; Arpacioğlu, O; Atalay, F; Eryavuz, M; Eskiyurt, N; Kavuncu, V; Kokino, S; Kuru, O; Nas, K; Ozerbil, O; Savaş, G; Sendur, OF; Soy, D; Tüzün, F, 2003) |
| "Alendronate and teparatide, recombinant human PTH (1-34) are available treatment for osteoporosis in postmenopausal women." | 3.72 | [Comparison of early bone histomorphometric effects of parathormone and alendronate in osteoporotic women]. ( Arlot, M; Boivin, G; Meunier, PJ; Portero, N; Roux, JP, 2004) |
| "To investigate the cost effectiveness of alendronate for male osteoporosis in Sweden by assuming the same relative risk reduction of fractures in men as for women, based on the FIT trial." | 3.72 | Cost effectiveness of alendronate for the treatment of male osteoporosis in Sweden. ( Borgström, F; Johnell, O; Jönsson, B; Sen, SS; Zethraeus, N, 2004) |
| "A 79-year-old Caucasian woman who had been taking alendronate 10 mg/day for over 2 years to prevent osteoporosis reported hearing "voices in her head" along with red-colored visual disturbances." | 3.72 | Alendronate-induced auditory hallucinations and visual disturbances. ( Coleman, CI; Lewis, A; Perkerson, KA, 2004) |
| "We performed an observational study of 1588 patients (163 men, 1425 women), 50 years of age and older, who were prescribed cyclic etidronate or alendronate for treatment of osteoporosis or osteopenia and had at least 2 years of followup registered in the Canadian Database for Osteoporosis and Osteopenia Patients (CANDOO)." | 3.72 | Are there differences between men and women prescribed bisphosphonate therapy in canadian subspecialty osteoporosis practices? ( Adachi, JD; Brown, JP; Davison, KS; Goldsmith, CH; Hanley, DA; Ioannidis, G; Josse, RG; Murray, TM; Olszynski, WP; Papaioannou, A; Petrie, A; Sawka, AM; Sebaldt, RJ; Tenenhouse, A; Thabane, L, 2004) |
| "We investigated the effect of alendronate on calcium, PTH, and bone mineral density in 27 female and 5 male patients with primary hyperparathyroidism." | 3.71 | Alendronate in the treatment of primary hyperparathyroid-related osteoporosis: a 2-year study. ( Blackwell, PJ; Fairbairn, KJ; Hosking, DJ; Parker, CR, 2002) |
| " The objective of this study was to determine whether the osteoporosis treatment agent alendronate accelerates the rate of CAC." | 3.71 | Progression of coronary artery calcification in patients taking alendronate for osteoporosis. ( Adams, JS; Aziz, D; Emerick, AM; Gjertson, D; Goldin, JG; Greaser, LD; Hill, JA; Khorrami, S; Yoon, HC, 2002) |
| "We identified patients aged > or = 20 years who received prescriptions for > or = 2 g of prednisone (or equivalent) during any 12-month period between January 1, 1998, and December 31, 1999, and who initiated use of osteoporosis-specific drugs (alendronate sodium, etidronate disodium, and calcitonin) during that period." | 3.71 | Prevalence and determinants of osteoporosis drug prescription among patients with high exposure to glucocorticoid drugs. ( Chidambaran, P; Ettinger, B; Pressman, A, 2001) |
| "We examined the effect of alendronate on bone following orchidectomy-induced osteoporosis." | 3.71 | Alendronate influences bending force of femoral diaphysis after orchidectomy in rats. ( Alhava, E; Arnala, I; Huuskonen, J; Olkkonen, H, 2001) |
| "To evaluate the anti-osteoporosis effect of alendronate on bone in rat model." | 3.71 | [The treatment of osteoporosis and bone resorption of alveoli with alendronate in rat model]. ( Wang, X; Yang, Z; Yu, S, 2001) |
| "Alendronate is indicated for the treatment of osteoporosis in post-menopausal women." | 3.70 | United Kingdom experience with alendronate and oesophageal reactions. ( Freemantle, SN; Mackay, FJ; Mann, RD; Pearce, GL; Wilton, LV, 1998) |
| "About 1 in 3 women taking alendronate for osteoporosis report gastrointestinal symptoms, a rate much higher than that found during clinical trials." | 3.70 | Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis. ( Ettinger, B; Pressman, A; Schein, J, 1998) |
| "We have evaluated three commercial assays for collagen cross-links, two urine assays and a recently developed serum assay, as markers of bone turnover in 30 postmenopausal women with osteoporosis during their first year of treatment with the anti-resorptive drug alendronate." | 3.70 | Clinical usefulness of biochemical resorption markers in osteoporosis. ( De Vooght, K; Fairney, A; Kerkhoff, F; Kyd, PA; Thomas, E, 1999) |
| "The authors report the case of a 54-year-old man suffering from steroid-induced osteoporosis, who presented with severe oral ulcerations due to sucking alendronate tablets instead of swallowing them." | 3.70 | Severe oral ulcerations induced by alendronate. ( Bolla, G; Demerjian, N; Spreux, A, 1999) |
| "This case report describes a patient who was previously prescribed alendronate (Fosamax) and presented with postoperative hypophosphatemia and hypocalcemic tetany after bowel preparation with Fleet Phospho-Soda." | 3.70 | Postoperative hypocalcemic tetany caused by fleet phospho-soda preparation in a patient taking alendronate sodium: report of a case. ( Badhwar, V; Campisi, P; Morin, S; Trudel, JL, 1999) |
| " The medications were pravastatin, a cholesterol-lowering drug for the prevention of cardiovascular disease; alendronate, a bisphosphonate for the treatment and prevention of osteoporosis; and aspirin, which is used for the prevention of cardiovascular disease." | 3.70 | Coverage by the news media of the benefits and risks of medications. ( Bero, L; Henry, D; Lee, K; Mah, C; Moynihan, R; Ross-Degnan, D; Soumerai, SB; Watkins, J, 2000) |
| "Appropriate osteoporosis treatment was defined as alendronate, etidronate, calcitonin, or hormone replacement therapy (HRT) for women with any bone mineral density (BMD) t score < -2." | 3.70 | Patterns of medication use before and after bone densitometry: factors associated with appropriate treatment. ( Helfgott, SM; Levin, E; Solomon, DH, 2000) |
| "The purpose of the investigation was to test the use of alendronate in the therapy of children affected by chronic rheumatic diseases and symptomatic drug-induced osteoporosis." | 3.69 | Intravenous administration of alendronate counteracts the in vivo effects of glucocorticoids on bone remodeling. ( Brandi, ML; Ermini, M; Falcini, F; Trapani, S, 1996) |
| "The aim of this study was to assess the effect of calcitonin (CCT) and alendronate (ALN) on bone quality through histomorphometric, histological, densitometric and crystallographic evaluations in an experimental model of osteoporosis obtained in ovariectomized rats." | 3.69 | [Effects of synthetic salmon calcitonin and alendronate on bone quality in ovariectomized rats]. ( Biagini, G; Fini, M; Gandolfi, MG; Giardino, R; Gnudi, S; Mongiorgi, R; Nicoli Aldini, N, 1997) |
| " Incidences of adverse events, asymptomatic decreases in serum calcium, and evolution of kidney function during the studies were similar across all baseline kidney function groups." | 3.11 | Efficacy and Safety of Romosozumab Among Postmenopausal Women With Osteoporosis and Mild-to-Moderate Chronic Kidney Disease. ( Adachi, JD; Albergaria, BH; Cheung, AM; Chines, AA; Gielen, E; Langdahl, BL; Miller, PD; Miyauchi, A; Oates, M; Reid, IR; Santiago, NR; Vanderkelen, M; Wang, Z; Yu, Z, 2022) |
| "Osteoporosis is a disorder of bone mineralisation occurring in about one third of adults with cystic fibrosis." | 3.01 | Bisphosphonates for osteoporosis in people with cystic fibrosis. ( Chang, AB; Conwell, LS; Jeffery, TC, 2023) |
| "Osteoporosis is characterized by low bone mass and micro-architectural deterioration of bone tissue leading to increased bone fragility." | 3.01 | Treatment for osteoporosis in people with beta-thalassaemia. ( Bhardwaj, A; Sinha, NK; Swe, KMM, 2023) |
| " We calculated the standard mean deviations with 95% confidence intervals (CI) for bone mineral density (BMD) and T scores after 6 and 12 months treatment, pooled odds ratio and 95% CI for fracture risk, and summarized adverse events." | 3.01 | Efficacy and safety of medications for osteoporosis in kidney transplant recipients or patients with chronic kidney disease: A meta-analysis. ( Leng, Y; Xia, Y; Yang, Y; Yu, X, 2023) |
| " Benefits of long-term use of BPs: Large and important trials (Fracture Intervention Trial Long-term Extension and Health Outcomes and Reduced Incidence with Zoledronic acid Once Yearly-Pivotal Fracture Trial) with extended use of alendronate (up to 10 years) and zoledronate (up to 6 years) evidenced significant gain of bone mineral density (BMD) and vertebral fracture risk reduction." | 3.01 | Long-term consequences of osteoporosis therapy with bisphosphonates. ( Alves Coelho, MC; Brasil d'Alva, C; Gehrke, B; Madeira, M, 2023) |
| " Their use is supported by over 3 decades of evidence; however, patient adherence to oral bisphosphonates remains poor in part due to complex dosing instructions and adverse events, including upper gastrointestinal symptoms." | 2.82 | Novel formulations of oral bisphosphonates in the treatment of osteoporosis. ( Al-Daghri, N; Bock, O; Branco, J; Bruyère, O; Casado, E; Cavalier, E; Cooper, C; Cortet, B; de Wit, M; Fuggle, N; Giusti, A; Halbout, P; Harvey, NC; Hiligsmann, M; Kanis, JA; Kaufman, JM; Kurth, A; Maggi, S; Matijevic, R; Minisola, S; Palacios, S; Radermecker, RP; Reginster, JY; Rizzoli, R; Thomasius, F; Tuzun, S; Veronese, N, 2022) |
| " However, ALN is characterized by restricted oral absorption and bioavailability and simultaneously its administration has serious side-effects (jaw osteonecrosis, irritation of the gastrointestinal system, nausea, musculoskeletal pain, and cardiovascular risks)." | 2.82 | How Efficient are Alendronate-Nano/Biomaterial Combinations for Anti-Osteoporosis Therapy? An Evidence-Based Review of the Literature. ( Klara, J; Lewandowska-Łańcucka, J, 2022) |
| "Osteoporosis and osteomalacia have been observed after gastrectomy and appear to be caused by reduced food intake and absorption, and steatorrhea." | 2.82 | Metabolic bone disorders after gastrectomy: inevitable or preventable? ( Aoyama, T; Atsumi, Y; Rino, Y; Yamada, T; Yukawa, N, 2022) |
| "Osteoporosis is the most prevalent metabolic bone disorder worldwide." | 2.82 | Comparing the Efficacies of Bisphosphonates' Therapies for Osteoporosis Persistence and Compliance: A Systematic Review. ( Almohaileb, FI; Rasheed, Z, 2022) |
| "Minodronate is a potent nitrogen-containing bisphosphonate that can be administered according to a monthly (every 4 weeks) dosing regimen." | 2.82 | Patient preference for monthly bisphosphonate versus weekly bisphosphonate in a cluster-randomized, open-label, crossover trial: Minodroate Alendronate/Risedronate Trial in Osteoporosis (MARTO). ( Furuya, T; Hasegawa, M; Hirabayashi, H; Iwamoto, J; Kumakubo, T; Makita, K; Okano, H; Urano, T, 2016) |
| " Repeated SRT dosing did not significantly affect PK, although C 24h increased slightly." | 2.80 | Bone turnover markers and pharmacokinetics of a new sustained-release formulation of the cathepsin K inhibitor, ONO-5334, in healthy post-menopausal women. ( Deacon, S; Hashimoto, Y; Kuwayama, T; Manako, J; Nagase, S; Ohyama, M; Sharpe, J; Small, M, 2015) |
| " sinensis dosage (300 and 500 mg/kg/day) or alendronate had a positive effect on body weights, mechanical strength, BMD, and BMC compared to the other HLS groups." | 2.77 | Prevention of disuse osteoporosis in rats by Cordyceps sinensis extract. ( Cao, PC; Lei, W; Liu, D; Liu, N; Qi, W; Shi, L; Wu, ZX; Yan, YB; Zhang, Y, 2012) |
| "Osteoporosis is defined as a reduction of bone density or the presence of a fragility fracture." | 2.76 | Comparison of gastrointestinal symptoms at daily 10 mg versus weekly 70 mg Alendronate prescription in 195 osteoporotic cases. ( Amiri, AH; Tarrahi, MJ, 2011) |
| "Secondary outcomes included changes in bone resorption (betaCTX) and 12-month changes in BMD." | 2.75 | Impact of bisphosphonate wash-out prior to teriparatide therapy in clinical practice. ( Keel, C; Kraenzlin, CA; Kraenzlin, ME; Meier, C; Müller, B, 2010) |
| "Alendronate was effective in suppressing bone resorption and subsequent BMD decrease at the lumbar spine in patients with high-dose GC treatment." | 2.75 | Effect of alendronate on bone metabolic indices and bone mineral density in patients treated with high-dose glucocorticoid: a prospective study. ( Funakawa, I; Funasaka, Y; Kaji, H; Kanda, F; Kuroki, Y; Murakawa, Y; Sugimoto, T, 2010) |
| "Thirty-nine patients with ulcerative colitis and treated with glucocorticoids were randomized to receive alendronate (5 mg/day) or alfacalcidol (1 microg/day) daily for 12 months." | 2.74 | Clinical trial: comparison of alendronate and alfacalcidol in glucocorticoid-associated osteoporosis in patients with ulcerative colitis. ( Harada, K; Kitazaki, S; Kuwaki, K; Masuda, J; Mitsuyama, K; Sata, M; Sugiyama, G; Takedatsu, H; Tsuruta, O; Yamasaki, H, 2009) |
| "Alendronate treatment is estimated to result in increases in hip bone density >or=0." | 2.74 | Value of routine monitoring of bone mineral density after starting bisphosphonate treatment: secondary analysis of trial data. ( Bauer, DC; Bell, KJ; Craig, JC; Ensrud, K; Hayen, A; Irwig, L; Macaskill, P, 2009) |
| "Alendronate therapy was well tolerated and produced a significantly greater increase in BMD over 12 months compared with placebo." | 2.73 | Alendronate once weekly for the prevention and treatment of bone loss in Canadian adult cystic fibrosis patients (CFOS trial). ( Adachi, JD; Berthiaume, Y; Freitag, A; Ioannidis, G; Jeanneret, A; Kennedy, CC; Matouk, E; Nixon, M; O'Neill, J; Papaioannou, A; Paterson, N; Pui, M; Rabin, HR; Villeneuve, J; Webber, C, 2008) |
| "Androgen-deprivation therapy (ADT) for prostate cancer is associated with bone loss and osteoporotic fractures." | 2.73 | Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy. ( Greenspan, SL; Miller, ME; Nelson, JB; Perera, S; Resnick, NM; Trump, DL; Wagner, JM, 2008) |
| "Alendronate was initiated at 7 days after Tx." | 2.73 | Comparison of alendronate vs alendronate plus mechanical loading as prophylaxis for osteoporosis in lung transplant recipients: a pilot study. ( Baz, MA; Braith, RW; Casey, DP; Conner, JA; Fulton, MN; Howe, KS; Lisor, CF, 2007) |
| "Alendronate was well tolerated, without significant adverse events." | 2.73 | Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV. ( Alston-Smith, B; Benson, C; Gopalakrishnan, G; Hogg, E; Kendall, MA; McComsey, GA; Suckow, C; Swindells, S; Tebas, P; Wohl, DA, 2007) |
| "Osteoporosis affects mostly postmenopausal women, leading to deterioration of the microarchitectural bone structure and low bone mass, with an increased fracture risk with associated disability, morbidity and mortality." | 2.72 | Effect of drugs on bone mineral density in postmenopausal osteoporosis: a Bayesian network meta-analysis. ( Betsch, M; Colarossi, G; Eschweiler, J; Maffulli, N; Migliorini, F; Tingart, M, 2021) |
| "Osteoporosis is a frequent complication after renal transplantation." | 2.71 | Alendronate for treatment of renal transplant patients with osteoporosis. ( Gutierrez, A; Moreno, A; Oppenheimer, F; Torregrosa, JV; Vidal, S, 2003) |
| "Alendronate therapy was given for 30 months; parathyroid hormone therapy was begun at month 6." | 2.71 | The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. ( Finkelstein, JS; Hayes, A; Hunzelman, JL; Lee, H; Neer, RM; Wyland, JJ, 2003) |
| "The alendronate-treated patients gained (mean +/- SD) 4." | 2.71 | Efficacy of alendronate in adults with cystic fibrosis with low bone density. ( Aris, RM; Blackwood, AD; Brown, SA; Caminiti, M; Chalermskulrat, W; Guillen, U; Hecker, TM; Hensler, M; Lark, RK; Lester, GE; Neuringer, IP; Ontjes, DA; Renner, JB, 2004) |
| "Alendronate treatment had significantly increased lumbar spine BMD by 4." | 2.71 | Alendronate treatment in men with primary osteoporosis: a three-year longitudinal study. ( Breschi, M; Bruni, D; Caffarelli, C; Cepollaro, C; Gennari, C; Gennari, L; Gonnelli, S; Montagnani, A; Nuti, R, 2003) |
| "Alendronate was associated with a gain in lumbar (trabecular) BMD but less than expected from studies of postmenopausal women." | 2.71 | Alendronate for the prevention of bone mineral loss during gonadotropin-releasing hormone agonist therapy. ( Mamish, Z; Minhas, B; Ripps, BA; VanGilder, K; Welford, M, 2003) |
| "The alendronate effect was gender independent (P = 0." | 2.71 | Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: a seven-year follow-up study. ( Biermasz, NR; Hamdy, NA; Pereira, AM; Roelfsema, F; Romijn, JA, 2004) |
| " Our results support the long-term administration of alendronate along with testosterone replacement to men with hypogonadism-induced osteoporosis." | 2.71 | Alendronate for osteoporosis in men with androgen-repleted hypogonadism. ( Doolman, R; Eshed, V; Karasik, A; Sela, BA; Shimon, I; Vered, I, 2005) |
| " Clodronate treatment at our dosage is ineffective in this pathology in spite of the good compliance of patients." | 2.70 | Bisphosphonates in the treatment of thalassemia-induced osteoporosis. ( Crisafulli, A; Di Pietro, C; Frisina, N; Gaudio, A; Lasco, A; Meo, A; Morabito, N, 2002) |
| "Men with osteoporosis have been neglected in the past, and only a few therapeutic trials have been performed in men." | 2.70 | Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study. ( Dorst, A; Faber, H; Ringe, JD, 2001) |
| "Alendronate treatment did not impair bone mineralisation, induce the formation of woven bone or have any other adverse effects on bone quality." | 2.69 | The effects of alendronate on bone turnover and bone quality. ( Arlot, M; Chavassieux, P; Meunier, PJ; Yates, AJ, 1999) |
| "Alendronate is an aminobisphosphonate that is able to increase bone mass mainly by inhibiting bone resorption." | 2.69 | Effectiveness of chronic treatment with alendronate in the osteoporosis of Cushing's disease. ( Colao, A; Di Somma, C; Faggiano, A; Klain, M; Lombardi, G; Merola, B; Pivonello, R; Salvatore, M; Tripodi, FS, 1998) |
| "Osteoporosis is a common complication of long-term glucocorticoid therapy for which there is no well-proved preventive or restorative treatment." | 2.69 | Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. ( Brown, JP; Czachur, M; Daifotis, AG; Delmas, PD; Emkey, R; Goemaere, S; Hawkins, F; Liberman, UA; Malice, MP; Saag, KG; Schnitzer, TJ; Thamsborg, G, 1998) |
| "The treatment with alendronate resulted in a significant and progressive increase in BMD of the lumbar spine and femoral neck." | 2.69 | Comparison of biochemical markers of bone remodelling in the assessment of the effects of alendronate on bone in postmenopausal osteoporosis. ( Stĕpán, JJ; Vokrouhlická, J, 1999) |
| "Osteoporosis is a frequent complication of rheumatoid arthritis (RA)." | 2.69 | Evaluation of bone turnover and osteoclastic cytokines in early rheumatoid arthritis treated with alendronate. ( Acquista, CA; Cantatore, FP; Pipitone, V, 1999) |
| "Alendronate treatment was not associated with any qualitative abnormalities." | 2.69 | Effects of alendronate on bone quality and remodeling in glucocorticoid-induced osteoporosis: a histomorphometric analysis of transiliac biopsies. ( Arlot, ME; Chavassieux, PM; Daifotis, A; Freedholm, D; Hamdy, NA; Malice, MP; Meunier, PJ; Portero, N; Roux, JP; Yates, AJ, 2000) |
| "Clinical studies were performed to examine the oral bioavailability of alendronate (4-amino-1-hydroxy-butylidene-1,1-bisphosphonate monosodium)." | 2.68 | Studies of the oral bioavailability of alendronate. ( Freeman, A; Gertz, BJ; Holland, SD; Kline, WF; Lasseter, KC; Matuszewski, BK; Mucklow, JC; Porras, AG; Quan, H, 1995) |
| "Alendronate was generally well tolerated over all dosages." | 2.67 | Short-term effect of alendronate on bone mass and bone remodeling in postmenopausal women. ( Chesnut, CH; Harris, ST, 1993) |
| "Osteoporosis and cardiovascular diseases are major public health issues." | 2.61 | Cardiovascular Outcomes of Romosozumab and Protective Role of Alendronate. ( Asadipooya, K; Weinstock, A, 2019) |
| "Alendronate was the most frequently administered ARD." | 2.55 | What is the effect of anti-resorptive drugs (ARDs) on the development of medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients: A systematic review. ( Aljohani, S; Ehrenfeld, M; Fliefel, R; Ihbe, J; Kühnisch, J; Otto, S, 2017) |
| "Osteoporosis is a growing concern among people living with HIV (PLWH) because of the recognized risk of fractures, which bring with them morbidity and mortality." | 2.53 | Pharmacologic approaches to the prevention and management of low bone mineral density in HIV-infected patients. ( Negredo, E; Warriner, AH, 2016) |
| "Osteoporosis is a systemic skeletal disease characterized by low bone mass and micro-architectural deterioration of bone tissue with a consequent increase in bone fragility and susceptibility to fracture." | 2.53 | Treatment for osteoporosis in people with ß-thalassaemia. ( Bhardwaj, A; Osunkwo, I; Sinha, NK; Swe, KM, 2016) |
| "Alendronate was not able to reduce the incidence of vertebral fractures (RR = 0." | 2.53 | Alendronate prevents glucocorticoid-induced osteoporosis in patients with rheumatic diseases: A meta-analysis. ( Ai, J; Feng, SQ; Kan, SL; Li, Y; Sun, JC; Xu, H; Yuan, ZF, 2016) |
| "The data on gastrointestinal side effects (47 trials) indicated that alendronate, risedronate etidronate, and zolendronate have similar rates of the adverse effects; application of Bayesian network meta-analysis showed that equivalence was demonstrated according to margins around ±10%." | 2.52 | Gastrointestinal and renal side effects of bisphosphonates: differentiating between no proof of difference and proof of no difference. ( Fadda, V; Maratea, D; Messori, A; Trippoli, S, 2015) |
| "Many drugs for the treatment of osteoporosis have also been associated with increased risks of serious adverse events." | 2.52 | Osteoporosis: the emperor has no clothes. ( Aspenberg, P; Järvinen, TL; Michaëlsson, K; Sievänen, H, 2015) |
| "The preferred treatment for osteoporosis in men is debated, and pairwise meta-analysis cannot obtain hierarchies of these treatments." | 2.52 | Comparison of Bone Mineral Density in Lumbar Spine and Fracture Rate among Eight Drugs in Treatments of Osteoporosis in Men: A Network Meta-Analysis. ( Chen, LX; Feng, SQ; Li, YL; Ning, GZ; Zhang, D; Zhang, TS; Zhou, ZR, 2015) |
| " Subgroup analysis revealed that among the patients in the combination therapy group, greater increases in the spine BMD were observed when the PTH was administered with a dosage of 20 μg (WMD = 2." | 2.52 | Parathyroid Hormone Plus Alendronate in Osteoporosis: A Meta-Analysis of Randomized Controlled Trials. ( Chen, J; Fan, J; Gu, M; Li, B; Wang, C; Zhang, G, 2015) |
| " This new formulation provides an alternative so that patients may select a method of dosing tailored to their preferences." | 2.49 | Alendronate sodium hydrate (oral jelly) for the treatment of osteoporosis: review of a novel, easy to swallow formulation. ( Imai, K, 2013) |
| "Osteoporosis is characterized by a reduction in bone mineral density (BMD) ." | 2.47 | [New therapy using bisphosphonate for urolithiasis]. ( Hirose, M; Niimi, K; Yasui, T, 2011) |
| "Patients with primary biliary cirrhosis often have osteoporosis - either postmenopausal or secondary to the liver disease." | 2.47 | Bisphosphonates for osteoporosis in primary biliary cirrhosis. ( Bjelakovic, G; Giljaca, V; Gluud, C; Krstic, MN; Rudic, JS, 2011) |
| "Overactive bone resorption and limited bone formation lead to unstable combination between bone tissue and scaffolds." | 2.44 | An osteoporosis bone defect regeneration strategy via three-dimension short fibers loaded with alendronate modified hydroxyapatite. ( Cheng, Z; Dai, Z; Jia, W; Jiang, X; Jiao, K; Liu, G; Liu, L; Liu, Y; Luo, Y; Sun, M; Wang, H; Wang, S; Yang, T; Yang, Y, 2024) |
| "Osteoporosis is a systemic skeletal disorder characterized by low bone mass and microarchitectural deterioration of bone tissue resulting in compromised bone strength and an increased risk of fracture." | 2.44 | Nonvertebral fracture risk reduction with nitrogen-containing bisphosphonates. ( Hochberg, MC, 2008) |
| "They are indicated for the treatment of osteoporosis." | 2.44 | Osteochemonecrosis of jaws and bisphosphonates. ( Beirne, JC; Khosa, AD; Nayyar, MS, 2007) |
| "Osteoporosis is a serious public health issue." | 2.44 | Osteoporosis--from hormonal replacement therapy to bisphosphonates and beyond: a review. ( Kariuki, JG; Oyoo, GO, 2007) |
| " Alternative dosing schedules and routes of administration have become available and may improve fracture protection, compliance, and tolerability for the long term treatment of a chronic condition such as osteoporosis." | 2.43 | Oral antiresorptive therapy. ( Hosking, DJ; Pande, I, 2005) |
| "Osteoporosis affects postmenopausal women and patients on glucocorticoid therapy." | 2.43 | Rapid prevention of vertebral fractures associated with osteoporosis. ( Wallace, DJ, 2005) |
| "In 2002, Adequate Treatment of Osteoporosis (A-TOP) Research Group was organized to obtain the evidence for treatment of osteoporosis in Japan." | 2.43 | [Current research in adequate treatment by Osteoporosis Research Group]. ( Kuroda, T; Miyakawa, N; Orimo, H, 2006) |
| "The main goal of postmenopausal osteoporosis treatment is to reduce the risk of fragility fractures." | 2.43 | [Osteoporosis: Optimizing treatment strategy]. ( Thomas, T, 2006) |
| " The variety of bisphosphonates currently available to us provides a wide range of tolerability and dosing profiles thus necessitating a thorough comparison of the most recent oral and intravenous bisphosphonates to differentiate the clinical context in which they should be used." | 2.43 | Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease. ( Adachi, JD; Beattie, K; Bobba, RS; Kumbhare, D; Parkinson, B, 2006) |
| "Osteoporosis is a complication of androgen deprivation therapy in men with prostate carcinoma." | 2.42 | Diagnosis and management of treatment-related osteoporosis in men with prostate carcinoma. ( Smith, MR, 2003) |
| " In histomorphometry with iliac bone biopsies, mineralization was normal, and trabecular bone turnover markedly decreased in patients receiving long-term dosing with alendronate." | 2.42 | [Clinical trials of alendronate]. ( Okano, T; Teshima, R, 2003) |
| "Osteoporosis is associated with increased risk of fractures at most skeletal sites." | 2.42 | [Treatment of osteoporosis provided from the orthopaedic surgeon's standpoint]. ( Sohen, S, 2003) |
| " The potent bisphosphonate zoledronate can be given at intervals of as long as 1 year and produces changes in bone density and in markers of bone turnover comparable with those seen with conventional daily oral dosing with alendronate or risedronate." | 2.42 | Bisphosphonates: new indications and methods of administration. ( Reid, IR, 2003) |
| "Osteoporosis is a common but neglected problem in India." | 2.42 | Management of osteoporosis: the Indian perspective. ( Handa, R, 2004) |
| "Steroid-induced osteoporosis is the most common form of osteoporosis in the dermatological diseases, but there have been only few data concerning the treatment based on clinical evidences." | 2.42 | [Measures for osteoporosis in the dermatological field--vitamin D3 and bisphosphonate]. ( Okada, N, 2004) |
| " Alternative dosing schedules and routes of administration have become available and may improve fracture protection, compliance, and tolerability for the long term treatment of a chronic condition such as osteoporosis." | 2.42 | Oral antiresorptive therapy. ( Hosking, DJ; Pande, I, 2004) |
| "Alendronate has been approved for treatment of osteoporosis in men, and other treatments for men are under evaluation." | 2.41 | Osteoporosis in elderly: prevention and treatment. ( Deal, C; Srivastava, M, 2002) |
| "Alendronate is an agent for the treatment of osteoporosis that has established safety with regards to bone quality since it neither inhibits bone calcification nor influences fracture healing in chronic administration." | 2.41 | [Pharmacological and clinical properties of alendronate sodium hydrate]. ( Komatsu, S; Ohta, T; Tokutake, N, 2002) |
| "Osteoporosis is a common complication of Cushing's disease/syndrome." | 2.41 | Osteoporotic fractures at presentation of Cushing's disease: two case reports and a literature review. ( Crouzet, J; Fournier, JJ; Khanine, V; Luton, JP; Requeda, E; Simon, F, 2000) |
| "Osteoporosis is a common and costly disease." | 2.41 | Osteoporosis: evaluation and treatment. ( Green, SS; Milott, JL; Schapira, MM, 2000) |
| "The goal of drug treatment of osteoporosis is to prevent fractures." | 2.41 | [Drug treatment for the treatment of primary osteoporosis]. ( Halbekath, J, 2000) |
| " The manuscript then reviews therapies available for osteoporosis in the United States and makes recommendations about choosing therapies that minimize GI adverse effects in RA patients at high risk for such events." | 2.41 | Osteoporosis therapies for rheumatoid arthritis patients: minimizing gastrointestinal side effects. ( Schein, JR; Sewell, K, 2001) |
| " A subsequent clinical trial reported that the once-weekly dosing regimen is therapeutically equivalent to the daily regimen." | 2.41 | Update on alendronate for osteoporosis: once-weekly dosing. ( Schnitzer, TJ, 2001) |
| "To review data describing use of intermittent dosing of alendronate." | 2.41 | Intermittent dosing of alendronate. ( Heck, AM; Tsun, EC, 2001) |
| "The early inhibition of bone resorption induces a reduction in serum calcium which leads to increased parathyroid hormone (PTH), and subsequently an increase in 1,25-dihydroxyvitamin D." | 2.41 | Bisphosphonates: an overview with special reference to alendronate. ( Vasikaran, SD, 2001) |
| " However, many patients find the daily dosing regimen inconvenient." | 2.41 | Once-weekly treatment for osteoporosis. ( Stone, M, 2002) |
| "Alendronate preferentially localises at bone resorption sites, where the drug inhibits osteoclastic activity." | 2.40 | Preclinical evidence of normal bone with alendronate. ( Hayes, WC; Rodan, GA; Shea, M, 1999) |
| "Many of the bisphosphonates inhibit bone resorption, the newest compounds being 10,000 times more active than etidronate, the first bisphosphonate described." | 2.40 | Bisphosphonates: preclinical aspects and use in osteoporosis. ( Fleisch, HA, 1997) |
| "Osteoporosis is a common and costly condition that can cause disability or death." | 2.40 | Osteoporosis: prevention, detection and treatment. ( Watts, NB, 1997) |
| "Alendronate has demonstrated its ability to increase bone mass significantly above the placebo values at any studied skeletal site in a wide variety of patient subgroups regardless of age, race, baseline rate of bone turnover or baseline bone mineral density." | 2.40 | A risk-benefit assessment of alendronate in the treatment of involutional osteoporosis. ( Devogelaer, JP, 1998) |
| "Because the severity of alveolar bone loss increases with age, it has long been hypothesized that it may, in part, be related to systemic conditions that also predispose the patient to osteoporosis/osteopenia." | 2.40 | Osteoporosis: a possible modifying factor in oral bone loss. ( Jeffcoat, MK, 1998) |
| "Many new agents for the treatment of osteoporosis are being examined." | 2.39 | Osteoporosis prevention and treatment. ( Bellantoni, MF, 1996) |
| "Osteoporosis is an increasingly prevalent chronic and debilitating disease." | 2.39 | Update on pharmacologic therapies for osteoporosis. ( Kessenich, CR, 1996) |
| "Osteoporosis is becoming a global epidemic in aging societies." | 1.91 | Comparisons Between Different Anti-osteoporosis Medications on Postfracture Mortality: A Population-Based Study. ( Chang, YF; Hsu, YH; Hwang, JS; Li, CC; Liang, FW; Wu, CH, 2023) |
| "Osteoporosis is a degenerative bone disease resulting from bone homeostasis imbalance regulated by osteoblasts and osteoclasts." | 1.91 | Multifunctional Scaffold for Osteoporotic Pathophysiological Microenvironment Improvement and Vascularized Bone Defect Regeneration. ( Dai, H; Goto, T; Kang, H; Li, F; Tu, R; Wu, X; Zhao, Y; Zhuang, P, 2023) |
| "Osteoporosis is a bone disease leading to bone fracture and affects 200 million women worldwide." | 1.91 | Quercetin potentiates the anti-osteoporotic effects of alendronate through modulation of autophagy and apoptosis mechanisms in ovariectomy-induced bone loss rat model. ( Azadbakht, O; Behrouj, H; Jafarinia, M; Mousavi, S; Razmjoue, D; Sabaghan, M; Sabetian, S; Savardashtaki, A; Vakili, S; Veisi, A; Zal, F, 2023) |
| "Osteoporosis is a common metabolic bone disease that benefits from many newly developed anti-osteoporosis medications (AOMs)." | 1.91 | Eleven years secular trend of the initiation of anti-osteoporosis medications and subsequent fractures in Taiwan: From 2008 to 2018. ( Chan, DC; Chen, HM; Fu, SH; Huang, CF; Hwang, JS; Lin, JW; Wang, CY; Wu, CH; Yang, JJ; Yang, RS; Yang, TH, 2023) |
| "The OMPR in the first year improved if the patients used AOMs with longer dosing intervals." | 1.91 | The real-world adherence of the first-line anti-osteoporosis medications in Taiwan: Visualize the gap between reality and expectations. ( Chen, HM; Fu, SH; Hsu, CC; Hwang, JS; Lee, CC; Lin, JW; Lin, SC; Wang, CY; Wu, CH; Yang, RS, 2023) |
| "She had been treated for postmenopausal osteoporosis with 70 mg of alendronate weekly for 2 years." | 1.91 | A Case Report of Oral Bisphosphonate Treatment for Osteoporosis Leading to Atypical Femoral Fracture and Pathologic Mandibular Fracture. ( Fernandes, TL; Franco, GCN; Jitumori, C; Viezzer Fernandes, B, 2023) |
| " Administration of risedronate gastric-resistant does not require fasting, and this more convenient dosing administration may explain its improved efficacy." | 1.72 | Fracture rates and economic outcomes in patients with osteoporosis prescribed risedronate gastro-resistant versus other oral bisphosphonates: a claims data analysis. ( Alam, A; Boolell, M; Gauthier, G; Palacios, S; Thomasius, F; Vekeman, F, 2022) |
| "Postmenopausal women compliance to alendronate therapy is suboptimal due to the complex dosing requirements." | 1.72 | Knowledge and compliance towards alendronate therapy among postmenopausal women with osteoporosis in Palestine. ( Elaraj, J; Fatayer, D; Hamad, A; Jarar, B; Johar, A; Radwan, A; Shraim, N; Zriqah, A, 2022) |
| "Considering the massive treatment gap for osteoporosis, and the related fracture risk, clinicians should continue treatment, even during a pandemic." | 1.72 | Dispensing anti-osteoporotic drugs changed during the COVID-19 pandemic. ( Behanova, M; Haschka, J; Kocijan, R; Reichardt, B; Resch, H; Stockinger, T; Zwerina, J, 2022) |
| "Alendronate was the most common initial therapy." | 1.72 | Patterns of Osteoporosis Medications Selection After Drug Holiday or Continued Therapy: A Real-World Experience. ( Baim, S; Bedrose, S; Casagrande, A; Go, MT; Goel, M; Hanna, M; Husni, H; Li, D; Mahrous, P; Morkos, M, 2022) |
| "Osteoporosis is defined by loss of bone mass and deteriorated bone microarchitecture." | 1.72 | Pharmacological and Non-Pharmacological Agents versus Bovine Colostrum Supplementation for the Management of Bone Health Using an Osteoporosis-Induced Rat Model. ( Amorim, T; Bastos, AR; Canadas, RF; Carrillo, AE; Correlo, VM; Fernandes, EM; Freitas, L; Gkiata, P; Koutedakis, Y; Kydonaki, EK; Marques, F; Ntina, G; Oliveira, JM; Pinto, R; Reguengo, H; Reis, RL; Simón, CR; Vliora, M, 2022) |
| "Osteoporosis is common in older adults leading to fragility fractures at enormous individual and economic cost." | 1.72 | Acceptability and engagement amongst patients on oral and intravenous bisphosphonates for the treatment of osteoporosis in older adults. ( Bishop, S; Gittoes, N; Langley, T; Narayanasamy, M; Paskins, Z; Sahota, O, 2022) |
| "Osteoporosis is caused by an imbalance of osteoclasts and osteoblasts, occurring in close proximity to hematopoietic cells in the bone marrow." | 1.62 | Dnmt3a-mutated clonal hematopoiesis promotes osteoporosis. ( Agrawal, M; Bick, A; Bouxsein, ML; Brooks, DJ; Charles, JF; Cohen, DN; Ebert, BL; Evans, DM; Gibson, CJ; Griffin, G; Jaiswal, S; Kemp, JP; Kiel, DP; Kim, PG; Lin, AE; McConkey, M; Natarajan, P; Niroula, A; Pirruccello, J; Richards, JB; Sekar, A; Shin, WJ; Shkolnik, V; Słabicki, M; Tsai, JM; Uddin, MM; Wein, MN; Wong, WJ, 2021) |
| " However, the use of Alen has been limited due to its low bioavailability and gastrointestinal side effects." | 1.62 | Alendronate-Decorated Nanoparticles as Bone-Targeted Alendronate Carriers for Potential Osteoporosis Treatment. ( Chen, S; Jing, C; Li, B; Liang, H; Liu, C; Na, H; Tan, H; Zhang, C; Zhao, L, 2021) |
| " They are associated with gastrointestinal adverse reactions the most severe being an esophageal ulcer." | 1.62 | Upper gastrointestinal safety of oral bisphosphonate in hospitalized patients. ( Bouin, M; Nguyen, PV; Ste-Marie, LG, 2021) |
| "Osteoporosis is a major systemic disease that can significantly deteriorate the quality of life of the affected individuals." | 1.62 | Prevalence of Periapical Lesions in Patients with Osteoporosis. ( Katz, J; Rotstein, I, 2021) |
| "Osteoporosis is a worldwide healthcare challenge." | 1.62 | Investigating the Preventive Effects of 99Tc-Methylenediphosphonate on a Glucocorticoid-Induced Osteoporosis Rabbit Model. ( Cai, M; Chen, Y; Li, Y; Min, W; Wang, C; Wang, J; Yan, L; Zhang, R; Zhu, H, 2021) |
| "Individuals being treated for osteoporosis should be reevaluated for fracture risk routinely, including via patient education about osteoporosis and fractures and monitoring for adverse treatment effects." | 1.56 | Secondary Fracture Prevention: Consensus Clinical Recommendations from a Multistakeholder Coalition. ( Adib, G; Adler, RA; Åkesson, KE; Alexander, IM; Amenta, KC; Blank, RD; Brox, WT; Carmody, EE; Chapman-Novakofski, K; Clarke, BL; Cody, KM; Conley, RB; Cooper, C; Crandall, CJ; Dirschl, DR; Eagen, TJ; Elderkin, AL; Fujita, M; Greenspan, SL; Halbout, P; Hochberg, MC; Javaid, M; Jeray, KJ; Kearns, AE; Khosla, S; Kiel, DP; King, T; Koinis, TF; Koontz, JS; Kužma, M; Lindsey, C; Lorentzon, M; Lyritis, GP; Michaud, LB; Miciano, A; Morin, SN; Mujahid, N; Napoli, N; Olenginski, TP; Puzas, JE; Rizou, S; Rosen, CJ; Saag, K; Thompson, E; Tosi, LL; Tracer, H, 2020) |
| " This, together with the need for less frequent administration of zoledronate, supports its wider use in clinical practice, particularly if longer dosing intervals than those currently recommended are shown to be effective." | 1.56 | Practical guidance for the use of bisphosphonates in osteoporosis. ( Compston, J, 2020) |
| " Nearly six-time enhancement of bioavailability was observed when alendronate was used in the nanoparticulate form in transdermal patches used with sonophoresis." | 1.56 | Ultrasound-assisted transdermal delivery of alendronate for the treatment of osteoporosis. ( Huang, G; Li, B; Ma, Z; Qin, S, 2020) |
| "Osteoporosis is a major problem in patients with Duchenne muscular dystrophy (DMD), due to glucocorticoid therapy and muscle weakness." | 1.56 | Oral bisphosphonate treatment in patients with Duchenne muscular dystrophy on long term glucocorticoid therapy. ( Hornung, L; Khoury, JC; Rutter, MM; Rybalsky, I; Shellenbarger, KC; Tian, C; Wong, BL, 2020) |
| "Osteoporosis is the most widespread metabolic bone disease which represents a major public health burden." | 1.51 | Hybrid particles derived from alendronate and bioactive glass for treatment of osteoporotic bone defects. ( Boccaccini, AR; Camargo, WA; Detsch, R; Diba, M; Grünewald, A; Kabiri, Y; Kentgens, APM; Leeuwenburgh, SCG; van den Beucken, JJJP; Zinkevich, T, 2019) |
| "Ovariectomy induced bone loss and mechanical hyperalgesia in the hindlimbs with upregulation of CGRP expression in the DRG neurons innervating the hindlimbs." | 1.51 | Interleukin-6 Inhibitor Suppresses Hyperalgesia Without Improvement in Osteoporosis in a Mouse Pain Model of Osteoporosis. ( Kato, S; Miyamura, G; Nagao, N; Naito, Y; Sudo, A; Wakabayashi, H, 2019) |
| "Osteoporosis is characterized by a progressive increase in bone fragility, leading to low bone mass and structural deterioration of bone tissue." | 1.51 | MicroRNA-155 inhibition up-regulates LEPR to inhibit osteoclast activation and bone resorption via activation of AMPK in alendronate-treated osteoporotic mice. ( Chu, C; Hao, W; Mao, Z; Su, H; Zhu, Y, 2019) |
| "Alendronate (ALN) is a BCS III bone resorption inhibitor, with very poor oral bioavailability." | 1.48 | Alendronate-loaded, biodegradable smart hydrogel: a promising injectable depot formulation for osteoporosis. ( Boraie, N; Nafee, N; Zewail, M, 2018) |
| "Alendronate use was associated with a lower risk of nonvertebral fracture, including hip fracture." | 1.48 | Alendronate Use and the Risk of Nonvertebral Fracture During Glucocorticoid Therapy: A Retrospective Cohort Study. ( Bergman, J; Nordström, A; Nordström, P, 2018) |
| "Osteoporosis is a global public health concern and, it can result from numerous pathogenic mechanisms, many of which are closely related with age, nutritional disorders, endocrine imbalance, or adverse drug side effects presented by glucocorticoids, heparin, and anti-epileptics." | 1.48 | Novel and rapid osteoporosis model established in zebrafish using high iron stress. ( Huang, Y; Leng, B; Li, X; Lin, J; Mei, X; Pan, Y; Qiu, J; Su, Y; Xing, C; Xu, J; Xue, Y; Zhang, W, 2018) |
| "Alendronate is a widely used drug for osteoporosis in the elderly and postmenopausal women." | 1.48 | Preventing muscle wasting by osteoporosis drug alendronate in vitro and in myopathy models via sirtuin-3 down-regulation. ( Chan, DC; Chiang, CK; Chiu, CY; Chiu, HC; Liu, SH; Yang, RS, 2018) |
| "Postmenopausal osteoporosis is a common disorder accompanied with estrogen deficiency in women." | 1.48 | In silico estrogen-like activity and in vivo osteoclastogenesis inhibitory effect of Cicer arietinum extract. ( Elfiky, AA; Sayed, AA, 2018) |
| "Chronic back pain is one of the most important complications of postmenopausal osteoporosis." | 1.46 | Alendronate inhibits hyperalgesia and suppresses neuropeptide markers of pain in a mouse model of osteoporosis. ( Iino, T; Kato, S; Naito, Y; Nakagawa, T; Sudo, A; Wakabayashi, H, 2017) |
| "Osteoporosis is characterised by trabecular bone loss resulting from increased osteoclast activation and unbalanced coupling between resorption and formation, which induces a thinning of trabeculae and trabecular perforations." | 1.46 | Long-term effects of bisphosphonate therapy: perforations, microcracks and mechanical properties. ( Abel, RL; Atwood, R; Bhattacharya, R; Boughton, OR; Cobb, JP; Goh, EL; Hansen, U; Jin, A; Karunaratne, A; Ma, S; Patel, B; Vo, NT, 2017) |
| "Patients with osteopenia showed statistically higher values of osteocyte density than patients with osteoporosis (P < 0." | 1.43 | Influence of osteoporosis on the osteocyte density of human mandibular bone samples: a controlled histological human study. ( Iezzi, G; Oliveira, PS; Perrotti, V; Piattelli, A; Rodrigues, JA; Shibli, JA, 2016) |
| "Odanacatib (ODN) is a selective and reversible CK inhibitor that inhibits bone loss in preclinical and clinical studies." | 1.43 | Odanacatib Restores Trabecular Bone of Skeletally Mature Female Rabbits With Osteopenia but Induces Brittleness of Cortical Bone: A Comparative Study of the Investigational Drug With PTH, Estrogen, and Alendronate. ( Bellare, JR; Bora, HK; Chattopadhyay, N; Khan, MP; Nagar, GK; Parameswaran, V; Sanyal, S; Shrivastava, P; Singh, AK; Tiwari, MC, 2016) |
| "Osteoporotic intertrochanteric fractures result in serious health problems and decrease health-related quality of life (HRQoL)." | 1.43 | Teriparatide Improves Fracture Healing and Early Functional Recovery in Treatment of Osteoporotic Intertrochanteric Fractures. ( Chuang, PY; Hsu, RW; Huang, KC; Huang, TW; Lee, CY; Lee, MS; Lin, SJ; Shen, WJ; Shih, HN, 2016) |
| "Osteoporosis was induced in rats by ovariectomy (OVX)." | 1.43 | Calcitonin alleviates hyperalgesia in osteoporotic rats by modulating serotonin transporter activity. ( Chan, JY; Chang, KW; Chen, TH; Cheng, JT; Chu, TH; Huang, SM; Ma, HS; Ma, KH; Shyu, JF; Wei, NK; Weng, SJ; Yeh, CB, 2016) |
| "Osteoporosis is a major health threat nowadays." | 1.43 | Use of drugs against osteoporosis in the Baltic countries during 2010-2014. ( Kõks, S; Laius, O; Maasalu, K; Märtson, A, 2016) |
| "Alendronate caused an increase in the pain threshold value and inhibited c-Fos expression." | 1.42 | Inhibitory effect of bisphosphonate on osteoclast function contributes to improved skeletal pain in ovariectomized mice. ( Abe, Y; Amizuka, N; Chiba, H; Iba, K; Kanaya, K; Kawamata, T; Oda, K; Sasaki, K; Sasaki, M; Yamashita, T, 2015) |
| "Alendronate is an antiosteoporotic drug that targets the mevalonate pathway." | 1.42 | Genetic polymorphisms in the mevalonate pathway affect the therapeutic response to alendronate treatment in postmenopausal Chinese women with low bone mineral density. ( Fu, WZ; Gu, JM; He, JW; Hu, WW; Hu, YQ; Li, M; Liu, YJ; Shao, C; Wang, C; Yue, H; Zhang, H; Zhang, ZL; Zheng, H, 2015) |
| "In 4 dogs, prednisolone was administered PO at a dosage of 2 mg/kg once daily for 2 weeks, 1 mg/kg once daily for 4 weeks, and 0." | 1.42 | Quantitative computed tomographic assessment of bone mineral density changes associated with administration of prednisolone or prednisolone and alendronate sodium in dogs. ( Cho, KO; Choi, J; Oh, J; Park, S; Son, KY, 2015) |
| "Bisphosphonates are effective for the treatment of osteoporosis despite recent reports of safety concerns such as atypical femur fracture." | 1.42 | Trends in Media Reports, Oral Bisphosphonate Prescriptions, and Hip Fractures 1996-2012: An Ecological Analysis. ( Bhattacharyya, T; Jha, S; Laucis, N; Wang, Z, 2015) |
| "Bisphosphonates are widely used to treat osteoporosis, but have been associated with atypical femoral fractures (AFFs) in the long term, which raises a critical health problem for the aging population." | 1.42 | Alendronate treatment alters bone tissues at multiple structural levels in healthy canine cortical bone. ( Acevedo, C; Allen, MR; Bale, H; Burr, DB; Busse, B; Gludovatz, B; Ritchie, RO; Schaible, E; Tang, SY; Wang, M; Wat, A; Zimmermann, EA, 2015) |
| "Zoledronic acid is a third-generation nitrogen-containing BP." | 1.40 | Pentoxifylline and tocopherol in the treatment of yearly zoledronic acid-related osteonecrosis of the jaw in a corticosteroid-induced osteoporosis. ( Magremanne, M; Reychler, H, 2014) |
| "Multiple therapies are approved for the treatment of osteoporosis (OP), but many patients with osteoporosis may not initiate treatment upon osteoporosis diagnosis." | 1.40 | Substantial under-treatment among women diagnosed with osteoporosis in a US managed-care population: a retrospective analysis. ( Gandhi, S; Modi, A; Sen, S; Siris, ES; Tang, J, 2014) |
| "Methionine treatment could be beneficial for the treatment of postmenopausal osteoporosis." | 1.40 | Methionine down-regulates TLR4/MyD88/NF-κB signalling in osteoclast precursors to reduce bone loss during osteoporosis. ( Gupta, S; Khandelwal, M; Manglani, K; Surolia, A; Vijayan, V, 2014) |
| "Ninety-seven prostate cancer patients treated with androgen deprivation therapy, and severe osteopenia or osteoporosis were retrospectively studied." | 1.40 | Bone mass behavior after 1 year of different treatment strategies in prostate cancer patients subjected to androgen deprivation therapy. ( Carles Galceran, J; Celma Domenech, A; Lorente Garcia, D; Morote Robles, J; Placer Santos, J; Planas Morin, J; Regis, L; Salvador Lacambra, C; Trilla Herrera, E, 2014) |
| "Individual agents used to treat human osteoporosis reduce fracture risk by ∼ 50-60%." | 1.40 | Effects of sequential osteoporosis treatments on trabecular bone in adult rats with low bone mass. ( Amugongo, SK; Dai, W; Dave, NK; Jia, J; Jiang, L; Lane, NE; Lay, YA; Li, CS; Olivera, D; Panganiban, B; Ritchie, RO; Walsh, D; Yao, W, 2014) |
| "Alendronate was stopped, and he was started on intravenous ibandronate injections given every 3 months." | 1.40 | Exacerbation of myasthenia gravis by alendronate. ( Alay, S; Güzelküçük, U; Kesikburun, S; Tan, AK; Yavuz, F, 2014) |
| "We term this strategy as the "local treatment of osteoporosis"." | 1.40 | Local treatment of osteoporosis with alendronate-loaded calcium phosphate cement. ( Li, G; Tang, H; Wang, J; Zhao, J, 2014) |
| "Alendronate (ALN) can increase bone mass and improve the microstructure of osteoporotic vertebrae, which might be helpful in preserving disc morphology and mechanical properties." | 1.39 | Alendronate retards the progression of lumbar intervertebral disc degeneration in ovariectomized rats. ( Hu, QF; Luo, Y; Song, HP; Su, YL; Wang, WY; Zhang, L; Zhang, YZ, 2013) |
| " Determinants associated with higher risk to non-persistence within the first year were daily dosing regimen [HR, 1." | 1.39 | Persistence with osteoporosis medication among newly-treated osteoporotic patients. ( de Boer, PT; Postma, MJ; van Boven, JF; Vegter, S, 2013) |
| "The guidance given in treating osteoporosis can potentially enhance adherence." | 1.39 | Differences in adherence to osteoporosis regimens: a 2-year analysis of a population treated under specific guidelines. ( Chen, SH; Cheng, TT; Hsu, CY; Su, BY; Yang, TS; Yu, SF, 2013) |
| "This study examined Barrett's esophagus (BE) risk factors in veterans to determine the association between risk of BE and use of oral bisphosphonates." | 1.39 | Oral bisphosphonates and the risk of Barrett's esophagus: case-control analysis of US veterans. ( Alsarraj, A; El-Serag, HB; Graham, DY; Kramer, JR; Lin, D; Parente, P; Ramsey, D; Rugge, M; Verstovsek, G, 2013) |
| "Breast or prostate cancer patients were treated with zoledronate." | 1.39 | Bisphosphonate-related osteonecrosis of jaw (BRONJ) in Japanese population: a case series of 13 patients at our clinic. ( Fujimoto, Y; Muramatsu, K; Murayama, M; Nakata, E; Nomura, T; Ogane, S; Sekine, R; Shibahara, T; Shibui, T; Uchiyama, T; Watanabe, A; Yakushiji, T; Yamamoto, N, 2013) |
| " Taking the weekly dosage of the drug was associated with a 7." | 1.39 | The impact of alendronate on bone mineral density of osteoporotic patients. ( Aghaei-Meybodi, H; Keshtkar, A; Khashayar, P; Montazeri, M; Rashidi, N, 2013) |
| "Patients with symptoms of osteoporosis, prostate cancer, or breast cancer were surveyed to determine their knowledge of bisphosphonates." | 1.38 | Awareness and education of patients receiving bisphosphonates. ( Bauer, JS; Beck, N; Eitner, S; Kiefer, J; Stockmann, P; Wichmann, M, 2012) |
| " However, an inverse dose-response relationship was seen, with an increased risk in those with low adherence (≤0." | 1.38 | Acute myocardial infarction and atherosclerosis of the coronary arteries in patients treated with drugs against osteoporosis: calcium in the vessels and not the bones? ( Vestergaard, P, 2012) |
| " As a preliminary study, the influences of applied AS dosage to CDHA coatings were evaluated using XRD and SEM." | 1.38 | Biomimetic coating of bisphosphonate incorporated CDHA on Ti6Al4V. ( Bhaduri, SB; Lawrence, JG; Touny, AH; Zhou, H, 2012) |
| "In addition, persons with high bone resorption in vitro on average had high levels of serum CTX." | 1.38 | Osteoclasts derived from patients with neurofibromatosis 1 (NF1) display insensitivity to bisphosphonates in vitro. ( Aro, HT; Heervä, E; Peltonen, J; Peltonen, S; Svedström, E; Väänänen, K, 2012) |
| " We did not find evidence for a reversal of fracture protection with long-term use of bisphosphonates." | 1.38 | Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy: a register-based cohort study using the US MarketScan claims databases. ( Abrahamsen, B; Pazianas, M; Russell, RG; Wang, Y, 2012) |
| " The present study was carried out to compare the effect of a novel agent glucosamine alendronate (GA) alone and is combination with dihydroquercetin (DHQ) against the effect of a known drug alendronate (ALN) in the senescence-accelerated OXYS rats as model of osteoporosis." | 1.38 | Efficacy of glucosamine alendronate alone & in combination with dihydroquercetin for treatment of osteoporosis in animal model. ( Kolosova, NG; Muraleva, NA; Ofitserov, EN; Tikhonov, VP, 2012) |
| "Pediatric osteoporosis is uncommon but can result in painful and debilitating insufficiency fractures." | 1.38 | Efficacy of alendronate in the treatment of low bone density in the pediatric and young adult population. ( Cheema, AM; Dominguez-Bartmess, SN; Szalay, EA; Tandberg, D, 2012) |
| "Poor persistence to treatment of osteoporosis should consequently be acknowledged as an important and costly health problem, and be taken into account when evaluating osteoporosis interventions." | 1.37 | The societal burden of poor persistence to treatment of osteoporosis in Sweden. ( Landfeldt, E; Lundkvist, J; Ström, O, 2011) |
| "Oral alendronate produces an increase in BMD in these patients, with good tolerance and no need for hospitalization, and so improves quality of life and reduces health care costs." | 1.37 | [Alendronate treatment of osteoporosis secondary to Duchenne muscular dystrophy]. ( Ballester Herrera, MJ; Carmona Vilchez, RM; Márquez de La Plata, MA; Medina Cano, E; Palomo Atance, E, 2011) |
| "Alendronate was effective for radiologic, biomechanical, and histologic success of spine fusion in an osteoporotic animal model." | 1.37 | The influence of alendronate on spine fusion in an osteoporotic animal model. ( Boden, SD; Kawakami, M; Minamide, A; Nakao, S; Yoshida, M, 2011) |
| "Osteoporotic fractures are associated with premature mortality." | 1.37 | Osteoporosis medication and reduced mortality risk in elderly women and men. ( Bliuc, D; Center, JR; Eisman, JA; Nguyen, ND; Nguyen, TV, 2011) |
| "Hip fractures are important because they are associated with an increased rate of death, substantial morbidity, enormous costs, and devastating effects on independence and quality of life." | 1.37 | Bisphosphonate-related subtrochanteric femoral fractures. ( Baxter, M; Gunawardena, I; Rasekh, Y, 2011) |
| " Among patients with osteoporosis in Taiwan who had experienced a fracture and had started alendronate therapy, compliance with the dosage regimen was suboptimal." | 1.37 | Alendronate adherence and its impact on hip-fracture risk in patients with established osteoporosis in Taiwan. ( Lin, SJ; Lin, TC; Yang, CY; Yang, YH, 2011) |
| "Rosiglitazone (RSG) is an insulin-sensitizing drug used to treat type 2 diabetes mellitus." | 1.37 | Effect of rosiglitazone on bone quality in a rat model of insulin resistance and osteoporosis. ( Fantus, IG; Grynpas, MD; Renlund, R; Sardone, LD; Willett, TL, 2011) |
| " Although existing evidence supports a good safety profile, there is concern that chronic administration of these agents could result in severe suppression of bone turnover with increased risk of nonvertebral fractures." | 1.36 | Unusual mid-shaft fractures during long-term bisphosphonate therapy. ( Levy, S; Odvina, CV; Rao, DS; Rao, S; Zerwekh, JE, 2010) |
| "Osteoporosis is accompanied by predominantly metaphyseal fractures with a delayed and qualitatively reduced healing process." | 1.36 | Do estrogen and alendronate improve metaphyseal fracture healing when applied as osteoporosis prophylaxis? ( Hoerster, AK; Kolios, L; Malcherek, MC; Rack, T; Sehmisch, S; Seidlova-Wuttke, D; Stuermer, EK; Stuermer, KM; Tezval, M; Wuttke, W, 2010) |
| "Male osteoporosis is not the epidemic problem that female osteoporosis is; however, the National Osteoporosis Foundation estimates that over 14 million American men have osteoporosis or low bone mass, and approximately 25% to 30% of all hip fractures occur in male individuals who incur greater morbidity and mortality than their female counterparts." | 1.36 | Intravenous zoledronic acid: what are the indications for male osteoporosis? ( Maricic, M, 2010) |
| " The bioavailability (BA) of alendronate in rats was approximately 8." | 1.36 | Development of a novel transdermal patch of alendronate, a nitrogen-containing bisphosphonate, for the treatment of osteoporosis. ( Abe, M; Hayashi, R; Hirai, Y; Kamiyama, F; Katsumi, H; Kusamori, K; Quan, YS; Sakai, R; Sakane, T; Ueda, A; Yamamoto, A, 2010) |
| "Pamidronate 30 mg was administered on 26 osteoporotic patients; and acute phase reactants, inflammatory cytokines and bone biomarkers were measured." | 1.36 | Acute effects of intravenous administration of pamidronate in patients with osteoporosis. ( Kwon, SR; Lim, MJ; Park, SG; Park, W, 2010) |
| "Alendronate was the most frequently implicated (six cases) and risedronate (five cases)." | 1.36 | [Jaw osteonecrosis induced by oral biphosphonates: 12 cases]. ( Barrier, A; Descroix, V; Goudot, P; Lescaille, G; Rigolet, A; Ruhin, B, 2010) |
| "Histopathologic analysis revealed a parathyroid adenoma." | 1.36 | Primary hyperparathyroidism with classic and severe skeletal involvement. ( Paz-Pacheco, E; Sandoval, MA, 2010) |
| " Strategies to improve adherence to osteoporosis therapy include reducing dosing frequency, changing the route of administration, educating the patient about optimum bisphosphonate administration, and sending patient reminders." | 1.35 | Maximizing effectiveness of bisphosphonate therapy for osteoporosis. ( Martens, MG; Shaw, H, 2008) |
| "Osteoporosis is widely prevalent in India and osteoporotic fractures are a common cause of morbidity and mortality." | 1.35 | Osteoporotic fracture management in India: a survey of orthopaedic surgeons. ( Lakhotia, SM, 2008) |
| " Although these agents are generally well tolerated, serious gastrointestinal adverse events, including hospitalization for gastrointestinal bleed, may arise." | 1.35 | Comparative gastrointestinal safety of weekly oral bisphosphonates. ( Brookhart, MA; Cadarette, SM; Katz, JN; Levin, R; Solomon, DH; Stedman, MR; Stürmer, T, 2009) |
| "Systemic mastocytosis is a rare but well-recognised cause of secondary osteoporosis, accounting for about 1." | 1.35 | Systemic mastocytosis presenting as osteoporosis--a case report. ( Dhillon, V; Mathew, R; Shepherd, P, 2009) |
| "A total of 196 consecutive patients treated for distal radius fractures were included in this study." | 1.35 | Comparison of radiographic fracture healing in the distal radius for patients on and off bisphosphonate therapy. ( Ayogu, N; Bouxsein, ML; Chacko, AT; Rozental, TD; Vazquez, MA, 2009) |
| "Osteoporosis is associated with the pathogenesis and risk of urolithiasis, which is higher among postmenopausal women (as opposed to premenopausal)." | 1.35 | Alendronate reduces the excretion of risk factors for calcium phosphate stone formation in postmenopausal women with osteoporosis. ( Hamamoto, S; Hirose, M; Itoh, Y; Kobayashi, T; Kohri, K; Okada, A; Tozawa, K; Yasui, T, 2009) |
| "Long-term treatment of osteoporosis is required for optimal efficacy, but adherence to therapy is suboptimal with daily and weekly oral bisphosphonates." | 1.35 | Persistence of weekly alendronate: a real-world study in Croatia. ( Babic-Naglic, D; Curkovic, B; Grazio, S; Kehler, T, 2008) |
| "Osteoporosis is a potential risk factor affecting implant stability following total joint arthroplasty." | 1.35 | Effect of preoperative combined treatment with alendronate and calcitriol on fixation of hydroxyapatite-coated implants in ovariectomized rats. ( Abu-Ali, S; Fotovati, A; Hayashi, K; Naito, M; Nakamura, Y, 2008) |
| "Alendronate was the reference category in all analyses." | 1.35 | Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture. ( Brookhart, MA; Cadarette, SM; Katz, JN; Solomon, DH; Stedman, MR; Stürmer, T, 2008) |
| "Treatment with alendronate improved trabecular volume and number by reducing bone resorption, although bone formation was also reduced through coupling of bone remodeling." | 1.34 | Age-related changes in marmoset trabecular and cortical bone and response to alendronate therapy resemble human bone physiology and architecture. ( Andresen, CJ; Bagi, CM; Berryman, E; Hanson, N; Moalli, M; Olson, E; Shen, V; Volberg, M, 2007) |
| "A history of fracture and a low bone mineral density (BMD) are the strongest predictors of future osteoporotic fracture." | 1.33 | Influence of fracture history and bone mineral density testing on the treatment of osteoporosis in two non-academic community centers. ( Adachi, JD; Goldsmith, CH; Hamel, ME; Papadimitropoulos, E; Petrie, A; Sebaldt, RJ; Siminoski, K, 2005) |
| "Granulomatous interstitial nephritis is a rare but characteristic hallmark of certain diseases such as sarcoidosis and tuberculosis." | 1.33 | Acute granulomatous interstitial nephritis secondary to bisphosphonate alendronate sodium. ( Fervenza, FC; Habermann, T; Lager, D; Leung, N; Peña de la Vega, L, 2005) |
| "Alendronate treatment of OPG-/- mice resulted in enhancement of the volume of heterotopic new bone." | 1.33 | Enhancement of crude bone morphogenetic protein-induced new bone formation and normalization of endochondral ossification by bisphosphonate treatment in osteoprotegerin-deficient mice. ( Goto, S; Kameyama, Y; Kawai, T; Kimura, M; Maeda, H; Miyazawa, K; Tabuchi, M, 2005) |
| "Sixty-two (52." | 1.33 | Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. ( Broumand, V; Fortin, M; Marx, RE; Sawatari, Y, 2005) |
| "Osteoporosis is a metabolic bone disease characterized by reduced bone mass and deterioration of bone microarchitecture." | 1.33 | Evaluation of modal damping factor as a diagnostic tool for osteoporosis and its relation with serum osteocalcin and collagen I N-telopeptide for monitoring the efficacy of alendronate in ovariectomized rats. ( Anastassopoulos, G; Christopoulou, GE; Karamanos, NK; Panagiotopoulos, E; Panteliou, SD; Papadaki, E; Stavropoulou, A, 2006) |
| "Alendronate has been studied extensively by large trials of high quality and its efficacy to reduce the risk of vertebral and nonvertebral fractures is in line with the criteria of evidence-based medicine." | 1.33 | [Drug therapy for prevention of falls and fractures]. ( Ringe, JD, 2006) |
| "In the rats with adjuvant arthritis, BMD of either end of the tibia was lower than in normal rats." | 1.33 | Differences in osteoclast formation between proximal and distal tibial osteoporosis in rats with adjuvant arthritis: inhibitory effects of bisphosphonates on osteoclasts. ( Nagashima, M; Shu, G; Yamamoto, K, 2006) |
| "Here we report 29 cases of bone necrosis of the jaws in patients treated with pamidronate (Aredia), zoledronate (Zometa) and alendronate: 15 underwent surgical procedures and 14 occurred spontaneously." | 1.33 | Bone necrosis of the jaws associated with bisphosphonate treatment: a report of twenty-nine cases. ( Bonaninil, M; Corcione, L; Corradi, D; D'Aleo, P; Ferrari, S; Guidotti, R; Manfredi, M; Meleti, M; Merigo, E; Poli, T; Ripasarti, A; Sesenna, E; Vescovi, P; Zanzucchi, E, 2006) |
| "Hadju-Cheney syndrome is characterized by short stature, distinctive facies, and a slowly progressive skeletal dysplasia including acro-osteolysis." | 1.32 | Hadju-Cheney syndrome: response to therapy with bisphosphonates in two patients. ( Drake, WM; Hiorns, MP; Kendler, DL, 2003) |
| "Alendronate is a bisphosphonate compound used to treat diseases of pathologic bone resorption." | 1.32 | Superficial gyrate erythema as a cutaneous reaction to alendronate for osteoporosis. ( Cockerell, CJ; Cohen, JB; High, WA; Wetherington, W, 2003) |
| "Alendronate is a drug that is being used to increase bone mineral content in patients with poor bone quality." | 1.32 | [Simulation through the method of finite element of alendronate in a model of bone remodeling based on damage mechanics]. ( Doblaré, M; García, JM; Zeman, ME, 2003) |
| "Male osteoporosis is an important disease, with 25-30% of all hip fractures occurring in men." | 1.32 | An investigation of the predictors of bone mineral density and response to therapy with alendronate in osteoporotic men. ( Drake, WM; Kendler, DL; Orwoll, ES; Rosen, CJ, 2003) |
| "Subjects were patients that were treated for osteoporosis at Department for physical medicine and rehabilitation in Clinical hospital Dubrava." | 1.32 | [Weekly and daily intake of alendronate: comparison of tolerance in osteoporosis treatment]. ( Badovinac, O; Delija, A; Sakić, D; Sakić, VA, 2004) |
| "Less than daily alendronate dosing has been identified as an attractive alternative to daily dosing for patients and physicians." | 1.31 | Long-term predictions of the therapeutic equivalence of daily and less than daily alendronate dosing. ( Beaupré, GS; Carter, DR; Hernandez, CJ; Marcus, R, 2002) |
| "Up to 80-90% of patients with treatment-requiring osteoporosis are not receiving specific treatment." | 1.31 | [Weeks of pain, vertebral body fractures during sleep, invalidism. Save your osteoporosis patients from this fate]. ( Begerow, B; Hinz, C; Minne, HW; Pfeifer, M; Pollähne, W, 2002) |
| "One class of agents used to treat osteoporosis is the bisphosphonates, which inhibit bone resorption, cause an increase in bone mineral density and reduce the risk of future fractures caused by aging, estrogen deficiency and corticosteroid use." | 1.31 | Bisphosphonates: safety and efficacy in the treatment and prevention of osteoporosis. ( Bone, H; Greenspan, SL; Harris, ST; Miller, PD; Orwoll, ES; Rosen, CJ; Watts, NB, 2000) |
| "Most CR investigated and treated osteoporosis themselves, 13% referred to other specialists for investigation, and 22% referred for treatment." | 1.31 | A Canadian survey on the management of corticosteroid induced osteoporosis by rheumatologists. ( Adachi, JD; Bellamy, N; Campbell, J; Flynn, J; Pope, JE; Soucy, E; Sutton, E, 2000) |
| "Alendronate is an aminobisphosphonate that inhibits bone resorption in osteoporotic humans and rats but does not induce osteomalacia." | 1.31 | Alendronate administration and skeletal response during chronic alcohol intake in the adolescent male rat. ( Emanuele, MA; Lapaglia, N; Moskal, SF; Steiner, J; Wezeman, FH, 2000) |
| " The study was designed as a dose-response study, and the site-specific effects of immobilization and of treatment are described." | 1.31 | Treatment with risedronate or alendronate prevents hind-limb immobilization-induced loss of bone density and strength in adult female rats. ( Mackey, MS; Mosekilde, L; Phipps, RJ; Thomsen, JS, 2000) |
| " The bisphosphonate alendronate was recently approved for once-a-week dosing for the prevention and treatment of postmenopausal osteoporosis." | 1.31 | Osteoporosis. Efficacy and safety of a bisphosphonate dosed once weekly. ( Baran, D, 2001) |
| "Many women now survive breast cancer, but find themselves at increased risk of menopausal complications." | 1.31 | Managing menopause after breast cancer: balancing risks and benefits. ( Moore, HC, 2001) |
| "Treatment with alendronate 10 mg/day improved bone density and back pain." | 1.31 | Male osteoporosis associated with longterm cyproterone treatment. ( Swinson, DR; Vasireddy, S, 2001) |
| "Osteoporosis is a substantial cause of morbidity and mortality in the United States." | 1.31 | Use of a peripheral dexa measurement for osteoporosis screening. ( Kirk, JK; Nichols, M; Spangler, JG, 2002) |
| "However, the role of bone resorption in the initial rapid phase of bone loss characteristic of glucocorticoid-induced osteoporosis is unexplained, and the reason for the efficacy of bisphosphonates in this condition remains unknown." | 1.31 | Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids. ( Bellido, T; Chen, JR; Jilka, RL; Landes, RD; Manolagas, SC; Parfitt, AM; Powers, CC; Stewart, SA; Weinstein, RS, 2002) |
| "Issues relating to the treatment of the osteoporosis as well as the lymphoma arise in patients that present in this way." | 1.31 | Lymphoplasmacytoid lymphoma presenting as severe osteoporosis. ( Atoyebi, W; Brown, M; Hatton, C; Littlewood, TJ; Wass, J, 2002) |
| "Acute toxicity studies showed that the LD50 values of oral alendronate in female animals corresponded to human oral doses of 27,800 mg in rats and 48,300 mg in mice; LD50 values in male animals were even higher." | 1.30 | Preclinical safety profile of alendronate. ( Peter, C; Rodan, GA, 1999) |
| "All the urinary markers of bone resorption showed a prompt decline after bisphosphonates, with maximum reductions after 7-14 days: Pyr decreased by 43% +/- 9% and 42% +/- 22% (mean +/- SD), respectively in osteoporotic and pagetic subjects, OHP by 51% +/- 14% and 51% +/- 20%, and NTx by 55% +/- 15% and 65% +/- 26%." | 1.29 | Acute effects of bisphosphonates on new and traditional markers of bone resorption. ( Alfano, FS; Basini, G; Campanini, C; Fantuzzi, M; Gatti, C; Girasole, G; Passeri, M; Pedrazzoni, M, 1995) |
| "Osteoporosis has major medical and economic costs and consequences for society, yet the most effective strategies to pursue in reducing these costs and consequences are uncertain." | 1.29 | Outcomes assessment in osteoporosis: strategies for improvement. ( Chrischilles, E, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 88 (8.26) | 18.2507 |
| 2000's | 466 (43.76) | 29.6817 |
| 2010's | 382 (35.87) | 24.3611 |
| 2020's | 129 (12.11) | 2.80 |
| Authors | Studies |
|---|---|
| Soper, DL | 1 |
| Milbank, JB | 1 |
| Mieling, GE | 1 |
| Dirr, MJ | 1 |
| Kende, AS | 1 |
| Cooper, R | 1 |
| Jee, WS | 1 |
| Yao, W | 2 |
| Chen, JL | 1 |
| Bodman, M | 1 |
| Lundy, MW | 1 |
| De, B | 1 |
| Stella, ME | 1 |
| Ebetino, FH | 1 |
| Wang, Y | 5 |
| deLong, MA | 1 |
| Wos, JA | 1 |
| Xie, H | 1 |
| Chen, G | 1 |
| Young, RN | 2 |
| Thomasius, F | 3 |
| Palacios, S | 2 |
| Alam, A | 1 |
| Boolell, M | 2 |
| Vekeman, F | 2 |
| Gauthier, G | 1 |
| Kim, PG | 1 |
| Niroula, A | 1 |
| Shkolnik, V | 1 |
| McConkey, M | 1 |
| Lin, AE | 1 |
| Słabicki, M | 1 |
| Kemp, JP | 1 |
| Bick, A | 1 |
| Gibson, CJ | 1 |
| Griffin, G | 1 |
| Sekar, A | 1 |
| Brooks, DJ | 1 |
| Wong, WJ | 1 |
| Cohen, DN | 1 |
| Uddin, MM | 1 |
| Shin, WJ | 1 |
| Pirruccello, J | 1 |
| Tsai, JM | 1 |
| Agrawal, M | 1 |
| Kiel, DP | 4 |
| Bouxsein, ML | 3 |
| Richards, JB | 1 |
| Evans, DM | 1 |
| Wein, MN | 1 |
| Charles, JF | 1 |
| Jaiswal, S | 1 |
| Natarajan, P | 1 |
| Ebert, BL | 1 |
| Tsuda, E | 2 |
| Fukuda, C | 2 |
| Okada, A | 3 |
| Karibe, T | 1 |
| Hiruma, Y | 2 |
| Takagi, N | 1 |
| Isumi, Y | 1 |
| Yamamoto, T | 3 |
| Hasegawa, T | 2 |
| Uehara, S | 1 |
| Koide, M | 1 |
| Udagawa, N | 1 |
| Amizuka, N | 3 |
| Kumakura, S | 1 |
| Shaul, JL | 1 |
| Hill, RS | 1 |
| Burr, DB | 10 |
| Tilton, AK | 1 |
| Howe, JG | 1 |
| Viggers, R | 1 |
| Al-Mashhadi, Z | 1 |
| Starup-Linde, J | 1 |
| Vestergaard, P | 6 |
| Zhao, S | 1 |
| Zhao, W | 3 |
| Du, D | 1 |
| Zhang, C | 4 |
| Zhao, T | 1 |
| Zheng, L | 1 |
| Jin, L | 1 |
| Gu, M | 2 |
| Xu, J | 3 |
| Yang, Z | 3 |
| Tanaka, I | 1 |
| Tanaka, Y | 7 |
| Soen, S | 8 |
| Oshima, H | 1 |
| Qiu, Z | 1 |
| Lin, C | 3 |
| Zhang, Y | 5 |
| Deng, J | 1 |
| Wu, M | 2 |
| Jing, C | 1 |
| Li, B | 4 |
| Tan, H | 1 |
| Liang, H | 1 |
| Na, H | 1 |
| Chen, S | 2 |
| Liu, C | 2 |
| Zhao, L | 1 |
| Hayes, KN | 3 |
| Brown, KA | 2 |
| Cheung, AM | 3 |
| Kim, SA | 1 |
| Juurlink, DN | 2 |
| Cadarette, SM | 6 |
| Jensen, P | 1 |
| Jakobsen, LH | 1 |
| Bøgsted, M | 1 |
| Baech, J | 1 |
| Lykkeboe, S | 1 |
| Severinsen, MT | 1 |
| El-Galaly, TC | 1 |
| Gossiel, F | 1 |
| Ugur, A | 1 |
| Peel, NFA | 1 |
| Walsh, JS | 1 |
| Eastell, R | 8 |
| Khalid, S | 1 |
| Calderon-Larranaga, S | 1 |
| Sami, A | 1 |
| Hawley, S | 1 |
| Judge, A | 1 |
| Arden, N | 1 |
| Van Staa, TP | 1 |
| Cooper, C | 4 |
| Abrahamsen, B | 7 |
| Javaid, MK | 1 |
| Prieto-Alhambra, D | 6 |
| Xiong, Z | 1 |
| Yi, P | 1 |
| Tang, X | 1 |
| Shu, L | 1 |
| Radwan, A | 1 |
| Shraim, N | 1 |
| Elaraj, J | 1 |
| Hamad, A | 1 |
| Fatayer, D | 1 |
| Jarar, B | 1 |
| Johar, A | 1 |
| Zriqah, A | 1 |
| Miller, PD | 6 |
| Adachi, JD | 14 |
| Albergaria, BH | 1 |
| Chines, AA | 1 |
| Gielen, E | 1 |
| Langdahl, BL | 2 |
| Miyauchi, A | 1 |
| Oates, M | 1 |
| Reid, IR | 3 |
| Santiago, NR | 1 |
| Vanderkelen, M | 1 |
| Wang, Z | 4 |
| Yu, Z | 1 |
| Liu, ZM | 1 |
| Zhang, M | 2 |
| Zong, Y | 1 |
| Zhang, D | 4 |
| Shen, ZB | 1 |
| Guan, XQ | 1 |
| Yin, F | 1 |
| Migliorini, F | 2 |
| Colarossi, G | 2 |
| Eschweiler, J | 2 |
| Oliva, F | 1 |
| Driessen, A | 1 |
| Maffulli, N | 3 |
| Mitsuboshi, S | 1 |
| Kaseda, R | 1 |
| Narita, I | 1 |
| González Macías, J | 1 |
| Olmos Martínez, JM | 1 |
| Kocijan, R | 1 |
| Stockinger, T | 1 |
| Haschka, J | 1 |
| Reichardt, B | 1 |
| Resch, H | 1 |
| Zwerina, J | 1 |
| Behanova, M | 1 |
| Morkos, M | 1 |
| Mahrous, P | 1 |
| Casagrande, A | 1 |
| Go, MT | 1 |
| Husni, H | 1 |
| Hanna, M | 1 |
| Goel, M | 1 |
| Bedrose, S | 1 |
| Li, D | 2 |
| Baim, S | 1 |
| Lin, SY | 1 |
| Chen, YM | 2 |
| Chen, WJ | 1 |
| Li, CY | 2 |
| Ku, CK | 1 |
| Chen, CH | 1 |
| Chien, LN | 1 |
| Xi, Y | 1 |
| Wang, W | 1 |
| Ma, L | 1 |
| Xu, N | 1 |
| Shi, C | 2 |
| Xu, G | 1 |
| He, H | 1 |
| Pan, W | 1 |
| Kydonaki, EK | 1 |
| Freitas, L | 1 |
| Reguengo, H | 1 |
| Simón, CR | 1 |
| Bastos, AR | 1 |
| Fernandes, EM | 1 |
| Canadas, RF | 1 |
| Oliveira, JM | 1 |
| Correlo, VM | 1 |
| Reis, RL | 1 |
| Vliora, M | 1 |
| Gkiata, P | 1 |
| Koutedakis, Y | 1 |
| Ntina, G | 1 |
| Pinto, R | 1 |
| Carrillo, AE | 1 |
| Marques, F | 1 |
| Amorim, T | 1 |
| Li, M | 9 |
| Zhang, Z | 2 |
| Xue, Q | 1 |
| Li, Q | 3 |
| Jin, X | 1 |
| Dong, J | 1 |
| Cheng, Q | 1 |
| You, L | 1 |
| Lin, H | 1 |
| Tang, H | 4 |
| Shen, L | 1 |
| Gao, X | 2 |
| Hu, J | 3 |
| Chao, A | 1 |
| Li, P | 2 |
| Shi, R | 1 |
| Zheng, S | 1 |
| Xiong, X | 1 |
| Yu, W | 1 |
| Xia, W | 2 |
| Pluskiewicz, W | 2 |
| Adamczyk, P | 1 |
| Drozdzowska, B | 2 |
| Wu, X | 2 |
| Li, Y | 7 |
| Huang, J | 4 |
| McConnell, M | 1 |
| Shieh, A | 1 |
| Mori, S | 6 |
| Hagino, H | 5 |
| Sugimoto, T | 8 |
| Tanaka, S | 7 |
| Mitomo, Y | 1 |
| Takahashi, K | 1 |
| Sone, T | 5 |
| Nakamura, T | 15 |
| Johnson, JW | 1 |
| von Stade, D | 1 |
| Gadomski, B | 1 |
| Easley, J | 1 |
| Nelson, B | 1 |
| Bisazza, K | 1 |
| Regan, D | 1 |
| Troyer, K | 1 |
| Zhou, T | 1 |
| McGilvray, K | 1 |
| Mannino, F | 1 |
| D'Angelo, T | 1 |
| Pallio, G | 1 |
| Ieni, A | 1 |
| Pirrotta, I | 1 |
| Giorgi, DA | 1 |
| Scarfone, A | 1 |
| Mazziotti, S | 1 |
| Booz, C | 1 |
| Bitto, A | 3 |
| Squadrito, F | 3 |
| Irrera, N | 3 |
| Heo, J | 1 |
| Kim, M | 2 |
| Kim, JH | 1 |
| Shin, H | 1 |
| Lim, SE | 1 |
| Jung, HS | 1 |
| Sohn, Y | 1 |
| Ku, J | 1 |
| Zheng, G | 1 |
| Ma, HW | 1 |
| Xiang, GH | 1 |
| He, GL | 1 |
| Cai, HC | 1 |
| Dai, ZH | 1 |
| Chen, YL | 1 |
| Lin, Y | 1 |
| Xu, HZ | 2 |
| Ni, WF | 1 |
| Xu, C | 1 |
| Liu, HX | 1 |
| Wang, XY | 1 |
| Wu, CH | 4 |
| Li, CC | 1 |
| Hsu, YH | 1 |
| Liang, FW | 1 |
| Chang, YF | 2 |
| Hwang, JS | 5 |
| Fuggle, N | 1 |
| Al-Daghri, N | 1 |
| Bock, O | 1 |
| Branco, J | 1 |
| Bruyère, O | 1 |
| Casado, E | 1 |
| Cavalier, E | 1 |
| Cortet, B | 3 |
| de Wit, M | 1 |
| Giusti, A | 2 |
| Halbout, P | 2 |
| Harvey, NC | 2 |
| Hiligsmann, M | 3 |
| Kaufman, JM | 2 |
| Kurth, A | 1 |
| Maggi, S | 3 |
| Matijevic, R | 1 |
| Minisola, S | 3 |
| Radermecker, RP | 1 |
| Tuzun, S | 1 |
| Veronese, N | 2 |
| Kanis, JA | 5 |
| Reginster, JY | 8 |
| Rizzoli, R | 3 |
| Ganapathy, A | 3 |
| Nieves, JW | 4 |
| Keaveny, TM | 5 |
| Cosman, F | 6 |
| Narayanasamy, M | 3 |
| Bishop, S | 4 |
| Sahota, O | 4 |
| Paskins, Z | 4 |
| Gittoes, N | 4 |
| Langley, T | 4 |
| Biernat, M | 3 |
| Szwed-Georgiou, A | 3 |
| Rudnicka, K | 3 |
| Płociński, P | 3 |
| Pagacz, J | 3 |
| Tymowicz-Grzyb, P | 3 |
| Woźniak, A | 3 |
| Włodarczyk, M | 3 |
| Urbaniak, MM | 3 |
| Krupa, A | 3 |
| Rusek-Wala, P | 3 |
| Karska, N | 3 |
| Rodziewicz-Motowidło, S | 3 |
| Wang, Q | 4 |
| Yu, Q | 3 |
| Zeng, P | 3 |
| Ai, W | 3 |
| Badary, DM | 3 |
| Galal, HA | 3 |
| Abdelraheim, MH | 3 |
| Sedeek, MI | 3 |
| Mohamed, NM | 3 |
| Abd Elmageed, ZY | 3 |
| Farrag, MMY | 3 |
| Klara, J | 2 |
| Lewandowska-Łańcucka, J | 2 |
| Rodríguez, AJ | 1 |
| Nerlekar, N | 1 |
| Ebeling, PR | 1 |
| Abdulaal, WH | 1 |
| Hosny, KM | 4 |
| Alhakamy, NA | 1 |
| Bakhaidar, RB | 1 |
| Almuhanna, Y | 1 |
| Sabei, FY | 1 |
| Alissa, M | 1 |
| Majrashi, M | 1 |
| Alamoudi, JA | 1 |
| Hazzazi, MS | 1 |
| Jafer, A | 1 |
| Khallaf, RA | 1 |
| Ayers, C | 1 |
| Kansagara, D | 1 |
| Lazur, B | 1 |
| Fu, R | 1 |
| Kwon, A | 1 |
| Harrod, C | 1 |
| Nicolopoulos, K | 2 |
| Moshi, MR | 2 |
| Stringer, D | 2 |
| Ma, N | 2 |
| Jenal, M | 2 |
| Vreugdenburg, T | 2 |
| Jeffery, TC | 1 |
| Chang, AB | 1 |
| Conwell, LS | 1 |
| Huang, W | 1 |
| Nagao, M | 1 |
| Yonemoto, N | 1 |
| Guo, S | 1 |
| Tanigawa, T | 1 |
| Nishizaki, Y | 1 |
| Yang, D | 1 |
| Tan, J | 2 |
| Long, Y | 1 |
| Huang, K | 2 |
| Han, W | 1 |
| Wang, M | 2 |
| Zhu, S | 2 |
| Zeng, S | 1 |
| Yi, W | 1 |
| Zhao, Y | 1 |
| Kang, H | 1 |
| Zhuang, P | 1 |
| Tu, R | 1 |
| Goto, T | 1 |
| Li, F | 1 |
| Dai, H | 1 |
| Mousavi, S | 1 |
| Vakili, S | 1 |
| Zal, F | 1 |
| Savardashtaki, A | 1 |
| Jafarinia, M | 1 |
| Sabetian, S | 1 |
| Razmjoue, D | 1 |
| Veisi, A | 1 |
| Azadbakht, O | 1 |
| Sabaghan, M | 1 |
| Behrouj, H | 1 |
| Villagómez Vega, A | 1 |
| Gámez Nava, JI | 1 |
| Ruiz González, F | 1 |
| Pérez Romero, M | 1 |
| Trujillo Rangel, WÁ | 1 |
| Nuño Arana, I | 1 |
| Eisman, JA | 7 |
| Ionescu-Ittu, R | 1 |
| Heroux, J | 1 |
| Lefeuvre, L | 1 |
| Caruso, A | 1 |
| Biver, E | 1 |
| Fayolle, D | 1 |
| Silverman, SS | 1 |
| Singer, AJ | 1 |
| Pearman, L | 1 |
| Mathew, J | 1 |
| Caminis, J | 1 |
| Lin, TC | 4 |
| Arora, T | 1 |
| Zhao, H | 2 |
| Balasubramanian, A | 1 |
| Stad, RK | 1 |
| O'Kelly, J | 1 |
| Spangler, L | 1 |
| Bradbury, BD | 1 |
| Curtis, JR | 5 |
| Aryani, T | 1 |
| Budiatin, AS | 1 |
| Maulidina, A | 1 |
| Firdaus, AI | 1 |
| Gani, MA | 1 |
| Nisak, K | 1 |
| Khotib, J | 1 |
| Syukriya, AJ | 1 |
| Camargo, WA | 2 |
| Hoekstra, JW | 1 |
| Jansen, JA | 2 |
| van den Beucken, JJJP | 3 |
| Bhardwaj, A | 2 |
| Swe, KMM | 1 |
| Sinha, NK | 2 |
| Amigues, C | 1 |
| Fresse, A | 1 |
| Roux, CH | 1 |
| Gauthier, S | 1 |
| Vieillard, MH | 1 |
| Drici, MD | 1 |
| Breuil, V | 1 |
| Wang, CY | 3 |
| Yang, TH | 2 |
| Fu, SH | 3 |
| Chen, HM | 4 |
| Lin, JW | 3 |
| Hsu, CC | 2 |
| Chan, DC | 5 |
| Yang, RS | 6 |
| Huang, CF | 1 |
| Yang, JJ | 1 |
| Lee, CC | 1 |
| Lin, SC | 1 |
| Leng, Y | 1 |
| Yu, X | 2 |
| Yang, Y | 3 |
| Xia, Y | 1 |
| Xiao, Y | 2 |
| Chen, Y | 2 |
| Huang, Y | 2 |
| Tan, EH | 1 |
| Robinson, DE | 1 |
| Jödicke, AM | 1 |
| Mosseveld, M | 1 |
| Bødkergaard, K | 1 |
| Reyes, C | 1 |
| Moayyeri, A | 1 |
| Voss, A | 1 |
| Marconi, E | 1 |
| Lapi, F | 1 |
| Reinold, J | 1 |
| Verhamme, KMC | 1 |
| Pedersen, L | 1 |
| Braitmaier, M | 1 |
| de Wilde, M | 1 |
| Ruiz, MF | 1 |
| Aragón, M | 1 |
| Bosco-Levy, P | 1 |
| Lassalle, R | 1 |
| Sanchez-Santos, MT | 1 |
| Tian, L | 1 |
| Luo, C | 1 |
| Li, YF | 1 |
| Wang, QY | 1 |
| Qu, XL | 1 |
| Yue, C | 1 |
| Xu, LL | 1 |
| Yang, YY | 1 |
| Sheng, ZF | 1 |
| Everts-Graber, J | 1 |
| Bonel, H | 1 |
| Lehmann, D | 1 |
| Gahl, B | 1 |
| Häuselmann, H | 1 |
| Studer, U | 1 |
| Ziswiler, HR | 1 |
| Reichenbach, S | 1 |
| Lehmann, T | 1 |
| Li, S | 1 |
| Chang, J | 1 |
| Narayanasamy, MJ | 1 |
| Corp, N | 1 |
| Bastounis, A | 1 |
| Griffin, J | 1 |
| Leonardi-Bee, J | 1 |
| Fernandes, TL | 1 |
| Viezzer Fernandes, B | 1 |
| Jitumori, C | 1 |
| Franco, GCN | 1 |
| Taguchi, A | 1 |
| Ozaki, T | 1 |
| Arai, K | 1 |
| Ohta, H | 4 |
| Shiraki, M | 12 |
| Unal, E | 2 |
| Abaci, A | 2 |
| Bober, E | 2 |
| Büyükgebiz, A | 2 |
| Gehrke, B | 1 |
| Alves Coelho, MC | 1 |
| Brasil d'Alva, C | 1 |
| Madeira, M | 1 |
| Sun, M | 1 |
| Jia, W | 1 |
| Jiao, K | 1 |
| Wang, S | 1 |
| Liu, Y | 1 |
| Liu, L | 1 |
| Dai, Z | 1 |
| Jiang, X | 2 |
| Yang, T | 1 |
| Luo, Y | 2 |
| Cheng, Z | 1 |
| Wang, H | 3 |
| Liu, G | 1 |
| Sibonga, J | 2 |
| Matsumoto, T | 5 |
| Jones, J | 2 |
| Shapiro, J | 2 |
| Lang, T | 3 |
| Shackelford, L | 2 |
| Smith, SM | 2 |
| Young, M | 1 |
| Keyak, J | 2 |
| Kohri, K | 3 |
| Ohshima, H | 2 |
| Spector, E | 2 |
| LeBlanc, A | 2 |
| Bliuc, D | 3 |
| Tran, T | 2 |
| van Geel, T | 2 |
| Berger, C | 2 |
| van den Bergh, J | 2 |
| Geusens, P | 2 |
| Goltzman, D | 2 |
| Hanley, DA | 9 |
| Josse, R | 3 |
| Kaiser, S | 2 |
| Kovacs, CS | 2 |
| Langsetmo, L | 2 |
| Prior, JC | 2 |
| Nguyen, TV | 3 |
| Center, JR | 3 |
| Bauer, DC | 6 |
| Conley, RB | 1 |
| Adib, G | 1 |
| Adler, RA | 4 |
| Åkesson, KE | 2 |
| Alexander, IM | 1 |
| Amenta, KC | 1 |
| Blank, RD | 1 |
| Brox, WT | 1 |
| Carmody, EE | 1 |
| Chapman-Novakofski, K | 1 |
| Clarke, BL | 1 |
| Cody, KM | 1 |
| Crandall, CJ | 1 |
| Dirschl, DR | 1 |
| Eagen, TJ | 1 |
| Elderkin, AL | 1 |
| Fujita, M | 1 |
| Greenspan, SL | 9 |
| Hochberg, MC | 3 |
| Javaid, M | 1 |
| Jeray, KJ | 1 |
| Kearns, AE | 1 |
| King, T | 1 |
| Koinis, TF | 1 |
| Koontz, JS | 1 |
| Kužma, M | 1 |
| Lindsey, C | 1 |
| Lorentzon, M | 3 |
| Lyritis, GP | 1 |
| Michaud, LB | 1 |
| Miciano, A | 1 |
| Morin, SN | 1 |
| Mujahid, N | 1 |
| Napoli, N | 2 |
| Olenginski, TP | 1 |
| Puzas, JE | 1 |
| Rizou, S | 1 |
| Rosen, CJ | 4 |
| Saag, K | 1 |
| Thompson, E | 1 |
| Tosi, LL | 1 |
| Tracer, H | 1 |
| Khosla, S | 3 |
| Iba, K | 3 |
| Takada, J | 2 |
| Sonoda, T | 1 |
| Yamashita, T | 3 |
| Cipriani, C | 1 |
| Bilezikian, JP | 4 |
| Tough DeSapri, K | 1 |
| Batur, P | 1 |
| Kong, F | 1 |
| Jia, B | 1 |
| Cui, P | 1 |
| Wang, D | 1 |
| Pham, CV | 1 |
| Pham, TT | 1 |
| Lai, TT | 1 |
| Trinh, DC | 1 |
| Nguyen, HVM | 1 |
| Ha, TTM | 1 |
| Phuong, TT | 1 |
| Tran, LD | 1 |
| Winkler, C | 1 |
| To, TT | 1 |
| Qian, S | 1 |
| Zhou, J | 3 |
| Bian, P | 1 |
| Shi, L | 2 |
| Lukert, BP | 1 |
| Nayak, S | 4 |
| Iwata, A | 1 |
| Kanayama, M | 1 |
| Oha, F | 1 |
| Shimamura, Y | 1 |
| Hashimoto, T | 1 |
| Takahata, M | 3 |
| Iwasaki, N | 4 |
| Sato, D | 2 |
| Ota, M | 2 |
| Fujita, R | 1 |
| Chen, YJ | 1 |
| Kung, PT | 1 |
| Chou, WY | 1 |
| Tsai, WC | 1 |
| Compston, J | 2 |
| Fontalis, A | 1 |
| Diba, M | 1 |
| Zinkevich, T | 1 |
| Grünewald, A | 1 |
| Detsch, R | 1 |
| Kabiri, Y | 1 |
| Kentgens, APM | 1 |
| Boccaccini, AR | 1 |
| Leeuwenburgh, SCG | 1 |
| Ma, Y | 1 |
| Han, X | 1 |
| Wang, X | 4 |
| Liu, S | 3 |
| Bi, J | 1 |
| Song, Q | 1 |
| Yu, M | 1 |
| Sun, X | 1 |
| Qu, D | 1 |
| Lesclous, P | 1 |
| Cloitre, A | 1 |
| Catros, S | 1 |
| Devoize, L | 1 |
| Louvet, B | 1 |
| Châtel, C | 1 |
| Foissac, F | 1 |
| Roux, C | 2 |
| Zeng, Y | 2 |
| Zhou, M | 1 |
| Mou, S | 1 |
| Yang, J | 2 |
| Yuan, Q | 1 |
| Guo, L | 1 |
| Zhong, A | 1 |
| Wang, J | 4 |
| Sun, J | 2 |
| Kurosawa, S | 1 |
| Doki, N | 1 |
| Senoo, Y | 1 |
| Kishida, Y | 1 |
| Nagata, A | 1 |
| Yamada, Y | 1 |
| Konishi, T | 1 |
| Kaito, S | 1 |
| Yoshifuji, K | 1 |
| Matsuyama, N | 1 |
| Shirane, S | 1 |
| Uchida, T | 1 |
| Inamoto, K | 1 |
| Toya, T | 1 |
| Igarashi, A | 1 |
| Najima, Y | 1 |
| Muto, H | 1 |
| Kobayashi, T | 2 |
| Kakihana, K | 1 |
| Sakamaki, H | 1 |
| Ohashi, K | 1 |
| Liu, B | 2 |
| Qin, MZ | 1 |
| Liu, JP | 1 |
| Huang, G | 1 |
| Ma, Z | 1 |
| Qin, S | 1 |
| Jia, P | 1 |
| Wang, R | 2 |
| Yuan, J | 1 |
| Chen, H | 3 |
| Bao, L | 1 |
| Feng, F | 1 |
| Eskandarynasab, M | 1 |
| Doustimotlagh, AH | 1 |
| Takzaree, N | 1 |
| Etemad-Moghadam, S | 1 |
| Alaeddini, M | 1 |
| Dehpour, AR | 2 |
| Goudarzi, R | 1 |
| Partoazar, A | 1 |
| Kim, Y | 1 |
| Tian, Y | 3 |
| Huser, V | 1 |
| Jin, P | 1 |
| Lambert, CG | 1 |
| Park, H | 1 |
| You, SC | 1 |
| Park, RW | 1 |
| Rijnbeek, PR | 1 |
| Van Zandt, M | 1 |
| Reich, C | 1 |
| Vashisht, R | 1 |
| Wu, Y | 1 |
| Duke, J | 1 |
| Hripcsak, G | 1 |
| Madigan, D | 1 |
| Shah, NH | 1 |
| Ryan, PB | 1 |
| Schuemie, MJ | 1 |
| Suchard, MA | 1 |
| Miyamura, G | 3 |
| Wakabayashi, H | 4 |
| Nagao, N | 2 |
| Kato, S | 4 |
| Nakagawa, T | 3 |
| Naito, Y | 4 |
| Sudo, A | 4 |
| Fitzpatrick, LA | 1 |
| Mitlak, B | 1 |
| Deal, C | 3 |
| McClung, M | 3 |
| Nguyen, PV | 1 |
| Bouin, M | 1 |
| Ste-Marie, LG | 3 |
| Tian, C | 1 |
| Wong, BL | 1 |
| Hornung, L | 1 |
| Khoury, JC | 1 |
| Rybalsky, I | 1 |
| Shellenbarger, KC | 1 |
| Rutter, MM | 1 |
| Liu, H | 3 |
| Guo, Y | 2 |
| Zhu, R | 1 |
| Wang, L | 5 |
| Chen, B | 2 |
| Li, R | 1 |
| Ma, R | 1 |
| Jia, Q | 1 |
| Zhang, H | 3 |
| Xia, B | 1 |
| Zhu, X | 1 |
| Zhang, R | 3 |
| Brӧmme, D | 1 |
| Gao, S | 1 |
| Pei, X | 1 |
| Liu, Q | 1 |
| Chen, D | 1 |
| Ye, Z | 1 |
| Jin, Z | 1 |
| Ma, T | 2 |
| Huang, X | 2 |
| Bagger, LW | 1 |
| Hansen, PKD | 1 |
| Schwarz, P | 1 |
| Nielsen, BR | 1 |
| Katz, J | 1 |
| Rotstein, I | 1 |
| Zhu, J | 1 |
| Jia, J | 2 |
| Guan, Z | 1 |
| Sun, T | 1 |
| Zhang, W | 2 |
| Yuan, W | 2 |
| Leng, H | 1 |
| Song, C | 1 |
| Yang, M | 1 |
| Ren, M | 1 |
| Tao, ZS | 1 |
| Söreskog, E | 1 |
| Lindberg, I | 1 |
| Willems, D | 1 |
| Ström, O | 6 |
| Berling, P | 1 |
| Borgström, F | 4 |
| He, N | 1 |
| Miyazaki-Asato, Y | 1 |
| Koi, K | 1 |
| Fujimoto, H | 1 |
| Kakura, K | 1 |
| Kido, H | 1 |
| Yanagi, T | 1 |
| Yamashita, J | 2 |
| Sartori, L | 4 |
| Bianchi, G | 1 |
| Barone, A | 1 |
| Black, DM | 3 |
| Zheng, WB | 1 |
| Dai, Y | 1 |
| Zhao, DC | 1 |
| Wang, O | 5 |
| Jiang, Y | 6 |
| Xia, WB | 5 |
| Xing, XP | 5 |
| Sifrig, B | 1 |
| Grozenski, A | 1 |
| Brown, L | 1 |
| Coleman, J | 1 |
| Sabry, M | 1 |
| Mostafa, S | 1 |
| Rashed, L | 1 |
| Abdelgwad, M | 1 |
| Kamar, S | 1 |
| Estaphan, S | 1 |
| Rino, Y | 1 |
| Aoyama, T | 1 |
| Atsumi, Y | 1 |
| Yamada, T | 1 |
| Yukawa, N | 2 |
| Eltit, F | 1 |
| Cox, M | 1 |
| Almohaileb, FI | 1 |
| Rasheed, Z | 1 |
| Uebelhart, B | 1 |
| Ferrari, S | 3 |
| Hoque, J | 1 |
| Shih, YV | 1 |
| Newman, H | 1 |
| Sangaj, N | 1 |
| Arjunji, N | 1 |
| Varghese, S | 1 |
| Sasaki, K | 4 |
| Cromer, SJ | 1 |
| D'Silva, KM | 1 |
| Yu, EW | 1 |
| Landon, J | 1 |
| Desai, RJ | 1 |
| Kim, SC | 1 |
| Brown, JP | 6 |
| Engelke, K | 1 |
| Chines, A | 1 |
| Chapurlat, R | 3 |
| Foldes, AJ | 1 |
| Nogues, X | 1 |
| Civitelli, R | 1 |
| De Villiers, T | 1 |
| Massari, F | 1 |
| Zerbini, CAF | 1 |
| Oates, MK | 1 |
| Recknor, C | 2 |
| Libanati, C | 1 |
| Barbosa, JS | 1 |
| Pinto, M | 1 |
| Barreiro, S | 1 |
| Fernandes, C | 1 |
| Mendes, RF | 1 |
| Lavrador, P | 1 |
| Gaspar, VM | 1 |
| Mano, JF | 1 |
| Borges, F | 1 |
| Remião, F | 1 |
| Braga, SS | 1 |
| Paz, FAA | 1 |
| Cai, M | 1 |
| Zhu, H | 1 |
| Wang, C | 3 |
| Min, W | 1 |
| Yan, L | 1 |
| Abdel-Gawad, SA | 1 |
| Afzal, O | 1 |
| Arab, HH | 1 |
| Alabbas, AB | 1 |
| Alqarni, AM | 1 |
| Tingart, M | 1 |
| Betsch, M | 1 |
| Faverani, LP | 3 |
| Polo, TOB | 1 |
| Ramalho-Ferreira, G | 3 |
| Momesso, GAC | 1 |
| Hassumi, JS | 1 |
| Rossi, AC | 1 |
| Freire, AR | 1 |
| Prado, FB | 2 |
| Luvizuto, ER | 1 |
| Gruber, R | 1 |
| Okamoto, R | 3 |
| Liu, CT | 1 |
| Yuan, XJ | 1 |
| Gao, GC | 1 |
| Martín-Merino, E | 1 |
| Huerta-Álvarez, C | 1 |
| Montero-Corominas, D | 1 |
| Roh, YH | 1 |
| Koh, YD | 1 |
| Noh, JH | 1 |
| Gong, HS | 1 |
| Baek, GH | 1 |
| Mostafavinia, A | 4 |
| Ahadi, R | 1 |
| Abdollahifar, M | 1 |
| Ghorishi, SK | 1 |
| Jalalifirouzkouhi, A | 1 |
| Bayat, M | 6 |
| Eom, SY | 1 |
| Yim, DH | 1 |
| Hong, SM | 1 |
| Kim, YD | 1 |
| Kim, H | 1 |
| Choi, BS | 1 |
| Park, JD | 1 |
| Park, CH | 1 |
| Kim, GB | 1 |
| Yu, SD | 1 |
| Shanb, AA | 1 |
| Youssef, EF | 1 |
| Muaidi, QI | 1 |
| Alothman, AA | 1 |
| Eiken, PA | 2 |
| Unnanuntana, A | 1 |
| Jarusriwanna, A | 1 |
| Songcharoen, P | 1 |
| Aljohani, S | 2 |
| Fliefel, R | 1 |
| Ihbe, J | 1 |
| Kühnisch, J | 1 |
| Ehrenfeld, M | 1 |
| Otto, S | 1 |
| Nikfar, Z | 1 |
| Shariatinia, Z | 1 |
| Sequetto, PL | 1 |
| Gonçalves, RV | 1 |
| Pinto, AS | 1 |
| Oliveira, MGA | 1 |
| Maldonado, IRSC | 1 |
| Oliveira, TT | 1 |
| Novaes, RD | 1 |
| Barak, U | 1 |
| Rosenthal, Y | 1 |
| Arami, A | 1 |
| Kosashvili, Y | 1 |
| Velkes, S | 1 |
| Allen, MR | 6 |
| McNerny, E | 1 |
| Aref, M | 1 |
| Organ, JM | 1 |
| Newman, CL | 1 |
| McGowan, B | 1 |
| Jang, T | 1 |
| Brown, DM | 1 |
| Hammond, M | 1 |
| Territo, PR | 1 |
| Persohn, S | 1 |
| Jiang, L | 2 |
| Riley, AA | 1 |
| McCarthy, BP | 1 |
| Hutchins, GD | 1 |
| Wallace, JM | 1 |
| Chen, YC | 2 |
| Lin, WC | 2 |
| Liu, ZW | 1 |
| Wu, Q | 1 |
| Chen, YF | 1 |
| Xu, P | 1 |
| Xie, HH | 1 |
| Yang, S | 1 |
| Dehdehi, L | 1 |
| Ghoreishi, SK | 1 |
| Hajihossainlou, B | 2 |
| Hsu, E | 1 |
| Nanes, M | 1 |
| Ren, H | 1 |
| Shen, G | 1 |
| Tang, J | 2 |
| Qiu, T | 1 |
| Yao, Z | 1 |
| Lou, J | 1 |
| Wen, G | 1 |
| Dong, K | 1 |
| Lange, U | 1 |
| Classen, K | 1 |
| Müller-Ladner, U | 1 |
| Richter, M | 1 |
| Nafee, N | 1 |
| Zewail, M | 1 |
| Boraie, N | 1 |
| Bergman, J | 1 |
| Nordström, A | 1 |
| Nordström, P | 1 |
| Vico-Alonso, C | 1 |
| Maroñas-Jiménez, L | 1 |
| Lozano-Morillo, F | 1 |
| Gomes, CC | 1 |
| Freitas, DQ | 1 |
| Medeiros Araújo, AM | 1 |
| Ramírez-Sotelo, LR | 1 |
| Yamamoto-Silva, FP | 1 |
| de Freitas Silva, BS | 1 |
| de Melo Távora, D | 1 |
| Almeida, SM | 1 |
| Lv, F | 1 |
| Guan, Y | 1 |
| Ma, D | 1 |
| Xu, X | 1 |
| Song, Y | 1 |
| Li, L | 1 |
| Xing, X | 1 |
| Qiu, J | 1 |
| Xing, C | 1 |
| Li, X | 1 |
| Leng, B | 1 |
| Su, Y | 1 |
| Lin, J | 3 |
| Mei, X | 1 |
| Pan, Y | 1 |
| Xue, Y | 1 |
| Saag, KG | 12 |
| Petersen, J | 1 |
| Grauer, A | 1 |
| Song, GG | 1 |
| Lee, YH | 1 |
| Lewis, JR | 1 |
| Schousboe, JT | 2 |
| Prince, RL | 1 |
| Tsourdi, E | 1 |
| Rachner, TD | 1 |
| Hofbauer, LC | 3 |
| Ferrari, SL | 1 |
| McCadden, L | 1 |
| Leonard, CG | 1 |
| Primrose, WJ | 1 |
| Chiu, HC | 1 |
| Chiu, CY | 1 |
| Liu, SH | 1 |
| Chiang, CK | 1 |
| Iseri, K | 1 |
| Iyoda, M | 1 |
| Watanabe, M | 1 |
| Matsumoto, K | 1 |
| Sanada, D | 1 |
| Inoue, T | 4 |
| Tachibana, S | 1 |
| Shibata, T | 1 |
| Wallis, C | 1 |
| Ding, N | 1 |
| Yao, L | 1 |
| Bai, Y | 1 |
| Cheng, P | 1 |
| Li, Z | 3 |
| Luo, K | 1 |
| Mei, T | 1 |
| Li, J | 3 |
| Xing, J | 1 |
| Ma, Q | 1 |
| Luo, F | 1 |
| Dou, C | 1 |
| Fallahnezhad, S | 2 |
| Amini, A | 2 |
| Chien, S | 1 |
| Dadras, S | 1 |
| Rezaei, F | 2 |
| Chiu, WY | 2 |
| Yang, WS | 2 |
| Chien, JY | 2 |
| Lee, JJ | 3 |
| Tsai, KS | 4 |
| Sayed, AA | 1 |
| Elfiky, AA | 1 |
| Sing, CW | 1 |
| Wong, AY | 1 |
| Cheung, EY | 1 |
| Lam, JK | 1 |
| Cheung, TT | 1 |
| Chan, EW | 1 |
| Kung, AW | 1 |
| Wong, IC | 1 |
| Cheung, CL | 1 |
| Rizg, WY | 1 |
| Geng, T | 1 |
| Chen, X | 1 |
| Zheng, M | 1 |
| Yu, H | 1 |
| Zhang, S | 1 |
| Sun, S | 1 |
| Guo, H | 1 |
| Jin, Q | 1 |
| Tamechika, SY | 1 |
| Hayami, Y | 1 |
| Ohmura, SI | 1 |
| Maeda, S | 1 |
| Iwagaitsu, S | 1 |
| Naniwa, T | 1 |
| Inoue, Y | 3 |
| Mitsunaga, K | 1 |
| Chiba, K | 1 |
| Yamaide, F | 1 |
| Nakano, T | 2 |
| Morita, Y | 1 |
| Yamaide, A | 1 |
| Suzuki, S | 2 |
| Arima, T | 2 |
| Yamaguchi, KI | 1 |
| Tomiita, M | 2 |
| Shimojo, N | 2 |
| Kohno, Y | 2 |
| Winzenrieth, R | 2 |
| Humbert, L | 1 |
| Di Gregorio, S | 2 |
| Bonel, E | 2 |
| García, M | 2 |
| Del Rio, L | 3 |
| Boche, M | 1 |
| Pokharkar, V | 1 |
| Aggarwal, HK | 1 |
| Jain, D | 1 |
| Chhabra, P | 1 |
| Yadav, RK | 1 |
| Kaga, Y | 1 |
| Ishii, S | 1 |
| Kuroda, I | 2 |
| Kamiya, Y | 1 |
| Nakamura, K | 1 |
| Kanemura, H | 1 |
| Sugita, K | 1 |
| Aihara, M | 1 |
| Wu, C | 1 |
| Chen, W | 1 |
| Lin, R | 1 |
| Wu, J | 1 |
| Zhang, X | 1 |
| Wang, YK | 1 |
| Zhang, YM | 1 |
| Qin, SQ | 1 |
| Guo, JB | 1 |
| Zhu, C | 1 |
| Luo, ZJ | 1 |
| van Houdt, CIA | 1 |
| Gabbai-Armelin, PR | 1 |
| Lopez-Perez, PM | 1 |
| Ulrich, DJO | 1 |
| Renno, ACM | 1 |
| Songpatanasilp, T | 1 |
| Rojanasthien, S | 1 |
| Sugkraroek, P | 1 |
| Ongphiphadhanakul, B | 1 |
| Robert, L | 1 |
| Robert, CS | 1 |
| Luevitoonvechkij, S | 1 |
| Santora, AC | 5 |
| Pan, BL | 1 |
| Tong, ZW | 1 |
| Li, SD | 1 |
| Wu, L | 1 |
| Liao, JL | 1 |
| Yang, YX | 1 |
| Li, HH | 1 |
| Dai, YJ | 1 |
| Li, JE | 1 |
| Pan, L | 1 |
| Iino, T | 2 |
| Josse, RG | 4 |
| Yamamoto, K | 3 |
| Kishino, M | 1 |
| Nakamura, S | 1 |
| Tokushige, K | 1 |
| Zhao, J | 2 |
| Shi, D | 1 |
| Meng, Y | 1 |
| Zuo, L | 1 |
| Gürler, EB | 1 |
| Çilingir-Kaya, ÖT | 1 |
| Peker Eyüboglu, I | 1 |
| Ercan, F | 1 |
| Akkiprik, M | 1 |
| Reiter, RJ | 1 |
| Yegen, BÇ | 1 |
| Pedersen, AB | 1 |
| Heide-Jørgensen, U | 1 |
| Sørensen, HT | 1 |
| Ehrenstein, V | 1 |
| Piao, C | 1 |
| Ding, J | 1 |
| Kong, D | 1 |
| Asadipooya, K | 1 |
| Weinstock, A | 1 |
| Wan, JM | 1 |
| Zhang, JF | 1 |
| Zhang, PL | 1 |
| Zhu, SY | 1 |
| Ban, JK | 1 |
| Athanasiadis, G | 1 |
| Burden, AM | 1 |
| Mao, Z | 1 |
| Zhu, Y | 1 |
| Hao, W | 1 |
| Chu, C | 1 |
| Su, H | 1 |
| Sano, H | 1 |
| Poole, K | 1 |
| Swenson, ED | 2 |
| Hansen, KE | 2 |
| Jones, AN | 2 |
| Baltz-Ward, B | 1 |
| Schuna, AA | 2 |
| Elliott, ME | 2 |
| Zhang, L | 2 |
| Wang, WY | 1 |
| Hu, QF | 1 |
| Song, HP | 1 |
| Su, YL | 1 |
| Zhang, YZ | 1 |
| Cheng, SJ | 1 |
| Wang, JJ | 2 |
| Chiang, CP | 1 |
| Chang, HH | 1 |
| Kok, SH | 1 |
| Mahmood, K | 1 |
| Koubar, S | 1 |
| Shofer, SL | 1 |
| Ninan, NA | 1 |
| Wahidi, MM | 1 |
| Kharazmi, M | 1 |
| Hallberg, P | 1 |
| Persson, U | 1 |
| Warfvinge, G | 1 |
| Amiri, AH | 1 |
| Tarrahi, MJ | 1 |
| Krieger, E | 1 |
| Jacobs, C | 1 |
| Walter, C | 1 |
| Wehrbein, H | 1 |
| van Boven, JF | 1 |
| de Boer, PT | 1 |
| Postma, MJ | 1 |
| Vegter, S | 1 |
| Olsen, KR | 1 |
| Hansen, C | 1 |
| Ahmed, OA | 1 |
| Al-Abdali, RT | 1 |
| Derakhshanian, H | 1 |
| Djalali, M | 1 |
| Djazayery, A | 1 |
| Nourijelyani, K | 1 |
| Ghadbeigi, S | 1 |
| Pishva, H | 1 |
| Saedisomeolia, A | 1 |
| Bahremand, A | 1 |
| Panahifar, A | 1 |
| Mahmoudi, M | 1 |
| Doschak, MR | 1 |
| Kendler, DL | 3 |
| Macarios, D | 1 |
| Lillestol, MJ | 1 |
| Moffett, A | 1 |
| Satram-Hoang, S | 1 |
| Kaur, P | 1 |
| Tang, ET | 1 |
| Wagman, RB | 1 |
| Horne, R | 1 |
| Imai, K | 2 |
| Di Fede, O | 2 |
| Fusco, V | 1 |
| Matranga, D | 1 |
| Solazzo, L | 1 |
| Gabriele, M | 1 |
| Gaeta, GM | 1 |
| Favia, G | 1 |
| Sprini, D | 1 |
| Peluso, F | 1 |
| Colella, G | 1 |
| Vescovi, P | 4 |
| Campisi, G | 2 |
| Ábalos-Medina, GM | 1 |
| Fernández Rodríguez, I | 1 |
| del Mar Almagro Ratia, M | 1 |
| Fuentes Ellauri, MA | 1 |
| Cheng, TT | 2 |
| Yu, SF | 2 |
| Hsu, CY | 1 |
| Chen, SH | 1 |
| Su, BY | 1 |
| Yang, TS | 1 |
| Lin, D | 2 |
| Kramer, JR | 1 |
| Ramsey, D | 1 |
| Alsarraj, A | 1 |
| Verstovsek, G | 1 |
| Rugge, M | 1 |
| Parente, P | 1 |
| Graham, DY | 1 |
| El-Serag, HB | 1 |
| Magremanne, M | 1 |
| Reychler, H | 1 |
| Nomura, T | 1 |
| Shibahara, T | 1 |
| Uchiyama, T | 1 |
| Yamamoto, N | 1 |
| Shibui, T | 1 |
| Yakushiji, T | 1 |
| Watanabe, A | 1 |
| Muramatsu, K | 1 |
| Ogane, S | 1 |
| Murayama, M | 1 |
| Sekine, R | 1 |
| Nakata, E | 1 |
| Fujimoto, Y | 1 |
| Pi, HY | 1 |
| Yan, YF | 1 |
| Hou, HR | 1 |
| Liu, MY | 1 |
| Fang, FS | 1 |
| Pei, Y | 1 |
| Li, CL | 1 |
| Chavassieux, P | 3 |
| Meunier, PJ | 6 |
| Roux, JP | 3 |
| Portero-Muzy, N | 1 |
| Pierre, M | 1 |
| Iolascon, G | 1 |
| Gimigliano, F | 1 |
| Orlando, V | 1 |
| Capaldo, A | 1 |
| Di Somma, C | 3 |
| Menditto, E | 1 |
| Siris, ES | 2 |
| Modi, A | 2 |
| Gandhi, S | 1 |
| Sen, S | 1 |
| Vijayan, V | 1 |
| Khandelwal, M | 1 |
| Manglani, K | 1 |
| Gupta, S | 1 |
| Surolia, A | 1 |
| Frankel, B | 1 |
| Krishna, V | 1 |
| Vandergrift, A | 1 |
| Nicholas, J | 1 |
| Vaishya, R | 1 |
| Vaish, A | 1 |
| Nadeem, A | 1 |
| Kuroshima, S | 1 |
| Entezami, P | 1 |
| McCauley, LK | 1 |
| Elshal, MF | 1 |
| Almalki, AL | 1 |
| Hussein, HK | 1 |
| Khan, JA | 1 |
| Ikeda, T | 1 |
| Maruyama, K | 1 |
| Kaji, H | 3 |
| Akagi, M | 1 |
| Ochi, Y | 1 |
| Yamada, H | 2 |
| Mori, H | 2 |
| Kawada, N | 1 |
| Kayasuga, R | 1 |
| Nakanishi, Y | 1 |
| Tanaka, M | 2 |
| Imagawa, A | 1 |
| Ohmoto, K | 1 |
| Kawabata, K | 1 |
| Yang, L | 1 |
| Tian, JH | 1 |
| He, ZY | 1 |
| Tang, XL | 1 |
| Yang, KH | 1 |
| Thompson, RN | 1 |
| Armstrong, CL | 1 |
| Heyburn, G | 1 |
| Heervä, E | 2 |
| Huilaja, L | 1 |
| Leinonen, P | 1 |
| Peltonen, S | 2 |
| Peltonen, J | 2 |
| Borm, JM | 1 |
| Moser, S | 1 |
| Locher, M | 1 |
| Damerau, G | 1 |
| Stadlinger, B | 1 |
| Grätz, KW | 2 |
| Jacobsen, C | 2 |
| Aghaei-Meybodi, H | 1 |
| Rashidi, N | 1 |
| Montazeri, M | 1 |
| Keshtkar, A | 1 |
| Khashayar, P | 1 |
| Nagase, S | 1 |
| Ohyama, M | 1 |
| Hashimoto, Y | 1 |
| Small, M | 1 |
| Sharpe, J | 1 |
| Manako, J | 1 |
| Kuwayama, T | 1 |
| Deacon, S | 1 |
| Yang, CY | 3 |
| Kao Yang, YH | 1 |
| Lin, SJ | 4 |
| Shiomi, K | 1 |
| Nagata, Y | 2 |
| Kiyono, T | 1 |
| Harada, A | 3 |
| Hashimoto, N | 1 |
| Peng, YL | 1 |
| Hu, HY | 1 |
| Luo, JC | 1 |
| Hou, MC | 1 |
| Lin, HC | 1 |
| Lee, FY | 1 |
| Lee, CH | 1 |
| Yang, YH | 2 |
| Lopalco, G | 1 |
| Rigante, D | 1 |
| Vitale, A | 1 |
| Frediani, B | 1 |
| Iannone, F | 1 |
| Cantarini, L | 1 |
| Planas Morin, J | 1 |
| Celma Domenech, A | 1 |
| Placer Santos, J | 1 |
| Trilla Herrera, E | 1 |
| Salvador Lacambra, C | 1 |
| Lorente Garcia, D | 1 |
| Regis, L | 1 |
| Carles Galceran, J | 1 |
| Morote Robles, J | 1 |
| Chatterjee, R | 1 |
| Bajoria, R | 1 |
| Shah, FT | 1 |
| Porter, JB | 1 |
| Fedele, S | 2 |
| Abe, Y | 1 |
| Chiba, H | 1 |
| Kanaya, K | 1 |
| Kawamata, T | 1 |
| Oda, K | 1 |
| Sasaki, M | 2 |
| Hosoi, T | 5 |
| Miki, T | 2 |
| Gorai, I | 2 |
| Yoshikawa, H | 1 |
| Ito, M | 6 |
| Matsui, S | 1 |
| Yoneda, T | 1 |
| Takami, H | 1 |
| Watanabe, K | 1 |
| Osakabe, T | 1 |
| Fukunaga, M | 8 |
| Atik, OS | 2 |
| Oztürk, AM | 2 |
| Kunat, C | 1 |
| Cetinkaya, M | 1 |
| Kaptan, Y | 1 |
| Ballas, EG | 1 |
| Mavrogenis, AF | 1 |
| Karamanis, E | 1 |
| Kokkalis, ZT | 1 |
| Mitsiokapa, E | 1 |
| Koulalis, D | 1 |
| Mastrokalos, D | 1 |
| Papagelopoulos, PJ | 1 |
| Hazzaa, HH | 1 |
| Amin, G | 1 |
| Abo Hager, EA | 1 |
| El Shiekh, MA | 1 |
| Amugongo, SK | 1 |
| Lay, YA | 1 |
| Dai, W | 1 |
| Walsh, D | 1 |
| Li, CS | 1 |
| Dave, NK | 1 |
| Olivera, D | 1 |
| Panganiban, B | 1 |
| Ritchie, RO | 2 |
| Lane, NE | 4 |
| Juang, JM | 1 |
| Abetel, G | 1 |
| Zhou, PR | 2 |
| Liu, HJ | 1 |
| Liao, EY | 2 |
| Zhang, ZL | 3 |
| Chen, DC | 2 |
| Liu, J | 2 |
| Wu, W | 2 |
| Xu, L | 2 |
| Vohra, F | 1 |
| Al-Rifaiy, MQ | 1 |
| Almas, K | 1 |
| Javed, F | 1 |
| Kesikburun, S | 1 |
| Güzelküçük, U | 1 |
| Alay, S | 1 |
| Yavuz, F | 1 |
| Tan, AK | 1 |
| Alsalleeh, F | 1 |
| Keippel, J | 1 |
| Adams, L | 1 |
| Bavitz, B | 1 |
| Chen, SY | 1 |
| Yu, HT | 1 |
| Kao, JP | 1 |
| Yang, CC | 1 |
| Chiang, SS | 1 |
| Mishchuk, DO | 1 |
| Mau, JL | 1 |
| Slupsky, CM | 1 |
| Bhadada, SK | 1 |
| Sridhar, S | 1 |
| Muthukrishnan, J | 1 |
| Mithal, A | 1 |
| Sharma, DC | 1 |
| Bhansali, A | 1 |
| Dhiman, V | 1 |
| Zheng, H | 1 |
| He, JW | 1 |
| Yue, H | 1 |
| Hu, WW | 1 |
| Gu, JM | 1 |
| Shao, C | 1 |
| Fu, WZ | 1 |
| Hu, YQ | 1 |
| Liu, YJ | 1 |
| Miyakoshi, N | 2 |
| Aizawa, T | 1 |
| Sasaki, S | 1 |
| Ando, S | 1 |
| Maekawa, S | 2 |
| Aonuma, H | 1 |
| Tsuchie, H | 1 |
| Sasaki, H | 2 |
| Kasukawa, Y | 2 |
| Shimada, Y | 2 |
| Huh, JE | 1 |
| Kim, SJ | 1 |
| Kang, JW | 1 |
| Nam, DW | 1 |
| Choi, DY | 1 |
| Park, DS | 1 |
| Lee, JD | 1 |
| Hatori, K | 1 |
| Camargos, GV | 1 |
| Chatterjee, M | 1 |
| Faot, F | 1 |
| Duyck, J | 1 |
| Vandamme, K | 1 |
| Liu, YQ | 1 |
| Han, XF | 1 |
| Liu, T | 1 |
| Cheng, MC | 1 |
| Xiao, HB | 1 |
| Landfeldt, E | 5 |
| Garellick, G | 1 |
| McCarthy, EF | 1 |
| Iwamoto, J | 7 |
| Uzawa, M | 4 |
| Fadda, V | 1 |
| Maratea, D | 1 |
| Trippoli, S | 1 |
| Messori, A | 1 |
| Li, G | 1 |
| Khedgikar, V | 1 |
| Ahmad, N | 1 |
| Kushwaha, P | 1 |
| Gautam, J | 1 |
| Nagar, GK | 2 |
| Singh, D | 1 |
| Trivedi, PK | 1 |
| Mishra, PR | 1 |
| Sangwan, NS | 1 |
| Trivedi, R | 1 |
| Oliveira, PS | 1 |
| Rodrigues, JA | 1 |
| Shibli, JA | 1 |
| Piattelli, A | 1 |
| Iezzi, G | 1 |
| Perrotti, V | 1 |
| Park, S | 1 |
| Oh, J | 1 |
| Son, KY | 1 |
| Cho, KO | 1 |
| Choi, J | 1 |
| de Bakker, CM | 1 |
| Altman, AR | 1 |
| Tseng, WJ | 1 |
| Tribble, MB | 1 |
| Li, C | 1 |
| Chandra, A | 1 |
| Qin, L | 1 |
| Liu, XS | 1 |
| Piscitelli, P | 1 |
| Auriemma, R | 1 |
| Neglia, C | 1 |
| Migliore, A | 1 |
| Rodriguez-Tolra, J | 1 |
| Khan, A | 1 |
| Dubois, S | 1 |
| Khan, AA | 1 |
| Zohair Rahman, M | 1 |
| Ahmed Khan, O | 1 |
| Syed, HT | 1 |
| Derzko, C | 1 |
| Sakai, A | 2 |
| Tomomitsu, T | 2 |
| Tsurukami, H | 1 |
| Ikeda, S | 2 |
| Fukuda, F | 1 |
| Mizunuma, H | 2 |
| Saito, H | 3 |
| Bae, J | 1 |
| Park, JW | 1 |
| Pasqualetti, S | 1 |
| Congiu, T | 1 |
| Banfi, G | 1 |
| Mariotti, M | 1 |
| Kaneko, K | 1 |
| Takahashi, H | 1 |
| Fridoni, M | 3 |
| Masteri Farahani, R | 1 |
| Nejati, H | 2 |
| Salimi, M | 2 |
| Gharavi, SM | 1 |
| Torkman, G | 1 |
| Bayat, S | 3 |
| Conti, V | 1 |
| Russomanno, G | 1 |
| Corbi, G | 1 |
| Toro, G | 1 |
| Simeon, V | 1 |
| Filippelli, W | 1 |
| Ferrara, N | 1 |
| Grimaldi, M | 1 |
| D'Argenio, V | 1 |
| Filippelli, A | 1 |
| Okano, H | 1 |
| Furuya, T | 1 |
| Urano, T | 1 |
| Hasegawa, M | 2 |
| Hirabayashi, H | 1 |
| Kumakubo, T | 1 |
| Makita, K | 1 |
| Cankaya, D | 1 |
| Tabak, Y | 1 |
| Gunay, MC | 1 |
| Järvinen, TL | 1 |
| Michaëlsson, K | 1 |
| Aspenberg, P | 2 |
| Sievänen, H | 1 |
| Garcia, IR | 1 |
| Grossi-Oliveira, GA | 1 |
| Okamoto, T | 1 |
| Cummings, SR | 2 |
| Steve Fan, CP | 1 |
| Sajjan, S | 1 |
| Ho, CH | 1 |
| Tsai, YS | 1 |
| Tsai, KT | 1 |
| Chen, LX | 2 |
| Ning, GZ | 2 |
| Zhou, ZR | 2 |
| Li, YL | 2 |
| Wu, QL | 1 |
| Zhang, TS | 2 |
| Cheng, L | 1 |
| Feng, SQ | 3 |
| Jha, S | 1 |
| Laucis, N | 1 |
| Bhattacharyya, T | 1 |
| Xu, XJ | 1 |
| Acevedo, C | 1 |
| Bale, H | 1 |
| Gludovatz, B | 1 |
| Wat, A | 1 |
| Tang, SY | 2 |
| Busse, B | 1 |
| Zimmermann, EA | 1 |
| Schaible, E | 1 |
| Kobayashi, N | 1 |
| Inaba, Y | 1 |
| Uchiyama, M | 1 |
| Ike, H | 1 |
| Kubota, S | 1 |
| Saito, T | 2 |
| Zhang, G | 2 |
| Fan, J | 1 |
| Chen, J | 1 |
| Aoki, T | 1 |
| Atsumi, T | 1 |
| Kawahito, Y | 1 |
| Nakayama, H | 3 |
| Tohma, S | 1 |
| Yamanishi, Y | 1 |
| Hasegawa, H | 1 |
| Tanimura, K | 1 |
| Negoro, N | 1 |
| Ueki, Y | 1 |
| Kawakami, A | 1 |
| Eguchi, K | 1 |
| Saito, K | 2 |
| Okada, Y | 2 |
| Schoppmeyer, M | 1 |
| Khan, MP | 1 |
| Singh, AK | 2 |
| Shrivastava, P | 1 |
| Tiwari, MC | 1 |
| Bora, HK | 1 |
| Parameswaran, V | 1 |
| Sanyal, S | 1 |
| Bellare, JR | 1 |
| Chattopadhyay, N | 1 |
| Naruse, K | 1 |
| Uchida, K | 2 |
| Suto, M | 1 |
| Miyagawa, K | 1 |
| Kawata, A | 1 |
| Urabe, K | 1 |
| Takaso, M | 1 |
| Itoman, M | 1 |
| Mikuni-Takagaki, Y | 1 |
| Stephens, MH | 1 |
| Grey, A | 1 |
| Fernandez, J | 1 |
| Kalluru, R | 1 |
| Faasse, K | 1 |
| Horne, A | 1 |
| Petrie, KJ | 1 |
| Al-Bogami, MM | 1 |
| Alkhorayef, MA | 1 |
| Bystrom, J | 1 |
| Akanle, OA | 1 |
| Al-Adhoubi, NK | 1 |
| Jawad, AS | 1 |
| Mageed, RA | 1 |
| Su, FM | 1 |
| Lai, HM | 1 |
| Martín Siguero, A | 1 |
| Áreas Del Águila, VL | 1 |
| Franco Sereno, MT | 1 |
| Fernández Marchante, AI | 1 |
| Pérez Serrano, R | 1 |
| Encinas Barrios, C | 1 |
| Acar, N | 1 |
| Balkarli, H | 1 |
| Soyuncu, Y | 1 |
| Ozbey, O | 1 |
| Celik-Ozenci, C | 1 |
| Korkusuz, P | 1 |
| Ustunel, I | 1 |
| Xu, LH | 1 |
| Adams-Huet, B | 1 |
| Poindexter, JR | 1 |
| Maalouf, NM | 1 |
| Ghatrehsamani, M | 2 |
| Abdollahifar, MA | 2 |
| Najar, A | 1 |
| Jandoc, R | 1 |
| Mamdani, M | 1 |
| Lévesque, LE | 1 |
| Ataoğlu, B | 1 |
| Kaptan, AY | 1 |
| Eren, TK | 1 |
| Yapar, AE | 1 |
| Berkay, AF | 1 |
| Negredo, E | 2 |
| Warriner, AH | 1 |
| Swe, KM | 1 |
| Osunkwo, I | 1 |
| Mohsenifar, Z | 1 |
| Abbaszadeh, H | 1 |
| Asghari, M | 1 |
| Marques, A | 1 |
| Lourenço, Ó | 1 |
| Ortsäter, G | 1 |
| da Silva, JA | 1 |
| Ryu, TK | 1 |
| Kang, RH | 1 |
| Jeong, KY | 1 |
| Jun, DR | 1 |
| Koh, JM | 1 |
| Kim, D | 2 |
| Bae, SK | 1 |
| Choi, SW | 1 |
| Agnusdei, D | 2 |
| Hans, D | 1 |
| Kohlmeier, LA | 1 |
| Krohn, KD | 1 |
| Leib, ES | 1 |
| MacLaughlin, EJ | 1 |
| Alam, J | 1 |
| Simonelli, C | 1 |
| Taylor, KA | 3 |
| Marcus, R | 3 |
| McCloskey, EV | 1 |
| Chang, CB | 1 |
| Lin, KP | 1 |
| Lim, LC | 1 |
| Huang, TW | 1 |
| Chuang, PY | 1 |
| Lee, CY | 1 |
| Huang, KC | 1 |
| Shih, HN | 1 |
| Lee, MS | 1 |
| Hsu, RW | 1 |
| Shen, WJ | 1 |
| Yeh, CB | 1 |
| Weng, SJ | 1 |
| Chang, KW | 1 |
| Chan, JY | 1 |
| Huang, SM | 1 |
| Chu, TH | 1 |
| Wei, NK | 1 |
| Ma, HS | 1 |
| Cheng, JT | 1 |
| Ma, KH | 1 |
| Chen, TH | 1 |
| Shyu, JF | 1 |
| Veszelyné Kotán, E | 2 |
| Mészaros, Á | 2 |
| Goldshtein, I | 1 |
| Rouach, V | 1 |
| Shamir-Stein, N | 1 |
| Yu, J | 2 |
| Chodick, G | 1 |
| Kan, SL | 1 |
| Yuan, ZF | 1 |
| Ai, J | 1 |
| Xu, H | 1 |
| Sun, JC | 1 |
| Eiken, P | 1 |
| Laius, O | 1 |
| Maasalu, K | 1 |
| Kõks, S | 1 |
| Märtson, A | 1 |
| Doria, C | 1 |
| Mosele, GR | 1 |
| Solla, F | 1 |
| Maestretti, G | 1 |
| Balsano, M | 1 |
| Scarpa, RM | 1 |
| Shimizu, T | 2 |
| Kanehira, Y | 1 |
| Kimura-Suda, H | 1 |
| Kameda, Y | 1 |
| Hamano, H | 1 |
| Hiratsuka, S | 1 |
| Sakaida, H | 1 |
| Yuasa, H | 1 |
| Fukutome, K | 1 |
| Takeuchi, K | 1 |
| Huang, XH | 1 |
| Liang, RH | 1 |
| Su, L | 1 |
| Guo, W | 1 |
| Wang, CJ | 2 |
| Han, XD | 1 |
| Tang, MB | 1 |
| Oon, HH | 1 |
| Arai, R | 1 |
| Takahashi, D | 1 |
| Inoue, M | 1 |
| Irie, T | 1 |
| Asano, T | 1 |
| Konno, T | 1 |
| Terkawi, MA | 1 |
| Onodera, T | 1 |
| Kondo, E | 1 |
| Kim, BS | 1 |
| Shkembi, F | 1 |
| Lee, J | 2 |
| Kunisaki, C | 1 |
| Kosaka, T | 1 |
| Miyamoto, H | 1 |
| Sato, S | 2 |
| Suematsu, H | 1 |
| Sato, K | 2 |
| Izumisawa, Y | 1 |
| Akiyama, H | 1 |
| Taguri, M | 1 |
| Yamanaka, T | 1 |
| Endo, I | 1 |
| Ma, S | 1 |
| Goh, EL | 1 |
| Jin, A | 1 |
| Bhattacharya, R | 1 |
| Boughton, OR | 1 |
| Patel, B | 1 |
| Karunaratne, A | 1 |
| Vo, NT | 1 |
| Atwood, R | 1 |
| Cobb, JP | 1 |
| Hansen, U | 1 |
| Abel, RL | 1 |
| Mohamed, MT | 1 |
| Abuelezz, SA | 1 |
| Atalla, SS | 1 |
| El Aziz, LFA | 1 |
| Gorge, SS | 1 |
| Rosen, H | 1 |
| Ettinger, B | 5 |
| Maves, T | 1 |
| Wong, YK | 1 |
| Cheng, JC | 1 |
| Martens, MG | 2 |
| Shaw, H | 1 |
| Ofluoglu, O | 1 |
| Ofluoglu, D | 1 |
| Papaioannou, A | 6 |
| Kennedy, CC | 1 |
| Freitag, A | 1 |
| Ioannidis, G | 6 |
| O'Neill, J | 1 |
| Webber, C | 1 |
| Pui, M | 1 |
| Berthiaume, Y | 1 |
| Rabin, HR | 1 |
| Paterson, N | 1 |
| Jeanneret, A | 1 |
| Matouk, E | 1 |
| Villeneuve, J | 1 |
| Nixon, M | 1 |
| Hoffmann, PF | 1 |
| Singh, M | 1 |
| Palermo, L | 2 |
| Burnett, BP | 2 |
| Polito, F | 2 |
| Marini, H | 2 |
| Levy, RM | 2 |
| Armbruster, MA | 2 |
| Minutoli, L | 2 |
| Di Stefano, V | 2 |
| Antoci, S | 1 |
| Granese, R | 1 |
| Altavilla, D | 2 |
| Miura, N | 1 |
| Mizuno, N | 1 |
| Aoyama, R | 1 |
| Kitagawa, W | 1 |
| Nishikawa, K | 1 |
| Imai, H | 1 |
| Takata, S | 1 |
| Takao, S | 1 |
| Yoshida, S | 1 |
| Hayashi, F | 1 |
| Yasui, N | 1 |
| Nelson, JB | 1 |
| Trump, DL | 1 |
| Wagner, JM | 1 |
| Miller, ME | 1 |
| Perera, S | 2 |
| Resnick, NM | 1 |
| Okazaki, R | 2 |
| Lakhotia, SM | 1 |
| Phipps, R | 1 |
| Vashishth, D | 1 |
| Westfall, AO | 3 |
| Cheng, H | 1 |
| Delzell, E | 1 |
| Cecilia, D | 1 |
| Jódar, E | 1 |
| Fernández, C | 1 |
| Resines, C | 1 |
| Hawkins, F | 3 |
| Gangoiti, MV | 1 |
| Cortizo, AM | 1 |
| Arnol, V | 1 |
| Felice, JI | 1 |
| McCarthy, AD | 1 |
| Verhaar, HJ | 1 |
| Yeap, SS | 2 |
| Fauzi, AR | 1 |
| Kong, NC | 1 |
| Halim, AG | 1 |
| Soehardy, Z | 1 |
| Rahimah, I | 1 |
| Chow, SK | 1 |
| Goh, EM | 1 |
| Jakob, F | 1 |
| Nitschmann, S | 1 |
| Sheehy, O | 1 |
| Kindundu, CM | 1 |
| Barbeau, M | 1 |
| LeLorier, J | 1 |
| Strandberg, TE | 1 |
| Nawata, M | 1 |
| Nakayamada, S | 1 |
| Kitazaki, S | 1 |
| Mitsuyama, K | 1 |
| Masuda, J | 1 |
| Harada, K | 1 |
| Yamasaki, H | 1 |
| Kuwaki, K | 1 |
| Takedatsu, H | 1 |
| Sugiyama, G | 1 |
| Tsuruta, O | 1 |
| Sata, M | 1 |
| Wang, QH | 1 |
| Wu, HX | 1 |
| Huang, YL | 1 |
| Xue, J | 1 |
| Yang, XY | 2 |
| Zhu, L | 1 |
| Wen, LH | 1 |
| Hayashi, K | 3 |
| Yamaguchi, T | 2 |
| Yano, S | 1 |
| Kanazawa, I | 1 |
| Yamauchi, M | 1 |
| Yamamoto, M | 2 |
| Blouin, J | 2 |
| Dragomir, A | 2 |
| Fredette, M | 1 |
| Fernandes, JC | 2 |
| Perreault, S | 2 |
| Zion, M | 1 |
| Barbuto, N | 1 |
| Lindsay, R | 1 |
| Inderjeeth, CA | 1 |
| Foo, AC | 1 |
| Lai, MM | 1 |
| Glendenning, P | 1 |
| Ringe, JD | 15 |
| Schacht, E | 4 |
| Binkley, N | 2 |
| Reed, JI | 1 |
| Ljunggren, O | 1 |
| Holick, MF | 1 |
| Minne, HW | 5 |
| Liu, M | 1 |
| Lamotta, A | 1 |
| West, JA | 1 |
| Ito, K | 3 |
| Hollenberg, JP | 1 |
| Charlson, ME | 1 |
| Silverman, SL | 2 |
| Schneider, JP | 2 |
| Katz, JN | 3 |
| Brookhart, MA | 3 |
| Stürmer, T | 2 |
| Stedman, MR | 2 |
| Levin, R | 1 |
| Solomon, DH | 3 |
| Odvina, CV | 2 |
| Levy, S | 1 |
| Rao, S | 1 |
| Zerwekh, JE | 2 |
| Rao, DS | 2 |
| Mathew, R | 1 |
| Dhillon, V | 1 |
| Shepherd, P | 1 |
| Gaál, J | 1 |
| Bender, T | 1 |
| Varga, J | 1 |
| Horváth, I | 1 |
| Kiss, J | 1 |
| Somogyi, P | 1 |
| Surányi, P | 1 |
| Blumentals, WA | 1 |
| Harris, ST | 3 |
| Cole, RE | 1 |
| Huang, L | 1 |
| Napoli, M | 1 |
| Skordis, N | 1 |
| Ioannou, YS | 1 |
| Kyriakou, A | 1 |
| Savva, SC | 1 |
| Efstathiou, E | 1 |
| Savvides, I | 1 |
| Christou, S | 1 |
| Skripitz, R | 1 |
| Johansson, HR | 1 |
| Ulrich, SD | 1 |
| Werner, A | 1 |
| Rozental, TD | 1 |
| Vazquez, MA | 1 |
| Chacko, AT | 1 |
| Ayogu, N | 1 |
| Marin, F | 3 |
| Shane, E | 3 |
| Dobnig, H | 3 |
| Zanchetta, JR | 2 |
| Maricic, M | 3 |
| Krohn, K | 3 |
| See, K | 3 |
| Warner, MR | 5 |
| Diab, T | 3 |
| Koivunemi, A | 2 |
| Koivunemi, M | 2 |
| Bayly, J | 1 |
| Finkelstein, JS | 4 |
| Wyland, JJ | 3 |
| Leder, BZ | 4 |
| Burnett-Bowie, SM | 1 |
| Lee, H | 3 |
| Jüppner, H | 1 |
| Neer, RM | 3 |
| Ohnishi, I | 1 |
| Kuroda, T | 4 |
| Miyakawa, N | 4 |
| Miyazaki, T | 2 |
| Kunchur, R | 1 |
| Need, A | 1 |
| Hughes, T | 1 |
| Goss, A | 1 |
| Stepan, JJ | 2 |
| Michalská, D | 1 |
| Sipos, A | 1 |
| Petto, H | 2 |
| Fahrleitner-Pammer, A | 2 |
| Pavo, I | 2 |
| McKenna, M | 1 |
| Mansfield, JC | 1 |
| Stoch, SA | 1 |
| Greenwald, M | 1 |
| Sebba, AI | 2 |
| Cohen, S | 1 |
| Verbruggen, N | 3 |
| Giezek, H | 1 |
| West, J | 1 |
| Schnitzer, TJ | 3 |
| Tsujikawa, T | 1 |
| Andoh, A | 1 |
| Inatomi, O | 1 |
| Bamba, S | 1 |
| Nakahara, T | 1 |
| Fujiyama, Y | 1 |
| Hoefert, S | 1 |
| Schmitz, I | 1 |
| Tannapfel, A | 1 |
| Eufinger, H | 1 |
| Planas, J | 1 |
| Trilla, E | 1 |
| Raventós, C | 1 |
| Cecchini, L | 1 |
| Orsola, A | 1 |
| Salvador, C | 1 |
| Placer, J | 1 |
| Encabo, G | 1 |
| Morote, J | 1 |
| Bell, KJ | 1 |
| Hayen, A | 1 |
| Macaskill, P | 1 |
| Irwig, L | 1 |
| Craig, JC | 1 |
| Ensrud, K | 1 |
| Lopes, RF | 1 |
| Coeli, CM | 1 |
| Vaisman, M | 1 |
| de Farias, ML | 1 |
| Ikeda, K | 1 |
| Zou, X | 1 |
| Keel, C | 1 |
| Kraenzlin, ME | 1 |
| Kraenzlin, CA | 1 |
| Müller, B | 1 |
| Meier, C | 1 |
| Ueno, M | 1 |
| Asano, S | 1 |
| Suzuki, A | 1 |
| Itoh, M | 1 |
| Moynihan, R | 3 |
| Ing-Lorenzini, K | 1 |
| Desmeules, J | 1 |
| Plachta, O | 1 |
| Suva, D | 1 |
| Dayer, P | 1 |
| Peter, R | 1 |
| Sato, Y | 4 |
| Takeda, T | 4 |
| Matsumoto, H | 3 |
| Yasui, T | 2 |
| Itoh, Y | 1 |
| Hamamoto, S | 1 |
| Hirose, M | 2 |
| Tozawa, K | 1 |
| Canettieri, AC | 1 |
| Colombo, CE | 1 |
| Chin, CM | 1 |
| Faig-Leite, H | 1 |
| Cesareo, R | 1 |
| Napolitano, C | 1 |
| Iozzino, M | 1 |
| Romitelli, F | 1 |
| Iarussi, G | 1 |
| Scona, M | 1 |
| De Rosa, B | 1 |
| Chevalier, Y | 1 |
| Quek, E | 1 |
| Borah, B | 1 |
| Gross, G | 1 |
| Stewart, J | 1 |
| Zysset, P | 1 |
| Nakajima, H | 1 |
| Yayama, T | 1 |
| Kawahara, H | 1 |
| Kobayashi, S | 2 |
| Tsuchida, T | 1 |
| Okazawa, H | 1 |
| Fujibayashi, Y | 1 |
| Baba, H | 1 |
| Feher, A | 1 |
| Fuchs, RK | 1 |
| Phipps, RJ | 2 |
| Reinwald, S | 2 |
| Devogelaer, JP | 4 |
| Krege, JH | 4 |
| Wong, M | 2 |
| Kuroki, Y | 1 |
| Murakawa, Y | 1 |
| Funakawa, I | 1 |
| Funasaka, Y | 1 |
| Kanda, F | 1 |
| Compston, JE | 3 |
| Paccou, J | 1 |
| Viget, N | 1 |
| Legrout-Gérot, I | 1 |
| Yazdanpanah, Y | 1 |
| Kolios, L | 1 |
| Hoerster, AK | 1 |
| Sehmisch, S | 1 |
| Malcherek, MC | 1 |
| Rack, T | 1 |
| Tezval, M | 1 |
| Seidlova-Wuttke, D | 1 |
| Wuttke, W | 1 |
| Stuermer, KM | 1 |
| Stuermer, EK | 1 |
| Chen, L | 1 |
| Chen, LW | 1 |
| Guo, XS | 1 |
| Zhang, GY | 1 |
| Qi, DS | 1 |
| Nomura, S | 1 |
| Kurata, Y | 1 |
| Tomiyama, Y | 1 |
| Takubo, T | 1 |
| Saigo, K | 1 |
| Nishikawa, M | 1 |
| Higasa, S | 1 |
| Maeda, Y | 1 |
| Anastassopoulos, G | 2 |
| Panteliou, S | 1 |
| Christopoulou, G | 1 |
| Stavropoulou, A | 2 |
| Panagiotopoulos, E | 2 |
| Lyritis, G | 1 |
| Khaldi, L | 1 |
| Varakis, J | 1 |
| Karamanos, N | 1 |
| Liou, MJ | 1 |
| Ho, C | 1 |
| Lin, JD | 1 |
| Huang, YY | 1 |
| Chen, JF | 1 |
| Chen, P | 3 |
| Burshell, AL | 2 |
| Möricke, R | 1 |
| Correa-Rotter, R | 1 |
| Dalsky, GP | 2 |
| Noguchi, H | 1 |
| Kamo, K | 1 |
| Gates, BJ | 1 |
| Sonnett, TE | 1 |
| Duvall, CA | 1 |
| Dobbins, EK | 1 |
| Berto, P | 1 |
| Noale, M | 1 |
| Lopatriello, S | 1 |
| Hisa, I | 1 |
| Seino, S | 1 |
| Craig, SJ | 1 |
| Youssef, PP | 1 |
| Vaile, JH | 1 |
| Sullivan, L | 1 |
| Bleasel, JF | 1 |
| Yamazaki, Y | 1 |
| Shiraki, Y | 1 |
| Tsugawa, N | 1 |
| Okano, T | 2 |
| Bartl, R | 5 |
| Suluova, F | 1 |
| Görmeli, G | 1 |
| Yildirim, A | 1 |
| Ali, AKh | 1 |
| Kelly, MP | 1 |
| Genant, HK | 1 |
| Bucci-Rechtweg, C | 2 |
| Cauley, J | 1 |
| Leung, PC | 1 |
| Boonen, S | 3 |
| Santora, A | 2 |
| de Papp, A | 2 |
| Lee, JK | 1 |
| Ahn, JK | 1 |
| Cha, HS | 1 |
| Koh, EM | 1 |
| Migliorati, CA | 1 |
| Mattos, K | 1 |
| Palazzolo, MJ | 1 |
| Schwartz, K | 2 |
| Pinholt, EM | 2 |
| Rejnmark, L | 2 |
| Mosekilde, L | 4 |
| Fujinawa, N | 1 |
| Tanzawa, K | 1 |
| Ishizuka, A | 1 |
| Itoi, E | 1 |
| Morimoto, S | 1 |
| Itabashi, A | 1 |
| Kishimoto, H | 4 |
| Endo, N | 1 |
| Nishizawa, Y | 2 |
| Takaoka, K | 2 |
| Ohashi, Y | 3 |
| Orimo, H | 4 |
| Girgis, CM | 1 |
| Sher, D | 1 |
| Seibel, MJ | 1 |
| Elkin, EB | 1 |
| Girotra, M | 1 |
| Morris, MJ | 1 |
| Chan, SS | 1 |
| Rosenberg, ZS | 1 |
| Chan, K | 1 |
| Capeci, C | 1 |
| Cizza, G | 2 |
| Nguyen, VT | 1 |
| Eskandari, F | 2 |
| Duan, Z | 1 |
| Wright, EC | 1 |
| Reynolds, JC | 2 |
| Ahima, RS | 1 |
| Blackman, MR | 2 |
| Orwoll, ES | 4 |
| Brown, J | 2 |
| Kendler, D | 2 |
| Readie, A | 1 |
| Mesenbrink, P | 1 |
| Weinstein, RS | 2 |
| Husein-Elahmed, H | 1 |
| Aneiros-Fernandez, J | 1 |
| Arias-Santiago, S | 2 |
| Aneiros-Cachaza, J | 1 |
| Naranjo-Sintes, R | 1 |
| Kusamori, K | 2 |
| Katsumi, H | 2 |
| Abe, M | 1 |
| Ueda, A | 1 |
| Sakai, R | 1 |
| Hayashi, R | 2 |
| Hirai, Y | 2 |
| Quan, YS | 2 |
| Kamiyama, F | 2 |
| Sakane, T | 2 |
| Yamamoto, A | 2 |
| Dorst, A | 3 |
| Farahmand, P | 1 |
| Shoji, S | 1 |
| Tabuchi, M | 2 |
| Miyazawa, K | 2 |
| Yabumoto, T | 1 |
| Kadota, M | 1 |
| Maeda, H | 2 |
| Goto, S | 2 |
| Leonida, A | 1 |
| Baldoni, M | 1 |
| Rossi, G | 1 |
| Lauritano, D | 1 |
| Berry, SD | 1 |
| Misra, D | 1 |
| Hannan, MT | 1 |
| Guldberg, RE | 2 |
| Jindong, Z | 1 |
| Hai, T | 1 |
| Junchao, G | 1 |
| Bo, W | 1 |
| Qiang, WB | 1 |
| Ezzat, BA | 1 |
| Lim, MJ | 1 |
| Kwon, SR | 1 |
| Park, SG | 1 |
| Park, W | 1 |
| Barrier, A | 1 |
| Lescaille, G | 1 |
| Rigolet, A | 1 |
| Descroix, V | 1 |
| Goudot, P | 1 |
| Ruhin, B | 1 |
| Resnick, J | 1 |
| Gupta, N | 1 |
| Wagner, J | 1 |
| Costa, G | 1 |
| Cruz, RJ | 1 |
| Martin, L | 1 |
| Koritsky, DA | 1 |
| Matarese, L | 1 |
| Eid, K | 1 |
| Schuster, B | 1 |
| Roberts, M | 1 |
| Greenspan, S | 3 |
| Abu-Elmagd, K | 1 |
| Lundkvist, J | 1 |
| Porter, SR | 1 |
| D'Aiuto, F | 1 |
| Manfredi, M | 2 |
| Arduino, PG | 1 |
| Broccoletti, R | 1 |
| Musciotto, A | 1 |
| Lazarovici, TS | 1 |
| Yarom, N | 2 |
| Kwon, YD | 1 |
| Ohe, JY | 1 |
| Kim, DY | 1 |
| Chung, DJ | 1 |
| Park, YD | 1 |
| Giro, G | 3 |
| Coelho, PG | 1 |
| Pereira, RM | 4 |
| Jorgetti, V | 2 |
| Marcantonio, E | 2 |
| Orrico, SR | 3 |
| Enjuanes, A | 1 |
| Ruiz-Gaspà, S | 1 |
| Peris, P | 2 |
| Ozalla, D | 1 |
| Álvarez, L | 1 |
| Combalia, A | 1 |
| Martínez de Osaba, MJ | 1 |
| Monegal, A | 2 |
| Pares, A | 1 |
| Guañabens, N | 2 |
| Teitelbaum, SL | 1 |
| Singer, FR | 2 |
| Sterbakova, G | 1 |
| Vyskocil, V | 1 |
| Linhartova, K | 1 |
| Studd, J | 1 |
| Palomo Atance, E | 1 |
| Ballester Herrera, MJ | 1 |
| Márquez de La Plata, MA | 1 |
| Medina Cano, E | 1 |
| Carmona Vilchez, RM | 1 |
| Naranjo, A | 1 |
| Ojeda-Bruno, S | 1 |
| Francisco-Hernández, F | 1 |
| Erausquin, C | 1 |
| Rúa-Figueroa, I | 1 |
| Rodríguez-Lozano, C | 1 |
| Nakao, S | 1 |
| Minamide, A | 1 |
| Kawakami, M | 1 |
| Boden, SD | 1 |
| Yoshida, M | 1 |
| Nguyen, ND | 1 |
| Mardas, N | 1 |
| Schwarz, F | 1 |
| Petrie, A | 7 |
| Hakimi, AR | 1 |
| Donos, N | 1 |
| Eslami, B | 1 |
| Zhou, S | 1 |
| Van Eekeren, I | 1 |
| LeBoff, MS | 1 |
| Glowacki, J | 1 |
| Paul, AK | 1 |
| Seetharaman, M | 1 |
| Barrett-Connor, E | 1 |
| Swern, AS | 1 |
| Hustad, CM | 1 |
| Bone, HG | 1 |
| Liberman, UA | 3 |
| Papapoulos, S | 1 |
| Kenealy, H | 1 |
| Paul, S | 1 |
| Walker, K | 1 |
| Garg, A | 1 |
| Dukas, L | 1 |
| Mazor, Z | 1 |
| Lu, TL | 1 |
| Hu, HJ | 1 |
| Chen, T | 1 |
| Sugata, Y | 1 |
| Sotome, S | 1 |
| Yuasa, M | 1 |
| Hirano, M | 1 |
| Shinomiya, K | 1 |
| Okawa, A | 1 |
| Gunawardena, I | 1 |
| Baxter, M | 1 |
| Rasekh, Y | 1 |
| Laroche, M | 1 |
| Cheen, MH | 1 |
| Kong, MC | 1 |
| Zhang, RF | 1 |
| Tee, FM | 1 |
| Chandran, M | 1 |
| Wang, K | 1 |
| Moaveni, A | 1 |
| Dowrick, A | 1 |
| Liew, S | 1 |
| Ueda, K | 1 |
| Muto, M | 1 |
| Chiba, T | 1 |
| Karaplis, AC | 1 |
| Chouha, F | 1 |
| Djandji, M | 1 |
| Sampalis, JS | 1 |
| Arrabal-Polo, MA | 2 |
| Arrabal-Martin, M | 2 |
| Zuluaga-Gomez, A | 2 |
| Uemura, Y | 1 |
| Inose, H | 1 |
| Zhou, B | 1 |
| Yadav, VK | 1 |
| Guo, XE | 1 |
| Karsenty, G | 1 |
| Ducy, P | 1 |
| Bauer, JS | 1 |
| Beck, N | 1 |
| Kiefer, J | 1 |
| Stockmann, P | 1 |
| Wichmann, M | 1 |
| Eitner, S | 1 |
| Lang, A | 1 |
| Robbins, S | 1 |
| Aibar Arregui, MA | 1 |
| de Escalante Yangüela, B | 1 |
| Muñoz Villalengua, M | 1 |
| Garcés Horna, V | 1 |
| Torra, M | 1 |
| Olivares, V | 1 |
| Reyes, R | 2 |
| Martínez-Ferrer, A | 1 |
| Kang, HS | 1 |
| Lee, JW | 2 |
| Kim, JS | 1 |
| Zhou, YM | 1 |
| Li, YQ | 1 |
| Fu, L | 1 |
| Gong, L | 1 |
| Muraleva, NA | 2 |
| Sadovoĭ, MA | 1 |
| Kolosova, NG | 2 |
| Sato, H | 1 |
| Tanno, K | 1 |
| Muro-oka, G | 1 |
| Itai, K | 1 |
| Lu, PY | 1 |
| Hsieh, CF | 1 |
| Tsai, YW | 2 |
| Huang, WF | 2 |
| Ott, SM | 1 |
| Sharma, V | 1 |
| Nagaraj, S | 1 |
| Choksey, U | 1 |
| Hegde, A | 1 |
| Samant, R | 1 |
| Balakrishnan, C | 1 |
| Martin, KE | 1 |
| Campbell, HE | 1 |
| Abarca, J | 1 |
| White, TJ | 1 |
| Niimi, K | 1 |
| Morgan Ortiz, F | 1 |
| Meza Mendoza, C | 1 |
| Beltrán Lugo, I | 1 |
| Caballero Rodríguez, B | 1 |
| Contreras Soto, JO | 1 |
| Yurci, A | 1 |
| Kalkan, AO | 1 |
| Ozbakir, O | 1 |
| Karaman, A | 1 |
| Torun, E | 1 |
| Kula, M | 1 |
| Baskol, M | 1 |
| Gursoy, S | 1 |
| Yucesoy, M | 1 |
| Bayram, F | 1 |
| Sardone, LD | 1 |
| Renlund, R | 1 |
| Willett, TL | 1 |
| Fantus, IG | 1 |
| Grynpas, MD | 1 |
| MacDonald, GI | 1 |
| Currie, GP | 1 |
| Reid, DM | 1 |
| Hsiao, FY | 1 |
| Wen, YW | 1 |
| Kao, YH | 1 |
| Chen, LK | 1 |
| Xie, D | 1 |
| Yang, X | 1 |
| Brandt, NJ | 1 |
| Stefanacci, RG | 1 |
| Tee, SI | 1 |
| Yosipovitch, G | 1 |
| Chan, YC | 1 |
| Chua, SH | 1 |
| Koh, ET | 1 |
| Chan, YH | 2 |
| Tan, SS | 1 |
| Tsou, IY | 1 |
| Tan, SH | 1 |
| Ko, YJ | 1 |
| Wu, JB | 1 |
| Ho, HY | 1 |
| Qi, W | 1 |
| Yan, YB | 1 |
| Lei, W | 1 |
| Wu, ZX | 1 |
| Liu, D | 1 |
| Cao, PC | 1 |
| Liu, N | 1 |
| Rudic, JS | 1 |
| Giljaca, V | 1 |
| Krstic, MN | 1 |
| Bjelakovic, G | 1 |
| Gluud, C | 1 |
| Zhou, H | 1 |
| Lawrence, JG | 1 |
| Touny, AH | 1 |
| Bhaduri, SB | 1 |
| Iglesias, P | 1 |
| Castro, JC | 1 |
| Abreu, C | 1 |
| Díez, JJ | 1 |
| Tommasini, SM | 1 |
| Trinward, A | 1 |
| Acerbo, AS | 1 |
| De Carlo, F | 1 |
| Miller, LM | 1 |
| Judex, S | 1 |
| Svedström, E | 1 |
| Aro, HT | 1 |
| Väänänen, K | 1 |
| Ronsaville, DS | 1 |
| Kleitz, H | 1 |
| Mistry, S | 1 |
| Torvik, S | 1 |
| Sonbolian, N | 1 |
| Gold, PW | 1 |
| Martinez, PE | 1 |
| Green, JO | 1 |
| Vidakovic, B | 1 |
| Devold, HM | 1 |
| Furu, K | 1 |
| Skurtveit, S | 1 |
| Tverdal, A | 1 |
| Falch, JA | 1 |
| Sogaard, AJ | 1 |
| Yilmaz, M | 1 |
| Taninmis, H | 1 |
| Kara, E | 1 |
| Ozagari, A | 1 |
| Unsal, A | 1 |
| Rozenbaum, M | 1 |
| Boulman, N | 1 |
| Rimar, D | 1 |
| Kaly, L | 1 |
| Rosner, I | 1 |
| Slobodin, G | 1 |
| Sultana, S | 1 |
| Talegaonkar, S | 1 |
| Ali, R | 1 |
| Mittal, G | 1 |
| Ahmad, FJ | 1 |
| Bhatnagar, A | 1 |
| Othman, AZ | 1 |
| Zain, AA | 1 |
| Chan, SP | 1 |
| Arns, S | 1 |
| Gibe, R | 1 |
| Moreau, A | 1 |
| Monzur Morshed, M | 1 |
| Rozenberg, S | 1 |
| Lanoy, E | 1 |
| Bentata, M | 1 |
| Viard, JP | 1 |
| Valantin, MA | 1 |
| Missy, P | 1 |
| Darasteanu, I | 1 |
| Kolta, S | 1 |
| Costagliola, D | 1 |
| González López-Valcárcel, B | 1 |
| Sosa Henríquez, M | 1 |
| Metzler, P | 1 |
| Rössle, M | 1 |
| Obwegeser, J | 1 |
| Zemann, W | 1 |
| Roberts, MS | 1 |
| Pazianas, M | 1 |
| Russell, RG | 1 |
| Albrecht, J | 1 |
| Werth, VP | 1 |
| Ofitserov, EN | 1 |
| Tikhonov, VP | 1 |
| Hitomi, K | 1 |
| Vigorita, VJ | 1 |
| Silver, JS | 1 |
| Eisemon, EO | 1 |
| Kubo, KY | 1 |
| Yang, LJ | 1 |
| Shen, FX | 1 |
| Zheng, JC | 1 |
| Zhang, HL | 1 |
| O'Ryan, FS | 1 |
| Lo, JC | 1 |
| Dominguez-Bartmess, SN | 1 |
| Tandberg, D | 1 |
| Cheema, AM | 1 |
| Szalay, EA | 1 |
| Poole, KE | 1 |
| Angthong, C | 1 |
| Angthong, W | 1 |
| Freiberger, JJ | 1 |
| Padilla-Burgos, R | 1 |
| McGraw, T | 1 |
| Suliman, HB | 1 |
| Kraft, KH | 1 |
| Stolp, BW | 1 |
| Moon, RE | 1 |
| Piantadosi, CA | 1 |
| Dytfeld, J | 1 |
| Horst-Sikorska, W | 1 |
| Sandoval, MA | 1 |
| Paz-Pacheco, E | 1 |
| Usami, A | 1 |
| Thamake, SI | 1 |
| Raut, SL | 1 |
| Gryczynski, Z | 1 |
| Ranjan, AP | 1 |
| Vishwanatha, JK | 1 |
| Sung, MJ | 1 |
| Davaatseren, M | 1 |
| Hur, HJ | 1 |
| Kim, HJ | 1 |
| Ryu, SY | 1 |
| Choi, YH | 1 |
| Cha, MR | 1 |
| Kwon, DY | 1 |
| Eriksen, EF | 1 |
| Halse, J | 1 |
| Uihlein, AV | 1 |
| Bieglmayer, C | 1 |
| Dimai, HP | 1 |
| Gasser, RW | 1 |
| Kudlacek, S | 1 |
| Obermayer-Pietsch, B | 2 |
| Woloszczuk, W | 1 |
| Zwettler, E | 1 |
| Griesmacher, A | 1 |
| Zadik, Y | 1 |
| Abu-Tair, J | 1 |
| Zaharia, B | 1 |
| Elad, S | 1 |
| Emad, Y | 1 |
| Ragab, Y | 1 |
| El-Shaarawy, N | 1 |
| Rasker, JJ | 1 |
| Loukota, RA | 1 |
| Musini, V | 1 |
| Mintzes, B | 1 |
| Tejani, A | 1 |
| Wright, JM | 1 |
| Klotz, LH | 1 |
| McNeill, IY | 1 |
| Kebabdjian, M | 1 |
| Chin, JL | 1 |
| Cho, DC | 1 |
| Kim, KT | 1 |
| Jeon, Y | 1 |
| Sung, JK | 1 |
| Rubin, KH | 1 |
| Arranz Caso, JA | 1 |
| Flores Ballester, E | 1 |
| Ngo Pombe, S | 1 |
| López Pizarro, V | 1 |
| Dominguez-Mompello, JL | 1 |
| Restoy Lozano, A | 1 |
| Huang, WH | 1 |
| Lee, SY | 1 |
| Weng, CH | 1 |
| Lai, PC | 1 |
| van der Jagt, OP | 1 |
| Waarsing, JH | 1 |
| Kops, N | 1 |
| Schaden, W | 1 |
| Jahr, H | 1 |
| Verhaar, JA | 1 |
| Weinans, H | 1 |
| Turner, C | 1 |
| Dalton, N | 1 |
| Inaoui, R | 1 |
| Fogelman, I | 1 |
| Fraser, WD | 1 |
| Hampson, G | 1 |
| Hanna, J | 1 |
| Bee, J | 1 |
| Sataloff, RT | 1 |
| Chen, K | 1 |
| Lan, Y | 1 |
| Zhang, N | 1 |
| Jiang, R | 1 |
| Lee, WY | 1 |
| Sun, LM | 1 |
| Lin, MC | 1 |
| Liang, JA | 1 |
| Chang, SN | 1 |
| Sung, FC | 1 |
| Muo, CH | 1 |
| Kao, CH | 1 |
| Majumdar, SR | 1 |
| Lier, DA | 1 |
| McAlister, FA | 1 |
| Rowe, BH | 1 |
| Siminoski, K | 2 |
| Russell, AS | 1 |
| Johnson, JA | 1 |
| Evans, H | 1 |
| Ploutz-Snyder, R | 1 |
| de Haro-Muñoz, T | 1 |
| Lopez-Ruiz, A | 1 |
| Orgaz-Molina, J | 1 |
| Gonzalez-Torres, S | 1 |
| Srivastava, AK | 1 |
| Mohan, S | 1 |
| Baylink, DJ | 1 |
| Morabito, N | 1 |
| Lasco, A | 1 |
| Gaudio, A | 1 |
| Crisafulli, A | 1 |
| Di Pietro, C | 1 |
| Meo, A | 1 |
| Frisina, N | 1 |
| Välimäki, MJ | 1 |
| Azuma, Y | 2 |
| Takagi, H | 2 |
| Komoriya, K | 2 |
| Ohta, T | 3 |
| Kawaguchi, H | 2 |
| Hernandez, CJ | 1 |
| Beaupré, GS | 1 |
| Carter, DR | 1 |
| Gulson, B | 1 |
| Mizon, K | 1 |
| Smith, H | 1 |
| Eisman, J | 1 |
| Palmer, J | 1 |
| Korsch, M | 1 |
| Donnelly, J | 1 |
| Waite, K | 1 |
| Parker, CR | 1 |
| Blackwell, PJ | 1 |
| Fairbairn, KJ | 1 |
| Hosking, DJ | 3 |
| Field-Munves, E | 1 |
| Tonino, R | 1 |
| Smith, M | 1 |
| Petruschke, R | 1 |
| Yates, J | 2 |
| de Papp, AE | 2 |
| Palmisano, J | 1 |
| Hood, E | 1 |
| Hill, JA | 2 |
| Goldin, JG | 1 |
| Gjertson, D | 1 |
| Emerick, AM | 1 |
| Greaser, LD | 1 |
| Yoon, HC | 1 |
| Khorrami, S | 1 |
| Aziz, D | 1 |
| Adams, JS | 2 |
| Srivastava, M | 1 |
| Pollähne, W | 2 |
| Pfeifer, M | 3 |
| Begerow, B | 3 |
| Hinz, C | 1 |
| Buckley, LM | 1 |
| Hillner, BE | 1 |
| Fittipaldi, MR | 3 |
| Fonderico, F | 3 |
| Vitale, G | 2 |
| Ciccarelli, A | 2 |
| Lupoli, GA | 3 |
| Cascella, T | 2 |
| Panico, A | 3 |
| Lupoli, G | 3 |
| Drake, WM | 2 |
| Hiorns, MP | 1 |
| Harrington, JT | 1 |
| Broy, SB | 1 |
| Derosa, AM | 1 |
| Licata, AA | 4 |
| Shewmon, DA | 1 |
| Koida, M | 1 |
| Komatsu, S | 1 |
| Tokutake, N | 1 |
| Smith, MR | 1 |
| Teshima, R | 1 |
| Sohen, S | 2 |
| Peter, C | 1 |
| Rodan, GA | 6 |
| Hayes, WC | 1 |
| Shea, M | 1 |
| Arlot, M | 3 |
| Yates, AJ | 3 |
| Pöllhane, W | 1 |
| Karpf, DB | 2 |
| Emkey, R | 3 |
| Delmas, PD | 6 |
| Goemaere, S | 2 |
| Poubelle, PE | 1 |
| Daifotis, AG | 2 |
| Lombardi, A | 3 |
| Czachur, M | 2 |
| Campion, JM | 1 |
| Maricic, MJ | 1 |
| Biswas, PN | 1 |
| Wilton, LV | 2 |
| Shakir, SA | 1 |
| Sambrook, PN | 3 |
| Kotowicz, M | 1 |
| Nash, P | 1 |
| Styles, CB | 1 |
| Naganathan, V | 1 |
| Henderson-Briffa, KN | 1 |
| Nicholson, GC | 1 |
| Prestwood, KM | 2 |
| Raisz, LG | 2 |
| High, WA | 1 |
| Cohen, JB | 1 |
| Wetherington, W | 1 |
| Cockerell, CJ | 1 |
| Rutgers-Verhage, AR | 1 |
| deVries, TW | 1 |
| Torringa, MJ | 1 |
| Torregrosa, JV | 1 |
| Moreno, A | 1 |
| Gutierrez, A | 2 |
| Vidal, S | 1 |
| Oppenheimer, F | 1 |
| Sambrook, P | 1 |
| Traut, V | 1 |
| Brixen, KT | 1 |
| Kamimura, T | 1 |
| Tosteson, AN | 1 |
| Grove, MR | 1 |
| Hammond, CS | 1 |
| Moncur, MM | 1 |
| Ray, GT | 1 |
| Hebert, GM | 1 |
| Pressman, AR | 1 |
| Faber, H | 2 |
| Ibach, K | 1 |
| Hayes, A | 1 |
| Hunzelman, JL | 1 |
| Zeman, ME | 1 |
| García, JM | 1 |
| Doblaré, M | 1 |
| Sebaldt, RJ | 6 |
| Ferko, N | 1 |
| Puglia, M | 1 |
| Tenenhouse, A | 4 |
| Olszynski, WP | 6 |
| Boulos, P | 2 |
| Murray, TM | 4 |
| Goldsmith, CH | 6 |
| Braith, RW | 2 |
| Magyari, PM | 1 |
| Fulton, MN | 2 |
| Aranda, J | 1 |
| Walker, T | 1 |
| Ettinger, MP | 2 |
| Taéron, C | 1 |
| Aris, RM | 1 |
| Lester, GE | 1 |
| Caminiti, M | 1 |
| Blackwood, AD | 1 |
| Hensler, M | 1 |
| Lark, RK | 1 |
| Hecker, TM | 1 |
| Renner, JB | 1 |
| Guillen, U | 1 |
| Brown, SA | 1 |
| Neuringer, IP | 1 |
| Chalermskulrat, W | 1 |
| Ontjes, DA | 1 |
| Gonnelli, S | 2 |
| Cepollaro, C | 2 |
| Montagnani, A | 1 |
| Bruni, D | 1 |
| Caffarelli, C | 1 |
| Breschi, M | 1 |
| Gennari, L | 1 |
| Gennari, C | 3 |
| Nuti, R | 2 |
| Miltner, O | 1 |
| Niedhart, C | 1 |
| Piroth, W | 1 |
| Weber, M | 1 |
| Siebert, CH | 1 |
| Shukla, VK | 1 |
| Ripps, BA | 1 |
| VanGilder, K | 1 |
| Minhas, B | 1 |
| Welford, M | 1 |
| Mamish, Z | 1 |
| Taha, EA | 1 |
| Youssef, NF | 1 |
| Miller, L | 1 |
| Grynpas, M | 1 |
| Boyde, A | 1 |
| Mashiba, T | 1 |
| Hirano, T | 1 |
| Johnston, CC | 1 |
| Aki, S | 1 |
| Eskiyurt, N | 1 |
| Akarirmak, U | 1 |
| Tüzün, F | 1 |
| Eryavuz, M | 1 |
| Alper, S | 1 |
| Arpacioğlu, O | 1 |
| Atalay, F | 1 |
| Kavuncu, V | 1 |
| Kokino, S | 1 |
| Kuru, O | 1 |
| Nas, K | 1 |
| Ozerbil, O | 1 |
| Savaş, G | 1 |
| Sendur, OF | 1 |
| Soy, D | 1 |
| Akyüz, G | 2 |
| Cohen, SB | 1 |
| Sawka, AM | 3 |
| Murray, T | 1 |
| Sarikaya, S | 1 |
| Ozdolap, S | 1 |
| Açikgöz, G | 1 |
| Erdem, CZ | 1 |
| SoRelle, R | 1 |
| Naka, H | 1 |
| Saito, S | 1 |
| Nakatsuka, K | 1 |
| Kamel, HK | 2 |
| Bida, A | 1 |
| Montagnini, M | 1 |
| Martin, TJ | 1 |
| Portero, N | 2 |
| Boivin, G | 1 |
| Doggrell, SA | 1 |
| Biermasz, NR | 2 |
| Hamdy, NA | 4 |
| Pereira, AM | 1 |
| Romijn, JA | 1 |
| Roelfsema, F | 2 |
| Noa, M | 1 |
| Más, R | 1 |
| Mendoza, S | 1 |
| Gámez, R | 1 |
| Mendoza, N | 1 |
| Roman-Ivorra, J | 1 |
| Lipschitz, S | 1 |
| Gaines, KA | 1 |
| Melton, ME | 2 |
| Qiu, GX | 1 |
| Wu, ZH | 1 |
| Shen, JX | 1 |
| Luo, XZ | 1 |
| Wang, YP | 1 |
| Weng, XS | 1 |
| Jin, J | 1 |
| Zhang, JG | 1 |
| Hershman, D | 1 |
| Narayanan, R | 1 |
| Johnell, O | 2 |
| Jönsson, B | 2 |
| Zethraeus, N | 1 |
| Sen, SS | 2 |
| Peter, B | 1 |
| Ramaniraka, N | 1 |
| Rakotomanana, LR | 1 |
| Zambelli, PY | 1 |
| Pioletti, DP | 1 |
| Gharib, S | 1 |
| Coleman, CI | 1 |
| Perkerson, KA | 1 |
| Lewis, A | 1 |
| Adami, S | 5 |
| Viapiana, O | 1 |
| Gatti, D | 2 |
| El-Husseini, AA | 2 |
| El-Agroudy, AE | 2 |
| El-Sayed, MF | 1 |
| Sobh, MA | 1 |
| Ghoneim, MA | 2 |
| Fernandes, JL | 1 |
| Viana, SL | 1 |
| Rocha, AL | 1 |
| Ribeiro, MC | 1 |
| Castro, LC | 1 |
| Rodan, G | 3 |
| Reszka, A | 1 |
| Golub, E | 1 |
| Ott, S | 1 |
| Marx, J | 1 |
| Thabane, L | 2 |
| Davison, KS | 3 |
| Papadaki, HA | 1 |
| Tsatsanis, C | 1 |
| Christoforidou, A | 1 |
| Malliaraki, N | 1 |
| Psyllaki, M | 1 |
| Pontikoglou, C | 1 |
| Miliaki, M | 1 |
| Margioris, AN | 1 |
| Eliopoulos, GD | 1 |
| Gourlay, M | 1 |
| Hamel, ME | 1 |
| Papadimitropoulos, E | 1 |
| Sakić, D | 1 |
| Badovinac, O | 1 |
| Delija, A | 1 |
| Sakić, VA | 1 |
| Handa, R | 1 |
| Okada, N | 1 |
| Maalouf, N | 1 |
| Gottschalk, FA | 1 |
| Pak, CY | 1 |
| Isogai, Y | 1 |
| Eshed, V | 3 |
| Dresner, J | 1 |
| Gross, D | 1 |
| Woo, A | 1 |
| Hittell, J | 1 |
| Beardsley, C | 1 |
| Noh, C | 1 |
| Stoukides, CA | 1 |
| Kaul, AF | 1 |
| Moran de Brito, CM | 1 |
| Battistella, LR | 1 |
| Saito, ET | 1 |
| Sakamoto, H | 1 |
| Bonnick, SL | 1 |
| Kagan, R | 1 |
| Thompson, DE | 1 |
| Skalky, CS | 1 |
| Chen, E | 2 |
| Martínez-López, E | 1 |
| Paredes, R | 1 |
| Rosales, J | 1 |
| Pérez-Alvarez, N | 1 |
| Holgado, S | 1 |
| Gel, S | 1 |
| Tena, X | 1 |
| Rey-Joly, C | 1 |
| Clotet, B | 1 |
| Cryer, B | 1 |
| Miller, P | 2 |
| Petruschke, RA | 1 |
| Geba, GP | 1 |
| Papp, AE | 1 |
| Pande, I | 2 |
| Eis, SR | 1 |
| Kaplan, RJ | 1 |
| Vo, AN | 1 |
| Stitik, TP | 1 |
| Kamen, LB | 1 |
| Bitar, AA | 1 |
| Shih, VC | 1 |
| Mondy, K | 1 |
| Powderly, WG | 1 |
| Claxton, SA | 1 |
| Yarasheski, KH | 1 |
| Royal, M | 1 |
| Stoneman, JS | 1 |
| Hoffmann, ME | 1 |
| Tebas, P | 2 |
| Wallace, DJ | 1 |
| Recker, R | 2 |
| Masarachia, P | 1 |
| Howard, T | 1 |
| Wehren, L | 1 |
| Kimmel, D | 1 |
| El-Sayed, M | 1 |
| Mohsen, T | 1 |
| Jiao, J | 2 |
| Meng, XW | 2 |
| Zhou, XY | 2 |
| Liu, HC | 2 |
| Hu, YY | 2 |
| Zhan, ZW | 1 |
| Liu, ZP | 1 |
| Li, WX | 1 |
| Yu, B | 1 |
| Huo, JS | 1 |
| Liu, CX | 1 |
| Hetzell, CB | 1 |
| Vis, M | 1 |
| Bultink, IE | 1 |
| Dijkmans, BA | 3 |
| Lems, WF | 3 |
| Cremers, SC | 1 |
| van Hogezand, R | 1 |
| Bänffer, D | 1 |
| den Hartigh, J | 1 |
| Vermeij, P | 1 |
| Papapoulos, SE | 3 |
| Laan, RF | 3 |
| Barton, IP | 1 |
| Watts, NB | 3 |
| Colarusso, S | 1 |
| Di Micco, L | 1 |
| Cavallo, A | 1 |
| Costa, L | 1 |
| Paglione, A | 1 |
| Tenenhouse, AM | 1 |
| Woo, SB | 1 |
| Hande, K | 1 |
| Richardson, PG | 1 |
| Millonig, G | 1 |
| Graziadei, IW | 1 |
| Eichler, D | 1 |
| Pfeiffer, KP | 1 |
| Finkenstedt, G | 1 |
| Muehllechner, P | 1 |
| Koenigsrainer, A | 1 |
| Margreiter, R | 1 |
| Vogel, W | 1 |
| Peña de la Vega, L | 1 |
| Fervenza, FC | 1 |
| Lager, D | 1 |
| Habermann, T | 1 |
| Leung, N | 1 |
| Shergy, WJ | 1 |
| Body, JJ | 1 |
| Rohe, ME | 1 |
| Hejdova, M | 1 |
| Palicka, V | 1 |
| Kucera, Z | 1 |
| Vlcek, J | 1 |
| Segal, E | 1 |
| Zinnman, C | 1 |
| Raz, B | 1 |
| Tamir, A | 1 |
| Gurevich, B | 1 |
| Siebzehner, MI | 1 |
| Ish-Shalom, S | 1 |
| Martinó, A | 1 |
| Rosa, J | 1 |
| Guzmán, J | 1 |
| Ramírez, M | 1 |
| Akahoshi, S | 1 |
| Arita, S | 1 |
| Morishita, Y | 1 |
| Tsutsumi, H | 1 |
| Shiraishi, A | 1 |
| Uchida, S | 1 |
| Taniguchi, T | 1 |
| Kakikawa, T | 1 |
| Okuyama, K | 1 |
| Okaniwa, M | 1 |
| Arizono, H | 1 |
| Nagata, K | 1 |
| Jhee, O | 1 |
| Yuan, H | 1 |
| Kim, T | 1 |
| Lee, M | 1 |
| Om, A | 1 |
| Lee, B | 1 |
| Park, SK | 1 |
| Kang, J | 1 |
| Seeman, E | 3 |
| Girón, RM | 1 |
| Sánchez Moliní, P | 1 |
| García Vadillo, A | 1 |
| Quintana, ML | 1 |
| Rodríguez Salvanés, F | 1 |
| Jiménez, I | 1 |
| Mancha, A | 1 |
| Cisneros, C | 1 |
| Ancochea, J | 1 |
| Kimura, M | 1 |
| Kawai, T | 1 |
| Kameyama, Y | 1 |
| Marx, RE | 1 |
| Sawatari, Y | 1 |
| Fortin, M | 1 |
| Broumand, V | 1 |
| Smith, BJ | 1 |
| Laslett, LL | 1 |
| Pile, KD | 1 |
| Phillips, PJ | 1 |
| Phillipov, G | 1 |
| Evans, SM | 1 |
| Esterman, AJ | 1 |
| Berry, JG | 1 |
| Kouroukis, T | 1 |
| McKinney, J | 1 |
| Bagi, CM | 2 |
| Hanson, N | 2 |
| Andresen, C | 1 |
| Pero, R | 1 |
| Lariviere, R | 1 |
| Turner, CH | 1 |
| Laib, A | 1 |
| Krueger, D | 1 |
| Christoffersen, H | 1 |
| Holmegaard, SN | 1 |
| Ivaska, KK | 1 |
| Pettersson, K | 1 |
| Nenonen, A | 1 |
| Uusi-Rasi, K | 1 |
| Heinonen, A | 1 |
| Kannus, P | 1 |
| Väänänen, HK | 1 |
| Reynolds, NA | 1 |
| Curran, MP | 1 |
| Orcel, P | 1 |
| Shimon, I | 1 |
| Doolman, R | 1 |
| Sela, BA | 1 |
| Karasik, A | 1 |
| Vered, I | 1 |
| Chong, C | 1 |
| Sarlet, N | 1 |
| Viereck, V | 1 |
| Christopoulou, GE | 1 |
| Panteliou, SD | 1 |
| Papadaki, E | 1 |
| Karamanos, NK | 1 |
| Allison, J | 1 |
| Freeman, A | 4 |
| Kovac, SH | 1 |
| Boyd, IW | 1 |
| McEwen, J | 1 |
| Calcino, LJ | 1 |
| Atamaz, F | 1 |
| Hepguler, S | 1 |
| Akyildiz, M | 1 |
| Karasu, Z | 1 |
| Kilic, M | 1 |
| Benbassat, CA | 1 |
| Laron, Z | 1 |
| Naunton, M | 1 |
| de Vernejoul, MC | 1 |
| Marshall, JK | 2 |
| Thabane, M | 1 |
| James, C | 2 |
| Burnett, SM | 1 |
| de la Paz, AV | 1 |
| Gibson, K | 1 |
| Vachal, P | 1 |
| Hale, JJ | 1 |
| Lu, Z | 1 |
| Streckfuss, EC | 1 |
| Mills, SG | 1 |
| MacCoss, M | 1 |
| Yin, DH | 1 |
| Algayer, K | 1 |
| Manser, K | 1 |
| Kesisoglou, F | 1 |
| Ghosh, S | 1 |
| Alani, LL | 1 |
| Allison, JJ | 1 |
| Kabi, F | 1 |
| Mkinsi, O | 1 |
| Zrigui, J | 1 |
| Michaud, K | 1 |
| Owens, DK | 1 |
| Garber, AM | 1 |
| Downey, TW | 1 |
| Foltz, SH | 1 |
| Boccuzzi, SJ | 1 |
| Omar, MA | 1 |
| Kahler, KH | 1 |
| Tragiannidis, A | 1 |
| Athanassiadou, F | 1 |
| Papageorgiou, T | 1 |
| Petsatodis, G | 1 |
| Gömez, L | 1 |
| García-Cazorla, A | 1 |
| Artuch, R | 1 |
| Varea, V | 1 |
| Martín, J | 1 |
| Pinillos, S | 1 |
| Vilaseca, MA | 1 |
| Ponte Fernández, N | 1 |
| Estefania Fresco, R | 1 |
| Aguirre Urizar, JM | 1 |
| de Nijs, RN | 2 |
| Jacobs, JW | 2 |
| Algra, A | 2 |
| Huisman, AM | 2 |
| Buskens, E | 2 |
| de Laet, CE | 1 |
| Oostveen, AC | 2 |
| Geusens, PP | 2 |
| Bruyn, GA | 2 |
| Bijlsma, JW | 2 |
| Aliberti, G | 1 |
| Pulignano, I | 1 |
| Pisani, D | 1 |
| Rocchietti March, M | 1 |
| Del Porto, F | 1 |
| Proietta, M | 1 |
| Epstein, S | 2 |
| Lips, P | 1 |
| Felsenberg, D | 1 |
| Lippuner, K | 2 |
| Benhamou, L | 1 |
| Rosen, C | 2 |
| Salzmann, G | 1 |
| He, W | 1 |
| Vittinghoff, E | 1 |
| Isaia, G | 2 |
| Luisetto, G | 2 |
| Sinigaglia, L | 1 |
| Gentilella, R | 1 |
| Iori, N | 1 |
| Ornoy, A | 1 |
| Wajnberg, R | 1 |
| Diav-Citrin, O | 1 |
| Cruse, LM | 1 |
| Valeriano, J | 1 |
| Vasey, FB | 1 |
| Carter, JD | 1 |
| Thomas, T | 1 |
| Hough, S | 2 |
| Duarte, PM | 1 |
| Gonçalves, P | 1 |
| Casati, MZ | 1 |
| de Toledo, S | 1 |
| Sallum, EA | 1 |
| Nociti, FH | 1 |
| Armamento-Villareal, R | 1 |
| Panwar, V | 1 |
| Novack, D | 1 |
| Kishimoto, M | 1 |
| Oishi, A | 1 |
| Motojima, S | 1 |
| Scillitani, A | 1 |
| Romagnoli, E | 1 |
| Rubegni, P | 1 |
| Fimiani, M | 1 |
| Bobba, RS | 1 |
| Beattie, K | 1 |
| Parkinson, B | 1 |
| Kumbhare, D | 1 |
| Kanfer, I | 1 |
| Shu, G | 1 |
| Nagashima, M | 1 |
| de Jongh, JN | 1 |
| Merigo, E | 1 |
| Meleti, M | 1 |
| Guidotti, R | 1 |
| Ripasarti, A | 1 |
| Zanzucchi, E | 1 |
| D'Aleo, P | 1 |
| Corradi, D | 1 |
| Corcione, L | 1 |
| Sesenna, E | 1 |
| Poli, T | 1 |
| Bonaninil, M | 1 |
| Fisher, AA | 1 |
| Davis, MW | 1 |
| Moroni, A | 1 |
| Faldini, C | 1 |
| Hoang-Kim, A | 1 |
| Pegreffi, F | 1 |
| Giannini, S | 2 |
| Conner, JA | 1 |
| Lisor, CF | 1 |
| Casey, DP | 1 |
| Howe, KS | 1 |
| Baz, MA | 1 |
| Robb-Nicholson, C | 2 |
| Lambrinoudaki, I | 1 |
| Christodoulakos, G | 1 |
| Botsis, D | 1 |
| Avorn, J | 1 |
| Arnold, M | 1 |
| Polinski, JM | 1 |
| Patrick, AR | 1 |
| Mogun, H | 1 |
| Solmon, DH | 1 |
| Ziegler, R | 1 |
| Tau, C | 1 |
| Russo, R | 1 |
| Rieder, MJ | 1 |
| Dicko, A | 1 |
| Toulemonde, A | 1 |
| Hoareau, F | 1 |
| Avenel-Audran, M | 1 |
| Verret, JL | 1 |
| Khosa, AD | 1 |
| Nayyar, MS | 1 |
| Beirne, JC | 1 |
| Schwenkglenks, M | 1 |
| Sakakura, CE | 2 |
| Gonçalves, D | 2 |
| Volberg, M | 1 |
| Moalli, M | 1 |
| Shen, V | 1 |
| Olson, E | 1 |
| Berryman, E | 1 |
| Andresen, CJ | 1 |
| Taylor, BC | 1 |
| Fink, HA | 1 |
| Kane, RL | 1 |
| Melton, LJ | 1 |
| Ensrud, KE | 1 |
| Løkken, P | 1 |
| Skoglund, LA | 1 |
| Skjelbred, P | 1 |
| Kamatari, M | 1 |
| Koto, S | 1 |
| Ozawa, N | 1 |
| Urao, C | 1 |
| Suzuki, Y | 1 |
| Akasaka, E | 1 |
| Yanagimoto, K | 1 |
| Sakota, K | 1 |
| Yamamoto, S | 1 |
| Anamizu, Y | 1 |
| Horiuchi, T | 1 |
| Christodoulakos, GE | 1 |
| Mellström, D | 1 |
| Nickelsen, T | 1 |
| Baltz, B | 1 |
| Apkon, S | 1 |
| Coll, J | 1 |
| Buckwalter, JG | 1 |
| Geiger, AM | 1 |
| Parsons, TD | 1 |
| Handler, J | 1 |
| Howes, J | 1 |
| Lehmer, RR | 1 |
| Donley, DW | 1 |
| Papierska, L | 1 |
| Rabijewski, M | 1 |
| McComsey, GA | 1 |
| Kendall, MA | 1 |
| Swindells, S | 1 |
| Hogg, E | 1 |
| Alston-Smith, B | 1 |
| Suckow, C | 1 |
| Gopalakrishnan, G | 1 |
| Benson, C | 1 |
| Wohl, DA | 1 |
| Guven, Z | 1 |
| Karadag-Saygi, E | 1 |
| Unlu-Ozkan, F | 1 |
| Adams, J | 1 |
| Preedy, D | 1 |
| Selby, P | 2 |
| Narusawa, K | 1 |
| Yamada, S | 1 |
| Inaba, M | 2 |
| Oda, D | 1 |
| Bagan, J | 1 |
| Grazio, S | 1 |
| Babic-Naglic, D | 1 |
| Kehler, T | 1 |
| Curkovic, B | 1 |
| Jansen, JP | 1 |
| Gaugris, S | 1 |
| Bergman, G | 1 |
| Marcantonio Júnior, E | 1 |
| Lee, T | 1 |
| Zambon, A | 1 |
| Baio, G | 1 |
| Mazzaglia, G | 1 |
| Merlino, L | 1 |
| Corrao, G | 1 |
| Oyoo, GO | 1 |
| Kariuki, JG | 1 |
| Mawatari, T | 1 |
| Miura, H | 1 |
| Iwamoto, Y | 1 |
| Higaki, H | 1 |
| Minagawa, M | 1 |
| Tanimoto, K | 1 |
| Okubo, Y | 1 |
| Harada, C | 1 |
| Sata, A | 1 |
| Nishikawa, A | 1 |
| Ohwada, R | 1 |
| Tsuiki, M | 1 |
| Hashimoto, E | 1 |
| Takano, K | 1 |
| Rossi, CM | 1 |
| Di Comite, G | 1 |
| Babb, RR | 1 |
| Nakamura, Y | 1 |
| Abu-Ali, S | 1 |
| Naito, M | 1 |
| Fotovati, A | 1 |
| Takeda, S | 1 |
| Kaneoka, H | 1 |
| Moride, Y | 1 |
| Geller, JL | 1 |
| Hu, B | 1 |
| Reed, S | 1 |
| Mirocha, J | 1 |
| Gertz, BJ | 2 |
| Holland, SD | 1 |
| Kline, WF | 1 |
| Matuszewski, BK | 1 |
| Quan, H | 3 |
| Lasseter, KC | 1 |
| Mucklow, JC | 1 |
| Porras, AG | 1 |
| Pedrazzoni, M | 1 |
| Alfano, FS | 1 |
| Gatti, C | 1 |
| Fantuzzi, M | 1 |
| Girasole, G | 1 |
| Campanini, C | 1 |
| Basini, G | 1 |
| Passeri, M | 1 |
| Singer, F | 1 |
| Ortolani, S | 1 |
| Balena, R | 2 |
| Chesnut, CH | 1 |
| Anderson, DC | 1 |
| Seedor, JG | 1 |
| Horan, AH | 1 |
| Holland, S | 1 |
| Maitland-Ramsey, L | 1 |
| Poku, M | 1 |
| Kher, U | 2 |
| Gertz, B | 1 |
| Bellantoni, MF | 1 |
| Falcini, F | 2 |
| Trapani, S | 1 |
| Ermini, M | 1 |
| Brandi, ML | 2 |
| Kessenich, CR | 2 |
| Selby, PL | 1 |
| Sorrentino, D | 1 |
| Trevisi, A | 1 |
| Bernardis, V | 1 |
| DeBiase, F | 1 |
| Labombarda, A | 1 |
| Bartoli, E | 1 |
| Crepaldi, G | 2 |
| Lockefeer, JH | 1 |
| Fleisch, HA | 1 |
| Roschger, P | 2 |
| Fratzl, P | 2 |
| Klaushofer, K | 2 |
| Davidson, ET | 1 |
| Coble, YD | 1 |
| Ashworth, L | 1 |
| Bonde, M | 1 |
| Garnero, P | 2 |
| Fledelius, C | 1 |
| Qvist, P | 1 |
| Christiansen, C | 2 |
| Hambro, S | 1 |
| Chavassieux, PM | 2 |
| Arlot, ME | 2 |
| Reda, C | 1 |
| Wei, L | 1 |
| Rottoli, P | 1 |
| Pondrelli, C | 1 |
| Cappiello, V | 1 |
| Vagliasindi, M | 1 |
| Yaffe, A | 1 |
| Iztkovich, M | 1 |
| Earon, Y | 1 |
| Alt, I | 1 |
| Lilov, R | 1 |
| Binderman, I | 1 |
| Wimalawansa, SJ | 1 |
| Simmons, DJ | 1 |
| Giardino, R | 1 |
| Fini, M | 1 |
| Nicoli Aldini, N | 1 |
| Gnudi, S | 1 |
| Biagini, G | 1 |
| Gandolfi, MG | 1 |
| Mongiorgi, R | 1 |
| Gibaldi, M | 1 |
| Levenets', VM | 1 |
| Kharytonov, OD | 1 |
| Pohodaieva, AV | 1 |
| Brunelli, MP | 1 |
| Einhorn, TA | 2 |
| MacInnis, C | 1 |
| Shiflett, S | 1 |
| Cooke, CE | 1 |
| Whiteside, C | 1 |
| Lange, B | 1 |
| Sørensen, HA | 1 |
| Hyldstrup, L | 1 |
| Annfinsen, SL | 1 |
| Pick, M | 1 |
| Woodward, JA | 1 |
| Ribeiro, A | 1 |
| DeVault, KR | 1 |
| Wolfe, JT | 1 |
| Stark, ME | 1 |
| Zaidi, M | 1 |
| Colao, A | 2 |
| Pivonello, R | 2 |
| Klain, M | 2 |
| Faggiano, A | 2 |
| Tripodi, FS | 1 |
| Merola, B | 1 |
| Salvatore, M | 2 |
| Lombardi, G | 2 |
| Mackay, FJ | 1 |
| Pearce, GL | 1 |
| Freemantle, SN | 1 |
| Mann, RD | 1 |
| Thamsborg, G | 1 |
| Malice, MP | 2 |
| Cowan, S | 1 |
| Morin, S | 2 |
| Ernst, P | 1 |
| Jeffcoat, MK | 1 |
| Lappe, JM | 1 |
| Tinley, ST | 1 |
| Tonino, RP | 1 |
| Kyd, PA | 2 |
| Vooght, KD | 1 |
| Kerkhoff, F | 2 |
| Thomas, E | 2 |
| Fairney, A | 3 |
| Chrischilles, E | 1 |
| Pressman, A | 2 |
| Schein, J | 1 |
| Mersfelder, T | 1 |
| Armitstead, JA | 1 |
| Ivey, MF | 1 |
| Cedars, M | 1 |
| Paul, KJ | 1 |
| Shih, WJ | 1 |
| Filippella, M | 1 |
| Ullom-Minnich, P | 1 |
| Kleerekoper, M | 1 |
| Oppenheimer, L | 1 |
| De Vooght, K | 1 |
| Demerjian, N | 1 |
| Bolla, G | 1 |
| Spreux, A | 1 |
| Kushida, K | 2 |
| Taga, M | 1 |
| Kaneda, K | 1 |
| Minaguchi, H | 1 |
| Morii, H | 1 |
| Tomita, A | 1 |
| Nakashima, M | 1 |
| Vokrouhlická, J | 1 |
| Dunlop, MB | 1 |
| Cantatore, FP | 1 |
| Acquista, CA | 1 |
| Pipitone, V | 1 |
| Campisi, P | 1 |
| Badhwar, V | 1 |
| Trudel, JL | 1 |
| Hamdy, RC | 1 |
| Goldstein, MF | 1 |
| Fallon, JJ | 1 |
| Harning, R | 1 |
| Alhava, E | 2 |
| Välimäki, M | 1 |
| Hartman, EE | 1 |
| Daley, J | 1 |
| Daifotis, A | 3 |
| Freedholm, D | 1 |
| Ho, YV | 1 |
| Frauman, AG | 1 |
| Thomson, W | 1 |
| Bone, H | 1 |
| Riggs, BL | 1 |
| Hardy, P | 1 |
| Dain, M | 1 |
| Bero, L | 1 |
| Ross-Degnan, D | 1 |
| Henry, D | 1 |
| Lee, K | 1 |
| Watkins, J | 1 |
| Mah, C | 1 |
| Soumerai, SB | 1 |
| Levin, E | 1 |
| Helfgott, SM | 1 |
| Soucy, E | 1 |
| Bellamy, N | 1 |
| Pope, JE | 1 |
| Flynn, J | 1 |
| Sutton, E | 1 |
| Campbell, J | 1 |
| Lambing, CL | 1 |
| Khanine, V | 1 |
| Fournier, JJ | 1 |
| Requeda, E | 1 |
| Luton, JP | 1 |
| Simon, F | 1 |
| Crouzet, J | 1 |
| Orwoll, E | 2 |
| Ettinger, M | 1 |
| Weiss, S | 1 |
| Graham, J | 1 |
| Weber, K | 1 |
| Lorenc, R | 1 |
| Pietschmann, P | 1 |
| Vandormael, K | 1 |
| Kronenberg, HM | 1 |
| Milott, JL | 1 |
| Green, SS | 1 |
| Schapira, MM | 1 |
| Hussain, MS | 1 |
| Tariq, S | 1 |
| Perry, HM | 1 |
| Morley, JE | 1 |
| Halbekath, J | 1 |
| Abadie, E | 1 |
| Audran, M | 1 |
| Avouac, B | 1 |
| Sedrine, WB | 1 |
| Calvo, G | 1 |
| Fuchs, V | 1 |
| Kreutz, G | 1 |
| Nilsson, P | 1 |
| Pols, H | 1 |
| Ringe, J | 1 |
| Van Haelst, L | 1 |
| Bianchi, ML | 1 |
| Cimaz, R | 1 |
| Bardare, M | 1 |
| Zulian, F | 1 |
| Lepore, L | 1 |
| Boncompagni, A | 1 |
| Galbiati, E | 1 |
| Corona, F | 1 |
| Giuntini, D | 1 |
| Picco, P | 1 |
| Wezeman, FH | 1 |
| Emanuele, MA | 1 |
| Moskal, SF | 1 |
| Steiner, J | 1 |
| Lapaglia, N | 1 |
| Baran, DT | 1 |
| Thomsen, JS | 1 |
| Mackey, MS | 1 |
| Rainsford, KD | 1 |
| Hunt, RH | 1 |
| Hawkins Carranza, F | 1 |
| López Alvarez, MB | 1 |
| Kovac, D | 1 |
| Lindic, J | 1 |
| Kandus, A | 1 |
| Bren, AF | 1 |
| Li, I | 1 |
| Rossini, M | 1 |
| Braga, V | 1 |
| Sewell, K | 1 |
| Schein, JR | 1 |
| Woodson, G | 1 |
| Mako, B | 1 |
| Smith, ME | 1 |
| Yates, SJ | 1 |
| Palmisano, JJ | 1 |
| Baran, D | 1 |
| Moore, HC | 1 |
| Alkhenizan, A | 1 |
| Almarri, S | 1 |
| Evans, MF | 1 |
| Price, PA | 1 |
| Faus, SA | 1 |
| Williamson, MK | 1 |
| Bailen, LS | 1 |
| Canfield, G | 1 |
| Cefalu, CA | 1 |
| Guaraldi, G | 1 |
| Ventura, P | 1 |
| Albuzza, M | 1 |
| Orlando, G | 1 |
| Bedini, A | 1 |
| Esposito, R | 1 |
| Chidambaran, P | 1 |
| Janssen, YJ | 1 |
| Huuskonen, J | 1 |
| Arnala, I | 1 |
| Olkkonen, H | 1 |
| Vasireddy, S | 1 |
| Swinson, DR | 1 |
| da Paz, LH | 1 |
| de Falco, V | 1 |
| Teng, NC | 1 |
| dos Reis, LM | 1 |
| Weber, TJ | 1 |
| Drezner, MK | 1 |
| Harsch, IA | 1 |
| Hübner, RH | 1 |
| Hahn, EG | 1 |
| Hensen, J | 1 |
| Rinnerthaler, S | 1 |
| Das, H | 1 |
| Kamath, A | 1 |
| Bukowski, JF | 1 |
| McClung, B | 1 |
| Cahill, BC | 1 |
| O'Rourke, MK | 1 |
| Parker, S | 1 |
| Stringham, JC | 1 |
| Karwande, SV | 1 |
| Knecht, TP | 1 |
| D'Angelo, A | 1 |
| Carraro, G | 1 |
| Nobile, M | 1 |
| Rigotti, P | 1 |
| Bonfante, L | 1 |
| Marchini, F | 1 |
| Zaninotto, M | 1 |
| Dalle Carbonare, L | 1 |
| Peters, ML | 1 |
| Leonard, M | 1 |
| Tsun, EC | 1 |
| Heck, AM | 1 |
| Lau, EM | 1 |
| Woo, J | 1 |
| Rovati, LC | 1 |
| Vasikaran, SD | 1 |
| Sniger, W | 1 |
| Garshick, E | 1 |
| Lanza, F | 1 |
| Sahba, B | 1 |
| Schwartz, H | 1 |
| Winograd, S | 1 |
| Torosis, J | 1 |
| Musliner, T | 1 |
| Leung, A | 1 |
| Yu, S | 1 |
| Curry, LC | 1 |
| Hogstel, MO | 1 |
| Kirk, JK | 1 |
| Nichols, M | 1 |
| Spangler, JG | 1 |
| Chen, JR | 1 |
| Powers, CC | 1 |
| Stewart, SA | 1 |
| Landes, RD | 1 |
| Bellido, T | 1 |
| Jilka, RL | 1 |
| Parfitt, AM | 1 |
| Manolagas, SC | 1 |
| Hayashi, Y | 1 |
| Ishii, J | 1 |
| Crandall, C | 1 |
| Atoyebi, W | 1 |
| Brown, M | 1 |
| Wass, J | 1 |
| Littlewood, TJ | 1 |
| Hatton, C | 1 |
| Stone, M | 1 |
| Lehmann, HJ | 1 |
| Mouritzen, U | 1 |
| Christgau, S | 1 |
| Cloos, PA | 1 |
| Casale, JA | 1 |
| Lazarov, A | 1 |
| Moss, K | 1 |
| Plosk, N | 1 |
| Cordoba, M | 1 |
| Baitelman, L | 1 |
| Shapiro, LS | 1 |
| Stuart, M | 1 |
| Cruz, DN | 1 |
| Brickel, HM | 1 |
| Wysolmerski, JJ | 1 |
| Gundberg, CG | 1 |
| Simpson, CA | 1 |
| Kliger, AS | 1 |
| Lorber, MI | 1 |
| Basadonna, GP | 1 |
| Friedman, AL | 1 |
| Insogna, KL | 1 |
| Bia, MJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, International, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis[NCT01575834] | Phase 3 | 7,180 participants (Actual) | Interventional | 2012-03-15 | Completed | ||
| An Extension Study to Evaluate 24 Months of Standard-of-Care Osteoporosis Management Following Completion of 18 Months of BA058 or Placebo Treatment in Protocol BA058-05-003[NCT01657162] | Phase 3 | 1,139 participants (Actual) | Interventional | 2012-11-20 | Completed | ||
| Risedronate With High-dose Vitamin D Resolves Hyperparathyroidism and Hypovitaminosis D But Not Osteoporosis in Mexican Postmenopausal Patients[NCT05346419] | 33 participants (Actual) | Interventional | 2021-07-01 | Completed | |||
| A Multicenter, International, Randomized, Double-blind, Alendronate-controlled Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis[NCT01631214] | Phase 3 | 4,093 participants (Actual) | Interventional | 2012-05-04 | Completed | ||
| Randomized Trial Comparing Efficacy and Safety of Brand Versus Generic Alendronate for Osteoporosis Treatment[NCT02371252] | Phase 4 | 140 participants (Actual) | Interventional | 2014-04-30 | Completed | ||
| Orthopaedic Conservative Treatment in the Time of Covid-19 Pandemic[NCT04623346] | 262 participants (Anticipated) | Observational | 2020-03-11 | Active, not recruiting | |||
| A Phase III (Phase IV Program) Open-Label, Multicenter Clinical Trial in Thailand to Study the Effect of MK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tablet (Fosamax Plus 70/5600) for 6 Months on 25-Hydroxyvitamin D Levels in the Treatm[NCT01437111] | Phase 3 | 200 participants (Actual) | Interventional | 2011-10-26 | Completed | ||
| A Multicenter, Randomized, Cross-Over, Open-label Study to Evaluate the Adherence, Preference, and Satisfaction of Denosumab and Alendronate in Postmenopausal Women With Low Bone Mineral Density[NCT00518531] | Phase 3 | 250 participants (Actual) | Interventional | 2007-09-01 | Completed | ||
| Pentoxifylline and Tocopherol (PENTO) in the Treatment of Medication-related Osteonecrosis of the Jaw (MRONJ): A Prospective, Randomized Controlled Trial to Evaluate a Novel Non-operative Treatment[NCT03040778] | Phase 3 | 100 participants (Anticipated) | Interventional | 2018-04-01 | Enrolling by invitation | ||
| A Randomized, Double-Blind, Placebo-controlled Phase 3 Study Evaluating Efficacy and Safety of Denosumab in Japanese Osteoporotic Subjects With Prevalent Fragility Vertebral Fracture(s)[NCT00680953] | Phase 3 | 1,262 participants (Actual) | Interventional | 2008-05-31 | Completed | ||
| STOP Vertigo: Supplementation of Vitamin D for Termination of Recurrences From Benign Paroxysmal Positional Vertigo[NCT05863949] | 860 participants (Anticipated) | Interventional | 2023-07-31 | Not yet recruiting | |||
| Multiparametric Assessment of Bone Response in mCRPC Patients Treated With Cabozantinib Upon Progression to Chemotherapy and Next Generation Hormonal Agents: a Phase II Study[NCT05265988] | Phase 2 | 32 participants (Anticipated) | Interventional | 2021-10-29 | Recruiting | ||
| Resolution of Hyperparathyroidism With High-dose Vitamin D Improves Osteoporosis in Multi-treated Postmenopausal Women[NCT05347082] | 47 participants (Actual) | Interventional | 2021-04-29 | Completed | |||
| An Open-Label Phase 2 Study of Abaloparatide to Mitigate Distal Femoral Bone Loss Following Total Knee Arthroplasty[NCT04167163] | Phase 4 | 58 participants (Actual) | Interventional | 2020-01-10 | Active, not recruiting | ||
| Comparison of the Effects of Teriparatide With Those of Alendronate Sodium on Lumbar Spine Bone Mineral Density in Glucocorticoid-Induced Osteoporosis[NCT00051558] | Phase 3 | 428 participants (Actual) | Interventional | 2002-11-30 | Completed | ||
| A Multicentre, Double-Blind, Randomized Placebo-Controlled Study of 70mg Alendronate Once Weekly for the Prevention and Treatment of Osteoporosis in Canadian Adult Cystic Fibrosis Patients[NCT00157690] | Phase 4 | 56 participants (Actual) | Interventional | 2003-12-31 | Completed | ||
| A 15-Week, Double-Blind, Randomized, Active-Controlled, Multi-Center Study With 24-Week Extension to Evaluate the Safety, Tolerability, Efficacy of Alendronate 70 mg Plus Vitamin D3 2800 IU Combination Tablet in Men and Postmenopausal Women With Osteoporo[NCT00092079] | Phase 3 | 652 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| Denosumab Versus Zoledronic Acid for Patients With Beta-Thalassemia Major-Induced Osteoporosis[NCT03040765] | Phase 3 | 17 participants (Actual) | Interventional | 2018-05-14 | Terminated (stopped due to failed to recruit eligible subjects) | ||
| Bone Formation-Resorption Coupling and Osteoporosis[NCT00000400] | Phase 2 | 176 participants (Actual) | Interventional | 1999-08-31 | Completed | ||
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 12-Month Study to Evaluate the Efficacy and Safety of Oral Alendronate Sodium Once Weekly for the Prevention and Treatment of Glucocorticoid-Induced Bone Loss[NCT00480766] | Phase 3 | 173 participants (Actual) | Interventional | 2001-07-31 | Completed | ||
| Impact of Oral Alendronate Therapy on Bone Mineral Density in HIV-infected Children and Adolescents With Low Bone Mineral Density[NCT00921557] | Phase 2 | 52 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| Quantifying Fatigue of the Respiratory and Swallowing Musculature in Patients With Amyotrophic Lateral Sclerosis[NCT04468191] | 0 participants (Actual) | Interventional | 2021-02-10 | Withdrawn (stopped due to COVID-19 pandemic restrictions for data collection) | |||
| Radiographic Peri-implant Alveolar Bone Changes in Post-menopausal Osteoporotic Women[NCT02884401] | 27 participants (Actual) | Interventional | 2016-09-30 | Completed | |||
| The P.O.W.E.R. STUDY (Premenopause, Osteopenia/Osteoporosis, Women, Alendronate, Depression)[NCT00006180] | Phase 4 | 220 participants | Interventional | 2000-08-10 | Completed | ||
| Efficacy of Alendronate Versus Placebo in the Treatment of HIV-1 Associated Osteoporosis, a Multicenter, Randomized, Controlled Trial. ANRS 120 Fosivir[NCT00120757] | Phase 3 | 140 participants | Interventional | 2004-10-31 | Completed | ||
| Addressing Vertebral Osteoporosis Incidentally Detected to Prevent Future Fractures: The AVOID FRACTURE Study[NCT00388908] | 240 participants (Actual) | Interventional | 2006-11-30 | Completed | |||
| Anabolic Actions of Parathyroid Hormone in Osteoporotic Men[NCT00000427] | Phase 3 | 81 participants | Interventional | 1999-09-30 | Completed | ||
| Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption[NCT01750086] | Phase 4 | 27 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
| The Denosumab And Teriparatide Administration Study (DATA)[NCT00926380] | Phase 2 | 94 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| Bisphosphonate Users Radiographic Characteristics of the Hip (BURCH) Study[NCT01360099] | 120 participants (Actual) | Observational | 2011-05-04 | Completed | |||
| A 12-Month Extension to: A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter Study to Evaluate and Compare the Effects of Once Weekly Alendronate and Risedronate on Bone Mineral Density in Postmenopausal Women With Osteoporosis[NCT00092014] | Phase 3 | 1,053 participants (Actual) | Interventional | 2002-09-01 | Completed | ||
| The Prevalence of Vitamin D Deficiency and Effects of Vitamin D Supplementation in HIV-1 Infected Patients[NCT00306410] | Phase 2 | 85 participants | Interventional | 2006-01-31 | Recruiting | ||
| Randomized Control Trial of Bone Loading Exercises Versus Risedronate on Bone Health in Post-Menopausal Women[NCT02186600] | Phase 3 | 276 participants (Actual) | Interventional | 2015-02-01 | Completed | ||
| Prevention of Glucocorticoid-Induced Osteoporosis in Patients With Rheumatic Diseases. The STOP-Study: a Randomized Placebo Controlled Trial With Alendronate Versus Alfacalcidol.[NCT00138983] | Phase 3 | 200 participants | Interventional | 2000-05-31 | Completed | ||
| A 15-Week, Double-Blind, Randomized, Active-Controlled, Multi-Center Study With 24-Week Extension to Evaluate the Safety, Tolerability, Efficacy of Alendronate 70 mg Plus Vitamin D3 2800 IU Combination Tablet in Men and Postmenopausal Women With Osteoporo[NCT00092066] | Phase 3 | 717 participants (Actual) | Interventional | 2003-09-24 | Completed | ||
| A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Once-Weekly Alendronate in HIV-Infected Subjects With Decreased Bone Mineral Density Receiving Calcium and Vitamin D[NCT00061256] | Phase 2 | 80 participants | Interventional | Completed | |||
| A Multi-centre, Prospective, Randomised Trial of Short Course Alendronate Therapy or Placebo Combined With Vitamin D and Calcium to Prevent Loss of Bone Mineral Density in Antiretroviral-naïve, HIV-1 Infected Subjects Initiating Antiretroviral Therapy[NCT02322099] | Phase 4 | 53 participants (Actual) | Interventional | 2016-05-31 | Terminated (stopped due to Due to the COVID-19 pandemic the study was terminated prematurely) | ||
| Alendronate Versus Placebo for Idiopathic Juvenile Osteoporosis[NCT00001720] | Phase 2 | 50 participants | Interventional | 1998-03-31 | Completed | ||
| Teriparatide for Joint Erosions in Rheumatoid Arthritis: The TERA Trial[NCT01400516] | Phase 4 | 26 participants (Actual) | Interventional | 2011-08-31 | Completed | ||
| Osteoporosis in Cystic Fibrosis: Study of Bone Mass and Bone Metabolism, and Prospective Randomized Therapeutic Trial.[NCT01812551] | Phase 3 | 171 participants (Actual) | Interventional | 2002-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. (NCT01575834)
Timeframe: Baseline and Month 12
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Placebo | 0.4 |
| Romosozumab | 13.1 |
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. (NCT01575834)
Timeframe: Baseline and Month 24
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Placebo/Denosumab | 5.5 |
| Romosozumab/Denosumab | 16.6 |
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. (NCT01575834)
Timeframe: Baseline and Month 12
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Placebo | 0.3 |
| Romosozumab | 5.5 |
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. (NCT01575834)
Timeframe: Baseline and Month 24
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Placebo/Denosumab | 2.3 |
| Romosozumab/Denosumab | 7.3 |
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. (NCT01575834)
Timeframe: Baseline and Month 12
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Placebo | 0.3 |
| Romosozumab | 6.0 |
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. (NCT01575834)
Timeframe: Baseline and Month 24
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Placebo/Denosumab | 3.2 |
| Romosozumab/Denosumab | 8.5 |
Clinical fractures included clinical vertebral and nonvertebral fractures (excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges) that were associated with signs and/or symptoms indicative of a fracture. Clinical vertebral fractures were included regardless of trauma severity or pathologic fractures; nonvertebral fractures associated with high trauma severity or pathologic fractures were excluded. (NCT01575834)
Timeframe: 12 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 2.5 |
| Romosozumab | 1.6 |
Clinical fractures included clinical vertebral and nonvertebral fractures (excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges) that were associated with signs and/or symptoms indicative of a fracture. Clinical vertebral fractures were included regardless of trauma severity or pathologic fractures; nonvertebral fractures associated with high trauma severity or pathologic fractures were excluded. (NCT01575834)
Timeframe: 24 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo/Denosumab | 4.1 |
| Romosozumab/Denosumab | 2.8 |
Hip fractures were defined as a subset of nonvertebral fractures including fractures of the femur neck, femur intertrochanter, and femur subtrochanter. (NCT01575834)
Timeframe: 12 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 0.4 |
| Romosozumab | 0.2 |
Hip fractures were defined as a subset of nonvertebral fractures including fractures of the femur neck, femur intertrochanter, and femur subtrochanter. (NCT01575834)
Timeframe: 24 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo/Denosumab | 0.6 |
| Romosozumab/Denosumab | 0.3 |
A major nonvertebral fracture was a subset of nonvertebral fractures including pelvis, distal femur (ie, femur excluding hip), proximal tibia (ie, tibia excluding ankle), ribs, proximal humerus (ie, humerus excluding elbow), forearm, and hip. (NCT01575834)
Timeframe: 12 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 1.5 |
| Romosozumab | 1.0 |
A major nonvertebral fracture was a subset of nonvertebral fractures including pelvis, distal femur (ie, femur excluding hip), proximal tibia (ie, tibia excluding ankle), ribs, proximal humerus (ie, humerus excluding elbow), forearm, and hip. (NCT01575834)
Timeframe: 24 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo/Denosumab | 2.8 |
| Romosozumab/Denosumab | 1.9 |
Major osteoporotic fractures included clinical vertebral fractures and fractures of the hip, forearm and humerus. Fractures associated with high trauma severity or pathologic fractures were excluded. (NCT01575834)
Timeframe: 12 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 1.8 |
| Romosozumab | 1.1 |
Major osteoporotic fractures included clinical vertebral fractures and fractures of the hip, forearm and humerus. Fractures associated with high trauma severity or pathologic fractures were excluded. (NCT01575834)
Timeframe: 24 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo/Denosumab | 3.1 |
| Romosozumab/Denosumab | 1.9 |
A new or worsening vertebral fracture was identified when there was a ≥ 1 grade increase from the previous grade in any vertebra from T4 to L4. (NCT01575834)
Timeframe: 12 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 1.8 |
| Romosozumab | 0.5 |
A new or worsening vertebral fracture was identified when there was a ≥ 1 grade increase from the previous grade in any vertebra from T4 to L4. (NCT01575834)
Timeframe: 24 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo/Denosumab | 2.5 |
| Romosozumab/Denosumab | 0.7 |
A nonvertebral fracture was defined as a fracture present on a copy of radiographs or other diagnostic images such as computerized tomography (CT) or magnetic resonance imaging confirming the fracture within 14 days of reported fracture image date recorded by the study site, and/or documented in a copy of the radiology report, surgical report, or discharge summary, excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges. In addition, fractures associated with high trauma severity or pathologic fractures were excluded. (NCT01575834)
Timeframe: 12 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 2.1 |
| Romosozumab | 1.6 |
A nonvertebral fracture was defined as a fracture present on a copy of radiographs or other diagnostic images such as computerized tomography (CT) or magnetic resonance imaging confirming the fracture within 14 days of reported fracture image date as recorded by the study site, and/or documented in a copy of the radiology report, surgical report, or discharge summary, excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges. In addition, fractures associated with high trauma severity or pathologic fractures were excluded. (NCT01575834)
Timeframe: 24 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo/Denosumab | 3.6 |
| Romosozumab/Denosumab | 2.7 |
A new or worsening vertebral fracture was identified when there was a ≥ 1 grade increase from the previous grade in any vertebra from T4 to L4. A participant had multiple new or worsening vertebral fractures when there were ≥ 2 vertebrae from T4 to L4 with ≥ 1 grade increase from the previous grade. The multiple new or worsening vertebral fractures need not have occurred at the same visit. (NCT01575834)
Timeframe: 12 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 0.3 |
| Romosozumab | 0.03 |
A new or worsening vertebral fracture was identified when there was a ≥ 1 grade increase from the previous grade in any vertebra from T4 to L4. A participant had multiple new or worsening vertebral fractures when there were ≥ 2 vertebrae from T4 to L4 with ≥ 1 grade increase from the previous grade. The multiple new or worsening vertebral fractures need not have occurred at the same visit. (NCT01575834)
Timeframe: 24 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo/Denosumab | 0.5 |
| Romosozumab/Denosumab | 0.03 |
"New vertebral fractures occurred when there was ≥ 1 grade increase from the previous grade of 0 in any vertebra from T4 to L4 using the Genant semiquantitative scoring method.~The Genant semiquantitative scoring method was based on assessment of x-rays according to the following scale:~Grade 0 (Normal) = no fracture;~Grade 1 (Mild) = mild fracture, 20 to 25% reduction in vertebral height (anterior, middle, or posterior);~Grade 2 (Moderate) = moderate fracture, 25 to 40% reduction in anterior, middle, and/or posterior height;~Grade 3 (Severe) = severe fracture, greater than 40% reduction in anterior, middle, and/or posterior height." (NCT01575834)
Timeframe: 12 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 1.8 |
| Romosozumab | 0.5 |
"New vertebral fractures occurred when there was ≥ 1 grade increase from the previous grade of 0 in any vertebra from T4 to L4 using the Genant semiquantitative scoring method.~The Genant semiquantitative scoring method was based on assessment of x-rays according to the following scale:~Grade 0 (Normal) = no fracture;~Grade 1 (Mild) = mild fracture, 20 to 25% reduction in vertebral height (anterior, middle, or posterior);~Grade 2 (Moderate) = moderate fracture, 25 to 40% reduction in anterior, middle, and/or posterior height;~Grade 3 (Severe) = severe fracture, greater than 40% reduction in anterior, middle, and/or posterior height." (NCT01575834)
Timeframe: 24 months
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo/Denosumab | 2.5 |
| Romosozumab/Denosumab | 0.6 |
Nonvertebral fractures were defined as clinical fractures that included: 1) those of the hip, wrist, forearm, shoulder, collar bone, upper arm, ribs, upper leg (not hip), knee, lower leg (not knee or ankle), foot, ankle, hand, pelvis (not hip), tailbone, and other; and 2) those associated with low trauma, defined as a fall from standing height or less; a fall on stairs, steps or curbs; a minimal trauma other than a fall; or moderate trauma other than a fall. Complete results for Study BA058-05-003 are reported in the ClinicalTrials.gov Study Record NCT02653417. (NCT01657162)
Timeframe: Study BA058-05-003 Baseline (Day 1) up to Study BA058-05-005 Month 6 (Study BA058-05-003 Month 25)
| Intervention | percentage of events (Number) |
|---|---|
| Abaloparatide-SC/Alendronate | 2.7 |
| Placebo/Alendronate | 5.6 |
Vertebral fractures were determined clinically and via protocol directed radiograph evaluation. Complete results for Study BA058-05-003 are reported in the ClinicalTrials.gov Study Record NCT02653417. (NCT01657162)
Timeframe: Study BA058-05-003 Baseline (Day 1) up to Study BA058-05-005 Month 6 (Study BA058-05-003 Month 25)
| Intervention | Participants (Count of Participants) |
|---|---|
| Abaloparatide-SC/Alendronate | 3 |
| Placebo/Alendronate | 25 |
Coagulation laboratory parameters that were evaluated via notable criteria (presented in parentheses) included: Activated Partial Thromboplastin Time (≥1.41*ULN), Prothrombin Time (≥1.21*ULN). Because the Activated Partial Thromboplastin Time was the only coagulation laboratory parameter with at least 1 participant with a notable laboratory value, this is the only parameter presented below. (NCT01657162)
Timeframe: Study BA058-05-005 Baseline (Day 1) up to Study BA058-05-005 Month 24
| Intervention | Participants (Count of Participants) |
|---|---|
| Abaloparatide-SC/Alendronate | 9 |
| Placebo/Alendronate | 4 |
Nonvertebral fractures were defined as clinical fractures that included: 1) those of the hip, wrist, forearm, shoulder, collar bone, upper arm, ribs, upper leg (not hip), knee, lower leg (not knee or ankle), foot, ankle, hand, pelvis (not hip), tailbone, and other; and 2) those associated with low trauma, defined as a fall from standing height or less; a fall on stairs, steps or curbs; a minimal trauma other than a fall; or moderate trauma other than a fall. Complete results for Study BA058-05-003 are reported in the ClinicalTrials.gov Study Record NCT02653417. (NCT01657162)
Timeframe: Study BA058-05-003 Baseline (Day 1) up to Study BA058-05-005 Month 6 (Study BA058-05-003 Month 25)
| Intervention | Participants (Count of Participants) |
|---|---|
| Abaloparatide-SC/Alendronate | 15 |
| Placebo/Alendronate | 32 |
Femoral neck BMD were measured via DXA. Complete results for Study BA058-05-003 are reported in the ClinicalTrials.gov Study Record NCT02653417. (NCT01657162)
Timeframe: Study BA058-05-003 Baseline (Day 1), Study BA058-05-005 Month 6 (Study BA058-05-003 Month 25)
| Intervention | percent change (Mean) |
|---|---|
| Abaloparatide-SC/Alendronate | 4.5113 |
| Placebo/Alendronate | 0.4649 |
Lumbar spine BMD were measured via DXA. Complete results for Study BA058-05-003 are reported in the ClinicalTrials.gov Study Record NCT02653417. (NCT01657162)
Timeframe: Study BA058-05-003 Baseline (Day 1), Study BA058-05-005 Month 6 (Study BA058-05-003 Month 25)
| Intervention | percent change (Mean) |
|---|---|
| Abaloparatide-SC/Alendronate | 12.7921 |
| Placebo/Alendronate | 3.5133 |
Total hip BMD were measured via DXA. Complete results for Study BA058-05-003 are reported in the ClinicalTrials.gov Study Record NCT02653417. (NCT01657162)
Timeframe: Study BA058-05-003 Baseline (Day 1), Study BA058-05-005 Month 6 (Study BA058-05-003 Month 25)
| Intervention | percent change (Mean) |
|---|---|
| Abaloparatide-SC/Alendronate | 5.4737 |
| Placebo/Alendronate | 1.3698 |
Hematology laboratory parameters that were evaluated via notable criteria (presented in parentheses) included: Absolute Eosinophils (>5000 cells/mm^3), Absolute Lymphocytes (≤499 cells/mm^3), Absolute Neutrophils (≤999 cells/mm^3), % Eosinophils (>50%), % Lymphocytes (≤5%), % Neutrophils (≤10%), Hemoglobin (Low: ≤9.4 g/dL; High: change from baseline ≥2.1 g/dL), Platelets (≤99000 cells/mm^3), and White Blood Cells (Low: ≤1499 cells/mm^3; High: ≥20001 cells/mm^3). Only the hematology parameters with at least 1 participant with a notable laboratory value are presented. (NCT01657162)
Timeframe: Study BA058-05-005 Baseline (Day 1) up to Study BA058-05-005 Month 24
| Intervention | Participants (Count of Participants) | ||||||
|---|---|---|---|---|---|---|---|
| Absolute Lymphocytes | Lymphocytes (Absolute Count or Percentage) | Absolute Neutrophils | Neutrophils (Absolute Count or Percentage) | Hemoglobin (Low) | Hemoglobin (High) | Platelets | |
| Abaloparatide-SC/Alendronate | 15 | 15 | 0 | 0 | 7 | 19 | 1 |
| Placebo/Alendronate | 11 | 11 | 2 | 2 | 2 | 17 | 0 |
Serum Chemistry laboratory parameters that were evaluated via notable criteria (presented in parentheses) included: sodium (Low: ≤129; High: ≥148 milliequivalent per liter [mEq/L]), potassium (Low: ≤3.2; High: ≥5.5 mEq/L), albumin (<2.5 grams [g]/deciliter [dL]), total protein (<5 g/dL), glucose (Low: ≤54; High: >125 mg/dL [fasting] or >200 milligrams [mg]/dL [random]), creatinine (≥2.1 mg/dL), aspartate aminotransferase (AST) (≥5.1*upper limit of normal [ULN]), alanine aminotransferase (ALT) (≥5.1*ULN), alkaline phosphatase (AP) (≥3.1*ULN), total bilirubin (≥1.51*ULN [with any increase in liver function tests] ≥2.0*ULN [with normal liver function tests]), creatine kinase (≥3.1*ULN), total cholesterol (>226 mg/dL), and total calcium (Low: ≤7.4; High: ≥11.6 mg/dL). Only the serum chemistry parameters with at least 1 participant with a notable laboratory value are presented. (NCT01657162)
Timeframe: Study BA058-05-005 Baseline (Day 1) up to Study BA058-05-005 Month 24
| Intervention | Participants (Count of Participants) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Alkaline Phosphatase | Cholesterol Total | Creatine Kinase | Glucose (Fasting; High) | Glucose (Random) | Potassium (Low) | Potassium (High) | Sodium (Low) | Sodium (High) | |
| Abaloparatide-SC/Alendronate | 1 | 75 | 2 | 22 | 1 | 1 | 4 | 1 | 6 |
| Placebo/Alendronate | 0 | 73 | 1 | 18 | 2 | 3 | 3 | 1 | 2 |
Urine laboratory parameters that were evaluated via notable criteria (presented in parentheses) included: Glucose (2+), Protein (2+), Blood (>50 red blood cells per high-power field [rbc/hpf]). (NCT01657162)
Timeframe: Study BA058-05-005 Baseline (Day 1) up to Study BA058-05-005 Month 24
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Glucose | Protein | Blood | |
| Abaloparatide-SC/Alendronate | 4 | 6 | 77 |
| Placebo/Alendronate | 3 | 6 | 50 |
A TEAE is any untoward medical occurrence or undesirable event(s) experienced in a participant that begins or worsens following administration of study drug, whether or not considered related to study drug by Investigator. A serious adverse event (SAE) was an adverse event (AE) resulting in any of the following outcomes or deemed significant for any other reason, death, initial or prolonged inpatient hospitalization, life-threatening experience (immediate risk of dying), congenital anomaly/birth defect, or persistent or significant disability/incapacity. Intensity for each AE was defined as mild, moderate, or severe. AEs included both SAEs and non-serious AEs. AEs whose causal relation was characterized as Possible or Probable were considered as related to study drug. AEs were coded using Medical Dictionary for Regulatory Activities (MedDRA). A summary of serious and all other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events module. (NCT01657162)
Timeframe: Study BA058-05-005 Baseline (Day 1) up to Study BA058-05-005 Month 24
| Intervention | Participants (Count of Participants) | |||||
|---|---|---|---|---|---|---|
| TEAEs | TEAEs Related to Study Treatment | Severe TEAEs | Serious TEAEs | TEAEs Leading to Death | TEAEs Leading to Discontinuation | |
| Abaloparatide-SC/Alendronate | 452 | 85 | 38 | 65 | 0 | 30 |
| Placebo/Alendronate | 466 | 80 | 40 | 58 | 2 | 36 |
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. (NCT01631214)
Timeframe: Baseline and month 12
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Alendronate/Alendronate | 1.7 |
| Romosozumab/Alendronate | 4.9 |
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. (NCT01631214)
Timeframe: Baseline and month 12
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Alendronate/Alendronate | 5.0 |
| Romosozumab/Alendronate | 13.7 |
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. (NCT01631214)
Timeframe: Baseline and month 24
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Alendronate/Alendronate | 7.2 |
| Romosozumab/Alendronate | 15.3 |
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. (NCT01631214)
Timeframe: Baseline and month 12
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Alendronate/Alendronate | 2.8 |
| Romosozumab/Alendronate | 6.2 |
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. (NCT01631214)
Timeframe: Baseline and month 24
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Alendronate/Alendronate | 2.3 |
| Romosozumab/Alendronate | 6.0 |
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. (NCT01631214)
Timeframe: Baseline and month 36
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Alendronate/Alendronate | 2.4 |
| Romosozumab/Alendronate | 6.0 |
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. (NCT01631214)
Timeframe: Baseline and month 36
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Alendronate/Alendronate | 7.8 |
| Romosozumab/Alendronate | 15.2 |
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. (NCT01631214)
Timeframe: Baseline and month 24
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Alendronate/Alendronate | 3.5 |
| Romosozumab/Alendronate | 7.2 |
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. (NCT01631214)
Timeframe: Baseline and month 36
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Alendronate/Alendronate | 3.5 |
| Romosozumab/Alendronate | 7.2 |
All fracture assessments were performed by blinded central imaging readers. Clinical fractures included clinical vertebral and nonvertebral fractures (excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges) that were associated with signs and/or symptoms indicative of a fracture. Clinical vertebral fractures were included regardless of trauma severity or pathologic fractures; nonvertebral fractures associated with high trauma severity or pathologic fractures were excluded. (NCT01631214)
Timeframe: The primary analysis was performed when clinical fracture events had been confirmed in at least 330 patients and all participants had completed the month 24 visit. The median follow-up was 2.7 years (interquartile range, 2.2 to 3.3).
| Intervention | percentage of participants (Number) |
|---|---|
| Alendronate/Alendronate | 13.0 |
| Romosozumab/Alendronate | 9.7 |
Clinical fractures included clinical vertebral and nonvertebral fractures (excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges) that were associated with signs and/or symptoms indicative of a fracture. Clinical vertebral fractures were included regardless of trauma severity or pathologic fractures; nonvertebral fractures associated with high trauma severity or pathologic fractures were excluded. (NCT01631214)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Alendronate/Alendronate | 5.4 |
| Romosozumab/Alendronate | 3.9 |
Clinical fractures included clinical vertebral and nonvertebral fractures (excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges) that were associated with signs and/or symptoms indicative of a fracture. Clinical vertebral fractures were included regardless of trauma severity or pathologic fractures; nonvertebral fractures associated with high trauma severity or pathologic fractures were excluded. (NCT01631214)
Timeframe: 24 months
| Intervention | percentage of participants (Number) |
|---|---|
| Alendronate/Alendronate | 9.6 |
| Romosozumab/Alendronate | 7.1 |
A clinical vertebral fracture is a new or worsening vertebral fracture assessed at either a scheduled or unscheduled visit and associated with any signs and/or symptoms of back pain indicative of a fracture, regardless of trauma severity or whether it is pathologic. (NCT01631214)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Alendronate/Alendronate | 0.9 |
| Romosozumab/Alendronate | 0.5 |
A clinical vertebral fracture is a new or worsening vertebral fracture assessed at either a scheduled or unscheduled visit and associated with any signs and/or symptoms of back pain indicative of a fracture, regardless of trauma severity or whether it is pathologic. (NCT01631214)
Timeframe: 24 months
| Intervention | percentage of participants (Number) |
|---|---|
| Alendronate/Alendronate | 2.1 |
| Romosozumab/Alendronate | 0.9 |
Hip fractures were defined as a subset of nonvertebral fractures including fractures of the femur neck, femur intertrochanter, and femur subtrochanter. (NCT01631214)
Timeframe: The primary analysis was performed when clinical fracture events had been confirmed in at least 330 patients and all participants had completed the month 24 visit. The median follow-up was 2.7 years (interquartile range, 2.2 to 3.3).
| Intervention | percentage of participants (Number) |
|---|---|
| Alendronate/Alendronate | 3.2 |
| Romosozumab/Alendronate | 2.0 |
Hip fractures were defined as a subset of nonvertebral fractures including fractures of the femur neck, femur intertrochanter, and femur subtrochanter. (NCT01631214)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Alendronate/Alendronate | 1.1 |
| Romosozumab/Alendronate | 0.7 |
Hip fractures were defined as a subset of nonvertebral fractures including fractures of the femur neck, femur intertrochanter, and femur subtrochanter. (NCT01631214)
Timeframe: 24 months
| Intervention | percentage of participants (Number) |
|---|---|
| Alendronate/Alendronate | 2.1 |
| Romosozumab/Alendronate | 1.5 |
Major nonvertebral fractures included a subset of nonvertebral fractures including pelvis, distal femur (ie, femur excluding hip), proximal tibia (ie, tibia excluding ankle), ribs, proximal humerus (ie, humerus excluding elbow), forearm, and hip. (NCT01631214)
Timeframe: The primary analysis was performed when clinical fracture events had been confirmed in at least 330 patients and all participants had completed the month 24 visit. The median follow-up was 2.7 years (interquartile range, 2.2 to 3.3).
| Intervention | percentage of participants (Number) |
|---|---|
| Alendronate/Alendronate | 9.6 |
| Romosozumab/Alendronate | 7.1 |
Major osteoporotic fractures included clinical vertebral fractures and fractures of the hip, forearm and humerus. Fractures associated with high trauma severity or pathologic fractures were excluded. (NCT01631214)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Alendronate/Alendronate | 4.2 |
| Romosozumab/Alendronate | 3.0 |
"A new or worsening vertebral fracture was identified when there was a ≥ 1 grade increase from the previous grade in any vertebra from T4 to L4 according to the Genant Semiquantitative Scoring method based on assessment of x-rays according to the following scale:~Grade 0 (Normal) = no fracture;~Grade 1 (Mild) = mild fracture, 20 to 25% reduction in vertebral height (anterior, middle, or posterior);~Grade 2 (Moderate) = moderate fracture, 25 to 40% reduction in anterior, middle, and/or posterior height;~Grade 3 (Severe) = severe fracture, greater than 40% reduction in anterior, middle, and/or posterior height.~Incident vertebral fractures were confirmed by a second independent reader using the Semiquantitative method." (NCT01631214)
Timeframe: 24 months
| Intervention | percentage of participants (Number) |
|---|---|
| Alendronate/Alendronate | 9.2 |
| Romosozumab/Alendronate | 4.8 |
A nonvertebral fracture was defined as a documented fracture excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges. In addition, fractures associated with high trauma severity or pathologic fractures were excluded. (NCT01631214)
Timeframe: The primary analysis was performed when clinical fracture events had been confirmed in at least 330 patients and all participants had completed the month 24 visit. The median follow-up was 2.7 years (interquartile range, 2.2 to 3.3).
| Intervention | percentage of participants (Number) |
|---|---|
| Alendronate/Alendronate | 10.6 |
| Romosozumab/Alendronate | 8.7 |
A nonvertebral fracture was defined as a fracture present on a copy of radiographs or other diagnostic images such as computerized tomography (CT) or magnetic resonance imaging confirming the fracture within 14 days of reported fracture image date recorded by the study site, and/or documented in a copy of the radiology report, surgical report, or discharge summary, excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges. In addition, fractures associated with high trauma severity or pathologic fractures were excluded. (NCT01631214)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Alendronate/Alendronate | 4.6 |
| Romosozumab/Alendronate | 3.4 |
A nonvertebral fracture was defined as a documented fracture excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges. In addition, fractures associated with high trauma severity or pathologic fractures were excluded. (NCT01631214)
Timeframe: 24 months
| Intervention | percentage of participants (Number) |
|---|---|
| Alendronate/Alendronate | 7.8 |
| Romosozumab/Alendronate | 6.3 |
All fractures include any osteoporotic nonvertebral fractures that are not associated with high trauma severity or pathologic fractures and new or worsening vertebral fractures regardless of trauma severity or pathologic fractures. (NCT01631214)
Timeframe: The primary analysis was performed when clinical fracture events had been confirmed in at least 330 patients and all participants had completed the month 24 visit. The median follow-up was 2.7 years (interquartile range, 2.2 to 3.3).
| Intervention | percentage of participants (Number) |
|---|---|
| Alendronate/Alendronate | 19.1 |
| Romosozumab/Alendronate | 13.0 |
All fractures include any osteoporotic nonvertebral fractures that are not associated with high trauma severity or pathologic fractures and new or worsening vertebral fractures regardless of trauma severity or pathologic fractures. (NCT01631214)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Alendronate/Alendronate | 9.2 |
| Romosozumab/Alendronate | 6.5 |
A new or worsening vertebral fracture was identified when there was a ≥ 1 grade increase from the previous grade in any vertebra from T4 to L4 according to the Genant Semiquantitative Scoring method. A participant had multiple new or worsening vertebral fractures when there were ≥ 2 vertebrae from T4 to L4 with ≥ 1 grade increase from the previous grade. The multiple new or worsening vertebral fractures need not have occurred at the same visit. Incident vertebral fractures were confirmed by a second independent reader. (NCT01631214)
Timeframe: 24 months
| Intervention | percentage of participants (Number) |
|---|---|
| Alendronate/Alendronate | 2.5 |
| Romosozumab/Alendronate | 1.3 |
"New vertebral fractures occurred when there was ≥ 1 grade increase from the previous grade of 0 in any vertebra from T4 to L4 using the Genant Semiquantitative Scoring method based on assessment of x-rays according to the following scale:~Grade 0 (Normal) = no fracture;~Grade 1 (Mild) = mild fracture, 20 to 25% reduction in vertebral height (anterior, middle, or posterior);~Grade 2 (Moderate) = moderate fracture, 25 to 40% reduction in anterior, middle, and/or posterior height;~Grade 3 (Severe) = severe fracture, greater than 40% reduction in anterior, middle, and/or posterior height.~Incident vertebral fractures were confirmed by a second independent reader." (NCT01631214)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Alendronate/Alendronate | 5.0 |
| Romosozumab/Alendronate | 3.2 |
"All fracture assessments were performed by blinded central imaging readers.~New vertebral fractures occurred when there was ≥ 1 grade increase from the previous grade of 0 in any vertebra from T4 to L4 using the Genant Semiquantitative Scoring method based on assessment of x-rays according to the following scale:~Grade 0 (Normal) = no fracture;~Grade 1 (Mild) = mild fracture, 20 to 25% reduction in vertebral height (anterior, middle, or posterior);~Grade 2 (Moderate) = moderate fracture, 25 to 40% reduction in anterior, middle, and/or posterior height;~Grade 3 (Severe) = severe fracture, greater than 40% reduction in anterior, middle, and/or posterior height.~Incident vertebral fractures were confirmed by a second independent reader using the Semiquantitative method." (NCT01631214)
Timeframe: 24 months
| Intervention | percentage of participants (Number) |
|---|---|
| Alendronate/Alendronate | 8.0 |
| Romosozumab/Alendronate | 4.1 |
Percent changes of bone mineral density at lumbar spine (L1-L4) from baseline to 1-year after treatment will be compared and analysed between 2 groups. (NCT02371252)
Timeframe: 1 year after treatment
| Intervention | percent (Mean) |
|---|---|
| Original Alendronate (Fosamax) | 5.54 |
| Generic Alendronate (Bonmax) | 5.39 |
Percent changes of bone mineral density at total hip from baseline to 1-year after treatment will be compared and analysed between 2 groups. (NCT02371252)
Timeframe: 1 year after treatment
| Intervention | percent (Mean) |
|---|---|
| Original Alendronate (Fosamax) | 2.48 |
| Generic Alendronate (Bonmax) | 2.52 |
Serum samples for Beta-CrossLaps (β-CTx) will be collected at specific visits during the treatment phase of the study. (NCT01437111)
Timeframe: Baseline and Week 26
| Intervention | Percent change (Mean) |
|---|---|
| Fosamax Plus: Recent/Current Osteoporosis Therapy at Baseline | -12.65 |
| Fosamax Plus: Other Osteoporosis Therapy at Baseline | -49.82 |
| Fosamax Plus: Treatment Naive at Baseline | -76.81 |
| Fosamax Plus: All Treated Participants | -57.74 |
Serum samples to measure serum 25-hydroxyvitamin D [25(OH)D] will be collected at specific visits during the treatment phase of the study. (NCT01437111)
Timeframe: Week 26
| Intervention | Participants (Number) |
|---|---|
| Fosamax Plus: Recent/Current Osteoporosis Therapy at Baseline | 1 |
| Fosamax Plus: Other Osteoporosis Therapy at Baseline | 3 |
| Fosamax Plus: Treatment Naive at Baseline | 1 |
| Fosamax Plus: All Treated Participants | 5 |
Time to treatment non-adherence for alendronate is defined for each treatment period as the time to treatment non-compliance or time to treatment non-persistence, whichever occurs earliest, for participants with uncensored values. Participants who had both censored time to non-compliance and censored time to non-persistence values were censored in the analysis at the end of treatment period visit. (NCT00518531)
Timeframe: Treatment Period 1 (Month 1 to Month 12)
| Intervention | weeks (Mean) |
|---|---|
| Alendronate | 43.29 |
Time to treatment non-adherence for alendronate is defined for each treatment period as the time to treatment non-compliance or time to treatment non-persistence, whichever occurs earliest, for participants with uncensored values. Participants who had both censored time to non-compliance and censored time to non-persistence values were censored in the analysis at the end of treatment period visit. (NCT00518531)
Timeframe: Treatment Period 2 (Month 13 to Month 24)
| Intervention | weeks (Mean) |
|---|---|
| Alendronate | 39.45 |
Time to treatment non-compliance for alendronate is based on the percent of QW tablets taken and is defined for each treatment period as the first week since Study Day 1 of the treatment period to the week where the percent of QW tablets taken falls below the threshold of ≥ 80% and where the participant can not reach this threshold again during the treatment period. (NCT00518531)
Timeframe: Treatment period 1 (Month 1 to Month 12)
| Intervention | weeks (Mean) |
|---|---|
| Alendronate | 43.75 |
Time to treatment non-compliance for alendronate is based on the percent of QW tablets taken and is defined for each treatment period as the first week since Study Day 1 of the treatment period to the week where the percent of QW tablets taken falls below the threshold of ≥ 80% and where the participant can not reach this threshold again during the treatment period. (NCT00518531)
Timeframe: Treatment period 2 (Month 13 to Month 24)
| Intervention | weeks (Mean) |
|---|---|
| Alendronate | 39.97 |
Time to non-persistence for alendronate is defined for each treatment period as the first time <2 tablets were taken in a rolling 4-week time period (e.g. study weeks 1-4, 2-5, 3-6 etc) and where the participant never reaches this threshold again during the treatment period. Tablet intake was tracked using a Medication Event Monitoring System. (NCT00518531)
Timeframe: Treatment period 1 (Month 1 to Month 12)
| Intervention | weeks (Mean) |
|---|---|
| Alendronate | 44.59 |
Time to non-persistence for alendronate is defined for each treatment period as the first time <2 tablets were taken in a rolling 4-week time period (e.g. study weeks 1-4, 2-5, 3-6 etc) and where the participant never reaches this threshold again during the treatment period. Tablet intake was tracked using a Medication Event Monitoring System. (NCT00518531)
Timeframe: Treatment period 2 (Month 13 to Month 24)
| Intervention | weeks (Mean) |
|---|---|
| Alendronate | 42.76 |
A participant was considered adherent to denosumab treatment if the participant: - received 2 denosumab injections (overall treatment compliance); - took each injection 6 months (± 4 weeks) apart (treatment compliance over time); - completed the relevant treatment period (treatment persistence). A participant was considered adherent to alendronate treatment if the participant: - took ≥ 80% QW tablets (overall treatment compliance); - took at least 2 tablets in the last month and completed the relevant treatment period (treatment persistence). Participants who did not meet all criteria for their assigned treatment were deemed non-adherent to treatment. (NCT00518531)
Timeframe: Treatment period 1 (Month 1 to Month 12)
| Intervention | Participants (Number) | |
|---|---|---|
| Yes | No | |
| Alendronate | 95 | 29 |
| Denosumab | 111 | 15 |
A participant was considered adherent to denosumab treatment if the participant: - received 2 denosumab injections (overall treatment compliance); - took each injection 6 months (± 4 weeks) apart (treatment compliance over time); - completed the relevant treatment period (treatment persistence). A participant was considered adherent to alendronate treatment if the participant: - took ≥ 80% QW tablets (overall treatment compliance); - took at least 2 tablets in the last month and completed the relevant treatment period (treatment persistence). Participants who did not meet all criteria for their assigned treatment were deemed nonadherent to treatment. (NCT00518531)
Timeframe: Treatment period 2 (Months 13 to 24)
| Intervention | Participants (Number) | |
|---|---|---|
| Yes | No | |
| Alendronate | 73 | 42 |
| Denosumab | 98 | 8 |
The BMQ is a 22- item self-reported questionnaire specific to osteoporosis that measures beliefs about the weekly pill or every 6 months injection. The BMQ consists of 3 subscales measuring beliefs about the necessity of the medication for controlling osteoporosis, concern with the adverse consequences of taking the medication, and preference for one medication over the other. Participants' concern about the adverse consequences of taking the medication for controlling osteoporosis was based on the average of 10 items from the BMQ that form the concern score. The concern score ranges from 1 to 5, with higher scores indicating stronger concerns about the adverse consequences of taking the prescribed medication for controlling osteoporosis. (NCT00518531)
Timeframe: Baseline and Month 6, Month 12, Month 18, and Month 24
| Intervention | scores on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline (n=104, 117) | Month 6 (n=106, 114) | Month 12 (n=103, 95) | Month 18 (n=98, 98) | Month 24 (n=91, 100) | |
| Alendronate | 2.33 | 2.22 | 2.57 | 2.43 | 2.39 |
| Denosumab | 2.43 | 2.12 | 2.51 | 2.24 | 2.18 |
The BMQ is a 22- item self-reported questionnaire specific to osteoporosis that measures beliefs about the weekly pill or every 6 months injection. The BMQ consists of 3 subscales measuring beliefs about the necessity of the medication for controlling osteoporosis, concern with the adverse consequences of taking the medication, and preference for one medication over the other. The BMQ preference score, which measures a participant's overall evaluation of a medication, is based on the average of 7 items in the BMQ. The preference score ranges from 1 to 5, with higher scores indicating stronger preference for one medication over the other. (NCT00518531)
Timeframe: Baseline and Month 6, Month 12, Month 18, and Month 24
| Intervention | scores on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline (n=104, 117) | Month 6 (n=106, 114) | Month 12 (n=103, 95) | Month 18 (n=98, 98) | Month 24 (n=91, 100) | |
| Alendronate | 2.97 | 3.01 | 2.62 | 2.55 | 2.57 |
| Denosumab | 3.47 | 3.72 | 3.43 | 3.77 | 3.80 |
"The BMQ is a 22- item self-reported questionnaire specific to osteoporosis that measures beliefs about the weekly pill or every 6 months injection. The BMQ consists of 3 subscales measuring beliefs about the necessity of the medication for controlling osteoporosis, concern with the adverse consequences of taking the medication, and preference for one medication over the other.~Participants' beliefs about the necessity of the prescribed medication to treat osteoporosis were based on the average of 5 items from the BMQ that form the necessity score. The necessity score ranges from 1 to 5, with higher scores indicating stronger beliefs about the necessity of the prescribed medication for controlling osteoporosis." (NCT00518531)
Timeframe: Baseline, Month 6, Month 12, Month 18 and Month 24
| Intervention | scores on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline (n=104, 117) | Month 6 (n=106, 114) | Month 12 (n=103, 95) | Month 18 (n=98, 98) | Month 24 (n=91, 100) | |
| Alendronate | 3.32 | 3.14 | 3.21 | 3.20 | 3.21 |
| Denosumab | 3.26 | 3.31 | 3.17 | 3.28 | 3.22 |
Participants were considered compliant to denosumab treatment if they received 2 denosumab injections (overall treatment compliance) and if they took each injection 6 months (± 4 weeks) apart (treatment compliance over time). Participants were considered compliant to alendronate treatment if they took ≥ 80% QW tablets (overall treatment compliance). (NCT00518531)
Timeframe: Treatment period 1 (Month 1 to Month 12)
| Intervention | Participants (Number) | |
|---|---|---|
| Yes | No | |
| Alendronate | 97 | 27 |
| Denosumab | 114 | 12 |
Participants were considered compliant to denosumab treatment if they received 2 denosumab injections (overall treatment compliance) and if they took each injection 6 months (± 4 weeks) apart (treatment compliance over time). Participants were considered compliant to alendronate treatment if they took ≥ 80% QW tablets (overall treatment compliance). (NCT00518531)
Timeframe: Treatment period 2 (Month 13 to Month 24)
| Intervention | Participants (Number) | |
|---|---|---|
| Yes | No | |
| Alendronate | 78 | 37 |
| Denosumab | 99 | 7 |
The MARs questionnaire is a validated, self-reported instrument for assessing treatment adherence. Participants report how often they engage in each of 5 aspects of non-adherent behavior (forgetting to take a dose, changing the dose, stop taking them for a while, deciding to not take a dose, or taking less than instructed). Scores are summed over the 5 items, the total score ranges from 5 to 25 with higher scores indicating greater self-reported adherence. The MARS was collected at the month 6 and month 12 visits of each treatment period only for those participants receiving oral alendronate during that period. (NCT00518531)
Timeframe: Month 6, Month 12 (treatment period 1)
| Intervention | scores on a scale (Mean) | |
|---|---|---|
| Month 6 (n=109) | Month 12 (n= 100) | |
| Alendronate | 24.3 | 24.4 |
The MARs questionnaire is a validated, self-reported instrument for assessing treatment adherence. Participants report how often they engage in each of 5 aspects of non-adherent behavior (forgetting to take a dose, changing the dose, stop taking them for a while, deciding to not take a dose, or taking less than instructed). Scores are summed over the 5 items, the total score ranges from 5 to 25 with higher scores indicating greater self-reported adherence. The MARS was collected at the month 6 and month 12 visits of each treatment period only for those participants receiving oral alendronate during that period. (NCT00518531)
Timeframe: Month 18, Month 24 (treatment period 2)
| Intervention | scores on a scale (Mean) | |
|---|---|---|
| Treatment period 2 Month 6 (n=98) | Treatment period 2 Month 12 (n= 90) | |
| Alendronate | 23.4 | 23.8 |
"Participant satisfaction with their treatment was assessed using question 7 (ie, Please rate your satisfaction with the weekly pill on the following: frequency of administration; mode of administration [taking a pill]; convenience; overall satisfaction) and question 8 (ie, Please rate your satisfaction with the six month injection on the following: frequency of administration; mode of administration [receiving an injection]; convenience; overall satisfaction) from the Preference Satisfaction Questionnaire (PSQ) at the end of each treatment period. The PSQ is a 34 item, self-report questionnaire of participants' preference and satisfaction for each of the two study treatments. Possible answers include: Not at all Satisfied, A Little Satisfied, Moderately Satisfied, Quite Satisfied, and Very Satisfied." (NCT00518531)
Timeframe: End of treatment period 1 (Month 12)
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| Not at all satisfied | A little satisfied | Moderately satisfied | Quite satisfied | Very satisfied | |
| Alendronate | 3 | 1 | 17 | 34 | 59 |
| Denosumab | 3 | 3 | 2 | 18 | 95 |
Denosumab-treated participants were considered persistent to treatment if they completed the relevant treatment period and alendronate-treated participants were considered persistent to treatment if they completed the relevant treatment period and took at least 2 tablets in the last month of the treatment period. (NCT00518531)
Timeframe: Treatment period 1 (Month 1 to Month 12)
| Intervention | Participants (Number) | |
|---|---|---|
| Yes | No | |
| Alendronate | 99 | 25 |
| Denosumab | 114 | 12 |
Denosumab-treated participants were considered persistent to treatment if they completed the relevant treatment period and alendronate-treated participants were considered persistent to treatment if they completed the relevant treatment period and took at least 2 tablets in the last month of the treatment period. (NCT00518531)
Timeframe: Treatment period 2 (Month 13 to Month 24)
| Intervention | Participants (Number) | |
|---|---|---|
| Yes | No | |
| Alendronate | 82 | 33 |
| Denosumab | 103 | 3 |
(NCT00680953)
Timeframe: Baseline to 24 months
| Intervention | Vertebral fractures (Mean) |
|---|---|
| Denosumab | 3.6 |
| Placebo | 10.3 |
| Alendronate | 7.2 |
The results are expressed as a percentage by Kaplan-Meier estimate. (NCT00680953)
Timeframe: Baseline to 24 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Denosumab | 0.0 |
| Placebo | 0.5 |
| Alendronate | 0.0 |
The results are expressed as percentage by Kaplan-Meier estimate the percentage of participants with non-vertebral fractures (NCT00680953)
Timeframe: Baseline to 24 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Denosumab | 4.1 |
| Placebo | 4.1 |
| Alendronate | 2.7 |
change from baseline at endpoint in bone mineral density of the lumbar spine as assessed by dual energy X-ray absorptiometry (DXA) (NCT00051558)
Timeframe: 18 month endpoint
| Intervention | grams per square centimeters (Least Squares Mean) |
|---|---|
| Teriparatide | 0.059 |
| Alendronate | 0.028 |
change from baseline at endpoint in bone mineral density of the lumbar spine as assessed by dual energy X-ray absorptiometry (DXA) (NCT00051558)
Timeframe: 18 month endpoint
| Intervention | grams per square centimeters (Least Squares Mean) |
|---|---|
| Teriparatide | 0.056 |
| Alendronate | 0.023 |
Clinical vertebral fracture was defined as a radiographically confirmed fracture that was associated with symptoms such as back pain. (NCT00051558)
Timeframe: 36 months
| Intervention | participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Any Fracture | Nonvertebral Fracture | Vertebral Fracture | Clinical Vertebral Fracture | Nonvertebral Fragility Fracture | Severity-Radiographic Vertebral Fracture: Mild | Severity-Radiographic Vertebral Fracture: Moderate | Severity-Radiographic Vertebral Fracture: Severe | |
| Alendronate | 27 | 15 | 13 | 4 | 5 | 7 | 2 | 4 |
| Teriparatide | 19 | 16 | 3 | 0 | 9 | 1 | 2 | 0 |
change from baseline in bone mineral density of the femoral neck as assessed by dual energy X-ray absorptiometry (DXA) (NCT00051558)
Timeframe: 18, 24, 36 months, and 18 and 36 month endpoints
| Intervention | grams per square centimeters (Least Squares Mean) | ||||
|---|---|---|---|---|---|
| Change, baseline to 36 month endpoint(N=185,N=177) | Change from baseline at 36 months(N=120,N=113) | Change from baseline at 24 months(N=135,N=131) | Change, baseline to 18 month endpoint(N=185,N=176) | Change from baseline at 18 months (N=156,N=145) | |
| Alendronate | 0.017 | 0.021 | 0.015 | 0.014 | 0.017 |
| Teriparatide | 0.033 | 0.041 | 0.030 | 0.024 | 0.028 |
change from baseline in bone mineral density of the lumbar spine as assessed by dual energy X-ray absorptiometry (DXA) (NCT00051558)
Timeframe: 24 and 36 months and Endpoint at 36 months
| Intervention | grams per square centimeters (Least Squares Mean) | ||
|---|---|---|---|
| Change, baseline to 36 month endpoint(N=198,N=195) | Change from baseline at 36 months (N=123, N=112) | Change from baseline at 24 months (N=136, N=131) | |
| Alendronate | 0.034 | 0.044 | 0.043 |
| Teriparatide | 0.073 | 0.090 | 0.081 |
change from baseline in bone mineral density of the total hip as assessed by dual energy X-ray absorptiometry (DXA) (NCT00051558)
Timeframe: 18, 24, 36 months, and 18 and 36 month endpoints
| Intervention | grams per square centimeters (Least Squares Mean) | ||||
|---|---|---|---|---|---|
| Change, baseline to 36 month endpoint(N=185,N=177) | Change from baseline at 36 months(N=120,N=113) | Change from baseline at 24 months(N=135,N=131) | Change, baseline to 18 month endpoint(N=185,N=176) | Change from baseline at 18 months (N=156,N=144) | |
| Alendronate | 0.017 | 0.020 | 0.018 | 0.017 | 0.018 |
| Teriparatide | 0.032 | 0.037 | 0.034 | 0.026 | 0.027 |
(NCT00051558)
Timeframe: 1, 6, 18, and 36 months
| Intervention | percent (Mean) | |||
|---|---|---|---|---|
| Percent change from baseline at Month 1(N=65,N=78) | Percent change from baseline at Month 6(N=66,N=76) | Percent change from baseline at Month18(N=54,N=65) | Percent change from baseline at Month36(N=44,N=49) | |
| Alendronate | 0.5 | -7.2 | -4.1 | 20.6 |
| Teriparatide | 35.0 | 52.3 | 34.4 | 44.7 |
(NCT00051558)
Timeframe: 1, 6, 18, and 36 months
| Intervention | percent (Mean) | |||
|---|---|---|---|---|
| Percent change from baseline at Month1(N=94,N=100) | Percent change from baseline at Month 6(N=84,N=88) | Percent change from baseline at Month18(N=77,N=77) | Percent change from baseline at Month36(N=56,N=58) | |
| Alendronate | -5.2 | -33.6 | -25.0 | -19.6 |
| Teriparatide | 147.1 | 120.0 | 108.9 | 62.1 |
(NCT00051558)
Timeframe: 1, 6, 18, and 36 months
| Intervention | percent (Mean) | |||
|---|---|---|---|---|
| Percent change from baseline at Month 1(N=66,N=78) | Percent change from baseline at Month 6(N=67,N=76) | Percent change from baseline at Month18(N=55,N=65) | Percent change from baseline at Month36(N=45,N=49) | |
| Alendronate | -8.8 | -22.3 | -21.3 | -15.4 |
| Teriparatide | 48.2 | 10.5 | 5.1 | -1.3 |
(NCT00051558)
Timeframe: 1, 6, 18, and 36 months
| Intervention | percent (Mean) | |||
|---|---|---|---|---|
| Percent change from baseline at Month 1(N=98,N=99) | Percent change from baseline at Month 6(N=86,N=85) | Percent change from baseline at Month18(N=77,N=76) | Percent change from baseline at Month36(N=59,N=57) | |
| Alendronate | -14.8 | -43.2 | -35.8 | -20.2 |
| Teriparatide | 107.0 | 130.8 | 86.3 | 61.7 |
(NCT00051558)
Timeframe: 1, 6, 18, and 36 months
| Intervention | percent (Mean) | |||
|---|---|---|---|---|
| Percent change from baseline at Month 1(N=70,N=79) | Percent change from baseline at Month 6(N=66,N=75) | Percent change from baseline at Month18(N=64,N=71) | Percent change from baseline at Month36(N=49,N=48) | |
| Alendronate | -38.6 | -42.4 | -47.5 | -16.2 |
| Teriparatide | 29.0 | 66.8 | 29.1 | 30.7 |
change from baseline in bone mineral density of the femoral neck as assessed by dual energy X-ray absorptiometry (DXA) (NCT00051558)
Timeframe: 12, 18, 24, and 36 months
| Intervention | grams per square centimeters (Least Squares Mean) | |||
|---|---|---|---|---|
| Change from baseline at Month 36 (N=120,N=113) | Change from baseline at Month 24 (N=135,N=131) | Change from baseline at Month 18 (N=156,N=145) | Change from baseline at Month 12 (N=167,N=158) | |
| Alendronate | 0.021 | 0.015 | 0.017 | 0.012 |
| Teriparatide | 0.041 | 0.030 | 0.028 | 0.026 |
change from baseline in bone mineral density of the lumbar spine as assessed by dual energy X-ray absorptiometry (DXA) (NCT00051558)
Timeframe: 3, 6, 12, and 18 months
| Intervention | grams per square centimeters (Least Squares Mean) | |||
|---|---|---|---|---|
| Change from baseline at Month 18 (N=127,N=119) | Change from baseline at Month 12 (N=139,N=129) | Change from baseline at Month 6 (N=147,N=139) | Change from baseline at Month 3 (N=149,N=150) | |
| Alendronate | 0.027 | 0.024 | 0.015 | 0.012 |
| Teriparatide | 0.062 | 0.052 | 0.031 | 0.017 |
change from baseline in bone mineral density of the lumbar spine as assessed by dual energy X-ray absorptiometry (DXA) (NCT00051558)
Timeframe: 3, 6, 12, 18, 24, 36 months
| Intervention | grams per square centimeters (Least Squares Mean) | |||||
|---|---|---|---|---|---|---|
| Change from baseline at Month 36 (N=123,N=112) | Change from baseline at Month 24 (N=136,N=131) | Change from baseline at Month 18 (N=156,N=148) | Change from baseline at Month 12 (N=170,N=159) | Change from baseline at Month 6 (N=178,N=173) | Change from baseline at Month 3 (N=183,N=184) | |
| Alendronate | 0.044 | 0.043 | 0.031 | 0.028 | 0.018 | 0.012 |
| Teriparatide | 0.090 | 0.081 | 0.066 | 0.054 | 0.034 | 0.019 |
change from baseline in bone mineral density of the total hip as assessed by dual energy X-ray absorptiometry (DXA) (NCT00051558)
Timeframe: 12, 18, 24, and 36 months
| Intervention | grams per square centimeters (Least Squares Mean) | |||
|---|---|---|---|---|
| Change from baseline at 36 Months (N=120, N=113) | Change from baseline at 24 Months (N=135, N=131) | Change from baseline at 18 Months (N=156, N=145) | Change from baseline at 12 Months (N=167, N=158) | |
| Alendronate | 0.020 | 0.018 | 0.018 | 0.014 |
| Teriparatide | 0.037 | 0.034 | 0.027 | 0.022 |
Percent change was calculated as (measurement at week 96 - measurement at baseline)/measurement at baseline * 100%. Includes Groups 1A and 1B only. (NCT00921557)
Timeframe: Weeks 0 and 96
| Intervention | Percent change from baseline (Median) |
|---|---|
| 1A: Alendronate/Alendronate | 24.9 |
| 1B: Alendronate/Placebo | 14.8 |
Percent change was calculated as (measurement at week 96 - measurement at baseline)/measurement at baseline * 100%. Includes Groups 1A and 1B only. (NCT00921557)
Timeframe: Weeks 0 and 96
| Intervention | Percent change from baseline (Median) |
|---|---|
| 1A: Alendronate/Alendronate | 19.6 |
| 1B: Alendronate/Placebo | 10.3 |
Percent change was calculated as (measurement at time T2 - measurement at time T1)/measurement at Time T1 * 100%. (NCT00921557)
Timeframe: Weeks 48, 96 and 144
| Intervention | Percent change (Median) |
|---|---|
| 1B: Alendronate/Placebo (48 Week Change) | 0.9 |
| 2: Placebo/Alendronate (48 Week Change) | 2.0 |
| 1B: Alendronate/Placebo (96 Week Change) | 1.7 |
Percent change was calculated as (measurement at time T2 - measurement at time T2)/measurement at time T1 * 100%. (NCT00921557)
Timeframe: Weeks 48, 96 and 144
| Intervention | Percent change (Median) |
|---|---|
| 1B: Alendronate/Placebo (48 Week Change) | 0.8 |
| 2: Placebo/Alendronate (48 Week Change) | 0.5 |
| 1B: Alendronate/Placebo (96 Week Change) | 0.9 |
Signs, symptoms, and laboratory values were graded using the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 1.0 (December 2004). Results for Groups 1A and 1B were combined as both were on alendronate for the first 48 weeks. (NCT00921557)
Timeframe: Week 0 to 48
| Intervention | Participants (Count of Participants) |
|---|---|
| 1: Alendronate | 5 |
| 2: Placebo | 2 |
Change in percentage of lymphocytes that are CD4 cells calculated as measurement at each time point minus baseline measurement (NCT00921557)
Timeframe: Weeks 0, 48, 96 and 144
| Intervention | percent of lymphocytes that are CD4 cell (Median) | ||
|---|---|---|---|
| Week 48 - Week 0 | Week 96 - Week 0 | Week 144 - Week 0 | |
| 1A: Alendronate/Alendronate | 0 | 0 | 1 |
| 1B: Alendronate/Placebo | 1 | -1 | -1 |
| 2: Placebo/Alendronate | 1 | 2 | -4 |
Percentage of participants advancing in CDC HIV disease category from baseline throughout study follow-up (NCT00921557)
Timeframe: Weeks 144
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Week 0 to 48 | Week 48 to 96 | Week 96 to 144 | |
| 1A: Alendronate/Alendronate | 1 | 0 | 0 |
| 1B: Alendronate/Placebo | 0 | 1 | 0 |
| 2: Placebo/Alendronate | 0 | 0 | 0 |
A slope was fit for each participant to their percent change [(measurement at time T - measurement at baseline)/measurement at baseline)*100%] in lumbar spine BMD from baseline. Results represent average changes in lumbar spine BMD over one year. Results are summarized for age, gender, ethnicity, tenofovir use, Tanner stage, bone age and vitamin D level. Only one participant was on steroids and none were using Dep-Provera. Inflammatory cytokine levels were not assayed. Results were combined for Groups 1A and 1B as both were on alendronate for the first 48 weeks. (NCT00921557)
Timeframe: Weeks 0, 24 and 48
| Intervention | percentage of baseline (Mean) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Male | Female | Non-hispanic | Hispanic | 11 - < 15 years | 15 - < 19 years | >= 19 years | On Tenofovir | Not on Tenofovir | 25-OH Vit D<30 ng/ml | 25-0H Vit D>=30 ng/ml | Bone age < 15 years | Bone age>=15 years | Tanner stage <= 3 | Tanner stage >= 4 | |
| 1: Alendronate | 20.3 | 25.4 | 19.4 | 23.6 | 37.1 | 16.5 | 8.1 | 24.8 | 19.9 | 22.0 | 22.1 | 36.0 | 11.3 | 33.0 | 15.4 |
| 2: Placebo | 6.8 | 9.4 | 4.8 | 7.8 | 10.6 | 8.0 | 1.9 | 6.8 | 8.2 | 6.8 | 7.8 | 10.0 | 5.0 | 10.6 | 5.9 |
A slope was fit for each participant to their percent change [(measurement at time T - measurement at baseline)/measurement at baseline)*100%] in whole body (with head) BMD from baseline. Results represent average changes in whole body (with head) BMD over one year. Results are summarized for age, gender, ethnicity, tenofovir use, Tanner stage, bone age and vitamin D level. Only one participant was on steroids and none were using Dep-Provera. Inflammatory cytokine levels were not assayed. Results were combined for Groups 1A and 1B as both were on alendronate for the first 48 weeks. (NCT00921557)
Timeframe: Weeks 0, 24 and 48
| Intervention | percentage of baseline (Mean) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Male | Female | Non-Hispanic | Hispanic | 11 - < 15 years | 15 - < 19 years | >= 19 years | On tenofovir | Not on tenofovir | 25-0H Vit D<30 ng/ml | 25-0H Vit D>=30 ng/ml | Bone age < 15 years | Bone age >=15 years | Tanner stage <= 3 | Tanner stage >= 4 | |
| 1: Alendronate | 11.4 | 14.0 | 9.8 | 13.9 | 19.2 | 10.5 | 4.7 | 13.2 | 11.6 | 10.6 | 15.1 | 19.0 | 7.7 | 18.0 | 9.4 |
| 2: Placebo | 4.1 | 8.2 | 0.3 | 6.1 | 8.0 | 6.5 | -0.3 | 5.0 | 5.8 | 5.8 | 5.2 | 8.4 | 2.3 | 8.0 | 3.8 |
Percent change was calculated as (measurement at time T - measurement at baseline)/measurement at baseline * 100%. Results for Groups 1A and 1B combined as both were on alendronate for the first 48 weeks. (NCT00921557)
Timeframe: Weeks 0, 24 and 48
| Intervention | Percent change from baseline (Median) | |
|---|---|---|
| Week 24 | Week 48 | |
| 1: Alendronate | 14.4 | 15.9 |
| 2: Placebo | 5.5 | 7.1 |
Percent change was calculated as (measurement at time T - measurement at baseline)/measurement at baseline * 100%. Results for Groups 1A and 1B were combined as both were on alendronate for the first 48 weeks. (NCT00921557)
Timeframe: Weeks 0, 24 and 48
| Intervention | Percent change from baseline (Median) | |
|---|---|---|
| Week 24 | Week 48 | |
| 1: Alendronate | 5.5 | 10.7 |
| 2: Placebo | 0.3 | 5.2 |
Percent calculated as number of participants with HIV-1 RNA <= 400 copies/ml relative to the number of participants with HIV-1 RNA measured at that time point. (NCT00921557)
Timeframe: Weeks 0, 48, 96 and 144
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Week 0 | Week 48 | Week 96 | Week 144 | |
| 1A: Alendronate/Alendronate | 10 | 10 | 12 | 10 |
| 1B: Alendronate/Placebo | 16 | 16 | 12 | 10 |
| 2: Placebo/Alendronate | 15 | 14 | 13 | 10 |
Signs, symptoms, and laboratory values were graded using the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 1.0 (December 2004). (NCT00921557)
Timeframe: Weeks 0 to 144
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Week 0 to 48 | Week 48 to 96 | Week 96 to 144 | |
| 1A: Alendronate/Alendronate | 2 | 1 | 3 |
| 1B: Alendronate/Placebo | 3 | 3 | 4 |
| 2: Placebo/Alendronate | 2 | 2 | 3 |
The primary outcome was the between-group difference in the teriparatide-induced change in serum c-telopeptide from baseline to week 8. (NCT01750086)
Timeframe: 8 weeks
| Intervention | percentage of change in CTX (Mean) |
|---|---|
| Denosumab 60mg Subcutaneous Injection | -7 |
| Alendronate 70mg Weekly x 8 Weeks | 43 |
(NCT00926380)
Timeframe: Baseline and 2 years
| Intervention | percent change (Mean) |
|---|---|
| Denosumab ONLY | 8.3 |
| Teriparatide (Forteo®) ONLY | 9.5 |
| Denosumab and Teriparatide (Forteo®) | 12.9 |
Bone mineral density is the gold standard for diagnosis of low bone mass and osteoporosis and will be measured at the spine using Dual Energy X-ray Absorptiometry (DXA). (NCT02186600)
Timeframe: Baseline,6, and 12 months
| Intervention | g/cm^2 (Mean) | ||
|---|---|---|---|
| Baseline | 6 Months | 12 Months | |
| Control | 0.889 | .887 | 0.885 |
| Exercise | 0.886 | .878 | 0.885 |
| Risedronate | 0.892 | .907 | 0.911 |
"Change in Bone Strength Index (BSI) of the distal tibia based on randomization to Control, Risedronate, or Exercise group.~BSI (mg2/mm4) at the 4% tibial site will be measured using peripheral quantitative computed tomography (pQCT)." (NCT02186600)
Timeframe: Baseline, 6, and 12 months
| Intervention | mg^2/mm^4 (Mean) | ||
|---|---|---|---|
| Baseline | 6 Months | 12 Months | |
| Control | 2098.7 | 2105.89 | 2107.2 |
| Exercise | 2001 | 1987.42 | 2009.2 |
| Risedronate | 1993.3 | 1997.32 | 2014.2 |
Bone turnover is the process of removing old bone (resorption by osteoclasts) and replacing it with new bone (formation by osteoblasts). Menopause results in a brief period (~5 years) of accelerated turnover with resorption far exceeding formation. In this study, resorption will be measured by Serum NTx. (NCT02186600)
Timeframe: Baseline, 6, 12 months
| Intervention | nanoMolar Bone Collagen Equivalents/L (Mean) | ||
|---|---|---|---|
| Baseline | 6 Months | 12 Months | |
| Control | 13.99 | 12.16 | 12.36 |
| Exercise | 15.03 | 13.36 | 13.92 |
| Risedronate | 14.31 | 10.30 | 11.42 |
BMD was measured at the lumbosacral spine antero-posterior and at the femoral neck using a densitometer. A positive change from Baseline (increased bone density) indicates improvement. (NCT01400516)
Timeframe: Baseline and Month 12
| Intervention | grams/centimeters squared (g/cm^2) (Mean) | |||
|---|---|---|---|---|
| Spine, Baseline | Spine, Change from Baseline at Month12 | Femoral neck, Baseline | Femoral neck, Change from Baseline at Month 12 | |
| Control Arm | 0.93 | -0.002 | 0.73 | -0.03 |
| Teriparatide | 0.91 | 0.06 | 0.68 | 0.03 |
The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) [28 joints], swollen joint count (SJC) [28 joints], patient's global assessment of disease activity [visual analog scale: 0=no disease activity to 100=maximum disease activity] and C-Reactive Protein (CRP) for a total possible score of 2 to 10. Higher values indicate higher disease activity. A negative change from baseline indicates improvement. (NCT01400516)
Timeframe: Baseline and Month 12
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Baseline | Change from Baseline at Month 12 | |
| Control Arm | 2.73 | -0.50 |
| Teriparatide | 2.66 | 0.42 |
Both hands were scanned using a CT scanner. A semi-automated software tool was used to segment the erosion margins in 3D. A board certified radiologist identified the individual erosions in six sub-regions: radius, ulna, proximal carpals, distal carpals, metacarpophalangeal (MCP) joints and proximal interphalangeal (PIP) joints. The average total in a single hand/wrist was calculated. A negative change from Baseline(less joint erosions) indicates improvement. (NCT01400516)
Timeframe: Baseline and Month 12
| Intervention | cubic millimeter (mm^3) (Median) | |
|---|---|---|
| Baseline | Change from Baseline at Month 12 | |
| Control Arm | 571.4 | 9.1 |
| Teriparatide | 369.8 | -0.4 |
220 reviews available for alendronate and Osteoporosis
| Article | Year |
|---|---|
Effect of bisphosphonate on hip fracture in patients with osteoporosis or osteopenia according to age: a meta-analysis and systematic review.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Hip Fractures; Humans; Middle A | 2022 |
Comparative risk of acute myocardial infarction for anti-osteoporosis drugs in primary care: a meta-analysis of propensity-matched cohort findings from the UK Clinical Practice Research Database and the Catalan SIDIAP Database.
Topics: Alendronate; Bone Density Conservation Agents; Cohort Studies; Databases, Factual; Diabetes Mellitus | 2022 |
Meta-Analysis of the Efficacy and Safety of Alendronate Combined with Atorvastatin in the Treatment of Osteoporosis in Diabetes Mellitus.
Topics: Alendronate; Alkaline Phosphatase; Atorvastatin; Bone Density; Bone Density Conservation Agents; Dia | 2022 |
The efficiency and safety of alendronate versus teriparatide for treatment glucocorticoid-induced osteoporosis: A meta-analysis and systematic review of randomized controlled trials.
Topics: Alendronate; Bone Density Conservation Agents; Glucocorticoids; Humans; Osteoporosis; Randomized Con | 2022 |
Antiresorptive treatments for corticosteroid-induced osteoporosis: a Bayesian network meta-analysis.
Topics: Adrenal Cortex Hormones; Alendronate; Bayes Theorem; Bone Density Conservation Agents; Denosumab; Et | 2022 |
Aminobisphosphonates: Reconsideration 25 years after their approval for the treatment of osteoporosis.
Topics: Alendronate; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Humans; Hydroxyapa | 2022 |
Denosumab Versus Bisphosphonates for the Prevention of the Vertebral Fractures in Men with Osteoporosis: An Updated Network Meta-Analysis.
Topics: Alendronate; Bone Density Conservation Agents; Denosumab; Diphosphonates; Humans; Ibandronic Acid; M | 2022 |
Polypharmacy in Osteoporosis Treatment.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Denosumab; Diphosphonates; Fractures, Bone; Hum | 2022 |
Novel formulations of oral bisphosphonates in the treatment of osteoporosis.
Topics: Alendronate; Diphosphonates; Fractures, Bone; Humans; Osteoporosis; Risedronic Acid | 2022 |
Efficacy and Safety of Annual Infusion of Zoledronic Acid and Weekly Oral Alendronate in the Treatment of Primary Osteoporosis: A Meta-Analysis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Osteopo | 2023 |
Efficacy and Safety of Annual Infusion of Zoledronic Acid and Weekly Oral Alendronate in the Treatment of Primary Osteoporosis: A Meta-Analysis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Osteopo | 2023 |
Efficacy and Safety of Annual Infusion of Zoledronic Acid and Weekly Oral Alendronate in the Treatment of Primary Osteoporosis: A Meta-Analysis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Osteopo | 2023 |
Efficacy and Safety of Annual Infusion of Zoledronic Acid and Weekly Oral Alendronate in the Treatment of Primary Osteoporosis: A Meta-Analysis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Osteopo | 2023 |
Efficacy and Safety of Annual Infusion of Zoledronic Acid and Weekly Oral Alendronate in the Treatment of Primary Osteoporosis: A Meta-Analysis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Osteopo | 2023 |
Efficacy and Safety of Annual Infusion of Zoledronic Acid and Weekly Oral Alendronate in the Treatment of Primary Osteoporosis: A Meta-Analysis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Osteopo | 2023 |
Efficacy and Safety of Annual Infusion of Zoledronic Acid and Weekly Oral Alendronate in the Treatment of Primary Osteoporosis: A Meta-Analysis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Osteopo | 2023 |
Efficacy and Safety of Annual Infusion of Zoledronic Acid and Weekly Oral Alendronate in the Treatment of Primary Osteoporosis: A Meta-Analysis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Osteopo | 2023 |
Efficacy and Safety of Annual Infusion of Zoledronic Acid and Weekly Oral Alendronate in the Treatment of Primary Osteoporosis: A Meta-Analysis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Osteopo | 2023 |
How Efficient are Alendronate-Nano/Biomaterial Combinations for Anti-Osteoporosis Therapy? An Evidence-Based Review of the Literature.
Topics: Alendronate; Biocompatible Materials; Bone and Bones; Bone Density Conservation Agents; Diphosphonat | 2022 |
How Efficient are Alendronate-Nano/Biomaterial Combinations for Anti-Osteoporosis Therapy? An Evidence-Based Review of the Literature.
Topics: Alendronate; Biocompatible Materials; Bone and Bones; Bone Density Conservation Agents; Diphosphonat | 2022 |
How Efficient are Alendronate-Nano/Biomaterial Combinations for Anti-Osteoporosis Therapy? An Evidence-Based Review of the Literature.
Topics: Alendronate; Biocompatible Materials; Bone and Bones; Bone Density Conservation Agents; Diphosphonat | 2022 |
How Efficient are Alendronate-Nano/Biomaterial Combinations for Anti-Osteoporosis Therapy? An Evidence-Based Review of the Literature.
Topics: Alendronate; Biocompatible Materials; Bone and Bones; Bone Density Conservation Agents; Diphosphonat | 2022 |
Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.
Topics: Adult; Aged; Alendronate; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Fract | 2023 |
The clinical effectiveness of denosumab (Prolia®) in patients with hormone-sensitive cancer receiving endocrine therapy, compared to bisphosphonates, selective estrogen receptor modulators (SERM), and placebo: a systematic review and network meta-analysis
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Horm | 2023 |
Bisphosphonates for osteoporosis in people with cystic fibrosis.
Topics: Adult; Alendronate; Bone Density Conservation Agents; Child; Cystic Fibrosis; Diphosphonates; Female | 2023 |
Evaluation of the efficacy and safety of romosozumab (evenity) for the treatment of osteoporotic vertebral compression fracture in postmenopausal women: A systematic review and meta-analysis of randomized controlled trials (CDM-J).
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Female; Fractures, Compression; Humans; | 2023 |
The Clinical Effectiveness of Denosumab (Prolia®) for the Treatment of Osteoporosis in Postmenopausal Women, Compared to Bisphosphonates, Selective Estrogen Receptor Modulators (SERM), and Placebo: A Systematic Review and Network Meta-Analysis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Huma | 2023 |
Treatment for osteoporosis in people with beta-thalassaemia.
Topics: Adult; Alendronate; beta-Thalassemia; Child; Clodronic Acid; Denosumab; Diphosphonates; Female; Frac | 2023 |
Efficacy and safety of medications for osteoporosis in kidney transplant recipients or patients with chronic kidney disease: A meta-analysis.
Topics: Adult; Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Fractures, Bone; | 2023 |
Long-term consequences of osteoporosis therapy with bisphosphonates.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Bone; Humans; Oste | 2023 |
The challenge of long-term adherence: The role of bone turnover markers in monitoring bisphosphonate treatment of osteoporosis.
Topics: Alendronate; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Female; Humans; Iban | 2020 |
A case of pregnancy and lactation-associated osteoporosis and a review of the literature.
Topics: Adult; Alendronate; Bone Density; Bone Density Conservation Agents; Calcium Carbonate; Drug Therapy, | 2020 |
Minodronate in the treatment of osteoporosis: A systematic review and meta-analysis.
Topics: Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Bone Density Conservation Agents; Case-C | 2020 |
Cost-effectiveness of buffered soluble alendronate 70 mg effervescent tablet for the treatment of postmenopausal women with osteoporosis in Italy.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Cost-Benefit Analysis; Female; Humans; Italy; M | 2021 |
Metabolic bone disorders after gastrectomy: inevitable or preventable?
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcitriol; F | 2022 |
Comparing the Efficacies of Bisphosphonates' Therapies for Osteoporosis Persistence and Compliance: A Systematic Review.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Humans; Osteoporosis; | 2022 |
Effect of drugs on bone mineral density in postmenopausal osteoporosis: a Bayesian network meta-analysis.
Topics: Alendronate; Bayes Theorem; Bone Density; Bone Density Conservation Agents; Denosumab; Female; Human | 2021 |
What is the effect of anti-resorptive drugs (ARDs) on the development of medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients: A systematic review.
Topics: Aged; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Age | 2017 |
Advances in treatment of glucocorticoid-induced osteoporosis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Denosumab; Diphosphonates; Glucocortico | 2017 |
Bisphosphonate-induced osteonecrosis of the ear canal: our experience and a review of the literature.
Topics: Aged; Aged, 80 and over; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Densi | 2018 |
Effect of Diphosphonates on Bone Mineral Density in Men Receiving Androgen Deprivation Therapy for Prostate Cancer.
Topics: Absorptiometry, Photon; Alendronate; Androgen Antagonists; Bone Density; Bone Density Conservation A | 2018 |
Effects of alendronate for treatment of glucocorticoid-induced osteoporosis: A meta-analysis of randomized controlled trials.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Female; Glucocorticoids; Humans; Male; | 2018 |
Fractures related to bone fragility: prevention First-choice treatments.
Topics: Accidental Falls; Alendronate; Bone Density Conservation Agents; Calcium, Dietary; Exercise; Humans; | 2017 |
Cardiovascular Outcomes of Romosozumab and Protective Role of Alendronate.
Topics: Adaptor Proteins, Signal Transducing; Alendronate; Antibodies, Monoclonal; Cardiovascular Diseases; | 2019 |
Antiresorptive-associated spontaneous fractures of both tibiae, followed by an atypical femur fracture during the sequential treatment with alendronate, denosumab then teriparatide.
Topics: Absorptiometry, Photon; Adult; Alendronate; Bone Density; Denosumab; Dose-Response Relationship, Dru | 2019 |
Bisphosphonate-associated osteonecrosis of the auditory canal.
Topics: Aged; Aged, 80 and over; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Densi | 2013 |
Current state of orthodontic patients under bisphosphonate therapy.
Topics: Alendronate; Bone and Bones; Bone Density Conservation Agents; Bone Remodeling; Humans; Orthodontic | 2013 |
Alendronate sodium hydrate (oral jelly) for the treatment of osteoporosis: review of a novel, easy to swallow formulation.
Topics: Administration, Oral; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Dosage Form | 2013 |
[A Meta-analysis of alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis].
Topics: Alendronate; Bone Density; Glucocorticoids; Humans; Osteoporosis; Randomized Controlled Trials as To | 2013 |
[Risk assessment in patients undergoing osseous antiresorptive therapy in dentistry. An update].
Topics: Aged; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Age | 2013 |
[Glucocorticoid and bone].
Topics: Administration, Ophthalmic; Adult; Aged; Alendronate; Animals; Bone Density; Bone Density Conservati | 2014 |
Efficacy of systemic bisphosphonate delivery on osseointegration of implants under osteoporotic conditions: lessons from animal studies.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Dental Implantation, Endosseous; Dental Impl | 2014 |
Predictors of atypical femoral fractures during long term bisphosphonate therapy: a case series & review of literature.
Topics: Absorptiometry, Photon; Adult; Aged; Alendronate; Diphosphonates; Female; Femoral Fractures; Humans; | 2014 |
Gastrointestinal and renal side effects of bisphosphonates: differentiating between no proof of difference and proof of no difference.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Gastrointesti | 2015 |
Alendronate: new formulations of an old and effective drug to improve adherence avoiding upper gastrointestinal side effects.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Chemistry, Pharmaceutical; Female; Fractures | 2014 |
Osteoporosis: the emperor has no clothes.
Topics: Aging; Alendronate; Bone Density; Bone Density Conservation Agents; Evidence-Based Medicine; Female; | 2015 |
Osteoporosis: the evolution of a diagnosis.
Topics: Absorptiometry, Photon; Aging; Alendronate; Bone Density; Bone Density Conservation Agents; Fracture | 2015 |
The carcinogenicity of alendronate in patients with osteoporosis: evidence from cohort studies.
Topics: Alendronate; Bone Density Conservation Agents; Cohort Studies; Colorectal Neoplasms; Female; Humans; | 2015 |
Comparison of Bone Mineral Density in Lumbar Spine and Fracture Rate among Eight Drugs in Treatments of Osteoporosis in Men: A Network Meta-Analysis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Fractures, Bone; Humans | 2015 |
Parathyroid Hormone Plus Alendronate in Osteoporosis: A Meta-Analysis of Randomized Controlled Trials.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Bone Resorption; Drug Therapy, Combinat | 2015 |
Pharmacologic approaches to the prevention and management of low bone mineral density in HIV-infected patients.
Topics: Alendronate; Anti-Inflammatory Agents; Bone Density; Bone Density Conservation Agents; Diphosphonate | 2016 |
Treatment for osteoporosis in people with ß-thalassaemia.
Topics: Adolescent; Adult; Alendronate; beta-Thalassemia; Bone Density; Bone Density Conservation Agents; Ch | 2016 |
[Therapeutic practice of bisphosphonate use and related pharmaceutical issues I].
Topics: Alendronate; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Neoplasms; Clodronic A | 2016 |
Alendronate prevents glucocorticoid-induced osteoporosis in patients with rheumatic diseases: A meta-analysis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Glucocorticoids; Humans; Osteoporosis; | 2016 |
Osteoporosis Treatment Efficacy for Men: A Systematic Review and Meta-Analysis.
Topics: Alendronate; Bone Density Conservation Agents; Calcitonin; Denosumab; Humans; Male; Osteoporosis; Os | 2017 |
Nonvertebral fracture risk reduction with nitrogen-containing bisphosphonates.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Dose-Response Relations | 2008 |
[Alendronate].
Topics: Activities of Daily Living; Alendronate; Bone Density; Bone Density Conservation Agents; Evidence-Ba | 2008 |
[New development in bisphosphonate treatment. Fracture prevention by bisphosphonates].
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Therapy, Combination; Evidence-B | 2009 |
[New development in bisphosphonate treatment. Characteristics and effectiveness of intermittent bisphophonates].
Topics: Alendronate; Bone Density Conservation Agents; Clinical Trials as Topic; Diphosphonates; Drug Admini | 2009 |
[New development in bisphosphonate treatment. When and how long should patients take bisphosphonates for osteoporosis?].
Topics: Alendronate; Animals; Bone and Bones; Bone Density; Bone Density Conservation Agents; Drug Administr | 2009 |
[New development in bisphosphonate treatment. Review of effect on bone metabolism by minodronic acid in primary osteoporosis].
Topics: Alendronate; Amino Acids; Biomarkers; Bone and Bones; Bone Density Conservation Agents; Clinical Tri | 2009 |
Efficacy and safety of pharmacological agents in managing osteoporosis in the old old: review of the evidence.
Topics: Alendronate; Bone Density Conservation Agents; Etidronic Acid; Fractures, Bone; Humans; Organometall | 2009 |
Glucocorticoid-induced osteoporosis.
Topics: Administration, Oral; Alendronate; Bone and Bones; Bone Density Conservation Agents; Calcium; Dietar | 2009 |
The marketing of osteoporosis.
Topics: Absorptiometry, Photon; Advertising; Alendronate; Bone Density Conservation Agents; Drug Industry; D | 2009 |
[Bone quality].
Topics: Absorptiometry, Photon; Alendronate; Bone and Bones; Bone Density Conservation Agents; Clinical Tria | 2009 |
[Prediction of vertebral strength using a CT based finite element method--clinical application in evaluation of the efficacy of alendronate].
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Clinical Trials as Topic; Compressive S | 2009 |
[Alendronate for treatment of osteoporoses].
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Evidence-Based Medicine; Femoral Fractu | 2009 |
[Drug therapy of secondary osteoporosis: glucocorticoid-induced osteoporosis].
Topics: Alendronate; Bone Density Conservation Agents; Cholecalciferol; Clinical Trials as Topic; Diphosphon | 2009 |
[A-TOP research group/JOINT program].
Topics: Alendronate; Bone Density Conservation Agents; Cholecalciferol; Drug Therapy, Combination; Evidence- | 2009 |
[Combination treatment in osteoporosis. Basic treatment plus specific osteoporosis medication].
Topics: Alendronate; Bone Density Conservation Agents; Calcium; Combined Modality Therapy; Drug Combinations | 2009 |
[Hormones and osteoporosis update. Glucocorticoids and bone].
Topics: Alendronate; Animals; Calcium; Fractures, Bone; Glucocorticoids; Humans; Hydrocortisone; Osteoporosi | 2009 |
[Biochemical markers of bone turnover. New aspect. Bone metabolic markers in prostatic carcinoma].
Topics: Alendronate; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bone Density; Bone Density Conserva | 2009 |
[Biochemical markers of bone turnover. New aspect. Biochemical markers of bone turnover in long term treatment with bisphosphonate].
Topics: Alendronate; Biomarkers; Bone and Bones; Bone Density Conservation Agents; Bone Remodeling; Diphosph | 2009 |
Bone loss in patients with HIV infection.
Topics: Alendronate; Anti-Retroviral Agents; Bone Density; Bone Density Conservation Agents; Bone Resorption | 2009 |
Review of osteoporosis pharmacotherapy for geriatric patients.
Topics: Aged; Alendronate; Bone Density; Calcitonin; Calcium, Dietary; Diphosphonates; Economics, Pharmaceut | 2009 |
Metabolic bone disease: atypical femoral fractures.
Topics: Aged; Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biopsy; Bone and Bones | 2011 |
'PROFOX'--the post HRT nightmare.
Topics: Alendronate; Depression; Estrogen Replacement Therapy; Estrogens; Female; Fluoxetine; Humans; Osteop | 2011 |
[Measurement of bone mineral density is necessary for monitoring of bisphosphonate treatment].
Topics: Alendronate; Biomarkers; Bone Density; Diphosphonates; Drug Monitoring; Fractures, Spontaneous; Huma | 2011 |
Alendronate and atrial fibrillation: a meta-analysis of randomized placebo-controlled clinical trials.
Topics: Alendronate; Atrial Fibrillation; Bone Density Conservation Agents; Cardiovascular Diseases; Dose-Re | 2012 |
What is the optimal duration of bisphosphonate therapy?
Topics: Alendronate; Biomarkers; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Femoral F | 2011 |
[New therapy using bisphosphonate for urolithiasis].
Topics: Alendronate; Animals; Bed Rest; Bone and Bones; Bone Density Conservation Agents; Bone Resorption; C | 2011 |
Bisphosphonates for osteoporosis in primary biliary cirrhosis.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Humans; Iband | 2011 |
[Efficacy of teriparatide in treatment of glucocorticoid-induced osteoporosis].
Topics: Alendronate; Bone Density Conservation Agents; Female; Glucocorticoids; Humans; Male; Osteoporosis; | 2012 |
Anabolic therapies for osteoporosis.
Topics: Alendronate; Anabolic Agents; Animals; Bone and Bones; Bone Density; Bone Density Conservation Agent | 2012 |
Transient osteoporosis of the hip, complete resolution after treatment with alendronate as observed by MRI description of eight cases and review of the literature.
Topics: Alendronate; Bone Density Conservation Agents; Bone Marrow; Diphosphonates; Edema; Hip Joint; Humans | 2012 |
[Bisphosphonate related osteonecrosis of the jaw and infection with Actinomyces].
Topics: Actinomyces; Actinomycosis; Aged; Aged, 80 and over; Alendronate; Anti-Bacterial Agents; Bisphosphon | 2012 |
Laryngeal ulceration and hemoptysis secondary to inadvertent alendronate overdose: case report and review of the literature.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Drug Overdose; Hemoptysis; Humans; Laryngeal Di | 2012 |
Osteoporosis in elderly: prevention and treatment.
Topics: Aged; Alendronate; Etidronic Acid; Exercise; Female; Fractures, Bone; Hormone Replacement Therapy; H | 2002 |
[Pharmacotherapy of osteoporosis].
Topics: Alendronate; Androgens; Animals; Binding Sites; Bone Remodeling; Clinical Trials as Topic; Estrogen | 2002 |
[Pharmacological and clinical properties of alendronate sodium hydrate].
Topics: Alendronate; Animals; Bone Density; Bone Resorption; Clinical Trials as Topic; Depression, Chemical; | 2002 |
[Osteoporosis: prevention of bone loss and fractures].
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Bone Diseases, Metabolic; Diagnosis, D | 2002 |
Diagnosis and management of treatment-related osteoporosis in men with prostate carcinoma.
Topics: Absorptiometry, Photon; Alendronate; Androgen Antagonists; Anilides; Bone Density; Calcium; Gonadotr | 2003 |
[Osteoporosis].
Topics: Alendronate; Bone Density; Drug Therapy, Combination; Estrogen Replacement Therapy; Etidronic Acid; | 2002 |
[Clinical trials of alendronate].
Topics: Alendronate; Clinical Trials as Topic; Fractures, Bone; Humans; Osteoporosis | 2003 |
[Treatment of osteoporosis provided from the orthopaedic surgeon's standpoint].
Topics: Alendronate; Etidronic Acid; Fractures, Bone; Humans; Osteoporosis; Risedronic Acid | 2003 |
Preclinical evidence of normal bone with alendronate.
Topics: Alendronate; Animals; Autoradiography; Bone and Bones; Bone Density; Bone Resorption; Drug Evaluatio | 1999 |
[Osteoporosis in men].
Topics: Alendronate; Androgens; Calcium Channel Blockers; Diagnosis, Differential; Etidronic Acid; Fractures | 2003 |
[Rehabilitation in osteoporosis].
Topics: Alendronate; Ergonomics; Exercise Therapy; Female; Fractures, Bone; Humans; Male; Osteoporosis; Pain | 2003 |
Osteoporosis in men.
Topics: Absorptiometry, Photon; Alendronate; Glucocorticoids; Humans; Male; Osteoporosis; Risk Factors; Smok | 2003 |
Prevention and treatment of osteoporosis.
Topics: Aged; Alendronate; Calcitonin; Calcium; Dietary Supplements; Estrogen Replacement Therapy; Etidronic | 2002 |
Bisphosphonates: new indications and methods of administration.
Topics: Alendronate; Animals; Diphosphonates; Etidronic Acid; Fractures, Spontaneous; Humans; Imidazoles; Os | 2003 |
Risk of fracture and treatment to prevent osteoporosis-related fracture in postmenopausal women. A review.
Topics: Aged; Alendronate; Calcitonin; Clinical Trials as Topic; Diphosphonates; Estrogen Antagonists; Femal | 2003 |
Once weekly alendronate.
Topics: Alendronate; Animals; Humans; Osteoporosis | 2003 |
Aging bone and osteoporosis: strategies for preventing fractures in the elderly.
Topics: Aged; Alendronate; Calcium Channel Blockers; Diphosphonates; Estrogen Replacement Therapy; Etidronic | 2003 |
The use of intermittent human parathyroid hormone as a treatment for osteoporosis.
Topics: Alendronate; Bone Density; Drug Administration Schedule; Female; Fractures, Bone; Humans; Lumbar Ver | 2004 |
An update on bisphosphonates.
Topics: Alendronate; Bone Density; Diphosphonates; Drug Therapy, Combination; Estrogens; Etidronic Acid; Hum | 2004 |
What predicts early fracture or bone loss on bisphosphonate therapy?
Topics: Alendronate; Etidronic Acid; Female; Forecasting; Fractures, Bone; Humans; Middle Aged; Osteoporosis | 2003 |
[Treatment of osteoporosis--a new paradigm].
Topics: Alendronate; Bone Density; Cholecalciferol; Diphosphonates; Drug Design; Fractures, Bone; Humans; Os | 2004 |
[Bone mass measurement and evaluation of therapeutical response].
Topics: Absorptiometry, Photon; Aging; Alendronate; Biomarkers; Bone Density; Calcium; Estrogen Replacement | 2004 |
[AOS-100].
Topics: Absorptiometry, Photon; Alendronate; Bone Density; Etidronic Acid; Humans; Mass Screening; Osteoporo | 2004 |
[Cross-linked N-telopeptides of type I collagen(NTX)].
Topics: Alendronate; Biomarkers; Bone Resorption; Cathepsin K; Cathepsins; Collagen; Collagen Type I; Enzyme | 2004 |
[New guideline for the treatment of osteoporosis].
Topics: Alendronate; Calcitonin; Calcium; Estrogen Replacement Therapy; Etidronic Acid; Evidence-Based Medic | 2004 |
[Treatment of osteoporosis with alendronate].
Topics: Alendronate; Apoptosis; Bone Density; Bone Resorption; Clinical Trials as Topic; Fractures, Bone; Hu | 2004 |
[Fracture Intervention Trial I and II(alendronate)].
Topics: Activities of Daily Living; Alendronate; Back Pain; Controlled Clinical Trials as Topic; Humans; Ost | 2004 |
[Treatment of osteoporosis combined with a bisphosphonate and vitamin D3].
Topics: Alendronate; Bone Density; Cholecalciferol; Drug Therapy, Combination; Etidronic Acid; Humans; Multi | 2004 |
[Combination therapy of bisphosphonate and estrogen for osteoporosis].
Topics: Alendronate; Bone Density; Diphosphonates; Drug Therapy, Combination; Estrogens; Etidronic Acid; Fem | 2004 |
Does bone resorption inhibition affect the anabolic response to parathyroid hormone?
Topics: Alendronate; Bone Density; Bone Resorption; Drug Interactions; Female; Humans; Osteoporosis; Parathy | 2004 |
Does the combination of alendronate and parathyroid hormone give a greater benefit than either agent alone in osteoporosis?
Topics: Alendronate; Drug Therapy, Combination; Female; Humans; Male; Osteoporosis; Osteoporosis, Postmenopa | 2004 |
Prevention and management of osteoporosis in women with breast cancer and men with prostate cancer.
Topics: Absorptiometry, Photon; Alendronate; Antineoplastic Agents; Bone Density; Bone Density Conservation | 2004 |
Prevention of glucocorticoid-induced osteoporosis.
Topics: Alendronate; Algorithms; Calcitonin; Diphosphonates; Etidronic Acid; Glucocorticoids; Humans; Osteop | 2004 |
Bone safety of long-term bisphosphonate treatment.
Topics: Alendronate; Bone and Bones; Bone Diseases; Bone Remodeling; Calcification, Physiologic; Diphosphona | 2004 |
Management of osteoporosis: the Indian perspective.
Topics: Age Factors; Alendronate; Bone Density; Calcium, Dietary; Female; Humans; India; Life Style; Male; N | 2004 |
[Measures for osteoporosis in the dermatological field--vitamin D3 and bisphosphonate].
Topics: Aged; Alendronate; Anti-Inflammatory Agents; Bone Density; Cholecalciferol; Drug Therapy, Combinatio | 2004 |
[Human parathyroid hormone (1-34) as a new therapeutic agent for osteoporosis].
Topics: Alendronate; Animals; Bone Density; Bone Resorption; Drug Therapy, Combination; Humans; Insulin Rece | 2005 |
Oral antiresorptive therapy.
Topics: Administration, Oral; Alendronate; Anabolic Agents; Bone Resorption; Diphosphonates; Drug Therapy, C | 2005 |
Rapid prevention of vertebral fractures associated with osteoporosis.
Topics: Aged; Alendronate; Calcitonin; Clinical Trials as Topic; Diphosphonates; Estrogens; Female; Glucocor | 2005 |
[Increase in bone mineral density and its effect on fracture risk].
Topics: Alendronate; Bone Density; Bone Remodeling; Fluorides; Fractures, Bone; Humans; Meta-Analysis as Top | 2005 |
Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Etidronic Acid; Fractures, Bone; Humans; Middle | 2005 |
Use of highly potent bisphosphonates in the treatment of osteoporosis.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Remodeling; Diphosp | 2003 |
Oral antiresorptive therapy.
Topics: Administration, Oral; Aged; Alendronate; Diphosphonates; Drug Therapy, Combination; Etidronic Acid; | 2004 |
Glucocorticoid-induced osteoporosis: treatment options and guidelines.
Topics: Alendronate; Bone Density; Bone Resorption; Diphosphonates; Etidronic Acid; Exercise; Female; Fractu | 2005 |
Combination therapy for osteoporosis: considerations and controversy.
Topics: Alendronate; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Drug Therapy, Combin | 2005 |
Alendronate/colecalciferol.
Topics: Alendronate; Biological Availability; Cholecalciferol; Dose-Response Relationship, Drug; Drug Admini | 2005 |
Prevention and treatment of glucocorticoid-induced osteoporosis in 2005.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Glucocorticoids; Huma | 2005 |
The treatment of severe postmenopausal osteoporosis : a review of current and emerging therapeutic options.
Topics: Alendronate; Bone Density; Humans; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochlor | 2006 |
[Application of anti-resorptive drugs for the treatment of osteoporosis].
Topics: Aged; Alendronate; Bone Resorption; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; | 2006 |
Bisphosphonates and oral pathology I. General and preventive aspects.
Topics: Administration, Oral; Alendronate; Antibiotic Prophylaxis; Bone Density Conservation Agents; Bone Re | 2006 |
[Current research in adequate treatment by Osteoporosis Research Group].
Topics: Alendronate; Bone Density Conservation Agents; Cholecalciferol; Clinical Trials as Topic; Drug Thera | 2006 |
[Osteoporosis: Optimizing treatment strategy].
Topics: Age Factors; Aged; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Calcium, | 2006 |
Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Etidronic Ac | 2006 |
Bisphosphonates.
Topics: Alendronate; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female; Humans; Ibandroni | 2006 |
[Secondary osteoporosis. Evidence of treatment efficacy in patients with glucocorticoid-induced osteoporosis].
Topics: Alendronate; Bone Density Conservation Agents; Calcitonin; Cholecalciferol; Etidronic Acid; Evidence | 2007 |
Interventions for the treatment of decreased bone mineral density associated with HIV infection.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcium, Diet | 2007 |
[Practical guidelines for the management of osteoporosis--evidence-based and cost-effective].
Topics: Absorptiometry, Photon; Adult; Age Factors; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone | 2007 |
Is cortical bone hip? What determines cortical bone properties?
Topics: Alendronate; Bone and Bones; Bone Density; Bone Remodeling; Etidronic Acid; Fractures, Spontaneous; | 2007 |
Osteochemonecrosis of jaws and bisphosphonates.
Topics: Alendronate; Bone Density Conservation Agents; Etidronic Acid; Humans; Jaw; Osteonecrosis; Osteoporo | 2007 |
[Recent topics in the treatment of osteoporosis in Japan].
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Humans; Osteoporosis; Raloxifene Hydr | 2007 |
Improving the outcome of established therapies for osteoporosis by adding the active D-hormone analog alfacalcidol.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Calcitriol; Diphosphonates; Dr | 2007 |
[Diphosphonate therapy and osteonecrosis of the jaw].
Topics: Aged; Alendronate; Bone Density Conservation Agents; Dental Care; Diphosphonates; Female; Humans; Ja | 2007 |
[Osteoporosis in the patients with rheumatoid arthritis (3) : the efficacy and the selection of the osteoporosis therapeutic drug].
Topics: Alendronate; Arthritis, Rheumatoid; Bone Density Conservation Agents; Etidronic Acid; Humans; Osteop | 2007 |
Effects of antifracture drugs in postmenopausal, male and glucocorticoid-induced osteoporosis--usefulness of alendronate and risedronate.
Topics: Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Ag | 2007 |
[Glucocorticoid-induced osteoporosis].
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Calcium; Diphosphonates; Female; Fractu | 2007 |
[Bisphosphonates for osteoporosis].
Topics: Alendronate; Bone Density Conservation Agents; Contraindications; Diphosphonates; Etidronic Acid; Ev | 2007 |
[Combination therapy for osteoporosis].
Topics: Alendronate; Bone Density Conservation Agents; Calcitonin; Calcium; Cholecalciferol; Diphosphonates; | 2007 |
[Evidence of alendronate treatment for osteoporosis].
Topics: Alendronate; Alkaline Phosphatase; Biomarkers; Bone Density; Bone Density Conservation Agents; Colla | 2007 |
[Influence on atherosclerosis of improvement of bone mineral density after medication for osteoporosis].
Topics: Alendronate; Apolipoprotein A-I; Arthritis, Rheumatoid; Atherosclerosis; Bone and Bones; Bone Densit | 2007 |
[Efficacy and tolerability of once-weekly administration of 35 mg alendronate and 17.5 mg risedronate].
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Clinical Trials as Top | 2007 |
[Diagnosis, clinical feature and treatment of glucocorticoid-induced osteoporosis in patients with rheumatoid arthritis].
Topics: Alendronate; Arthritis, Rheumatoid; Bone Density Conservation Agents; Glucocorticoids; Humans; Osteo | 2007 |
Alendronate for the treatment of osteoporosis in men.
Topics: Alendronate; Bone Density Conservation Agents; Fractures, Bone; Glucocorticoids; Humans; Male; Osteo | 2008 |
Osteoporosis--from hormonal replacement therapy to bisphosphonates and beyond: a review.
Topics: Absorptiometry, Photon; Alendronate; Bone Density; Diphosphonates; Etidronic Acid; Female; Hormone R | 2007 |
[Assessment of bone quality. Effects of osteoporosis medications on structural and mechanical integrity of bone].
Topics: Alendronate; Animals; Biomechanical Phenomena; Bone and Bones; Bone Density; Bone Density Conservati | 2008 |
Rationale for the use of alendronate in osteoporosis.
Topics: Alendronate; Bone Diseases; Bone Remodeling; Diphosphonates; Humans; Osteoporosis | 1995 |
Bisphosphonates in the treatment of metabolic bone diseases.
Topics: Alendronate; Animals; Bone Diseases, Metabolic; Bone Resorption; Diphosphonates; Female; Humans; Hyp | 1993 |
Preclinical pharmacology of alendronate.
Topics: Alendronate; Animals; Calcification, Physiologic; Diphosphonates; Disease Models, Animal; Estrogens; | 1993 |
Osteoporosis prevention and treatment.
Topics: Absorptiometry, Photon; Alendronate; Calcitonin; Diphosphonates; Exercise; Female; Fluorides; Humans | 1996 |
Update on pharmacologic therapies for osteoporosis.
Topics: Alendronate; Bone Density; Calcitonin; Estrogen Replacement Therapy; Humans; Osteoporosis; Sodium Fl | 1996 |
Alendronate--a new bisphosphonate.
Topics: Alendronate; Bone Density; Diphosphonates; Fractures, Bone; Humans; Osteoporosis; Treatment Outcome | 1996 |
Osteoporosis treatment: focusing the target.
Topics: Aged; Alendronate; Bone Density; Female; Fractures, Bone; Humans; Male; Middle Aged; Osteoporosis; O | 1996 |
[Bisphosphonates in osteoporosis; a reevaluation].
Topics: Alendronate; Bone Density; Diphosphonates; Etidronic Acid; Humans; Osteoporosis | 1996 |
Bisphosphonate therapy.
Topics: Alendronate; Animals; Bone Density; Bone Resorption; Clodronic Acid; Diphosphonates; Etidronic Acid; | 1997 |
Bisphosphonates: preclinical aspects and use in osteoporosis.
Topics: Alendronate; Animals; Bone Resorption; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Osteo | 1997 |
Alendronate treatment for osteoporosis: a review of the clinical evidence.
Topics: Alendronate; Bone Density; Fractures, Bone; Humans; Osteoporosis; Safety; Treatment Outcome | 1996 |
Can alendronate help my osteoporosis?
Topics: Aged; Alendronate; Bone Remodeling; Female; Humans; Male; Middle Aged; Osteoporosis; Patient Educati | 1997 |
[Alendronate--a new drug for treatment of osteoporosis].
Topics: Alendronate; Animals; Bone Density; Female; Humans; Osteoporosis | 1997 |
[How I treat...senile osteoporosis].
Topics: Age Factors; Aged; Alendronate; Calcium; Estrogen Replacement Therapy; Exercise Therapy; Female; Hum | 1997 |
Bisphosphonates in the treatment of osteoporosis.
Topics: Aged; Alendronate; Diphosphonates; Etidronic Acid; Female; Humans; Male; Middle Aged; Osteoporosis; | 1997 |
Osteoporosis: prevention, detection and treatment.
Topics: Aged; Alendronate; Bone Density; Female; Humans; Male; Middle Aged; Osteoporosis; Risk Factors | 1997 |
Osteoporosis: trials and tribulations.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Calcitonin; Calcium, Dietary; Estrogen Replaceme | 1997 |
Prevention and treatment of osteoporosis: does the future belong to hormone replacement therapy?
Topics: Alendronate; Alzheimer Disease; Calcitonin; Calcium; Coronary Disease; Diphosphonates; Endometrial N | 1997 |
Medical management of osteoporosis. Fracture prevention.
Topics: Aged; Alendronate; Benzothiadiazines; Bone Density; Calcitonin; Calcium; Calcium, Dietary; Diuretics | 1998 |
Osteoporosis: a focus on treatment.
Topics: Accidental Falls; Aged; Aging; Alendronate; Bone Density; Calcitonin; Contraindications; Estrogen Re | 1997 |
A risk-benefit assessment of alendronate in the treatment of involutional osteoporosis.
Topics: Aged; Alendronate; Bone and Bones; Bone Density; Female; Fractures, Bone; Humans; Osteoporosis; Spin | 1998 |
Osteoporosis: a possible modifying factor in oral bone loss.
Topics: Alendronate; Alveolar Bone Loss; Bone Density; Estrogen Replacement Therapy; Female; Humans; Male; M | 1998 |
Ultrasound and alendronate: new tools for osteoporosis screening and treatment.
Topics: Absorptiometry, Photon; Aged; Alendronate; Calcium; Clinical Trials as Topic; Estrogen Antagonists; | 1998 |
Bisphosphonates and osteoporosis treatment in Italy.
Topics: Aged; Alendronate; Bone and Bones; Bone Density; Clodronic Acid; Diphosphonates; Etidronic Acid; Fem | 1998 |
Evidence-based medicine and osteoporosis: a comparison of fracture risk reduction data from osteoporosis randomised clinical trials.
Topics: Alendronate; Calcitonin; Calcitriol; Calcium; Calcium Fluoride; Evidence-Based Medicine; Fractures, | 1999 |
Prevention of osteoporosis and fractures.
Topics: Alendronate; Bone Density; Calcium; Estrogen Replacement Therapy; Estrogens; Etidronic Acid; Female; | 1999 |
Bone loss and glucocorticoid therapy in patients with respiratory disease.
Topics: Alendronate; Glucocorticoids; Humans; Osteoporosis; Respiration Disorders | 1999 |
Osteoporosis: diagnosis, prevention, and treatment of established disease.
Topics: Age Factors; Aged; Alendronate; Calcitonin; Calcium Channel Blockers; Calcium, Dietary; Dietary Supp | 1999 |
Chronic glucocorticoid therapy-induced osteoporosis in patients with obstructive lung disease.
Topics: Administration, Inhalation; Administration, Oral; Adult; Alendronate; Asthma; Bone Density; Bone Rem | 1999 |
Osteoporosis prevention and treatment.
Topics: Alendronate; Anabolic Agents; Bone Density; Calcitriol; Calcium; Estrogen Replacement Therapy; Etidr | 2000 |
Osteoporosis prevention, detection, and treatment. A mandate for primary care physicians.
Topics: Alendronate; Bone Development; Densitometry; Estrogen Replacement Therapy; Family Practice; Female; | 2000 |
Prevention and treatment of osteoporosis.
Topics: Accidental Falls; Adult; Age Factors; Aged; Aged, 80 and over; Alendronate; Calcitonin; Calcium Chan | 2000 |
Osteoporotic fractures at presentation of Cushing's disease: two case reports and a literature review.
Topics: Absorptiometry, Photon; Adult; Alendronate; Bone and Bones; Cushing Syndrome; Fractures, Spontaneous | 2000 |
Gastroenterologists and choosing the right bisphosphonate.
Topics: Alendronate; Diphosphonates; Etidronic Acid; Female; Gastroenterology; Glucocorticoids; Humans; Oste | 2000 |
Osteoporosis: evaluation and treatment.
Topics: Aged; Alendronate; Calcitonin; Estrogen Replacement Therapy; Female; Humans; Life Style; Male; Osteo | 2000 |
[Drug treatment for the treatment of primary osteoporosis].
Topics: Alendronate; Fluorides; Fractures, Bone; Humans; Osteoporosis; Raloxifene Hydrochloride; Selective E | 2000 |
Background for studies on the treatment of male osteoporosis: state of the art.
Topics: Age Factors; Aged; Aged, 80 and over; Alendronate; Body Height; Body Weight; Bone Density; Fractures | 2000 |
Osteoporosis: which current treatments reduce fracture risk?
Topics: Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density; Calcium Channel Blockers; Estrogen R | 2000 |
[Therapeutic strategies for osteoporosis].
Topics: Accidental Falls; Age Factors; Aged; Aged, 80 and over; Alendronate; Bone Density; Calcitonin; Calci | 2000 |
Bisphosphonates in the treatment of osteoporosis. Principles and efficacy.
Topics: Administration, Oral; Alendronate; Animals; Bone and Bones; Bone Density; Calcium Channel Blockers; | 2000 |
Osteoporosis therapies for rheumatoid arthritis patients: minimizing gastrointestinal side effects.
Topics: Alendronate; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Estrogen Replacement Th | 2001 |
Osteoporosis.
Topics: Absorptiometry, Photon; Aged; Alendronate; Calcitonin; Calcium; Estrogen Replacement Therapy; Female | 2001 |
Pharmacologic therapy for the treatment and prevention of osteoporosis.
Topics: Aged; Alendronate; Bone Density; Calcitonin; Diphosphonates; Estrogen Replacement Therapy; Etidronic | 2001 |
Update on alendronate for osteoporosis: once-weekly dosing.
Topics: Alendronate; Animals; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administratio | 2001 |
Bisphosphonates for osteoporosis.
Topics: Aged; Alendronate; Diphosphonates; Etidronic Acid; Female; Humans; Male; Middle Aged; Osteoporosis; | 2001 |
Role of alendronate and risedronate in preventing and treating osteoporosis.
Topics: Alendronate; Cost-Benefit Analysis; Diphosphonates; Dose-Response Relationship, Drug; Etidronic Acid | 2001 |
Intermittent dosing of alendronate.
Topics: Aged; Alendronate; Clinical Trials as Topic; Humans; Osteoporosis | 2001 |
Treatment of osteoporosis in men with fluoride alone or in combination with bisphosphonates.
Topics: Alendronate; Bone and Bones; Bone Density; Climacteric; Drug Therapy, Combination; Etidronic Acid; F | 2001 |
Bisphosphonates: an overview with special reference to alendronate.
Topics: Alendronate; Bone Density; Bone Neoplasms; Bone Resorption; Calcium; Clinical Trials as Topic; Dipho | 2001 |
Osteoporosis.
Topics: Absorptiometry, Photon; Accidental Falls; Aged; Alendronate; Calcium, Dietary; Estrogen Replacement | 2002 |
[Advancement of treatment for osteoporosis].
Topics: Alendronate; Bone Density; Cholecalciferol; Clinical Trials as Topic; Estrogen Replacement Therapy; | 2002 |
[Bone densitometry: its clinical application and current status].
Topics: Alendronate; Bone Density; Clinical Trials as Topic; Densitometry; Fractures, Stress; Humans; Osteop | 2002 |
[Comparative analyses on osteoporosis guidelines in Japan, EU and USA].
Topics: Alendronate; Calcitonin; Clinical Trials as Topic; Drug Approval; Estriol; Etidronic Acid; Europe; H | 2002 |
[Treatment of male osteoporosis].
Topics: Alendronate; Alkaline Phosphatase; Amino Acids; Biomarkers; Bone Density; Calcium; Fractures, Stress | 2002 |
[Bisphosphonates: pharmacology and use in the treatment of osteoporosis].
Topics: Alendronate; Bone Density; Bone Remodeling; Clinical Trials as Topic; Diphosphonates; Etidronic Acid | 2002 |
[Alendronate in the treatment of osteoporosis].
Topics: Alendronate; Bone Density; Bone Resorption; Clinical Trials as Topic; Femoral Neck Fractures; Fractu | 2002 |
Combination treatment of osteoporosis: a clinical review.
Topics: Alendronate; Bone Density; Clinical Trials as Topic; Drug Therapy, Combination; Estrogens, Conjugate | 2002 |
Treatment of male osteoporosis: recent advances with alendronate.
Topics: Adult; Aged; Alendronate; Bone Density; Bone Resorption; Calcium; Female; Fractures, Bone; Humans; H | 2002 |
Once-weekly treatment for osteoporosis.
Topics: Alendronate; Drug Administration Schedule; Humans; Osteoporosis; Therapeutic Equivalency | 2002 |
Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children.
Topics: Adolescent; Alendronate; Child; Child, Preschool; Connective Tissue Diseases; Humans; Osteoporosis | 2002 |
167 trials available for alendronate and Osteoporosis
| Article | Year |
|---|---|
A randomized trial of alendronate as prophylaxis against loss in bone mineral density following lymphoma treatment.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Female; Glucocorticoids; Humans; Lympho | 2022 |
Efficacy and Safety of Romosozumab Among Postmenopausal Women With Osteoporosis and Mild-to-Moderate Chronic Kidney Disease.
Topics: Alendronate; Antibodies, Monoclonal; Bone Density; Bone Density Conservation Agents; Female; Femur N | 2022 |
Efficacy of generic teriparatide and alendronate in Chinese postmenopausal women with osteoporosis: a prospective study.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; China; Female; Humans; Osteoporosis; Os | 2022 |
Sequential therapy with once-weekly teriparatide injection followed by alendronate versus monotherapy with alendronate alone in patients at high risk of osteoporotic fracture: final results of the Japanese Osteoporosis Intervention Trial-05.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; East Asian People; Female; Humans; Oste | 2023 |
Effects of four-year cyclic versus two-year daily teriparatide treatment on volumetric bone density and bone strength in postmenopausal women with osteoporosis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Female; Humans; Osteoporosis; Osteoporo | 2023 |
Effects of four-year cyclic versus two-year daily teriparatide treatment on volumetric bone density and bone strength in postmenopausal women with osteoporosis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Female; Humans; Osteoporosis; Osteoporo | 2023 |
Effects of four-year cyclic versus two-year daily teriparatide treatment on volumetric bone density and bone strength in postmenopausal women with osteoporosis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Female; Humans; Osteoporosis; Osteoporo | 2023 |
Effects of four-year cyclic versus two-year daily teriparatide treatment on volumetric bone density and bone strength in postmenopausal women with osteoporosis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Female; Humans; Osteoporosis; Osteoporo | 2023 |
Effects of four-year cyclic versus two-year daily teriparatide treatment on volumetric bone density and bone strength in postmenopausal women with osteoporosis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Female; Humans; Osteoporosis; Osteoporo | 2023 |
Effects of four-year cyclic versus two-year daily teriparatide treatment on volumetric bone density and bone strength in postmenopausal women with osteoporosis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Female; Humans; Osteoporosis; Osteoporo | 2023 |
Effects of four-year cyclic versus two-year daily teriparatide treatment on volumetric bone density and bone strength in postmenopausal women with osteoporosis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Female; Humans; Osteoporosis; Osteoporo | 2023 |
Effects of four-year cyclic versus two-year daily teriparatide treatment on volumetric bone density and bone strength in postmenopausal women with osteoporosis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Female; Humans; Osteoporosis; Osteoporo | 2023 |
Effects of four-year cyclic versus two-year daily teriparatide treatment on volumetric bone density and bone strength in postmenopausal women with osteoporosis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Female; Humans; Osteoporosis; Osteoporo | 2023 |
Reliability of early stage symptoms/clinical findings of osteonecrosis of the jaw: Japanese Osteoporosis Intervention Trial-05 (JOINT-05).
Topics: Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; D | 2023 |
Resistive exercise in astronauts on prolonged spaceflights provides partial protection against spaceflight-induced bone loss.
Topics: Absorptiometry, Photon; Adult; Alendronate; Astronauts; Bone and Bones; Bone Density; Bone Diseases, | 2019 |
Reduced Bone Loss Is Associated With Reduced Mortality Risk in Subjects Exposed to Nitrogen Bisphosphonates: A Mediation Analysis.
Topics: Aged; Alendronate; Bone Density; Disease-Free Survival; Female; Humans; Male; Middle Aged; Osteoporo | 2019 |
Design of a randomized trial of teriparatide followed by alendronate: Japanese Osteoporosis Intervention Trial-05 (JOINT-05).
Topics: Aged; Alendronate; Bone Density Conservation Agents; Endpoint Determination; Female; Humans; Japan; | 2020 |
Bone turnover markers as an aid to monitor osteoporosis following allogeneic hematopoietic stem cell transplantation.
Topics: Adult; Aged; Alendronate; Alkaline Phosphatase; Allografts; Biomarkers; Bone Density; Bone Remodelin | 2020 |
Fall Prevention and Anti-Osteoporosis in Osteopenia Patients of 80 Years of Age and Older: A Randomized Controlled Study.
Topics: Accidental Falls; Aged, 80 and over; Alendronate; Biomarkers; Bone Density Conservation Agents; Bone | 2020 |
A randomized, controlled trial of once-weekly teriparatide injection versus alendronate in patients at high risk of osteoporotic fracture: primary results of the Japanese Osteoporosis Intervention Trial-05.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Female; Humans; Japan; Osteoporosis; Os | 2021 |
Romosozumab improves lumbar spine bone mass and bone strength parameters relative to alendronate in postmenopausal women: results from the Active-Controlled Fracture Study in Postmenopausal Women With Osteoporosis at High Risk (ARCH) trial.
Topics: Alendronate; Antibodies, Monoclonal; Bone Density; Bone Density Conservation Agents; Female; Humans; | 2021 |
Whole body vibration versus magnetic therapy on bone mineral density in elderly osteoporotic individuals.
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Calcium; | 2017 |
Randomized clinical trial comparing efficacy and safety of brand versus generic alendronate (Bonmax®) for osteoporosis treatment.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Arthralgia; Bone Density; Bone Density | 2017 |
Early monitoring of osteoporosis treatment response by technetium-99m-methylene diphosphonate bone scan.
Topics: Aged; Alendronate; Bone Density; Female; Femur Neck; Humans; Lumbar Vertebrae; Middle Aged; Osteopor | 2017 |
The effects of denosumab and alendronate on glucocorticoid-induced osteoporosis in patients with glomerular disease: A randomized, controlled trial.
Topics: Adult; Aged; Alendronate; Biomarkers; Bone Density Conservation Agents; Bone Remodeling; Denosumab; | 2018 |
Patient satisfaction and efficacy of switching from weekly bisphosphonates to monthly minodronate for treatment and prevention of glucocorticoid-induced osteoporosis in Japanese patients with systemic rheumatic diseases: a randomized, clinical trial.
Topics: Administration, Oral; Adult; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Diph | 2018 |
Effects of Short Term Alendronate Administration on Bone Mineral Density in Patients with Chronic Kidney Disease.
Topics: Adult; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Dose-Response Relationship | 2018 |
Open-label study of treatment with alendronate sodium plus vitamin D in men and women with osteoporosis in Thailand.
Topics: Administration, Oral; Aged; Alendronate; Bone Density Conservation Agents; Cholecalciferol; Drug The | 2018 |
[Comparison of the clinical effects between Dihuang Decoction and alendronate sodium in the treatment of primary osteoporosis].
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Female; H | 2019 |
Comparison of gastrointestinal symptoms at daily 10 mg versus weekly 70 mg Alendronate prescription in 195 osteoporotic cases.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Female; Gastrointestinal Diseases; Humans; Male | 2011 |
Influence of patient perceptions and preferences for osteoporosis medication on adherence behavior in the Denosumab Adherence Preference Satisfaction study.
Topics: Administration, Oral; Aged; Alendronate; Antibodies, Monoclonal, Humanized; Bone Density Conservatio | 2014 |
Bone histomorphometry of transiliac paired bone biopsies after 6 or 12 months of treatment with oral strontium ranelate in 387 osteoporotic women: randomized comparison to alendronate.
Topics: Administration, Oral; Alendronate; Biopsy; Bone and Bones; Female; Humans; Middle Aged; Osteoporosis | 2014 |
Natural history and risk factors for adjacent vertebral fractures in the fracture intervention trial.
Topics: Aged; Alendronate; Bone Density; Female; Follow-Up Studies; Humans; Middle Aged; Osteoporosis; Retro | 2013 |
Follow-up of six patients with neurofibromatosis 1-related osteoporosis treated with alendronate for 23 months.
Topics: Adult; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Female; F | 2014 |
Bone turnover markers and pharmacokinetics of a new sustained-release formulation of the cathepsin K inhibitor, ONO-5334, in healthy post-menopausal women.
Topics: Aged; Alendronate; Area Under Curve; Bone and Bones; Bone Density; Bone Resorption; Cathepsin K; Col | 2015 |
Clinical Trials Express: fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: denosumab fracture intervention randomized placebo controlled trial (DIRECT).
Topics: Aged; Aged, 80 and over; Alendronate; Antibodies, Monoclonal, Humanized; Denosumab; Female; Humans; | 2014 |
A randomized, double-blind, placebo-controlled study to evaluate the effects of alendronate on bone mineral density and bone remodelling in perimenopausal women with low bone mineral density.
Topics: Adult; Alendronate; Bone Density Conservation Agents; Bone Remodeling; Cholecalciferol; Double-Blind | 2014 |
Efficacy of combined treatment with alendronate (ALN) and eldecalcitol, a new active vitamin D analog, compared to that of concomitant ALN, vitamin D plus calcium treatment in Japanese patients with primary osteoporosis.
Topics: Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Bo | 2015 |
Patient preference for monthly bisphosphonate versus weekly bisphosphonate in a cluster-randomized, open-label, crossover trial: Minodroate Alendronate/Risedronate Trial in Osteoporosis (MARTO).
Topics: Aged; Aged, 80 and over; Alendronate; Cross-Over Studies; Demography; Diphosphonates; Drug Administr | 2016 |
Teriparatide Versus Alendronate for the Preservation of Bone Mineral Density After Total Hip Arthroplasty - A randomized Controlled Trial.
Topics: Absorptiometry, Photon; Aged; Alendronate; Arthroplasty, Replacement, Hip; Body Mass Index; Bone Den | 2016 |
Analysis of bone metabolism during early stage and clinical benefits of early intervention with alendronate in patients with systemic rheumatic diseases treated with high-dose glucocorticoid: Early DIagnosis and Treatment of OsteopoRosis in Japan (EDITOR-
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alendronate; Bone Density; Female; Fractures, Bone; Gluc | 2016 |
3-D bone models to improve treatment initiation among patients with osteoporosis: A randomised controlled pilot trial.
Topics: Aged; Alendronate; Bone and Bones; Bone Density Conservation Agents; Diphosphonates; Female; Follow- | 2016 |
Trabecular Bone Score in Patients With Chronic Glucocorticoid Therapy-Induced Osteoporosis Treated With Alendronate or Teriparatide.
Topics: Alendronate; Bone Density Conservation Agents; Cancellous Bone; Chronic Disease; Double-Blind Method | 2016 |
Treatment of osteoporosis secondary to hypogonadism in prostate cancer patients: a prospective randomized multicenter international study with denosumab vs. alendronate.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Denosumab; Double-Blind Meth | 2017 |
A Comparative Study of Intravenous Injection Form and Oral Jelly Form of Alendronate Sodium Hydrate for Bone Mineral Disorder after Gastrectomy.
Topics: Administration, Oral; Aged; Alendronate; Alkaline Phosphatase; Bone Density; Bone Density Conservati | 2017 |
Alendronate once weekly for the prevention and treatment of bone loss in Canadian adult cystic fibrosis patients (CFOS trial).
Topics: Administration, Oral; Adult; Alendronate; Bone Density; Bone Density Conservation Agents; Canada; Co | 2008 |
Femoral bone strength and its relation to cortical and trabecular changes after treatment with PTH, alendronate, and their combination as assessed by finite element analysis of quantitative CT scans.
Topics: Alendronate; Bone and Bones; Bone Density; Densitometry; Double-Blind Method; Female; Femur; Finite | 2008 |
Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy.
Topics: Administration, Oral; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Double-Blin | 2008 |
Effect of alendronate in elderly patients after low trauma hip fracture repair.
Topics: Accidental Falls; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Co | 2009 |
A comparison of calcium, calcitriol, and alendronate in corticosteroid-treated premenopausal patients with systemic lupus erythematosus.
Topics: Adrenal Cortex Hormones; Adult; Alendronate; Bone Density; Bone Density Conservation Agents; Calcitr | 2008 |
Alendronate protects premenopausal women from bone loss and fracture associated with high-dose glucocorticoid therapy.
Topics: Adolescent; Adult; Alendronate; Autoimmune Diseases; Bone Density; Bone Density Conservation Agents; | 2008 |
Clinical trial: comparison of alendronate and alfacalcidol in glucocorticoid-associated osteoporosis in patients with ulcerative colitis.
Topics: Adolescent; Adult; Aged; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Co | 2009 |
[Alendronate prevents steroid-induced osteoporosis in patients with rheumatic diseases].
Topics: Adult; Alendronate; Bone Density; Bone Density Conservation Agents; Female; Glucocorticoids; Humans; | 2008 |
Retreatment with teriparatide one year after the first teriparatide course in patients on continued long-term alendronate.
Topics: Aged; Alendronate; Bone Density; Female; Humans; Middle Aged; Osteoporosis; Retreatment; Teriparatid | 2009 |
Alendronate/vitamin D3 70 mg/2800 IU with and without additional 2800 IU vitamin D3 for osteoporosis: results from the 24-week extension of a 15-week randomized, controlled trial.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Cholecalciferol; Double-Blind Met | 2009 |
Effect of bisphosphonate treatment on bone mineral density in patients with thalassaemia major.
Topics: Absorptiometry, Photon; Adult; Alendronate; beta-Thalassemia; Bone Density; Bone Density Conservatio | 2008 |
Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status.
Topics: Adult; Age Factors; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Double-Blind | 2009 |
Effects of teriparatide retreatment in osteoporotic men and women.
Topics: Aged; Aged, 80 and over; Alendronate; Algorithms; Bone Density; Bone Density Conservation Agents; Do | 2009 |
Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density Co | 2009 |
Teriparatide reduces bone microdamage accumulation in postmenopausal women previously treated with alendronate.
Topics: Alendronate; Bone and Bones; Bone Density; Bone Density Conservation Agents; Female; Humans; Middle | 2009 |
Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial.
Topics: Administration, Oral; Adult; Aged; Alendronate; Biomarkers; Bone Density; Bone Density Conservation | 2009 |
Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial.
Topics: Administration, Oral; Adult; Aged; Alendronate; Biomarkers; Bone Density; Bone Density Conservation | 2009 |
Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial.
Topics: Administration, Oral; Adult; Aged; Alendronate; Biomarkers; Bone Density; Bone Density Conservation | 2009 |
Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial.
Topics: Administration, Oral; Adult; Aged; Alendronate; Biomarkers; Bone Density; Bone Density Conservation | 2009 |
Alendronate improves low bone mineral density induced by steroid therapy in Crohn's disease.
Topics: Absorptiometry, Photon; Adult; Alendronate; Alkaline Phosphatase; Bone Density; Bone Density Conserv | 2009 |
Value of routine monitoring of bone mineral density after starting bisphosphonate treatment: secondary analysis of trial data.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Female; Fractures, Spontaneous; Hip Joi | 2009 |
Additional beneficial effects of recombinant growth hormone in alendronate-treated patients with idiopathic osteoporosis.
Topics: Absorptiometry, Photon; Adult; Alendronate; Alkaline Phosphatase; Bone Density Conservation Agents; | 2009 |
[Effect of alendronate on glucocorticoid-induced osteoporosis].
Topics: Adult; Alendronate; Bone Density; Bone Density Conservation Agents; Female; Humans; Male; Middle Age | 2009 |
Impact of bisphosphonate wash-out prior to teriparatide therapy in clinical practice.
Topics: Aged; Alendronate; Alkaline Phosphatase; Biomarkers; Bone Density; Bone Density Conservation Agents; | 2010 |
Effect of alendronate on bone mineral density and bone turnover markers in post-gastrectomy osteoporotic patients.
Topics: Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Biomarkers; Bone and Bones; Bone Density | 2010 |
Comparison of the effects of alendronate and alfacalcidol on hip bone mineral density and bone turnover in Japanese men having osteoporosis or osteopenia with clinical risk factors for fractures.
Topics: Aged; Aged, 80 and over; Alendronate; Asian People; Bone Density; Bone Density Conservation Agents; | 2009 |
Biomechanical effects of teriparatide in women with osteoporosis treated previously with alendronate and risedronate: results from quantitative computed tomography-based finite element analysis of the vertebral body.
Topics: Aged; Alendronate; Biomechanical Phenomena; Bone Density Conservation Agents; Etidronic Acid; Female | 2010 |
Effects of alendronate on bone metabolism in glucocorticoid-induced osteoporosis measured by 18F-fluoride PET: a prospective study.
Topics: Aged; Alendronate; Biomarkers; Bone and Bones; Bone Density; Female; Fluorides; Fluorine Radioisotop | 2009 |
Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial.
Topics: Adult; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Collagen Type I; Dose-Resp | 2009 |
Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Double-Blind Method; Female; Femur Neck | 2010 |
Effect of alendronate on bone metabolic indices and bone mineral density in patients treated with high-dose glucocorticoid: a prospective study.
Topics: Adult; Aged; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Resorptio | 2010 |
The effects of weekly alendronate therapy in Taiwanese males with osteoporosis.
Topics: Absorptiometry, Photon; Alendronate; Alkaline Phosphatase; Amino Acids; Biomarkers; Body Mass Index; | 2010 |
Bone formation markers in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate.
Topics: Adult; Aged; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Chi-Square Dis | 2010 |
Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate.
Topics: Alendronate; Alkaline Phosphatase; Analysis of Variance; Biomarkers; Bone Density; Bone Remodeling; | 2010 |
Design of a pragmatic approach to evaluate the effectiveness of concurrent treatment for the prevention of osteoporotic fractures: rationale, aims and organization of a Japanese Osteoporosis Intervention Trial (JOINT) initiated by the Research Group of Ad
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density Conservation Agents; Humans; Hydroxycholecal | 2011 |
Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; Drug Admin | 2010 |
Efficacy of strontium ranelate on bone mineral density in men with osteoporosis.
Topics: Absorptiometry, Photon; Adult; Aged; Alendronate; Body Height; Bone Density; Bone Density Conservati | 2010 |
Low acceptance of treatment in the elderly for the secondary prevention of osteoporotic fracture in the acute rehabilitation setting.
Topics: Acute Disease; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Calcium; Chol | 2010 |
Effects of alendronate plus alfacalcidol in osteoporosis patients with a high risk of fracture: the Japanese Osteoporosis Intervention Trial (JOINT) - 02.
Topics: Alendronate; Bone Density Conservation Agents; Fractures, Bone; Hydroxycholecalciferols; Japan; Oste | 2011 |
Efficacy of different therapeutic regimens on hepatic osteodystrophy in chronic viral liver disease.
Topics: Absorptiometry, Photon; Adult; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agen | 2011 |
Prevention of glucocorticoid-induced osteoporosis in immunobullous diseases with alendronate: a randomized, double-blind, placebo-controlled study.
Topics: Administration, Oral; Adult; Alendronate; Anti-Inflammatory Agents; Autoimmune Diseases; Bone Densit | 2012 |
Prevention of disuse osteoporosis in rats by Cordyceps sinensis extract.
Topics: Alendronate; Animals; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; C | 2012 |
Clinical subtypes of depression are associated with specific metabolic parameters and circadian endocrine profiles in women: the power study.
Topics: Adrenocorticotropic Hormone; Adult; Alendronate; Biomarkers; Body Composition; Bone Density; Circadi | 2012 |
Vitamin D levels: its relationship to bone mineral density response and disease activity in premenopausal Malaysian systemic lupus erythematosus patients on corticosteroids.
Topics: Absorptiometry, Photon; Adrenal Cortex Hormones; Adult; Alendronate; Asian People; Biomarkers; Bone | 2012 |
Effect of alendronate on HIV-associated osteoporosis: a randomized, double-blind, placebo-controlled, 96-week trial (ANRS 120).
Topics: Absorptiometry, Photon; Acquired Immunodeficiency Syndrome; Adult; Alendronate; Anti-HIV Agents; Bon | 2012 |
[Clinical application of alendronate for osteoporosis/osteopenia secondary to hyperthyroidism].
Topics: Adult; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Female | 2012 |
What is the role of hyperbaric oxygen in the management of bisphosphonate-related osteonecrosis of the jaw: a randomized controlled trial of hyperbaric oxygen as an adjunct to surgery and antibiotics.
Topics: Aged; Alendronate; Anti-Bacterial Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone D | 2012 |
A multicenter randomized double-masked comparative study of different preparations of alendronate in osteoporosis - monthly (four weeks) intravenous versus once weekly oral administrations.
Topics: Administration, Intravenous; Administration, Oral; Aged; Aged, 80 and over; Alendronate; Algorithms; | 2012 |
A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leupr
Topics: Absorptiometry, Photon; Administration, Oral; Aged; Aged, 80 and over; Alendronate; Alkaline Phospha | 2013 |
Use of alendronate sodium (Fosamax) to ameliorate osteoporosis in renal transplant patients: a case-control study.
Topics: Alendronate; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Case-C | 2012 |
Bisphosphonates as a supplement to exercise to protect bone during long-duration spaceflight.
Topics: Absorptiometry, Photon; Adult; Alendronate; Biomarkers; Body Composition; Bone Density; Bone Density | 2013 |
Bisphosphonates in the treatment of thalassemia-induced osteoporosis.
Topics: Absorptiometry, Photon; Adolescent; Adult; Alendronate; Analysis of Variance; beta-Thalassemia; Biom | 2002 |
Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study.
Topics: Alendronate; Analysis of Variance; Bone Density; Bone Resorption; Double-Blind Method; Female; Gastr | 2002 |
Osteoporosis treatment in elderly hyperthyroid male patients.
Topics: Aged; Alendronate; Antithyroid Agents; Bone Density; Drug Therapy, Combination; Femur Neck; Humans; | 2002 |
The effects of alendronate on bone turnover and bone quality.
Topics: Alendronate; Bone and Bones; Bone Remodeling; Bone Resorption; Calcium Carbonate; Double-Blind Metho | 1999 |
The effects of alendronate on stature and the spine deformity index.
Topics: Administration, Oral; Alendronate; Analysis of Variance; Body Height; Double-Blind Method; Female; H | 1999 |
Changes in bone mineral density following discontinuation or continuation of alendronate therapy in glucocorticoid-treated patients: a retrospective, observational study.
Topics: Adult; Aged; Alendronate; Bone Density; Dose-Response Relationship, Drug; Drug Administration Schedu | 2003 |
Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium.
Topics: Absorptiometry, Photon; Adult; Aged; Aged, 80 and over; Alendronate; Bone Density; Calcitriol; Calci | 2003 |
Alendronate for treatment of renal transplant patients with osteoporosis.
Topics: Alendronate; Bone Density; Female; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; M | 2003 |
Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study.
Topics: Adjuvants, Immunologic; Administration, Oral; Alendronate; Body Height; Bone Density; Calcium; Dipho | 2004 |
The effects of parathyroid hormone, alendronate, or both in men with osteoporosis.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Bone Density; Bo | 2003 |
The effects of parathyroid hormone, alendronate, or both in men with osteoporosis.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Bone Density; Bo | 2003 |
The effects of parathyroid hormone, alendronate, or both in men with osteoporosis.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Bone Density; Bo | 2003 |
The effects of parathyroid hormone, alendronate, or both in men with osteoporosis.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Bone Density; Bo | 2003 |
The effects of parathyroid hormone, alendronate, or both in men with osteoporosis.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Bone Density; Bo | 2003 |
The effects of parathyroid hormone, alendronate, or both in men with osteoporosis.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Bone Density; Bo | 2003 |
The effects of parathyroid hormone, alendronate, or both in men with osteoporosis.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Bone Density; Bo | 2003 |
The effects of parathyroid hormone, alendronate, or both in men with osteoporosis.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Bone Density; Bo | 2003 |
The effects of parathyroid hormone, alendronate, or both in men with osteoporosis.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Bone Density; Bo | 2003 |
Resistance exercise training and alendronate reverse glucocorticoid-induced osteoporosis in heart transplant recipients.
Topics: Alendronate; Bone Density; Exercise Therapy; Female; Glucocorticoids; Graft Rejection; Heart Transpl | 2003 |
Efficacy of alendronate in adults with cystic fibrosis with low bone density.
Topics: Administration, Oral; Adult; Alendronate; Analysis of Variance; Bone Density; Bone Resorption; Cysti | 2004 |
Alendronate treatment in men with primary osteoporosis: a three-year longitudinal study.
Topics: Absorptiometry, Photon; Adult; Aged; Alendronate; Bone Density; Calcium; Femur Neck; Hip; Humans; Lo | 2003 |
Alendronate for the prevention of bone mineral loss during gonadotropin-releasing hormone agonist therapy.
Topics: Absorptiometry, Photon; Administration, Oral; Adult; Alendronate; Bone Density; Double-Blind Method; | 2003 |
Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: a seven-year follow-up study.
Topics: Adult; Aged; Alendronate; Analysis of Variance; Bone Density; Bone Resorption; Case-Control Studies; | 2004 |
Upper gastrointestinal and overall tolerability of alendronate once weekly in patients with osteoporosis: results of a randomized, double-blind, placebo-controlled study.
Topics: Administration, Oral; Alendronate; Analysis of Variance; Double-Blind Method; Female; Gastrointestin | 2004 |
[Clinic effect of alendronate sodium treatment in osteoporosis patients with hip fracture].
Topics: Absorptiometry, Photon; Aged; Alanine Transaminase; Alendronate; Bone Density; Calcium; Case-Control | 2004 |
Treatment of osteopenia and osteoporosis in renal transplant children and adolescents.
Topics: Absorptiometry, Photon; Adjuvants, Immunologic; Adolescent; Alendronate; Bone and Bones; Bone Densit | 2004 |
Alendronate reduces serum TNFalpha and IL-1beta, increases neutrophil counts, and improves bone mineral density and bone metabolism indices in patients with chronic idiopathic neutropenia (CIN)-associated osteopenia/osteoporosis.
Topics: Adult; Aged; Alendronate; Biomarkers; Bone Density; Bone Diseases, Metabolic; Chronic Disease; Femal | 2004 |
Effect of alendronate on bone mineral density in spinal cord injury patients: a pilot study.
Topics: Administration, Oral; Adult; Alendronate; Bone Density; Calcium; Drug Combinations; Female; Humans; | 2005 |
Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis.
Topics: Administration, Oral; Aged; Alendronate; Bone Density; Bone Resorption; Calcium Channel Blockers; Do | 2004 |
Reversal of HIV-1-associated osteoporosis with once-weekly alendronate.
Topics: Alendronate; Bone Density; Combined Modality Therapy; Follow-Up Studies; HIV Infections; HIV-1; Huma | 2005 |
Upper gastrointestinal tolerability of once weekly alendronate 70 mg with concomitant non-steroidal anti-inflammatory drug use.
Topics: Aged; Alendronate; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Drug Therapy, Combi | 2005 |
Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection.
Topics: Absorptiometry, Photon; Adult; Alendronate; Bone Density; Bone Diseases, Metabolic; Calcium; CD4 Lym | 2005 |
Trabecular bone microarchitecture after alendronate treatment of osteoporotic women.
Topics: Aged; Aged, 80 and over; Alendronate; Biopsy; Bone Density; Bone Resorption; Electron Probe Microana | 2005 |
A prospective randomized study for prevention of postrenal transplantation bone loss.
Topics: Adult; Alendronate; Bone Density; Calcitonin; Calcium Carbonate; Humans; Hydroxycholecalciferols; Ki | 2005 |
[Methimazole versus methimazole and diphosphonates in hyperthyroid and osteoporotic patients].
Topics: Aged; Alendronate; Alkaline Phosphatase; Antithyroid Agents; Bone Density; Calcium; Case-Control Stu | 2005 |
Alendronate in combination with calcium and vitamin D prevents bone loss after orthotopic liver transplantation: a prospective single-center study.
Topics: Adult; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; | 2005 |
Longterm reduction of back pain risk in women with osteoporosis treated with teriparatide compared with alendronate.
Topics: Aged; Alendronate; Back Pain; Female; Follow-Up Studies; Humans; Incidence; Middle Aged; Osteoporosi | 2005 |
Therapeutic effects of alendronate 35 mg once weekly and 5 mg once daily in Japanese patients with osteoporosis: a double-blind, randomized study.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone and Bones; Bone Density; Double-Blind Method; Fema | 2005 |
Randomized controlled trial of alendronate in airways disease and low bone mineral density.
Topics: Absorptiometry, Photon; Aged; Alendronate; Asthma; Bone Density; Bone Density Conservation Agents; F | 2004 |
Urinary osteocalcin is a useful marker for monitoring the effect of alendronate therapy.
Topics: Alendronate; Biomarkers; Drug Monitoring; Female; Humans; Immunoassay; Middle Aged; Osteocalcin; Ost | 2005 |
Alendronate for osteoporosis in men with androgen-repleted hypogonadism.
Topics: Adult; Aged; Alendronate; Amino Acids; Androgens; Biomarkers; Bone Density; Bone Density Conservatio | 2005 |
Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients.
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Remo | 2006 |
[A head-to-head comparative study for evaluation of effectiveness among drugs for osteoporosis].
Topics: Aged; Alendronate; Bone and Bones; Bone Density; Bone Density Conservation Agents; Drug Evaluation; | 2006 |
Effects of alendronate on bone mineral density and bone metabolic markers in patients with liver transplantation.
Topics: Absorptiometry, Photon; Adult; Alendronate; Biomarkers; Bone and Bones; Bone Density; Bone Density C | 2006 |
Randomized active and placebo-controlled endoscopy study of a novel protected formulation of oral alendronate.
Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Endoscopy; Esophagus; Female; H | 2006 |
Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Bone Remodeling; Collagen Ty | 2006 |
Efficacy and safety of oral alendronate treatment in children and adolescents with osteoporosis.
Topics: Administration, Oral; Adolescent; Adult; Alendronate; Body Height; Bone Density; Child; Child, Presc | 2006 |
Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Double-Blind Method; Female; Gluc | 2006 |
Bisphosphonate treatment in ochronotic osteoporotic patients.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Female; Femur; | 2007 |
Alendronate with and without cholecalciferol for osteoporosis: results of a 15-week randomized controlled trial.
Topics: Aged; Alendronate; Bone and Bones; Cholecalciferol; Double-Blind Method; Drug Combinations; Female; | 2006 |
Alendronate with and without cholecalciferol for osteoporosis: results of a 15-week randomized controlled trial.
Topics: Aged; Alendronate; Bone and Bones; Cholecalciferol; Double-Blind Method; Drug Combinations; Female; | 2006 |
Alendronate with and without cholecalciferol for osteoporosis: results of a 15-week randomized controlled trial.
Topics: Aged; Alendronate; Bone and Bones; Cholecalciferol; Double-Blind Method; Drug Combinations; Female; | 2006 |
Alendronate with and without cholecalciferol for osteoporosis: results of a 15-week randomized controlled trial.
Topics: Aged; Alendronate; Bone and Bones; Cholecalciferol; Double-Blind Method; Drug Combinations; Female; | 2006 |
Alendronate improves screw fixation in osteoporotic bone.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Screws; C | 2007 |
Comparison of alendronate vs alendronate plus mechanical loading as prophylaxis for osteoporosis in lung transplant recipients: a pilot study.
Topics: Alendronate; Bone Density Conservation Agents; Combined Modality Therapy; Exercise Therapy; Female; | 2007 |
Prevention of glucocorticoid induced osteoporosis with alendronate or alfacalcidol: relations of change in bone mineral density, bone markers, and calcium homeostasis.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone and Bones; Bone Density; Bone Density | 2007 |
Cognitive effects of short-term use of raloxifene: a randomized clinical trial.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Cognition; Educational Status; Female; Humans; | 2007 |
Teriparatide or alendronate in glucocorticoid-induced osteoporosis.
Topics: Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Bo | 2007 |
Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV.
Topics: Absorptiometry, Photon; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Cal | 2007 |
Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV.
Topics: Absorptiometry, Photon; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Cal | 2007 |
Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV.
Topics: Absorptiometry, Photon; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Cal | 2007 |
Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV.
Topics: Absorptiometry, Photon; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Cal | 2007 |
Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV.
Topics: Absorptiometry, Photon; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Cal | 2007 |
Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV.
Topics: Absorptiometry, Photon; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Cal | 2007 |
Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV.
Topics: Absorptiometry, Photon; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Cal | 2007 |
Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV.
Topics: Absorptiometry, Photon; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Cal | 2007 |
Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV.
Topics: Absorptiometry, Photon; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Cal | 2007 |
The effects of daily alendronate, daily calcitonin and alendronate every other day on bone mineral density in osteoporotic men.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Calcitonin; Humans; Male; Middle | 2007 |
Comparison of effects of alendronate and raloxifene on lumbar bone mineral density, bone turnover, and lipid metabolism in elderly women with osteoporosis.
Topics: Aged; Alendronate; Biomarkers; Bone Density; Calcium; Female; Fractures, Bone; Humans; Lipid Metabol | 2008 |
Effect of alendronate on glucocorticoid-induced osteoporosis in Japanese women with systemic autoimmune diseases: versus alfacalcidol.
Topics: Adult; Alendronate; Autoimmune Diseases; Biomarkers; Bone Density; Bone Density Conservation Agents; | 2008 |
Studies of the oral bioavailability of alendronate.
Topics: Achlorhydria; Administration, Oral; Adult; Aged; Alendronate; Analysis of Variance; Beverages; Biolo | 1995 |
Short-term effect of alendronate on bone mass and bone remodeling in postmenopausal women.
Topics: Alendronate; Bone Density; Bone Development; Bone Resorption; Diphosphonates; Dose-Response Relation | 1993 |
New drugs for osteoporosis.
Topics: Administration, Intranasal; Aged; Alendronate; Calcitonin; Calcium; Costs and Cost Analysis; Delayed | 1996 |
Alendronate stimulation of nocturnal parathyroid hormone secretion: a mechanism to explain the continued improvement in bone mineral density accompanying alendronate therapy.
Topics: Aged; Alendronate; Bone Density; Double-Blind Method; Female; Humans; Osteoporosis; Parathyroid Horm | 1996 |
Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Biopsy; Bone and Bones; Bone Remodeling; Calcification, | 1997 |
Prevention of corticosteroid-induced osteoporosis with alendronate in sarcoid patients.
Topics: Absorptiometry, Photon; Adult; Aged; Alendronate; Analysis of Variance; Anti-Inflammatory Agents; Bi | 1997 |
Effectiveness of chronic treatment with alendronate in the osteoporosis of Cushing's disease.
Topics: Acute Disease; Adult; Alendronate; Antifungal Agents; Biomarkers; Bone Density; Collagen; Collagen T | 1998 |
Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group.
Topics: Adolescent; Aged; Aged, 80 and over; Alendronate; Bone Density; Double-Blind Method; Female; Glucoco | 1998 |
Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group.
Topics: Adolescent; Aged; Aged, 80 and over; Alendronate; Bone Density; Double-Blind Method; Female; Glucoco | 1998 |
Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group.
Topics: Adolescent; Aged; Aged, 80 and over; Alendronate; Bone Density; Double-Blind Method; Female; Glucoco | 1998 |
Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group.
Topics: Adolescent; Aged; Aged, 80 and over; Alendronate; Bone Density; Double-Blind Method; Female; Glucoco | 1998 |
Clinical usefulness of bone alkaline phosphatase in osteoporosis.
Topics: Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Biomarkers; Bone and Bones; Bone Density | 1998 |
Alendronate increased bone mineral density but did not reduce new fractures in glucocorticoid induced osteoporosis.
Topics: Alendronate; Bone Density; Etidronic Acid; Female; Fractures, Bone; Glucocorticoids; Humans; Osteopo | 1999 |
Effect of a short-term treatment with alendronate on bone density and bone markers in patients with central diabetes insipidus.
Topics: Adolescent; Adult; Alendronate; Bone and Bones; Bone Density; Bone Diseases; Collagen; Collagen Type | 1999 |
The impact of measurement error on the comparison of two treatments using a responder analysis.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Analysis of Variance; Bone Density; Data | 1999 |
A double-masked multicenter comparative study between alendronate and alfacalcidol in Japanese patients with osteoporosis. The Alendronate Phase III Osteoporosis Treatment Research Group.
Topics: Aged; Alendronate; Biomarkers; Bone Density; Bone Remodeling; Calcium; Double-Blind Method; Humans; | 1999 |
Comparison of biochemical markers of bone remodelling in the assessment of the effects of alendronate on bone in postmenopausal osteoporosis.
Topics: Adult; Aged; Alendronate; Biomarkers; Bone Density; Bone Remodeling; Double-Blind Method; Female; Hu | 1999 |
Evaluation of bone turnover and osteoclastic cytokines in early rheumatoid arthritis treated with alendronate.
Topics: Adult; Alendronate; Antirheumatic Agents; Arthritis, Rheumatoid; beta 2-Microglobulin; Bone and Bone | 1999 |
Effects of alendronate on bone quality and remodeling in glucocorticoid-induced osteoporosis: a histomorphometric analysis of transiliac biopsies.
Topics: Adult; Aged; Alendronate; Bone Density; Bone Remodeling; Calcification, Physiologic; Female; Femur; | 2000 |
Effects of alendronate on bone density in men with primary and secondary osteoporosis.
Topics: Absorptiometry, Photon; Adult; Aged; Aged, 80 and over; Alendronate; Antimetabolites; Bone Density; | 2000 |
Alendronate for the treatment of osteoporosis in men.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Analysis of Variance; Biomarkers; | 2000 |
Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children: a prospective multicenter study.
Topics: Adolescent; Alendronate; Body Height; Bone Density; Child; Child, Preschool; Connective Tissue Disea | 2000 |
A randomized controlled trial to assess alendronate-associated injury of the upper gastrointestinal tract.
Topics: Adult; Alendronate; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dinopros | 2000 |
Does alendronate treatment prevent vertebral fractures in men with osteoporosis?
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Body Height; Bone Density; Calcium; Double-Blind Method | 2000 |
Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism.
Topics: Absorptiometry, Photon; Administration, Oral; Aged; Aged, 80 and over; Alendronate; Alkaline Phospha | 2001 |
Rechallenge of patients who had discontinued alendronate therapy because of upper gastrointestinal symptoms.
Topics: Alendronate; Collagen; Collagen Type I; Digestive System; Double-Blind Method; Female; Humans; Osteo | 2000 |
Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial.
Topics: Adult; Aged; Alendronate; Alkaline Phosphatase; Bone and Bones; Bone Density; Bone Remodeling; Colla | 2001 |
Prevention of bone loss and fracture after lung transplantation: a pilot study.
Topics: Absorptiometry, Photon; Adult; Alendronate; Bone Density; Diphosphonates; Drug Administration Schedu | 2001 |
Alendronate prevents further bone loss in renal transplant recipients.
Topics: Adult; Alendronate; Bone and Bones; Bone Density; Bone Remodeling; Calcitriol; Calcium, Dietary; Fem | 2001 |
Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study.
Topics: Aged; Alendronate; Body Height; Body Mass Index; Fractures, Bone; Humans; Male; Middle Aged; Osteopo | 2001 |
Alendronate for the prevention of bone loss in patients on inhaled steroid therapy.
Topics: Administration, Inhalation; Alendronate; Asthma; Bone Density; Double-Blind Method; Female; Glucocor | 2001 |
The upper GI safety and tolerability of oral alendronate at a dose of 70 milligrams once weekly: a placebo-controlled endoscopy study.
Topics: Administration, Oral; Adult; Aged; Alendronate; Confidence Intervals; Dose-Response Relationship, Dr | 2002 |
Effect of bisphosphonates on cartilage turnover assessed with a newly developed assay for collagen type II degradation products.
Topics: Alendronate; Analysis of Variance; Bone Resorption; Cartilage; Collagen Type I; Collagen Type II; Di | 2002 |
Treatment of osteoporosis and osteopenia in long-term renal transplant patients with alendronate.
Topics: Alendronate; Alkaline Phosphatase; Biomarkers; Bone Density; Bone Diseases, Metabolic; Calcium; Crea | 2002 |
678 other studies available for alendronate and Osteoporosis
| Article | Year |
|---|---|
Synthesis and biological evaluation of prostaglandin-F alkylphosphinic acid derivatives as bone anabolic agents for the treatment of osteoporosis.
Topics: Absorptiometry, Photon; Amino Acid Sequence; Animals; Binding, Competitive; Bone and Bones; Bone Den | 2001 |
Design, Synthesis, and Pharmacokinetics of a Bone-Targeting Dual-Action Prodrug for the Treatment of Osteoporosis.
Topics: Alendronate; Animals; Bone and Bones; Bone Density Conservation Agents; Bone Resorption; Cathepsin K | 2017 |
Fracture rates and economic outcomes in patients with osteoporosis prescribed risedronate gastro-resistant versus other oral bisphosphonates: a claims data analysis.
Topics: Alendronate; Bone Density Conservation Agents; Data Analysis; Diphosphonates; Etidronic Acid; Female | 2022 |
Dnmt3a-mutated clonal hematopoiesis promotes osteoporosis.
Topics: Adult; Aged; Alendronate; Animals; Antibodies, Neutralizing; Cell Differentiation; Clonal Hematopoie | 2021 |
Characterization, pharmacokinetics, and pharmacodynamics of anti-Siglec-15 antibody and its potency for treating osteoporosis and as follow-up treatment after parathyroid hormone use.
Topics: Alendronate; Animals; Bone Density; Bone Resorption; Female; Follow-Up Studies; Humans; Immunoglobul | 2022 |
AGN1 implant material to treat bone loss: Resorbable implant forms normal bone with and without alendronate in a canine critical size humeral defect model.
Topics: Alendronate; Animals; Dogs; Humerus; Male; Osteogenesis; Osteoporosis; Prostheses and Implants | 2022 |
Alendronate Use and Risk of Type 2 Diabetes: A Nationwide Danish Nested Case-Control Study.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Case-Control Studies; Denmar | 2021 |
Efficacy of once-weekly teriparatide for primary prevention of glucocorticoid-induced osteoporosis: A post hoc analysis of the TOWER-GO study.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Glucocorticoids; Humans; Osteoporosis; | 2022 |
Analysis of the Efficacy and Safety of Teriparatide and Alendronate in the Treatment of Osteoporosis After Renal Transplantation.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Female; Humans; Kidney Transplantation; | 2021 |
Alendronate-Decorated Nanoparticles as Bone-Targeted Alendronate Carriers for Potential Osteoporosis Treatment.
Topics: Alendronate; Alginates; Animals; beta-Cyclodextrins; Bone and Bones; Bone Density Conservation Agent | 2021 |
Comparative Fracture Risk During Osteoporosis Drug Holidays After Long-Term Risedronate Versus Alendronate Therapy : A Propensity Score-Matched Cohort Study.
Topics: Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Canada; Cohort Studies; Female; Hu | 2022 |
The clinical utility of TRACP-5b to monitor anti-resorptive treatments of osteoporosis.
Topics: Aged; Alendronate; Biomarkers; Bone Density; Denosumab; Female; Humans; Male; Osteoporosis; Tartrate | 2022 |
Knowledge and compliance towards alendronate therapy among postmenopausal women with osteoporosis in Palestine.
Topics: Alendronate; Bone Density Conservation Agents; Cross-Sectional Studies; Female; Humans; Osteoporosis | 2022 |
Association Between Antiosteoporotic Drugs and Risk of Acute Kidney Injury: A Cross-Sectional Study Using Disproportional Analysis and a Pharmacovigilance Database.
Topics: Acute Kidney Injury; Adverse Drug Reaction Reporting Systems; Alendronate; Cross-Sectional Studies; | 2022 |
Dispensing anti-osteoporotic drugs changed during the COVID-19 pandemic.
Topics: Alendronate; Bone Density Conservation Agents; Communicable Disease Control; COVID-19 Drug Treatment | 2022 |
Patterns of Osteoporosis Medications Selection After Drug Holiday or Continued Therapy: A Real-World Experience.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Humans; Iban | 2022 |
Treatment patterns of long-dose-interval medication for persistent management of osteoporosis in Taiwan.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Denosumab; Female; Humans; Ibandronic Acid; Mal | 2022 |
Alendronate modified mPEG-PLGA nano-micelle drug delivery system loaded with astragaloside has anti-osteoporotic effect in rats.
Topics: Alendronate; Animals; Delayed-Action Preparations; Drug Carriers; Micelles; Nanoparticle Drug Delive | 2022 |
Pharmacological and Non-Pharmacological Agents versus Bovine Colostrum Supplementation for the Management of Bone Health Using an Osteoporosis-Induced Rat Model.
Topics: Alendronate; Animals; Body Weight; Bone Density; Cattle; Colostrum; Dietary Supplements; Female; Hum | 2022 |
Changes in osteoporosis therapy in postmenopausal women from the RAC‑OST‑POL study: a 10‑year follow‑up.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Calcium; Female; Follow-Up Studie | 2022 |
Modified Alendronate Mitigates Mechanical Degradation of the Rotator Cuff in an Osteoporotic Ovine Model.
Topics: Alendronate; Animals; Osteoporosis; Rotator Cuff; Rotator Cuff Injuries; Sheep; X-Ray Microtomograph | 2022 |
The Nutraceutical Genistein-Lycopene Combination Improves Bone Damage Induced by Glucocorticoids by Stimulating the Osteoblast Formation Process.
Topics: Alendronate; Animals; Antioxidants; beta Catenin; Bone Density; Core Binding Factor Alpha 1 Subunit; | 2022 |
Effect of
Topics: Alendronate; Animals; Anti-Inflammatory Agents; Bone Resorption; Cell Differentiation; Estradiol; Es | 2022 |
Bone-targeting delivery of platelet lysate exosomes ameliorates glucocorticoid-induced osteoporosis by enhancing bone-vessel coupling.
Topics: Alendronate; Exosomes; Glucocorticoids; Humans; Mesenchymal Stem Cells; Osteogenesis; Osteoporosis | 2022 |
Comparisons Between Different Anti-osteoporosis Medications on Postfracture Mortality: A Population-Based Study.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Cohort Studies; Female; Humans; Male; Osteoporo | 2023 |
Acceptability and engagement amongst patients on oral and intravenous bisphosphonates for the treatment of osteoporosis in older adults.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Bone; Humans | 2022 |
Acceptability and engagement amongst patients on oral and intravenous bisphosphonates for the treatment of osteoporosis in older adults.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Bone; Humans | 2022 |
Acceptability and engagement amongst patients on oral and intravenous bisphosphonates for the treatment of osteoporosis in older adults.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Bone; Humans | 2022 |
Acceptability and engagement amongst patients on oral and intravenous bisphosphonates for the treatment of osteoporosis in older adults.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Bone; Humans | 2022 |
Acceptability and engagement amongst patients on oral and intravenous bisphosphonates for the treatment of osteoporosis in older adults.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Bone; Humans | 2022 |
Acceptability and engagement amongst patients on oral and intravenous bisphosphonates for the treatment of osteoporosis in older adults.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Bone; Humans | 2022 |
Acceptability and engagement amongst patients on oral and intravenous bisphosphonates for the treatment of osteoporosis in older adults.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Bone; Humans | 2022 |
Acceptability and engagement amongst patients on oral and intravenous bisphosphonates for the treatment of osteoporosis in older adults.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Bone; Humans | 2022 |
Acceptability and engagement amongst patients on oral and intravenous bisphosphonates for the treatment of osteoporosis in older adults.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Bone; Humans | 2022 |
Dual Modification of Porous Ca-P/PLA Composites with APTES and Alendronate Improves Their Mechanical Strength and Cytobiocompatibility towards Human Osteoblasts.
Topics: Alendronate; Humans; Osteoblasts; Osteoporosis; Polyesters; Porosity; Silanes | 2022 |
Dual Modification of Porous Ca-P/PLA Composites with APTES and Alendronate Improves Their Mechanical Strength and Cytobiocompatibility towards Human Osteoblasts.
Topics: Alendronate; Humans; Osteoblasts; Osteoporosis; Polyesters; Porosity; Silanes | 2022 |
Dual Modification of Porous Ca-P/PLA Composites with APTES and Alendronate Improves Their Mechanical Strength and Cytobiocompatibility towards Human Osteoblasts.
Topics: Alendronate; Humans; Osteoblasts; Osteoporosis; Polyesters; Porosity; Silanes | 2022 |
Dual Modification of Porous Ca-P/PLA Composites with APTES and Alendronate Improves Their Mechanical Strength and Cytobiocompatibility towards Human Osteoblasts.
Topics: Alendronate; Humans; Osteoblasts; Osteoporosis; Polyesters; Porosity; Silanes | 2022 |
Dual Modification of Porous Ca-P/PLA Composites with APTES and Alendronate Improves Their Mechanical Strength and Cytobiocompatibility towards Human Osteoblasts.
Topics: Alendronate; Humans; Osteoblasts; Osteoporosis; Polyesters; Porosity; Silanes | 2022 |
Dual Modification of Porous Ca-P/PLA Composites with APTES and Alendronate Improves Their Mechanical Strength and Cytobiocompatibility towards Human Osteoblasts.
Topics: Alendronate; Humans; Osteoblasts; Osteoporosis; Polyesters; Porosity; Silanes | 2022 |
Dual Modification of Porous Ca-P/PLA Composites with APTES and Alendronate Improves Their Mechanical Strength and Cytobiocompatibility towards Human Osteoblasts.
Topics: Alendronate; Humans; Osteoblasts; Osteoporosis; Polyesters; Porosity; Silanes | 2022 |
Dual Modification of Porous Ca-P/PLA Composites with APTES and Alendronate Improves Their Mechanical Strength and Cytobiocompatibility towards Human Osteoblasts.
Topics: Alendronate; Humans; Osteoblasts; Osteoporosis; Polyesters; Porosity; Silanes | 2022 |
Dual Modification of Porous Ca-P/PLA Composites with APTES and Alendronate Improves Their Mechanical Strength and Cytobiocompatibility towards Human Osteoblasts.
Topics: Alendronate; Humans; Osteoblasts; Osteoporosis; Polyesters; Porosity; Silanes | 2022 |
The combination of olive oil and Lepidium sativum improves the deleterious effects resulting from dexamethasone-induced osteoporosis in rats.
Topics: Alendronate; Animals; Dexamethasone; Lepidium sativum; Olive Oil; Osteocalcin; Osteopontin; Osteopor | 2022 |
The combination of olive oil and Lepidium sativum improves the deleterious effects resulting from dexamethasone-induced osteoporosis in rats.
Topics: Alendronate; Animals; Dexamethasone; Lepidium sativum; Olive Oil; Osteocalcin; Osteopontin; Osteopor | 2022 |
The combination of olive oil and Lepidium sativum improves the deleterious effects resulting from dexamethasone-induced osteoporosis in rats.
Topics: Alendronate; Animals; Dexamethasone; Lepidium sativum; Olive Oil; Osteocalcin; Osteopontin; Osteopor | 2022 |
The combination of olive oil and Lepidium sativum improves the deleterious effects resulting from dexamethasone-induced osteoporosis in rats.
Topics: Alendronate; Animals; Dexamethasone; Lepidium sativum; Olive Oil; Osteocalcin; Osteopontin; Osteopor | 2022 |
The combination of olive oil and Lepidium sativum improves the deleterious effects resulting from dexamethasone-induced osteoporosis in rats.
Topics: Alendronate; Animals; Dexamethasone; Lepidium sativum; Olive Oil; Osteocalcin; Osteopontin; Osteopor | 2022 |
The combination of olive oil and Lepidium sativum improves the deleterious effects resulting from dexamethasone-induced osteoporosis in rats.
Topics: Alendronate; Animals; Dexamethasone; Lepidium sativum; Olive Oil; Osteocalcin; Osteopontin; Osteopor | 2022 |
The combination of olive oil and Lepidium sativum improves the deleterious effects resulting from dexamethasone-induced osteoporosis in rats.
Topics: Alendronate; Animals; Dexamethasone; Lepidium sativum; Olive Oil; Osteocalcin; Osteopontin; Osteopor | 2022 |
The combination of olive oil and Lepidium sativum improves the deleterious effects resulting from dexamethasone-induced osteoporosis in rats.
Topics: Alendronate; Animals; Dexamethasone; Lepidium sativum; Olive Oil; Osteocalcin; Osteopontin; Osteopor | 2022 |
The combination of olive oil and Lepidium sativum improves the deleterious effects resulting from dexamethasone-induced osteoporosis in rats.
Topics: Alendronate; Animals; Dexamethasone; Lepidium sativum; Olive Oil; Osteocalcin; Osteopontin; Osteopor | 2022 |
Cardiac adverse events in bisphosphonate and teriparatide users: An international pharmacovigilance study.
Topics: Alendronate; Bone Density Conservation Agents; Coronary Artery Disease; Diphosphonates; DNA-Binding | 2023 |
Fabrication, assessment, and optimization of alendronate sodium nanoemulsion-based injectable
Topics: Alendronate; Animals; Emulsions; Osteoporosis; Rats; Water | 2023 |
Sequential treatment of teriparatide and alendronate versus alendronate alone for elevation of bone mineral density and prevention of refracture after percutaneous vertebroplasty in osteoporosis: a prospective study.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Female; Fractures, Compression; Humans; | 2023 |
Multifunctional Scaffold for Osteoporotic Pathophysiological Microenvironment Improvement and Vascularized Bone Defect Regeneration.
Topics: Alendronate; Animals; Biocompatible Materials; Bone Regeneration; Osteoclasts; Osteogenesis; Osteopo | 2023 |
Quercetin potentiates the anti-osteoporotic effects of alendronate through modulation of autophagy and apoptosis mechanisms in ovariectomy-induced bone loss rat model.
Topics: Alendronate; Animals; Bone Density; Bone Diseases, Metabolic; Female; Humans; Osteoporosis; Ovariect | 2023 |
Influence of the Osteogenomic Profile in Response to Alendronate Therapy in Postmenopausal Women with Osteoporosis: A Retrospective Cohort Study.
Topics: Alendronate; Bone Density Conservation Agents; Female; Humans; Lumbar Vertebrae; Osteoporosis; Postm | 2023 |
Fracture risk in women with osteoporosis initiated on gastro-resistant risedronate versus immediate release risedronate or alendronate: a claims data analysis in the USA.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Fractures, Bo | 2023 |
Orbital myositis induced by alendronate: A case report.
Topics: Aged; Alendronate; Diphosphonates; Female; Humans; Orbital Myositis; Osteoporosis; Prednisone | 2023 |
Cost-Effectiveness of Sequential Abaloparatide/Alendronate in Men at High Risk of Fractures in the United States.
Topics: Alendronate; Bone Density Conservation Agents; Cost-Benefit Analysis; Female; Humans; Male; Middle A | 2023 |
Comparability of Osteoporosis Treatment Groups Among Female Medicare Beneficiaries in the United States.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Fractures, B | 2023 |
The administration of bovine hydroxyapatite-alendronate implant accelerates bone defect healing in an osteoporotic rat.
Topics: Alendronate; Animals; Cattle; Durapatite; Female; Osteoporosis; Rats; Rats, Wistar; Vascular Endothe | 2023 |
Influence of bisphosphonate treatment on bone substitute performance in osteoporotic conditions.
Topics: Alendronate; Animals; Bone Regeneration; Bone Substitutes; Diphosphonates; Male; Osteoporosis; Rats; | 2023 |
Zoledronate and osteonecrosis of the jaw in osteoporosis: incidence and risk factors. Analysis of the French Pharmacovigilance Database.
Topics: Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; D | 2023 |
Constraining in reimbursement criteria and the adherence to anti-osteoporosis medications (AOMs) in Taiwan: Urbanization makes the difference.
Topics: Alendronate; Bone Density Conservation Agents; Humans; Ibandronic Acid; Osteoporosis; Taiwan; Urbani | 2023 |
Eleven years secular trend of the initiation of anti-osteoporosis medications and subsequent fractures in Taiwan: From 2008 to 2018.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Female; Fractures, Bone; Humans; Male; Osteopor | 2023 |
The real-world adherence of the first-line anti-osteoporosis medications in Taiwan: Visualize the gap between reality and expectations.
Topics: Alendronate; Bone Density Conservation Agents; Cohort Studies; Denosumab; Humans; Medication Adheren | 2023 |
Atypical femur fracture associated with common anti-osteoporosis drugs in FDA adverse event reporting system.
Topics: Alendronate; Bone Density Conservation Agents; Denosumab; Diphosphonates; Femur; Humans; Ibandronic | 2023 |
Drug utilization analysis of osteoporosis medications in seven European electronic health databases.
Topics: Adult; Alendronate; Bone Density Conservation Agents; Cohort Studies; Denosumab; Diphosphonates; Dru | 2023 |
Economic evaluation of four treatment strategies for postmenopausal patients with osteoporosis and a recent fracture in mainland China: a cost-effectiveness analysis.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Cost-Benefit Analysis; Cost-Effectiveness Analy | 2023 |
Comparison of anti-fracture effectiveness of zoledronate, ibandronate and alendronate versus denosumab in a registry-based cohort study.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Cohort Studies; Denosumab; Diphosphonates; Fema | 2023 |
Novel iontophoretic drug delivery of estradiol with alendronate for osteoporosis treatment.
Topics: Administration, Cutaneous; Alendronate; Animals; Drug Delivery Systems; Iontophoresis; Osteoporosis; | 2023 |
Clinicians' views of prescribing oral and intravenous bisphosphonates for osteoporosis: a qualitative study.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Ibandronic Acid; Oste | 2023 |
A Case Report of Oral Bisphosphonate Treatment for Osteoporosis Leading to Atypical Femoral Fracture and Pathologic Mandibular Fracture.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Femoral Fractures; Fractures, | 2023 |
Efficacy and Safety of Oral Alendronate Treatment in Children and Adolescents with Osteoporosis.
Topics: Adolescent; Alendronate; Child; Humans; Osteoporosis | 2006 |
An osteoporosis bone defect regeneration strategy via three-dimension short fibers loaded with alendronate modified hydroxyapatite.
Topics: Alendronate; Bone Regeneration; Bone Resorption; Durapatite; Humans; Osteogenesis; Osteoporosis; Pol | 2024 |
Review: Long-term alendronate or zoledronic acid reduces fractures in postmenopausal women with osteoporosis.
Topics: Alendronate; Female; Holidays; Humans; Osteoporosis; Postmenopause; Zoledronic Acid | 2019 |
Secondary Fracture Prevention: Consensus Clinical Recommendations from a Multistakeholder Coalition.
Topics: Alendronate; Bone Density Conservation Agents; Consensus; Diphosphonates; Humans; Osteoporosis; Oste | 2020 |
Effect of continuous long-term treatment for 10 years with bisphosphonate on Japanese osteoporosis patients.
Topics: Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Asian People; Bone Density; Calcium; Col | 2020 |
Osteoanabolics Versus Antiresorptives: Which First?
Topics: Alendronate; Female; Humans; Osteoporosis; Parathyroid Hormone-Related Protein; Postmenopause; Risk | 2020 |
Osteoporosis Management.
Topics: Alendronate; Anorexia Nervosa; Bone and Bones; Bone Density Conservation Agents; Contraceptives, Ora | 2020 |
Novel combinatorial transdermal drug delivery of alendronate with risedronate for the treatment of osteoporosis.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Calcium; Drug Delivery Systems; Drug Therapy | 2019 |
Icariin reduces bone loss in a Rankl-induced transgenic medaka (Oryzias latipes) model for osteoporosis.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Disease Models, Animal; Etidronic Acid; Fish | 2021 |
Transient increase in international normalized ratio (INR) and bleeding risk following Alendronate sodium in elderly patients on warfarin: Two case reports.
Topics: Aged; Aged, 80 and over; Alendronate; Anticoagulants; Atrial Fibrillation; Bone Density Conservation | 2020 |
Which Drug Next? Sequential Therapy for Osteoporosis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Denosumab; Diphosphonates; Humans; Oste | 2020 |
Cost-effectiveness of five versus ten years of alendronate treatment prior to drug holiday for women with osteoporosis.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cost-Benefit Analysis; Femal | 2020 |
Is Bone Nonunion, Vertebral Deformity, or Spinopelvic Malalignment the Best Therapeutic Target for Amelioration of Low Back Pain After Osteoporotic Vertebral Fracture?
Topics: Aged; Aged, 80 and over; Alendronate; Cohort Studies; Conservative Treatment; Female; Humans; Kyphos | 2020 |
Siglec-15-targeting therapy protects against glucocorticoid-induced osteoporosis of growing skeleton in juvenile rats.
Topics: Alendronate; Animals; Bone and Bones; Bone Resorption; Glucocorticoids; Humans; Osteoporosis; Rats; | 2020 |
Alendronate medication possession ratio and the risk of second hip fracture: an 11-year population-based cohort study in Taiwan.
Topics: Alendronate; Bone Density Conservation Agents; Cohort Studies; Female; Hip Fractures; Humans; Osteop | 2020 |
Practical guidance for the use of bisphosphonates in osteoporosis.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Humans; M | 2020 |
Hybrid particles derived from alendronate and bioactive glass for treatment of osteoporotic bone defects.
Topics: Alendronate; Biocompatible Materials; Bone Density Conservation Agents; Bone Regeneration; Bone Subs | 2019 |
Long-term delivery of alendronate through an injectable tetra-PEG hydrogel to promote osteoporosis therapy.
Topics: Alendronate; Animals; Biocompatible Materials; Bone Density Conservation Agents; Cell Survival; Drug | 2020 |
Preliminary study on the electromagnetic field treatment of osteoporosis in rats.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Disease Models, Animal; Female | 2020 |
Alendronate or Zoledronic acid do not impair wound healing after tooth extraction in postmenopausal women with osteoporosis.
Topics: Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; D | 2020 |
Sustained delivery of alendronate by engineered collagen scaffold for the repair of osteoporotic bone defects and resistance to bone loss.
Topics: Alendronate; Animals; Collagen; Delayed-Action Preparations; Female; Osteoblasts; Osteoporosis; Ovar | 2020 |
Ultrasound-assisted transdermal delivery of alendronate for the treatment of osteoporosis.
Topics: Administration, Cutaneous; Alendronate; Animals; Biological Availability; Bone Density Conservation | 2020 |
Phosphatidylserine nanoliposomes inhibit glucocorticoid-induced osteoporosis: A potential combination therapy with alendronate.
Topics: Alendronate; Animals; Bone and Bones; Bone Density; Bone Density Conservation Agents; Disease Models | 2020 |
Comparative safety and effectiveness of alendronate versus raloxifene in women with osteoporosis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Female; Follow-Up Studies; Humans; Midd | 2020 |
Prevention of bone loss and improvement of pain-related behavior in hind limb-unloaded mice by administration of teriparatide and bisphosphonate.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Hindli | 2021 |
Abaloparatide followed by alendronate in women ≥80 years with osteoporosis: post hoc analysis of ACTIVExtend.
Topics: Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Double-Blind Method; | 2020 |
Upper gastrointestinal safety of oral bisphosphonate in hospitalized patients.
Topics: Administration, Oral; Adult; Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Hu | 2021 |
Oral bisphosphonate treatment in patients with Duchenne muscular dystrophy on long term glucocorticoid therapy.
Topics: Absorptiometry, Photon; Adolescent; Alendronate; Bone Density; Bone Density Conservation Agents; Chi | 2020 |
Fructus Ligustri Lucidi preserves bone quality through induction of canonical Wnt/β-catenin signaling pathway in ovariectomized rats.
Topics: Alendronate; Animals; Bone and Bones; Bone Density; Bone Morphogenetic Proteins; Drugs, Chinese Herb | 2021 |
Severe hypophosphataemia following oral bisphosphonate treatment in a patient with osteoporosis.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Calcium; Diagnosis, Differential; Diphosphonate | 2020 |
Prevalence of Periapical Lesions in Patients with Osteoporosis.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Osteoporosis; Prevale | 2021 |
Once-weekly parathyroid hormone combined with ongoing long-term alendronate treatment promotes osteoporotic fracture healing in ovariectomized rats.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Female; Fracture Healing; Oste | 2021 |
Effect of alendronate on the femoral metaphyseal defect under carbamazepine in ovariectomized rats.
Topics: Alendronate; Animals; Anticonvulsants; Bone Density Conservation Agents; Bone Regeneration; Carbamaz | 2021 |
Cost-effectiveness of romosozumab for the treatment of postmenopausal women with severe osteoporosis at high risk of fracture in Sweden.
Topics: Aged; Aged, 80 and over; Alendronate; Antibodies, Monoclonal; Bone Density Conservation Agents; Cost | 2021 |
Over half of seniors who start oral bisphosphonate therapy are exposed for 3 or more years: novel rolling window approach and patterns of use.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Male; Medication Adhe | 2021 |
Intramedullary injury combined with osteoporosis therapeutics regulates targeted local osteogenesis.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Marrow; Bone Regeneration; Calcium-Regu | 2021 |
A novel effervescent formulation of oral weekly alendronate (70 mg) improves persistence compared to alendronate tablets in post-menopausal women with osteoporosis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Female; Humans; Osteoporosis; Osteoporo | 2021 |
Effects of Bisphosphonates on Osteoporosis Induced by Duchenne Muscular Dystrophy: A Prospective Study.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Child; Diphosphonates; Female; Humans; | 2020 |
An Uncommon Cause of Debilitating Hip Pain in Pregnancy.
Topics: Adult; Alendronate; Arthralgia; Bed Rest; Bone Density Conservation Agents; Crutches; Female; Hip; H | 2021 |
Matrix metalloproteinase 9 a potential major player connecting atherosclerosis and osteoporosis in high fat diet fed rats.
Topics: Alendronate; Alkaline Phosphatase; Animals; Atherosclerosis; Biomarkers; Bone Density; Bone Remodeli | 2021 |
An Ammonia-Induced Calcium Phosphate Nanostructure: A Potential Assay for Studying Osteoporosis and Bone Metastasis.
Topics: Alendronate; Ammonia; Animals; Bone and Bones; Calcium Phosphates; Cell Differentiation; Drug Carrie | 2021 |
[Romosozumab : a new treatment for severe osteoporosis].
Topics: Alendronate; Antibodies, Monoclonal; Bone Density; Bone Density Conservation Agents; Humans; Osteopo | 2021 |
Bone targeting nanocarrier-assisted delivery of adenosine to combat osteoporotic bone loss.
Topics: Adenosine; Alendronate; Animals; Bone and Bones; Bone Density; Bone Density Conservation Agents; Fem | 2021 |
Secular Trends in the Pharmacologic Treatment of Osteoporosis and Malignancy-Related Bone Disease from 2009 to 2020.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Cohort Studies; Denosumab; Female; Humans; Male | 2022 |
Coordination Compounds As Multi-Delivery Systems for Osteoporosis.
Topics: Alendronate; Bone Density Conservation Agents; Coordination Complexes; Drug Liberation; Drug Therapy | 2021 |
Investigating the Preventive Effects of 99Tc-Methylenediphosphonate on a Glucocorticoid-Induced Osteoporosis Rabbit Model.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Calcium Carbonate; Diphosphonates; Disease M | 2021 |
Fabrication of Membrane Sensitive Electrodes for the Validated Electrochemical Quantification of Anti-Osteoporotic Drug Residues in Pharmaceutical Industrial Wastewater.
Topics: Alendronate; Carbon; Drug Industry; Drug Residues; Electrochemical Techniques; Electrodes; Glass; Hy | 2021 |
Raloxifene but not alendronate can compensate the impaired osseointegration in osteoporotic rats.
Topics: Alendronate; Animals; Bone Density; Dental Implants; Disease Models, Animal; Female; Immunoenzyme Te | 2018 |
Effects of alendronate on osteoporosis treatment and levels of related cytokines.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Morphogenetic Protein 2; Cytokines; Dis | 2017 |
Cessation rate of anti-osteoporosis treatments and risk factors in Spanish primary care settings: a population-based cohort analysis.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Cohort Studies; Denosumab; Female; Fractures, B | 2017 |
Effect of health literacy on adherence to osteoporosis treatment among patients with distal radius fracture.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Comorbidity; Female; Health | 2017 |
Evaluation of the Effects of Photobiomodulation on Biomechanical Properties and Hounsfield Unit of Partial Osteotomy Healing in an Experimental Rat Model of Type I Diabetes and Osteoporosis.
Topics: Alendronate; Animals; Biomechanical Phenomena; Blood Glucose; Diabetes Mellitus, Type 1; Disease Mod | 2017 |
Changes in blood and urinary cadmium levels and bone mineral density according to osteoporosis medication in individuals with an increased cadmium body burden.
Topics: Absorptiometry, Photon; Aged; Alendronate; Body Burden; Bone Density; Bone Density Conservation Agen | 2018 |
Surgically treated osteonecrosis and osteomyelitis of the jaw and oral cavity in patients highly adherent to alendronate treatment: a nationwide user-only cohort study including over 60,000 alendronate users.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bisphosphonate-Associated Osteonecrosis | 2017 |
Phosphate functionalized (4,4)-armchair CNTs as novel drug delivery systems for alendronate and etidronate anti-osteoporosis drugs.
Topics: Alendronate; Drug Carriers; Drug Delivery Systems; Durapatite; Etidronic Acid; Osteoporosis; Phospha | 2017 |
Low Doses of Simvastatin Potentiate the Effect of Sodium Alendronate in Inhibiting Bone Resorption and Restore Microstructural and Mechanical Bone Properties in Glucocorticoid-Induced Osteoporosis.
Topics: Alendronate; Alkaline Phosphatase; Animals; Bone and Bones; Bone Density; Bone Density Conservation | 2017 |
[BISPHOSPHONATES AS A PREVENTATIVE TREATMENT FOR OSTEOPOROTIC HIP FRACTURES: A MIXED BLESSING].
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Femoral Fractures; Hip | 2017 |
Effects of combination treatment with alendronate and raloxifene on skeletal properties in a beagle dog model.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Diaphyses; Do | 2017 |
Risk of long-term infection-related death in clinical osteoporotic vertebral fractures: A hospital-based analysis.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Cross Infection; Female; Humans; Male; Osteopor | 2017 |
[Effect of Er-xian decoction on femur proteomics in ovariectomized osteoporosis rats].
Topics: Alendronate; Animals; Bone Density; Drugs, Chinese Herbal; Female; Femur; Osteoporosis; Ovariectomy; | 2017 |
Effect of in vivo low-level laser therapy on bone marrow-derived mesenchymal stem cells in ovariectomy-induced osteoporosis of rats.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Marrow Cells; Calcium; Cell Differentia | 2017 |
Promotion effect of extracts from plastrum testudinis on alendronate against glucocorticoid-induced osteoporosis in rat spine.
Topics: Alendronate; Animals; Biomarkers; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bo | 2017 |
Weekly oral bisphosphonates over 2 years prevent bone loss in cardiac transplant patients.
Topics: Alendronate; Bone Density Conservation Agents; Bone Diseases, Metabolic; Diphosphonates; Female; Fol | 2017 |
Bone diseases: Romosozumab - on track or derailed?
Topics: Alendronate; Antibodies, Monoclonal; Female; Fractures, Bone; Humans; Osteoporosis | 2017 |
The emperor redressed: treating osteoporosis to prevent hip fractures in the oldest old.
Topics: Aged, 80 and over; Alendronate; Hip Fractures; Humans; Osteoporosis | 2017 |
Alendronate-loaded, biodegradable smart hydrogel: a promising injectable depot formulation for osteoporosis.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Calorimetry, Differential Scanning; Chemistr | 2018 |
Alendronate Use and the Risk of Nonvertebral Fracture During Glucocorticoid Therapy: A Retrospective Cohort Study.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Female; Follow-Up Studies; Glucocorticoids; Hip | 2018 |
Management of Corticosteroid-Induced Osteoporosis: A Practical Approach for the Dermatologist.
Topics: Adrenal Cortex Hormones; Adult; Alendronate; Bone Density; Bone Density Conservation Agents; Calcium | 2018 |
Effect of Alendronate on Bone Microarchitecture in Irradiated Rats With Osteoporosis: Micro-CT and Histomorphometric Analysis.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Female; Osteoporosis; Ovariect | 2018 |
Effects of alendronate and alfacalcidol on bone in patients with myasthenia gravis initiating glucocorticoids treatment.
Topics: Aged; Alendronate; Asian People; Bone and Bones; Bone Density; Bone Remodeling; Drug Therapy, Combin | 2018 |
Novel and rapid osteoporosis model established in zebrafish using high iron stress.
Topics: Alendronate; Animals; Bone and Bones; Bone Density Conservation Agents; Calcification, Physiologic; | 2018 |
Romosozumab versus Alendronate and Fracture Risk in Women with Osteoporosis.
Topics: Alendronate; Antibodies, Monoclonal; Bone Density; Bone Density Conservation Agents; Female; Fractur | 2018 |
Romosozumab versus Alendronate and Fracture Risk in Women with Osteoporosis.
Topics: Alendronate; Antibodies, Monoclonal; Female; Fractures, Bone; Humans; Osteoporosis | 2018 |
Romosozumab versus Alendronate and Fracture Risk in Women with Osteoporosis.
Topics: Alendronate; Antibodies, Monoclonal; Female; Fractures, Bone; Humans; Osteoporosis | 2018 |
Romosozumab versus Alendronate and Fracture Risk in Women with Osteoporosis.
Topics: Alendronate; Antibodies, Monoclonal; Female; Fractures, Bone; Humans; Osteoporosis | 2018 |
Osteoporosis: Romosozumab to rebuild the foundations of bone strength.
Topics: Alendronate; Antibodies, Monoclonal; Female; Fractures, Bone; Humans; Osteoporosis | 2018 |
Preventing muscle wasting by osteoporosis drug alendronate in vitro and in myopathy models via sirtuin-3 down-regulation.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Animals; Bone Density Conservation Agents; Cells, Cultu | 2018 |
A Perfectly Avoidable Crisis.
Topics: Alendronate; Bone Density Conservation Agents; Female; Fractures, Bone; Humans; Middle Aged; Osteopo | 2018 |
Alendronate induces osteoclast precursor apoptosis via peroxisomal dysfunction mediated ER stress.
Topics: Alendronate; Animals; Apoptosis; Becaplermin; Cell Count; Cell Cycle Checkpoints; Endoplasmic Reticu | 2018 |
Combined effects of photobiomodulation and alendronate on viability of osteoporotic bone marrow-derived mesenchymal stem cells.
Topics: Alendronate; Animals; Bone Marrow Cells; Cell Differentiation; Cell Survival; Female; Lasers; Mesenc | 2018 |
The influence of alendronate and tooth extraction on the incidence of osteonecrosis of the jaw among osteoporotic subjects.
Topics: Aged; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Age | 2018 |
In silico estrogen-like activity and in vivo osteoclastogenesis inhibitory effect of Cicer arietinum extract.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Calcium-Binding Proteins; Cicer; Disease Mod | 2018 |
Association of Alendronate and Risk of Cardiovascular Events in Patients With Hip Fracture.
Topics: Aged; Aged, 80 and over; Alendronate; Cardiovascular Diseases; Cause of Death; Female; Hip Fractures | 2018 |
Quality by design approach to optimize the formulation variables influencing the characteristics of biodegradable intramuscular in-situ gel loaded with alendronate sodium for osteoporosis.
Topics: Alendronate; Animals; Biological Availability; Chemistry, Pharmaceutical; Delayed-Action Preparation | 2018 |
Effects of strontium ranelate on wear particle‑induced aseptic loosening in female ovariectomized mice.
Topics: Aged; Alendronate; Animals; Core Binding Factor Alpha 1 Subunit; Disease Models, Animal; Female; Hum | 2018 |
Early use of alendronate as a protective factor against the development of glucocorticoid-induced bone loss in childhood-onset rheumatic diseases: a cross-sectional study.
Topics: Adolescent; Adult; Alendronate; Bone Density; Bone Density Conservation Agents; Child; Cross-Section | 2018 |
Effects of osteoporosis drug treatments on cortical and trabecular bone in the femur using DXA-based 3D modeling.
Topics: Absorptiometry, Photon; Adult; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Ca | 2018 |
Positive effect of alendronate on bone turnover in ovariectomised rats' osteoporosis: comparison of transdermal lipid-based delivery with conventional oral administration.
Topics: Absorptiometry, Photon; Administration, Cutaneous; Administration, Oral; Alendronate; Animals; Bone | 2018 |
[The efficacy of intravenous alendronate for osteoporosis in patients with severe motor intellectual disabilities].
Topics: Adult; Alendronate; Bone Density Conservation Agents; Female; Humans; Infusions, Intravenous; Intell | 2017 |
Alendronate release from calcium phosphate cement for bone regeneration in osteoporotic conditions.
Topics: Alendronate; Animals; Bone Cements; Bone Density Conservation Agents; Bone Regeneration; Calcium Pho | 2018 |
Decreased microRNA-182-5p helps alendronate promote osteoblast proliferation and differentiation in osteoporosis via the Rap1/MAPK pathway.
Topics: Adenylyl Cyclases; Alendronate; Animals; Butadienes; Cell Differentiation; Cell Proliferation; Gene | 2018 |
The effects of bisphosphonate on pain-related behavior and immunohistochemical analyses in hindlimb-unloaded mice.
Topics: Alendronate; Animals; Behavior, Animal; Bone Density Conservation Agents; Disease Models, Animal; Hi | 2018 |
Mortality risk reduction differs according to bisphosphonate class: a 15-year observational study.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Canada; Diphosphonates; Etidronic Acid; Female; | 2019 |
Symptoms and Upper Gastrointestinal Mucosal Injury Associated with Bisphosphonate Therapy.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Female; Gastrointesti | 2019 |
Interleukin-6 Inhibitor Suppresses Hyperalgesia Without Improvement in Osteoporosis in a Mouse Pain Model of Osteoporosis.
Topics: Alendronate; Animals; Antibodies; Behavior, Animal; Bone Density Conservation Agents; Combined Modal | 2019 |
Preventative effects of metformin on glucocorticoid-induced osteoporosis in rats.
Topics: Alendronate; Animals; Blood Glucose; Body Weight; Bone Density; Female; Femur; Glucocorticoids; Lipi | 2019 |
Melatonin supports alendronate in preserving bone matrix and prevents gastric inflammation in ovariectomized rats.
Topics: Alendronate; Animals; Bone Matrix; Female; Gastritis; Inflammation; Melatonin; Osteoporosis; Ovariec | 2019 |
Comparison of Risk of Osteoporotic Fracture in Denosumab vs Alendronate Treatment Within 3 Years of Initiation.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Denmark; Denosumab; Female; Hip Fractures; Huma | 2019 |
Comparison of bone biomechanical properties after bone marrow mesenchymal stem cell or alendronate treatment in an osteoporotic animal model.
Topics: Alendronate; Animals; Bone Density; Collagen Type I; Female; Mesenchymal Stem Cells; Mice; Models, A | 2019 |
Time trends in oral bisphosphonate initiation in Ontario, Canada over 20 years reflect drug policy and healthcare delivery changes.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diphos | 2019 |
MicroRNA-155 inhibition up-regulates LEPR to inhibit osteoclast activation and bone resorption via activation of AMPK in alendronate-treated osteoporotic mice.
Topics: Alendronate; AMP-Activated Protein Kinases; Animals; Bone Density Conservation Agents; Bone Resorpti | 2019 |
Characteristics associated with bone mineral density responses to alendronate in men.
Topics: Absorptiometry, Photon; Age Factors; Aged; Alendronate; Body Weight; Bone Density; Bone Density Cons | 2013 |
Alendronate retards the progression of lumbar intervertebral disc degeneration in ovariectomized rats.
Topics: Absorptiometry, Photon; Alendronate; Animals; Biomechanical Phenomena; Bone Density; Bone Density Co | 2013 |
Factors predicting the prognosis of oral alendronate-related osteonecrosis of the jaws: a 4-year cohort study.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Amoxicillin; Amoxicillin-Potassiu | 2013 |
Alendronate tracheobronchitis.
Topics: Alendronate; Anti-Bacterial Agents; Anti-Inflammatory Agents; Biopsy; Bone Density Conservation Agen | 2013 |
Persistence with osteoporosis medication among newly-treated osteoporotic patients.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Etidronic Acid; Female; Huma | 2013 |
Association between refill compliance to oral bisphosphonate treatment, incident fractures, and health care costs--an analysis using national health databases.
Topics: Administration, Oral; Aged; Alendronate; Bone Density Conservation Agents; Cost of Illness; Database | 2013 |
Enteric-coated alendronate sodium nanoliposomes: a novel formula to overcome barriers for the treatment of osteoporosis.
Topics: Alendronate; Animals; Biological Availability; Bone Density Conservation Agents; Chemistry, Pharmace | 2013 |
Quercetin prevents experimental glucocorticoid-induced osteoporosis: a comparative study with alendronate.
Topics: Alendronate; Animals; Biomarkers; Body Mass Index; Bone Density Conservation Agents; Disease Models, | 2013 |
Synthesis and in vitro evaluation of bone-seeking superparamagnetic iron oxide nanoparticles as contrast agents for imaging bone metabolic activity.
Topics: Adult; Alendronate; Bone and Bones; Bone Density Conservation Agents; Contrast Media; Dextrans; Ferr | 2013 |
Osteonecrosis of the jaws in patients assuming oral bisphosphonates for osteoporosis: a retrospective multi-hospital-based study of 87 Italian cases.
Topics: Administration, Oral; Adrenal Cortex Hormones; Age Factors; Aged; Aged, 80 and over; Alendronate; Bi | 2013 |
[Mineral and bone disorder associated with Cacchi-Ricci disease].
Topics: Adult; Alendronate; Bone Density Conservation Agents; Bone Remodeling; Calcifediol; Calcium; Drug Th | 2014 |
Differences in adherence to osteoporosis regimens: a 2-year analysis of a population treated under specific guidelines.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Calcitonin; Female; H | 2013 |
Oral bisphosphonates and the risk of Barrett's esophagus: case-control analysis of US veterans.
Topics: Aged; Alendronate; Barrett Esophagus; Bone Density Conservation Agents; Case-Control Studies; Diphos | 2013 |
Pentoxifylline and tocopherol in the treatment of yearly zoledronic acid-related osteonecrosis of the jaw in a corticosteroid-induced osteoporosis.
Topics: Adrenal Cortex Hormones; Alendronate; Antioxidants; Bisphosphonate-Associated Osteonecrosis of the J | 2014 |
Bisphosphonate-related osteonecrosis of jaw (BRONJ) in Japanese population: a case series of 13 patients at our clinic.
Topics: Administration, Oral; Adrenal Cortex Hormones; Aged; Aged, 80 and over; Alendronate; Anti-Bacterial | 2013 |
[The compliance in elderly male with osteoporosis treated with oral alendronate].
Topics: Aged; Aged, 80 and over; Alendronate; Follow-Up Studies; Humans; Male; Medication Adherence; Osteopo | 2013 |
Osteoporosis drugs in real-world clinical practice: an analysis of persistence.
Topics: Adult; Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Substitution; Etidr | 2013 |
Substantial under-treatment among women diagnosed with osteoporosis in a US managed-care population: a retrospective analysis.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Calcitonin; Cohort Studies; | 2014 |
Methionine down-regulates TLR4/MyD88/NF-κB signalling in osteoclast precursors to reduce bone loss during osteoporosis.
Topics: Acid Phosphatase; Administration, Oral; Alendronate; Animals; Bone Density; Bone Density Conservatio | 2014 |
Bisphosphonate-induced atypical subtrochanteric femoral fracture.
Topics: Absorptiometry, Photon; Alendronate; Bone Density Conservation Agents; Diagnosis, Differential; Fema | 2013 |
Early effects of parathyroid hormone on bisphosphonate/steroid-associated compromised osseous wound healing.
Topics: Alendronate; Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density; Bone Density | 2014 |
Synergistic antiosteoporotic effect of Lepidium sativum and alendronate in glucocorticoid-induced osteoporosis in Wistar rats.
Topics: Alendronate; Animals; Biomarkers; Bone and Bones; Bone Density Conservation Agents; Calcium; Disease | 2013 |
Effects of alendronate or alfacalcidol on bone metabolic indices and bone mineral density in patients with ophthalmologic disease treated with glucocorticoid.
Topics: Adult; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Resorption; Eye Disea | 2014 |
ONO-5334, a cathepsin K inhibitor, improves bone strength by preferentially increasing cortical bone mass in ovariectomized rats.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Cathepsin K; Female; Osteoporo | 2014 |
Bilateral atypical femoral fractures in a patient prescribed denosumab - a case report.
Topics: Alendronate; Antibodies, Monoclonal, Humanized; Arthritis, Rheumatoid; Bone Density Conservation Age | 2014 |
The impact of alendronate on bone mineral density of osteoporotic patients.
Topics: Adult; Aged; Alendronate; Body Mass Index; Bone Density; Case-Control Studies; Cohort Studies; Femal | 2013 |
Incidence and risk of osteonecrosis of the jaw among the Taiwan osteoporosis population.
Topics: Aged; Aged, 80 and over; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Densi | 2014 |
Differential impact of the bisphosphonate alendronate on undifferentiated and terminally differentiated human myogenic cells.
Topics: Alendronate; Bone Density Conservation Agents; Cell Differentiation; Cells, Cultured; Humans; Muscle | 2014 |
Alendronate, a bisphosphonate, increased upper and lower gastrointestinal bleeding: risk factor analysis from a nationwide population-based study.
Topics: Age Factors; Aged; Aged, 80 and over; Alendronate; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; | 2014 |
Incidence and risk of venous thromboembolism among Taiwan osteoporotic fracture population under osteoporosis pharmacological treatments.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Calcitonin; Female; Humans; | 2014 |
Tumor necrosis factor receptor-associated periodic syndrome managed with the couple canakinumab-alendronate.
Topics: Adult; Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Drug Therapy, Combina | 2015 |
Bone mass behavior after 1 year of different treatment strategies in prostate cancer patients subjected to androgen deprivation therapy.
Topics: Aged; Aged, 80 and over; Alendronate; Androgen Antagonists; Anilides; Antibodies, Monoclonal, Humani | 2014 |
High index of suspicion for early diagnosis of alendronate-induced stage zero osteonecrosis of jaw in thalassaemia major.
Topics: Alendronate; beta-Thalassemia; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Cons | 2014 |
Inhibitory effect of bisphosphonate on osteoclast function contributes to improved skeletal pain in ovariectomized mice.
Topics: Acid Phosphatase; Alendronate; Animals; Diphosphonates; Disease Models, Animal; Female; Isoenzymes; | 2015 |
Do atypical femoral fractures in patients with prolonged alendronate treatment heal?
Topics: Adult; Aged; Alendronate; Bone Density Conservation Agents; Calcium; Female; Femoral Fractures; Frac | 2014 |
Low-energy femoral shaft fractures after long-term alendronate therapy: report of seven cases.
Topics: Accidental Falls; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diaphyses; | 2015 |
Influence of alendronate administration regimen on the final outcome of implant osseointegration in an osteoporotic model.
Topics: Alendronate; Animals; Bone Cements; Bone Density Conservation Agents; Calcium Phosphates; Dexamethas | 2014 |
Effects of sequential osteoporosis treatments on trabecular bone in adult rats with low bone mass.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Disease Models, Animal; Drug E | 2014 |
The risk of osteonecrosis of the jaws in Taiwanese osteoporotic patients treated with oral alendronate or raloxifene.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bisphosphonate-Associated Osteonecrosis | 2014 |
[Osteoporotic fractures: not only in females].
Topics: Aged; Alendronate; Bone Density Conservation Agents; Calcitonin; Calcium; Cholecalciferol; Humans; L | 2014 |
LRP5 polymorphisms and response to alendronate treatment in Chinese postmenopausal women with osteoporosis.
Topics: Adult; Aged; Alendronate; Biomarkers; Bone Density; Collagen Type I; Female; Genotype; Humans; Low D | 2014 |
Exacerbation of myasthenia gravis by alendronate.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Glucocorticoids; Humans; Ibandronic A | 2014 |
Bisphosphonate-associated osteonecrosis of jaw reoccurrence after methotrexate therapy: a case report.
Topics: Aged; Alendronate; Amoxicillin; Anti-Bacterial Agents; Apicoectomy; Arthritis, Rheumatoid; Bisphosph | 2014 |
An NMR metabolomic study on the effect of alendronate in ovariectomized mice.
Topics: Alendronate; Animals; Bone Density; Disease Models, Animal; Female; Glucose; Humans; Inactivation, M | 2014 |
Genetic polymorphisms in the mevalonate pathway affect the therapeutic response to alendronate treatment in postmenopausal Chinese women with low bone mineral density.
Topics: Aged; Alendronate; Alleles; Asian People; Bone Density; Bone Density Conservation Agents; Bone Disea | 2015 |
Healing of bisphosphonate-associated atypical femoral fractures in patients with osteoporosis: a comparison between treatment with and without teriparatide.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Femo | 2015 |
The standardized BHH10 extract, a combination of Astragalus membranaceus, Cinnamomum cassia, and Phellodendron amurense, reverses bone mass and metabolism in a rat model of postmenopausal osteoporosis.
Topics: Alendronate; Animals; Astragalus propinquus; Body Weight; Bone Density; Bone Resorption; Cinnamomum | 2015 |
Single and combined effect of high-frequency loading and bisphosphonate treatment on the bone micro-architecture of ovariectomized rats.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Combined Modality Therapy; Female; Hormones; | 2015 |
A cell-based model of bone remodeling for identifying activity of icarrin in the treatment of osteoporosis.
Topics: Alendronate; Animals; Bone Remodeling; Cell Line; Epimedium; Flavonoids; Glucosides; Mice; Mice, Inb | 2015 |
Residual effect after oral bisphosphonate treatment and healthy adherer effects--the Swedish Adherence Register Analysis (SARA).
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Comorb | 2015 |
Bisphosphonate-associated atypical sub-trochanteric femur fractures: paired bone biopsy quantitative histomorphometry before and after teriparatide administration.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Female; Femora | 2015 |
Experience with alendronate treatment for 7 years among Japanese men with osteoporosis or osteopenia and clinical risk factors for fractures.
Topics: Absorptiometry, Photon; Adult; Aged; Alendronate; Alkaline Phosphatase; Asian People; Bone Density; | 2016 |
Local treatment of osteoporosis with alendronate-loaded calcium phosphate cement.
Topics: Alendronate; Animals; Bone Cements; Bone Density; Calcium Phosphates; Female; Osteoporosis; Rats; Ra | 2014 |
Preventive effects of withaferin A isolated from the leaves of an Indian medicinal plant Withania somnifera (L.): comparisons with 17-β-estradiol and alendronate.
Topics: Acid Phosphatase; Alendronate; Animals; Biomarkers; Bone and Bones; Disease Models, Animal; Dose-Res | 2015 |
Influence of osteoporosis on the osteocyte density of human mandibular bone samples: a controlled histological human study.
Topics: Absorptiometry, Photon; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, | 2016 |
Efficacy, effectiveness and side effects of medications used to prevent fractures.
Topics: Alendronate; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Calcium Compounds; | 2015 |
Quantitative computed tomographic assessment of bone mineral density changes associated with administration of prednisolone or prednisolone and alendronate sodium in dogs.
Topics: Administration, Oral; Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Dog Dise | 2015 |
μCT-based, in vivo dynamic bone histomorphometry allows 3D evaluation of the early responses of bone resorption and formation to PTH and alendronate combination therapy.
Topics: Alendronate; Animals; Bone and Bones; Bone Density Conservation Agents; Bone Resorption; Drug Therap | 2015 |
Comparison between different bone treatments on areal bone mineral density (aBMD) and bone microarchitectural texture as assessed by the trabecular bone score (TBS).
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Calcium; | 2015 |
Preparation of an injectable depot system for long-term delivery of alendronate and evaluation of its anti-osteoporotic effect in an ovariectomized rat model.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Chemistry, Pharmaceutical; Del | 2015 |
Alendronate rescued osteoporotic phenotype in a model of glucocorticoid-induced osteoporosis in adult zebrafish scale.
Topics: Acid Phosphatase; Alendronate; Alkaline Phosphatase; Animals; Biomarkers; Bone Density Conservation | 2015 |
Bisphosphonate-related osteonecrosis of the palatal torus.
Topics: Aged; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Age | 2014 |
Evaluation of the effects of LLLT on biomechanical properties of tibial diaphysis in two rat models of experimental osteoporosis by a three point bending test.
Topics: Alendronate; Animals; Biomechanical Phenomena; Bone Density Conservation Agents; Chemoradiotherapy; | 2015 |
A polymorphism at the translation start site of the vitamin D receptor gene is associated with the response to anti-osteoporotic therapy in postmenopausal women from southern Italy.
Topics: Alendronate; Bone Density Conservation Agents; Case-Control Studies; Female; Humans; Italy; Middle A | 2015 |
Perioperative alendronate, risedronate, calcitonin and indomethacin treatment alters femoral stem fixation and periprosthetic bone mineral density in ovariectomized rats.
Topics: Absorptiometry, Photon; Alendronate; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthroplasty, | 2015 |
Raloxifene enhances peri-implant bone healing in osteoporotic rats.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Dental Implants; Female; Impla | 2015 |
Alveolar bone dynamics in osteoporotic rats treated with raloxifene or alendronate: confocal microscopy analysis.
Topics: Alendronate; Alveolar Process; Animals; Bone Density; Bone Density Conservation Agents; Bone Remodel | 2015 |
Gastrointestinal Events Among Patients Initiating Osteoporosis Therapy: A Retrospective Administrative Claims Database Analysis.
Topics: Administrative Claims, Healthcare; Aged; Alendronate; Databases, Factual; Diphosphonates; Female; Ga | 2015 |
The use of alendronate is associated with a decreased incidence of type 2 diabetes mellitus--a population-based cohort study in Taiwan.
Topics: Alendronate; Body Mass Index; Bone Remodeling; Diabetes Mellitus, Type 2; Female; Humans; Incidence; | 2015 |
Trends in Media Reports, Oral Bisphosphonate Prescriptions, and Hip Fractures 1996-2012: An Ecological Analysis.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Data C | 2015 |
SOST polymorphisms and response to alendronate treatment in postmenopausal Chinese women with osteoporosis.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Alendronate; Asian People; Biomarkers; Bone Densi | 2015 |
Alendronate treatment alters bone tissues at multiple structural levels in healthy canine cortical bone.
Topics: Administration, Oral; Alendronate; Animals; Bone and Bones; Bone Density Conservation Agents; Collag | 2015 |
[Bone density measurements after alendronate therapy?].
Topics: Alendronate; Bone Density Conservation Agents; Humans; Osteoporosis; Randomized Controlled Trials as | 2015 |
Odanacatib Restores Trabecular Bone of Skeletally Mature Female Rabbits With Osteopenia but Induces Brittleness of Cortical Bone: A Comparative Study of the Investigational Drug With PTH, Estrogen, and Alendronate.
Topics: Alendronate; Animals; Biomechanical Phenomena; Biphenyl Compounds; Bone Density; Bone Diseases, Meta | 2016 |
Alendronate does not prevent long bone fragility in an inactive rat model.
Topics: Aging; Alendronate; Animals; Bone Density; Female; Fractures, Bone; Immobilization; Osteoporosis; Ov | 2016 |
Favorable therapeutic response of osteoporosis patients to treatment with intravenous zoledronate compared with oral alendronate.
Topics: Administration, Oral; Aged; Alendronate; Bone Density Conservation Agents; Cohort Studies; Diphospho | 2015 |
Is Long-Term Anti-Osteoporotic Treatment Associated with Greater Risk of Cancer in People with Severe Vertebral Fractures? A Hospital-Based Cohort Study.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Calcitonin; Cohort Studies; Female; Hospitaliza | 2015 |
Efficacy and safety of alendronic acid in the treatment of osteoporosis in children.
Topics: Adolescent; Alendronate; Bone Density; Bone Density Conservation Agents; Child; Female; Humans; Male | 2015 |
The determination of apoptosis rates on articular cartilages of ovariectomized rats with and without alendronate treatment.
Topics: Alendronate; Animals; Apoptosis; Bone Density Conservation Agents; Cartilage, Articular; Disease Mod | 2016 |
Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday.
Topics: Aged; Alendronate; Body Weight; Bone Density; Bone Density Conservation Agents; Diphosphonates; Fema | 2016 |
An evaluation of the effect of pulsed wave low-level laser therapy on the biomechanical properties of the vertebral body in two experimental osteoporosis rat models.
Topics: Alendronate; Animals; Biomechanical Phenomena; Female; Glucocorticoids; Low-Level Light Therapy; Mal | 2016 |
Urban-rural differences in the uptake of new oral bisphosphonate formulations.
Topics: Administration, Oral; Aged; Alendronate; Bone Density Conservation Agents; Cholecalciferol; Diphosph | 2016 |
Atypical femoral fracture following zoledronic acid treatment.
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Th | 2016 |
Evaluation of the effects of pulsed wave LLLT on tibial diaphysis in two rat models of experimental osteoporosis, as examined by stereological and real-time PCR gene expression analyses.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Regeneration; Diaphyses; Female; Humans | 2016 |
Cost-Effectiveness of Intervention Thresholds for the Treatment of Osteoporosis Based on FRAX(®) in Portugal.
Topics: Aged; Alendronate; Algorithms; Bone Density Conservation Agents; Cohort Studies; Cost-Benefit Analys | 2016 |
Bone-targeted delivery of nanodiamond-based drug carriers conjugated with alendronate for potential osteoporosis treatment.
Topics: Alendronate; Alkaline Phosphatase; Animals; Bone and Bones; Bone Density Conservation Agents; Cell L | 2016 |
Establishing and evaluating FRAX
Topics: Age Distribution; Aged; Aged, 80 and over; Alendronate; Algorithms; Bone Density Conservation Agents | 2017 |
Alendronate Sodium as Enteric Coated Solid Lipid Nanoparticles; Preparation, Optimization, and In Vivo Evaluation to Enhance Its Oral Bioavailability.
Topics: Administration, Oral; Alendronate; Animals; Biological Availability; Chemistry, Pharmaceutical; Drug | 2016 |
Teriparatide Improves Fracture Healing and Early Functional Recovery in Treatment of Osteoporotic Intertrochanteric Fractures.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Calcium; Female; Fracture He | 2016 |
Calcitonin alleviates hyperalgesia in osteoporotic rats by modulating serotonin transporter activity.
Topics: Alendronate; Animals; Calcitonin; Female; Hyperalgesia; Osteoporosis; Ovariectomy; Random Allocation | 2016 |
[Bisphosphonate use and related pharmaceutical issues II].
Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Bone Neoplasms; Clodronic Acid; | 2016 |
Role of Side Effects, Physician Involvement, and Patient Perception in Non-Adherence with Oral Bisphosphonates.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Cross-Sectional Studies; Databases, Factual; Fe | 2016 |
Risk of hip, subtrochanteric, and femoral shaft fractures among mid and long term users of alendronate: nationwide cohort and nested case-control study.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Case-Control Studies; Cohort | 2016 |
Use of drugs against osteoporosis in the Baltic countries during 2010-2014.
Topics: Alendronate; Baltic States; Bone Density Conservation Agents; Calcium Channel Blockers; Denosumab; D | 2016 |
Efficacy and safety of osteoporosis medications in a rat model of late-stage chronic kidney disease accompanied by secondary hyperparathyroidism and hyperphosphatemia.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Remodeling; Disease Models, Animal; Dru | 2017 |
Pharyngolaryngeal ulcers associated with the improper use of alendronate.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Female; Humans; Laryngeal Diseases; Osteoporosi | 2017 |
Mechanism of Bushen Jianpi decoction in preventing and treating osteoporosis caused by aromatase inhibitors in breast cancer treatment.
Topics: Alendronate; Alkaline Phosphatase; Anastrozole; Animals; Aromatase Inhibitors; Bone Density; Bone De | 2017 |
Discharging nodule on the jaw.
Topics: Aged, 80 and over; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Con | 2016 |
Efficacy of teriparatide in the treatment of nontraumatic osteonecrosis of the femoral head: a retrospective comparative study with alendronate.
Topics: Adult; Alendronate; Bone Density Conservation Agents; Bone Resorption; Disease Progression; Drug Eva | 2017 |
In Vitro and In Vivo Evaluation of Commercially Available Fibrin Gel as a Carrier of Alendronate for Bone Tissue Engineering.
Topics: Alendronate; Animals; Bone Regeneration; Cell Differentiation; Cell Proliferation; Fibrin; Fibrin Ti | 2017 |
Alendronate inhibits hyperalgesia and suppresses neuropeptide markers of pain in a mouse model of osteoporosis.
Topics: Alendronate; Animals; Biomarkers; Bone Density Conservation Agents; Calcitonin Gene-Related Peptide; | 2017 |
Long-term effects of bisphosphonate therapy: perforations, microcracks and mechanical properties.
Topics: Aged; Aged, 80 and over; Alendronate; Bone and Bones; Bone Density; Bone Density Conservation Agents | 2017 |
The anti-osteoporotic and anti-atherogenic effects of alendronate and simvastatin in ovariectomized rats fed high fat diet: A comparative study of combination therapy versus monotherapy.
Topics: Alendronate; Alkaline Phosphatase; Animals; Atherosclerosis; Body Weight; Bone and Bones; Bone Densi | 2017 |
Review of comparative effectiveness of treatments to prevent fractures.
Topics: Alendronate; Bone Density Conservation Agents; Fractures, Bone; Humans; Osteoporosis; Renal Insuffic | 2008 |
Appropriate intervention through fracture risk assessment.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Female; Fractu | 2005 |
The role of managed care in the management of osteoporosis.
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density Conservation Agents; Disease Management; Fem | 2005 |
Bisphosphonate-related osteonecrosis of the jaws--report of 2 cases and strategies on prevention and management.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Humans; | 2008 |
Maximizing effectiveness of bisphosphonate therapy for osteoporosis.
Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; | 2008 |
A case report: pregnancy-induced severe osteoporosis with eight vertebral fractures.
Topics: Adult; Alendronate; Back Pain; Bone Density; Bone Density Conservation Agents; Female; Fractures, Sp | 2008 |
Effects of genistein aglycone in osteoporotic, ovariectomized rats: a comparison with alendronate, raloxifene and oestradiol.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Disease Models, Animal; Dose-R | 2008 |
Massive proteinuria and acute renal failure after oral bisphosphonate (alendronate) administration in a patient with focal segmental glomerulosclerosis.
Topics: Acute Kidney Injury; Administration, Oral; Alendronate; Blood Component Removal; Bone Density Conser | 2009 |
Therapeutic effects of one-year alendronate treatment in three cases of osteoporosis with parietal thinning of skull.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Female; Humans; Male; Osteoporosi | 2008 |
Osteoporotic fracture management in India: a survey of orthopaedic surgeons.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Disease Progression; Etidronic Acid; | 2008 |
Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate.
Topics: Alendronate; Animals; Biomechanical Phenomena; Bone Density; Bone Density Conservation Agents; Bone | 2009 |
RisedronatE and ALendronate Intervention over Three Years (REALITY): minimal differences in fracture risk reduction.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; F | 2009 |
Opposing effects of bisphosphonates and advanced glycation end-products on osteoblastic cells.
Topics: 3T3 Cells; Alendronate; Animals; Bone Density Conservation Agents; Calcium; Calcium Channels, L-Type | 2008 |
[Treatment of osteoporosis in the elderly: what is the evidence?].
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Alendronate; Bone Density; Bone Density Conservation Ag | 2008 |
[New therapeutic approach in glucocorticoid-induce osteoporosis].
Topics: Alendronate; Bone Density Conservation Agents; Double-Blind Method; Female; Glucocorticoids; Humans; | 2008 |
Differences in persistence among different weekly oral bisphosphonate medications.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diphos | 2009 |
Alendronate, osteoporosis, and atherosclerosis.
Topics: Alendronate; Atherosclerosis; Atrial Fibrillation; Bone Density Conservation Agents; Humans; Osteopo | 2008 |
BMP/Wnt antagonists are upregulated by dexamethasone in osteoblasts and reversed by alendronate and PTH: potential therapeutic targets for glucocorticoid-induced osteoporosis.
Topics: Alendronate; Animals; Axin Protein; Bone Density Conservation Agents; Bone Morphogenetic Proteins; C | 2009 |
Comparison of direct health care costs related to the pharmacological treatment of osteoporosis and to the management of osteoporotic fractures among compliant and noncompliant users of alendronate and risedronate: a population-based study.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Confidence Intervals; Etidronic Acid; Female; F | 2009 |
Potential of alfacalcidol for reducing increased risk of falls and fractures.
Topics: Accidental Falls; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Calcitriol; Cal | 2009 |
[New bisphosphonates and trends in drug therapy for osteoporosis: preface].
Topics: Alendronate; Bone Density Conservation Agents; Clinical Trials as Topic; Diphosphonates; Etidronic A | 2009 |
Using the osteoporosis self-assessment tool for referring older men for bone densitometry: a decision analysis.
Topics: Aged; Aged, 80 and over; Alendronate; Bone and Bones; Cost-Benefit Analysis; Densitometry; Humans; M | 2009 |
Bisphosphonates and low-impact femoral fractures: current evidence on alendronate-fracture risk.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Bone Resorption; Drug Administration Schedule; | 2009 |
Comparative gastrointestinal safety of weekly oral bisphosphonates.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diphos | 2009 |
Unusual mid-shaft fractures during long-term bisphosphonate therapy.
Topics: Adult; Aged; Alendronate; Bone and Bones; Bone Density Conservation Agents; Diphosphonates; Etidroni | 2010 |
Genistein aglycone reverses glucocorticoid-induced osteoporosis and increases bone breaking strength in rats: a comparative study with alendronate.
Topics: Alendronate; Alkaline Phosphatase; Animals; Biomarkers; Bone Density; Bone Density Conservation Agen | 2009 |
Systemic mastocytosis presenting as osteoporosis--a case report.
Topics: Alendronate; Bone Density Conservation Agents; Diagnosis, Differential; Exanthema; Humans; Lumbar Ve | 2009 |
Overcoming resistance to bisphosphonates through the administration of alfacalcidol: results of a 1-year, open follow-up study.
Topics: Absorptiometry, Photon; Aged; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agent | 2009 |
Risk of severe gastrointestinal events in women treated with monthly ibandronate or weekly alendronate and risedronate.
Topics: Aged; Alendronate; Cohort Studies; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Fem | 2009 |
Effect of alendronate and intermittent parathyroid hormone on implant fixation in ovariectomized rats.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Female; Implants, Experimental | 2009 |
Comparison of radiographic fracture healing in the distal radius for patients on and off bisphosphonate therapy.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bo | 2009 |
Effects of 1 to 3 years' treatment with alendronate on mechanical properties of the femoral shaft in a canine model: implications for subtrochanteric femoral fracture risk.
Topics: Alendronate; Animals; Biomechanical Phenomena; Bone Density Conservation Agents; Disease Models, Ani | 2009 |
A fractured service: will NOGG mend it?
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Female; Fractures, Bone; Hum | 2009 |
Safety of bisphosphonates in women of child bearing age.
Topics: Alendronate; Bone Density Conservation Agents; Colitis, Ulcerative; Diphosphonates; Female; Humans; | 2009 |
Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Connective Tissue; Di | 2010 |
Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis.
Topics: Absorptiometry, Photon; Aged; Alendronate; Androgen Antagonists; Bone Density; Bone Density Conserva | 2009 |
Battle over popular bone drug Fosamax bursts into court.
Topics: Alendronate; Bone Density Conservation Agents; Drug Industry; Humans; Jaw Diseases; Legislation, Dru | 2009 |
US judge rules Merck won't face "punitive damages" in first Fosamax case.
Topics: Alendronate; Bone Density Conservation Agents; Bone Remodeling; Drug Industry; Humans; Jaw Diseases; | 2009 |
Low-energy femoral fractures associated with the long-term use of bisphosphonates: a case series from a Swiss university hospital.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Bone Nails; Diphosphonates; | 2009 |
Corticosteroids: no drug prevention of fractures needed.
Topics: Adrenal Cortex Hormones; Alendronate; Bone and Bones; Bone Density; Bone Density Conservation Agents | 2009 |
Alendronate reduces the excretion of risk factors for calcium phosphate stone formation in postmenopausal women with osteoporosis.
Topics: Alendronate; Bone Density Conservation Agents; Calcium Phosphates; Female; Humans; Middle Aged; Oste | 2009 |
Femur bone repair in ovariectomized rats under the local action of alendronate, hydroxyapatite and the association of alendronate and hydroxyapatite.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Regeneration; Drug Combinations; Drug E | 2009 |
[Using parathyroid hormone 1-84 in the treatment of osteoporosis: presentation and comments of main clinical trial].
Topics: Alendronate; Bone Density Conservation Agents; Female; Humans; Middle Aged; Osteoporosis; Parathyroi | 2009 |
Bisphosphonates do not inhibit periosteal bone formation in estrogen deficient animals and allow enhanced bone modeling in response to mechanical loading.
Topics: Alendronate; Animals; Bone and Bones; Bone Density Conservation Agents; Diphosphonates; Etidronic Ac | 2010 |
Bisphosphonates and atypical femoral fractures: a time for reflection.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Femoral | 2010 |
Do estrogen and alendronate improve metaphyseal fracture healing when applied as osteoporosis prophylaxis?
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Plates; Bone Regeneration; Bony Callus; | 2010 |
[Skeletal biomechanical effectiveness of retinoic acid on induction of osteoporotic rats treated by alendronate and qianggu capsules].
Topics: Alendronate; Animals; Biomechanical Phenomena; Disease Models, Animal; Drugs, Chinese Herbal; Female | 2009 |
Effects of bisphosphonate administration on the bone mass in immune thrombocytopenic purpura patients under treatment with steroids.
Topics: Adult; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Gl | 2010 |
Vibrational bone characteristics versus bone density for the assessment of osteoporosis in ovariectomized rats.
Topics: Alendronate; Animals; Bone Density; Disease Models, Animal; Female; Fourier Analysis; Linear Models; | 2010 |
Effects of combination treatment with alendronate and vitamin K(2) on bone mineral density and strength in ovariectomized mice.
Topics: Alendronate; Animals; Biomechanical Phenomena; Body Weight; Bone Density; Bone Density Conservation | 2010 |
Risedronate versus alendronate in older patients with osteoporosis at high risk of fracture: an Italian cost-effectiveness analysis.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cost-Benefit Analysis; Costs | 2010 |
Alendronate induces mineralization in mouse osteoblastic MC3T3-E1 cells: regulation of mineralization-related genes.
Topics: Alendronate; Alkaline Phosphatase; Animals; Anthraquinones; Bone Density Conservation Agents; Calcif | 2010 |
Intravenous zoledronic acid and oral alendronate in patients with a low trauma fracture: experience from an osteoporosis clinic.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cohort | 2011 |
High level of serum undercarboxylated osteocalcin in patients with incident fractures during bisphosphonate treatment.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; F | 2010 |
[Osteodensitometry and duration of treatment in osteoporosis].
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Female; H | 2010 |
Insufficiency femoral fractures in patients undergoing prolonged alendronate therapy.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Female; Femoral Fractures; Humans; Osteoporosis | 2010 |
Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur.
Topics: Alendronate; Bone Density Conservation Agents; Confidence Intervals; Diphosphonates; Female; Femoral | 2010 |
Evolving data about subtrochanteric fractures and bisphosphonates.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Femoral Fractures; Hip Fractu | 2010 |
Bilateral atypical femoral diaphyseal fractures in a patient treated with alendronate sodium.
Topics: Absorptiometry, Photon; Aged, 80 and over; Alendronate; Biomarkers; Bone Density Conservation Agents | 2009 |
Non-traumatic fracture of the femoral shaft in a patient taking long-term bisphosphonate therapy.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Female; Femora | 2011 |
Intravenous zoledronic acid: what are the indications for male osteoporosis?
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Clinical Trials as Topic; Diphosphonate | 2010 |
How patients' lack of knowledge about oral bisphosphonates can interfere with medical and dental care.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conser | 2010 |
Stroke in relation to use of raloxifene and other drugs against osteoporosis.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Case-Control Studies; Denmar | 2011 |
Atypical femoral fractures and bisphosphonate use.
Topics: Aged; Aged, 80 and over; Alendronate; Diphosphonates; Etidronic Acid; Female; Femoral Fractures; Hum | 2010 |
Cost-effectiveness of fracture prevention in men who receive androgen deprivation therapy for localized prostate cancer.
Topics: Aged; Aged, 80 and over; Alendronate; Androgen Antagonists; Antineoplastic Agents; Bone Density; Bon | 2010 |
Thighbone fractures in women taking bisphosponate drugs.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Femo | 2010 |
Subtrochanteric femoral fractures in patients receiving long-term alendronate therapy: imaging features.
Topics: Accidental Falls; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Female; Fe | 2010 |
Low 24-hour adiponectin and high nocturnal leptin concentrations in a case-control study of community-dwelling premenopausal women with major depressive disorder: the Premenopausal, Osteopenia/Osteoporosis, Women, Alendronate, Depression (POWER) study.
Topics: Adiponectin; Adrenocorticotropic Hormone; Adult; Alendronate; Body Mass Index; Case-Control Studies; | 2010 |
Lichenoid dermatosis induced by alendronate: an unusual skin drug reaction.
Topics: Aged; Alendronate; Biopsy; Bone Density Conservation Agents; Glucocorticoids; Humans; Lichenoid Erup | 2010 |
Development of a novel transdermal patch of alendronate, a nitrogen-containing bisphosphonate, for the treatment of osteoporosis.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Butylated Hydroxytoluene; Calcium; Female; G | 2010 |
Bisphosphonate inhibits bone turnover in OPG(-/-) mice via a depressive effect on both osteoclasts and osteoblasts.
Topics: Alendronate; Alkaline Phosphatase; Animals; Bone and Bones; Bone Density Conservation Agents; Diphos | 2010 |
Immediate loading in mandible full-arch: pilot study in patients with osteoporosis in bisphosphonate therapy.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Dental Arch; Dental Prosthesis, I | 2012 |
Effects of the combination treatment of raloxifene and alendronate on the biomechanical properties of vertebral bone.
Topics: Alendronate; Animals; Biomechanical Phenomena; Bone Density; Bone Density Conservation Agents; Densi | 2011 |
Evaluation of a novel osteoporotic drug delivery system in vitro: alendronate-loaded calcium phosphate cement.
Topics: Alendronate; Animals; Bone Cements; Bone Density Conservation Agents; Calcium Phosphates; Cell Proli | 2010 |
Validity of prevention of glucocorticoid-induced alveolar bone loss in rat by either calcitonin or alendronate administration.
Topics: Alendronate; Alveolar Bone Loss; Animals; Bone Density; Bone Density Conservation Agents; Calcitonin | 2010 |
Acute effects of intravenous administration of pamidronate in patients with osteoporosis.
Topics: Acute-Phase Proteins; Adult; Aged; Aged, 80 and over; Alendronate; Biomarkers; Blood Cells; Bone Den | 2010 |
[Jaw osteonecrosis induced by oral biphosphonates: 12 cases].
Topics: Administration, Oral; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Alendronate; Autoimmu | 2010 |
Skeletal integrity and visceral transplantation.
Topics: Adult; Alendronate; Biomarkers; Bone Density; Female; Fractures, Bone; Humans; Hyperparathyroidism, | 2010 |
The societal burden of poor persistence to treatment of osteoporosis in Sweden.
Topics: Alendronate; Bone Density Conservation Agents; Cost-Benefit Analysis; Humans; Osteoporosis; Sweden | 2011 |
Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw: a case series.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Breast Neoplasms; Dip | 2010 |
Retrospective study of two biochemical markers for the risk assessment of oral bisphosphonate-related osteonecrosis of the jaws: can they be utilized as risk markers?
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density Conservation Ag | 2011 |
The effect of oestrogen and alendronate therapies on postmenopausal bone loss around osseointegrated titanium implants.
Topics: Absorptiometry, Photon; Alendronate; Amino Acids; Animals; Biomarkers; Bone Density; Bone Density Co | 2011 |
The effect of the alendronate on OPG/RANKL system in differentiated primary human osteoblasts.
Topics: Aged; Alendronate; Alkaline Phosphatase; Bone Density Conservation Agents; Cell Differentiation; Cel | 2010 |
Stem cells and osteoporosis therapy.
Topics: Alendronate; Bone Density Conservation Agents; Humans; Mesenchymal Stem Cells; Osteoblasts; Osteocla | 2010 |
Bisphosphonates in calcific aortic stenosis: association with slower progression in mild disease--a pilot retrospective study.
Topics: Aged; Alendronate; Aortic Valve Stenosis; Bone Density Conservation Agents; Calcinosis; Comorbidity; | 2010 |
[Alendronate treatment of osteoporosis secondary to Duchenne muscular dystrophy].
Topics: Alendronate; Bone Density Conservation Agents; Child; Humans; Muscular Dystrophy, Duchenne; Osteopor | 2011 |
[Application of guidelines for secondary prevention of fracture and the FRAX index in patients with fragility fracture].
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservatio | 2011 |
The influence of alendronate on spine fusion in an osteoporotic animal model.
Topics: Alendronate; Animals; Biomechanical Phenomena; Bone Density Conservation Agents; Bone Transplantatio | 2011 |
Osteoporosis medication and reduced mortality risk in elderly women and men.
Topics: Aged; Aged, 80 and over; Alendronate; Algorithms; Bone Density Conservation Agents; Cohort Studies; | 2011 |
The effect of SLActive surface in guided bone formation in osteoporotic-like conditions.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Calcium; Female; Guided Tissue Regeneration, | 2011 |
Reduced osteoclastogenesis and RANKL expression in marrow from women taking alendronate.
Topics: Aged, 80 and over; Alendronate; Bone Marrow Cells; Case-Control Studies; Cell Differentiation; Dipho | 2011 |
Esophageal stricture associated with alendronate use.
Topics: Aged, 80 and over; Alendronate; Esophageal Stenosis; Female; Humans; Osteoporosis; Tomography, X-Ray | 2011 |
Risk reduction of falls and fractures, reduction of back pain and safety in elderly high risk patients receiving combined therapy with alfacalcidol and alendronate: a prospective study.
Topics: Accidental Falls; Aged; Aged, 80 and over; Alendronate; Back Pain; Bone Density Conservation Agents; | 2011 |
Secondary prophylaxis of osteoporotic fractures in an orthogeriatric service.
Topics: Alendronate; Attitude of Health Personnel; Bone Density Conservation Agents; Fractures, Bone; Health | 2011 |
Potency of a combined alfacalcidol-alendronate therapy to reduce the risk of falls and fractures in elderly patients with glucocorticoid-induced osteoporosis.
Topics: Absorptiometry, Photon; Accidental Falls; Aged; Alendronate; Back Pain; Bone Density; Bone Density C | 2011 |
Synthesis and in vivo bioactivity of lipophilic alendronate derivatives against osteoporosis.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Chromatography, High Pressure Liquid; Diseas | 2011 |
Effects of the systemic administration of alendronate on bone formation in a porous hydroxyapatite/collagen composite and resorption by osteoclasts in a bone defect model in rabbits.
Topics: Alendronate; Animals; Biocompatible Materials; Bone Density Conservation Agents; Case-Control Studie | 2011 |
Bisphosphonate-related subtrochanteric femoral fractures.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Female; Femoral Fractures; Hip Fractures; Human | 2011 |
Heterogeneity of biological bone markers in idiopathic male osteoporosis.
Topics: Adult; Aged; Alendronate; Alkaline Phosphatase; Biomarkers; Bone and Bones; Bone Density; Bone Densi | 2012 |
Adherence to osteoporosis medications amongst Singaporean patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diphosph | 2012 |
Alendronate-associated femoral insufficiency fractures and femoral stress reactions.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Bone Nails; Female; Femoral | 2011 |
A case of esophageal ulcer caused by alendronate sodium tablets.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diagnosis, Differential; Endoscopy, Gastrointes | 2011 |
Vitamin D status and response to daily 400 IU vitamin D3 and weekly alendronate 70 mg in men and women with osteoporosis.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Canada; Cholecalciferol; Cohort Studies; Dietar | 2011 |
Alendronate adherence and its impact on hip-fracture risk in patients with established osteoporosis in Taiwan.
Topics: Aged; Alendronate; Analysis of Variance; Asian People; Bone Density Conservation Agents; Cohort Stud | 2011 |
[Alendronate and resorptive hypercalciuria].
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Resorption; C | 2011 |
Efficacy of serotonin inhibition in mouse models of bone loss.
Topics: Aging; Alendronate; Animals; Bone and Bones; Bone Resorption; Disease Models, Animal; Dose-Response | 2011 |
Awareness and education of patients receiving bisphosphonates.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Arthralgia; Bisphosphonate-Associated Os | 2012 |
Osteoporosis: yesterday, today and tomorrow.
Topics: Absorptiometry, Photon; Age Distribution; Aged; Alendronate; Bone Density; Bone Density Conservation | 2011 |
Gastrointestinal tolerability and patterns of switching in patients treated for primary osteoporosis: the Swedish Adherence Register Analysis (SARA).
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Drug Substitution; Drug-Rela | 2011 |
Risk of newly diagnosed type 2 diabetes is reduced in users of alendronate.
Topics: Age of Onset; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Case-Control S | 2011 |
Esophageal stenosis caused by alendronate.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Burns, Chemical; Catheterization; Deglutition D | 2011 |
Prolonged bisphosphonate release after treatment in women with osteoporosis. Relationship with bone turnover.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Remodeling; Case-Control Studies; Diphosphonates; | 2011 |
Oral bisphosphonate use increases the risk for inflammatory jaw disease: a cohort study.
Topics: Administration, Oral; Aged; Alcoholism; Alendronate; Bisphosphonate-Associated Osteonecrosis of the | 2012 |
Dental sinus tracts mimicking scrofuloderma: cutaneous presentation of underlying bisphosphonate-related osteonecrosis of the jaw.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Cutaneous Fistula; Diagnosis, Differential; Dip | 2011 |
[Effect of alendronate sodium on torque-out testing on implant-bone interfaces in estrogen-deficient rabbits with alendronate systemic administration].
Topics: Alendronate; Animals; Bone and Bones; Bone Density; Bone Density Conservation Agents; Estrogens; Fem | 2011 |
[Effect of alendronate on bone tissue status of senescence-accelerated OXYS rats].
Topics: Aging, Premature; Alendronate; Animals; Bone and Bones; Bone Density; Bone Density Conservation Agen | 2011 |
Serum ionic fluoride concentrations are significantly decreased after treatment with alendronate in patients with osteoporosis.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Fluorides; Hum | 2011 |
Alendronate and raloxifene use related to cardiovascular diseases: differentiation by different dosing regimens of alendronate.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cardiovascular Diseases; Coh | 2011 |
Bisphosphonate-induced osteonecrosis of the jaw.
Topics: Adult; Aged; Alendronate; Bone Density Conservation Agents; Female; Humans; Jaw Diseases; Osteonecro | 2011 |
Analysis of the comparative effectiveness of 3 oral bisphosphonates in a large managed care organization: adherence, fracture rates, and all-cause cost.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Comparative Effectiveness Research; Diph | 2011 |
[Resistant ovary syndrome. Case report].
Topics: Adolescent; Alendronate; Bone Density Conservation Agents; Estrogens; Female; Hormone Replacement Th | 2011 |
[Inflammation of the jaws during treatment with bisphosphonates].
Topics: Administration, Oral; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseas | 2011 |
Effect of rosiglitazone on bone quality in a rat model of insulin resistance and osteoporosis.
Topics: Alendronate; Animals; Biomechanical Phenomena; Bone and Bones; Bone Density Conservation Agents; Fem | 2011 |
Aspiration of alendronic acid leading to localized bronchiectasis.
Topics: Aged; Alendronate; Bronchiectasis; Cough; Female; Humans; Osteoporosis; Respiratory Aspiration | 2012 |
Hip and subtrochanteric or diaphyseal femoral fractures in alendronate users: a 10-year, nationwide retrospective cohort study in Taiwanese women.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Female; Hip Fractures; Human | 2011 |
Low-magnitude high-frequency loading via whole body vibration enhances bone-implant osseointegration in ovariectomized rats.
Topics: Alendronate; Animals; Biomechanical Phenomena; Body Weight; Bone Density; Bone Density Conservation | 2012 |
Discontinuation of unnecessary medications in older adults.
Topics: Aged; Aged, 80 and over; Alendronate; Anti-Ulcer Agents; Antihypertensive Agents; Assisted Living Fa | 2011 |
Acute myocardial infarction and atherosclerosis of the coronary arteries in patients treated with drugs against osteoporosis: calcium in the vessels and not the bones?
Topics: Aged; Alendronate; Atherosclerosis; Bone Density Conservation Agents; Calcium; Cohort Studies; Dipho | 2012 |
The association between automatic generic substitution and treatment persistence with oral bisphosphonates.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Substitution; Drugs, Gener | 2012 |
Antiosteoporotic activity of Davallia formosana.
Topics: Alendronate; Alkaline Phosphatase; Amino Acids; Animals; Biomechanical Phenomena; Bone Density; Bone | 2012 |
Biomimetic coating of bisphosphonate incorporated CDHA on Ti6Al4V.
Topics: Alendronate; Alloys; Calcium; Cell Proliferation; Coated Materials, Biocompatible; Diphosphonates; D | 2012 |
[Long-term combined treatment with cinacalcet and bisphosphonates in persistent primary hyperparathyroidism after surgery].
Topics: Alendronate; Bone Density Conservation Agents; Cinacalcet; Drug Therapy, Combination; Female; Humans | 2012 |
Changes in intracortical microporosities induced by pharmaceutical treatment of osteoporosis as detected by high resolution micro-CT.
Topics: Alendronate; Animals; Bone and Bones; Bone Density; Bone Density Conservation Agents; Female; Osteop | 2012 |
Osteoclasts derived from patients with neurofibromatosis 1 (NF1) display insensitivity to bisphosphonates in vitro.
Topics: Adult; Aged; Alendronate; Biomarkers; Bone Density; Bone Resorption; Cells, Cultured; Clodronic Acid | 2012 |
Three years of alendronate treatment does not continue to decrease microstructural stresses and strains associated with trabecular microdamage initiation beyond those at 1 year.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Dogs; Femur; Finite Element An | 2012 |
Influence of socioeconomic factors on the adherence of alendronate treatment in incident users in Norway.
Topics: Adult; Aged; Alendronate; Bone Density Conservation Agents; Cohort Studies; Databases, Factual; Drug | 2012 |
Nephrotic syndrome after oral bisphosphonate (alendronate) administration in a patient with osteoporosis.
Topics: Adult; Alendronate; Bone Density Conservation Agents; Humans; Male; Nephrotic Syndrome; Osteoporosis | 2012 |
Uncommon transient osteoporosis of pregnancy at multiple sites associated with cytomegalovirus infection: is there a link?
Topics: Absorptiometry, Photon; Adult; Alendronate; Ankle Joint; Bone Density Conservation Agents; Cytomegal | 2011 |
Inhalation of alendronate nanoparticles as dry powder inhaler for the treatment of osteoporosis.
Topics: Administration, Inhalation; Alendronate; Bone Density Conservation Agents; Chemical Precipitation; D | 2012 |
Design and synthesis of novel bone-targeting dual-action pro-drugs for the treatment and reversal of osteoporosis.
Topics: Alendronate; Animals; Bone and Bones; Bone Density Conservation Agents; Drug Design; Female; Osteopo | 2012 |
[Estimate of the 10-year risk of osteoporotic fractures in the Spanish population].
Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Alendronate; Algorithms; Bone Density Conservation | 2013 |
Osteopathology induced by bisphosphonates and dental implants: clinical observations.
Topics: Actinomycosis; Administration, Intravenous; Administration, Oral; Alendronate; Anti-Bacterial Agents | 2013 |
Impact of generic alendronate cost on the cost-effectiveness of osteoporosis screening and treatment.
Topics: Absorptiometry, Photon; Aged; Alendronate; Cost-Benefit Analysis; Drugs, Generic; Female; Humans; Ma | 2012 |
Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy: a register-based cohort study using the US MarketScan claims databases.
Topics: Administration, Oral; Aged; Alendronate; Cohort Studies; Diphosphonates; Drug Administration Schedul | 2012 |
Practice Gaps. Improving the care of our patients who are receiving glucocorticoid therapy.
Topics: Alendronate; Anti-Inflammatory Agents; Autoimmune Diseases; Bone Density Conservation Agents; Female | 2012 |
Efficacy of glucosamine alendronate alone & in combination with dihydroquercetin for treatment of osteoporosis in animal model.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Calcium; Collagen Type I; Coll | 2012 |
Development of a novel self-dissolving microneedle array of alendronate, a nitrogen-containing bisphosphonate: evaluation of transdermal absorption, safety, and pharmacological effects after application in rats.
Topics: Administration, Cutaneous; Alendronate; Animals; Biological Availability; Bone Density Conservation | 2012 |
Osteoclast abnormalities in fractured bone during bisphosphonate treatment for osteoporosis: a case report.
Topics: Aged; Alendronate; Diphosphonates; Female; Femoral Fractures; Humans; Osteoclasts; Osteoporosis; Ost | 2012 |
Combined treatment with a traditional Chinese medicine, Hachimi-jio-gan (Ba-Wei-Di-Huang-Wan) and alendronate improves bone microstructure in ovariectomized rats.
Topics: Acid Phosphatase; Alendronate; Animals; Bone Density Conservation Agents; Drug Therapy, Combination; | 2012 |
Bisphosphonate-related osteonecrosis of the jaw in patients with oral bisphosphonate exposure: clinical course and outcomes.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Anti-Bacterial Agents; Antirheumatic Age | 2012 |
Efficacy of alendronate in the treatment of low bone density in the pediatric and young adult population.
Topics: Absorptiometry, Photon; Adolescent; Alendronate; Bone Density; Bone Density Conservation Agents; Cas | 2012 |
Bisphosphonates in the treatment of osteoporosis.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Female; Hip Fractures; Humans; Osteoporosis; Tr | 2012 |
Unusual subtrochanteric femoral insufficiency fractures associated with the prolonged use of alendronate and risedronate: a report of two cases.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Drug Administration Schedule; Etidronic Acid; F | 2011 |
[Concomitant treatment of the osteoporotic drugs].
Topics: Alendronate; Bone Density Conservation Agents; Drug Therapy, Combination; Humans; Osteoporosis; Vita | 2012 |
Pregnancy associated osteoporosis--a case report.
Topics: Adult; Alendronate; Back Pain; Bone Density; Bone Density Conservation Agents; Calcium, Dietary; Fem | 2012 |
Primary hyperparathyroidism with classic and severe skeletal involvement.
Topics: Adenoma; Alendronate; Calcitriol; Calcium Carbonate; Female; Follow-Up Studies; Fractures, Spontaneo | 2010 |
Alendronate coated poly-lactic-co-glycolic acid (PLGA) nanoparticles for active targeting of metastatic breast cancer.
Topics: Alendronate; Animals; Antineoplastic Agents; Bone and Bones; Bone Neoplasms; Boronic Acids; Bortezom | 2012 |
Antiosteoporotic activity of Saururus chinensis extract in ovariectomized rats.
Topics: Alendronate; Alkaline Phosphatase; Amino Acids; Animals; Biomarkers; Body Weight; Bone Density; Bone | 2012 |
The comparative gastrointestinal tolerability of proprietary versus generic alendronate in patients treated for primary osteoporosis.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Drugs, Generic; Female; Gastrointestinal Tract; | 2012 |
[When should bisphosphonate treatment be discontinued?].
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Female | 2012 |
Biomarkers of bone turnover in diagnosis and therapy of osteoporosis: a consensus advice from an Austrian working group.
Topics: Absorptiometry, Photon; Alendronate; Algorithms; Austria; Biomarkers; Bone Density; Bone Density Con | 2012 |
The importance of a thorough medical and pharmacological history before dental implant placement.
Topics: Aged; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Age | 2012 |
Osteonecrosis of the jaw is becoming more common.
Topics: Alendronate; Bone Density Conservation Agents; Female; Hip Fractures; Humans; Osteoporosis | 2012 |
Review overemphasises benefits and downplays serious harms.
Topics: Alendronate; Bone Density Conservation Agents; Female; Hip Fractures; Humans; Osteoporosis | 2012 |
A synergistic bone sparing effect of curcumin and alendronate in ovariectomized rat.
Topics: Alendronate; Alkaline Phosphatase; Animals; Bone and Bones; Bone Density; Bone Remodeling; Collagen | 2012 |
In brief: effervescent alendronate.
Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Drug Approval; Humans; Osteopor | 2012 |
Characteristics of patients who suffer major osteoporotic fractures despite adhering to alendronate treatment: a National Prescription registry study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Comorbid | 2013 |
Unfocused extracorporeal shock waves induce anabolic effects in osteoporotic rats.
Topics: Alendronate; Anabolic Agents; Animals; Biomechanical Phenomena; Bone Density Conservation Agents; Co | 2013 |
Effect of a 300 000-IU loading dose of ergocalciferol (Vitamin D2) on circulating 1,25(OH)2-vitamin D and fibroblast growth factor-23 (FGF-23) in vitamin D insufficiency.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Ergocalciferols; Female; Fibrobla | 2013 |
Alendronate protects against articular cartilage erosion by inhibiting subchondral bone loss in ovariectomized rats.
Topics: Alendronate; Animals; Cartilage, Articular; Female; Immunohistochemistry; Osteoarthritis; Osteoporos | 2013 |
A higher dosage of oral alendronate will increase the subsequent cancer risk of osteoporosis patients in Taiwan: a population-based cohort study.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Breast Neoplasms; Coh | 2012 |
Cost-effectiveness of osteoporosis interventions for 'incidental' vertebral fractures.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Computer Simulation; Cost-Benefit Analysis; Dec | 2013 |
Effects of aminobisphosphonates and thiazides in patients with osteopenia/osteoporosis, hypercalciuria, and recurring renal calcium lithiasis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcium; Fema | 2013 |
A urine midmolecule osteocalcin assay shows higher discriminatory power than a serum midmolecule osteocalcin assay during short-term alendronate treatment of osteoporotic patients.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Amino Acid Sequence; Female; Humans; Middle Aged; Molec | 2002 |
[Patients with fractures are in the front line for osteoporosis treatment but how to treat?].
Topics: Alendronate; Bone Density; Calcitonin; Etidronic Acid; Fractures, Bone; Health Services Accessibilit | 2001 |
Curative effect of combined treatment with alendronate and 1 alpha-hydroxyvitamin D3 on bone loss by ovariectomy in aged rats.
Topics: Aging; Alendronate; Animals; Bone Density; Drug Therapy, Combination; Female; Hydroxycholecalciferol | 2002 |
Long-term predictions of the therapeutic equivalence of daily and less than daily alendronate dosing.
Topics: Alendronate; Bone and Bones; Bone Density; Bone Remodeling; Computer Simulation; Drug Administration | 2002 |
Skeletal lead release during bone resorption: effect of bisphosphonate treatment in a pilot study.
Topics: Adult; Aged; Alendronate; Bone Remodeling; Bone Resorption; Female; Fractures, Bone; Humans; Isotope | 2002 |
Alendronate in the treatment of primary hyperparathyroid-related osteoporosis: a 2-year study.
Topics: Absorptiometry, Photon; Alendronate; Bone Density; Calcium; Creatinine; Female; Humans; Hydroxyproli | 2002 |
New bone drug benefit. Less skeletal lead released.
Topics: Adult; Aged; Alendronate; Bone Resorption; Female; Humans; Isotopes; Lead; Male; Middle Aged; Osteop | 2002 |
Progression of coronary artery calcification in patients taking alendronate for osteoporosis.
Topics: Absorptiometry, Photon; Adult; Aged; Aged, 80 and over; Alendronate; Bone and Bones; Calcinosis; Cal | 2002 |
[Weeks of pain, vertebral body fractures during sleep, invalidism. Save your osteoporosis patients from this fate].
Topics: Activities of Daily Living; Age Factors; Alendronate; Analgesics, Opioid; Anti-Inflammatory Agents, | 2002 |
A cost effectiveness analysis of calcium and vitamin D supplementation, etidronate, and alendronate in the prevention of vertebral fractures in women treated with glucocorticoids.
Topics: Adult; Aged; Alendronate; Bone Density; Calcium; Cost-Benefit Analysis; Estrogen Replacement Therapy | 2003 |
Medical treatment of male osteoporosis.
Topics: Administration, Oral; Aged; Alendronate; Bone Density; Calcium; Drug Therapy, Combination; Femur Nec | 2002 |
Hadju-Cheney syndrome: response to therapy with bisphosphonates in two patients.
Topics: Acro-Osteolysis; Adult; Alendronate; Bone Density; Bone Diseases, Developmental; Bone Resorption; Fe | 2003 |
Hip fracture patients are not treated for osteoporosis: a call to action.
Topics: Absorptiometry, Photon; Alendronate; Calcitonin; Calcium; Estrogen Antagonists; Estrogens; Hip Fract | 2002 |
[Convenient, effective and well accepted. The weekly pill against osteoporosis].
Topics: Alendronate; Cross-Over Studies; Female; Humans; Male; Middle Aged; Osteoporosis; Osteoporosis, Post | 2002 |
Preclinical safety profile of alendronate.
Topics: Alendronate; Animals; Bone and Bones; Carcinogenicity Tests; Dogs; Drug Evaluation, Preclinical; Fem | 1999 |
Pharmacovigilance study of alendronate in England.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Angioedema; Cohort Studies; Erythema Multiforme; Family | 2003 |
Superficial gyrate erythema as a cutaneous reaction to alendronate for osteoporosis.
Topics: Aged; Alendronate; Erythema; Female; Humans; Osteoporosis | 2003 |
No effects of bisphosphonates on the human fetus.
Topics: Alendronate; Female; Humans; Maternal Age; Maternal Exposure; Middle Aged; Osteoporosis; Pregnancy; | 2003 |
[Fragility fracture and its control].
Topics: Accidental Falls; Aged; Alendronate; Female; Fractures, Spontaneous; Hip Fractures; Humans; Male; Os | 2003 |
Osteoporosis options. Choose medication based on age, health, and family history.
Topics: Alendronate; Bone Density; Bone Resorption; Diphosphonates; Estrogens; Humans; Osteogenesis; Osteopo | 2003 |
[When do men's bones become brittle. A cause can be found only in every second patient].
Topics: Alendronate; Clinical Trials as Topic; Humans; Hydroxycholecalciferols; Male; Osteoporosis; Osteopor | 2003 |
[Evidence-based therapy of osteoporosis--comment on DMW 17/2003].
Topics: Alendronate; Budgets; Drug Costs; Etidronic Acid; Evidence-Based Medicine; Germany; Humans; National | 2003 |
[Alendronate once a week].
Topics: Alendronate; Bone Density; Female; Fractures, Spontaneous; Gastrointestinal Diseases; Humans; Male; | 2003 |
Preventive effects of sequential treatment with alendronate and 1 alpha-hydroxyvitamin D3 on bone mass and strength in ovariectomized rats.
Topics: Aging; Alendronate; Animals; Bone Density; Compressive Strength; Drug Therapy, Combination; Female; | 2003 |
Early discontinuation of treatment for osteoporosis.
Topics: Alendronate; Bone Diseases, Metabolic; Breast Neoplasms; California; Cohort Studies; Estrogen Replac | 2003 |
Parathyroid hormone plus alendronate--a combination that does not add up.
Topics: Alendronate; Bone Density; Bone Remodeling; Drug Interactions; Drug Therapy, Combination; Female; Fe | 2003 |
[Simulation through the method of finite element of alendronate in a model of bone remodeling based on damage mechanics].
Topics: Alendronate; Arthroplasty, Replacement, Hip; Biomechanical Phenomena; Bone Density; Bone Remodeling; | 2003 |
Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database.
Topics: Aged; Alendronate; Analysis of Variance; Canada; Diphosphonates; Drug Therapy, Combination; Etidroni | 2003 |
[Alendronate. Prevention and treatment of osteoporosis].
Topics: Alendronate; Drug Monitoring; Humans; Osteoporosis; Primary Prevention; Risk Factors | 2003 |
[Osteoporosis. Don't forget the men!].
Topics: Aged; Alendronate; Bone Density; Clinical Trials as Topic; Fractures, Spontaneous; Humans; Hydroxych | 2003 |
[Evidence-based assessment of therapeutic agents of osteoporosis. Bisphosphonates, SERM and basic therapy in front].
Topics: Age Factors; Aged; Alendronate; Calcium; Cholecalciferol; Diphosphonates; Drug Therapy, Combination; | 2003 |
Transient osteoporosis of the navicular bone in a runner.
Topics: Adult; Alendronate; Female; Humans; Magnetic Resonance Imaging; Osteoporosis; Radiography; Running; | 2003 |
Treating osteoporosis with teriparatide: many unknowns?
Topics: Adult; Alendronate; Animals; Bone Density; Canada; Clinical Trials, Phase III as Topic; Drug Costs; | 2003 |
Spectrophotometric determination of some drugs for osteoporosis.
Topics: Alendronate; Etidronic Acid; Osteoporosis; Risedronic Acid; Spectrophotometry | 2003 |
An investigation of the predictors of bone mineral density and response to therapy with alendronate in osteoporotic men.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Biomarkers; Body Mass Index; Bone Density; Humans; Male | 2003 |
Tissue mineralization is increased following 1-year treatment with high doses of bisphosphonates in dogs.
Topics: Alendronate; Animals; Bone Density; Bone Remodeling; Calcification, Physiologic; Carbonates; Collage | 2003 |
Gastrointestinal side effect profile due to the use of alendronate in the treatment of osteoporosis.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Female; Gastrointestinal Diseases; Humans; Middle Aged; | 2003 |
Pregnancy-associated osteoporosis with vertebral fractures and scoliosis.
Topics: Absorptiometry, Photon; Adult; Alendronate; Back Pain; Bone Density; Calcium Carbonate; Exercise The | 2004 |
Two markers complement each other in identifying risk.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Alendronate; Biomarkers; C-Reactive Protein; Calcitr | 2004 |
Secondary prevention of hip fractures in veterans: can we do better?
Topics: Aged; Aged, 80 and over; Alendronate; Calcium; Drug Utilization; Geriatrics; Great Lakes Region; Hip | 2004 |
[Comparison of early bone histomorphometric effects of parathormone and alendronate in osteoporotic women].
Topics: Alendronate; Female; Humans; Osteoporosis; Parathyroid Hormone; Teriparatide | 2004 |
Transient osteoporosis of the navicular bone in a runner.
Topics: Adult; Alendronate; Female; Humans; Osteoporosis; Running; Tarsal Bones; Time Factors | 2004 |
Boosting brittle bones. Fosamax fends off osteoporosis long-term.
Topics: Alendronate; Calcium, Dietary; Exercise; Female; Humans; Osteoporosis; Vitamin D | 2004 |
Effects of D-003, a mixture of high molecular weight aliphatic acids from sugar cane wax, on bones from ovariectomized rats.
Topics: Administration, Oral; Alendronate; Animals; Bone Density; Disease Models, Animal; Dose-Response Rela | 2004 |
Cost effectiveness of alendronate for the treatment of male osteoporosis in Sweden.
Topics: Aged; Aged, 80 and over; Alendronate; Cost-Benefit Analysis; Humans; Male; Markov Chains; Middle Age | 2004 |
Peri-implant bone remodeling after total hip replacement combined with systemic alendronate treatment: a finite element analysis.
Topics: Administration, Oral; Alendronate; Arthroplasty, Replacement, Hip; Bone Density; Bone Remodeling; Co | 2004 |
By the way, doctor. My wife is 80. In order to increase her bone calcium, she takes calcium citrate tablets. Her doctor now wants to put her on Aredia by IV injection every three months. Since this is not FDA approved, is it a good idea?
Topics: Aged; Aged, 80 and over; Alendronate; Antineoplastic Agents; Calcium Citrate; Diphosphonates; Female | 2004 |
Alendronate-induced auditory hallucinations and visual disturbances.
Topics: Aged; Alendronate; Female; Hallucinations; Humans; Osteoporosis; Vision Disorders | 2004 |
Bone anabolic agents: the unanswered queries.
Topics: Alendronate; Anabolic Agents; Animals; Bone Resorption; Clinical Trials as Topic; Female; Humans; Ma | 2004 |
Biphosphonate-induced radiographic changes in two pediatric patients with rheumatic diseases.
Topics: Alendronate; Arthritis, Juvenile; Bone Density; Bone Remodeling; Child; Diphosphonates; Humans; Lupu | 2004 |
[Data comparison of osteoporosis patients demonstrates nasal administration is not optimal].
Topics: Administration, Intranasal; Administration, Oral; Aerosols; Aged; Alendronate; Calcitonin; Etidronic | 2004 |
New treatments for brittle bones.
Topics: Alendronate; Animals; Bone Density; Etidronic Acid; Humans; Osteoporosis; Risedronic Acid | 2004 |
Coming to grips with bone loss.
Topics: Alendronate; Animals; Bone and Bones; Bone Density; Bone Remodeling; Carrier Proteins; Estrenes; Est | 2004 |
Are there differences between men and women prescribed bisphosphonate therapy in canadian subspecialty osteoporosis practices?
Topics: Aged; Alendronate; Canada; Etidronic Acid; Female; Humans; Male; Middle Aged; Osteoporosis; Prejudic | 2004 |
Osteoporosis management: out of subspecialty practice and into primary care.
Topics: Alendronate; Bone Density; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis; Primary Healt | 2004 |
Influence of fracture history and bone mineral density testing on the treatment of osteoporosis in two non-academic community centers.
Topics: Adult; Age Factors; Alendronate; Bone Density; Bone Diseases, Metabolic; Calcium, Dietary; Estrogens | 2005 |
[Are there differences in bisphosphonates? (interview by Dr. Beate Schumacher)].
Topics: Alendronate; Diphosphonates; Dose-Response Relationship, Drug; Etidronic Acid; Fractures, Spontaneou | 2004 |
[Weekly and daily intake of alendronate: comparison of tolerance in osteoporosis treatment].
Topics: Aged; Aged, 80 and over; Alendronate; Drug Administration Schedule; Female; Humans; Middle Aged; Ost | 2004 |
Severely suppressed bone turnover: a potential complication of alendronate therapy.
Topics: Aged; Alendronate; Biopsy; Bone Density; Bone Resorption; Female; Fracture Healing; Fractures, Bone; | 2005 |
Osteoporosis and amenorrhea in a young patient with von Hippel-Lindau disease.
Topics: Adult; Alendronate; Amenorrhea; Calcium; Cerebellar Neoplasms; Female; Hemangioblastoma; Humans; Hyp | 2005 |
An ongoing six-year innovative osteoporosis disease management program: challenges and success in an IPA physician group environment.
Topics: Absorptiometry, Photon; Age Distribution; Aged; Alendronate; California; Disease Management; Family | 2004 |
[Update 2004. Osteoporosis--management--current status].
Topics: Aged; Aged, 80 and over; Alendronate; Calcium, Dietary; Cross-Sectional Studies; Etidronic Acid; Fem | 2004 |
[Routine osteoporosis therapy].
Topics: Administration, Intranasal; Aged; Alendronate; Calcitonin; Clinical Trials as Topic; Diphosphonates; | 2004 |
I am in my 60s and have been taking Fosamax for osteoporosis. I was recently diagnosed with osteo arthritis in my knees. Since Fosamax helps bones, could it do something for the bones in my knees?
Topics: Alendronate; Female; Humans; Middle Aged; Osteoarthritis, Knee; Osteoporosis | 2005 |
[The prize and the value of osteoporosis treatment].
Topics: Alendronate; Drugs, Generic; Osteoporosis; Time Factors | 2004 |
Rehabilitation of orthopedic and rheumatologic disorders. 1. Osteoporosis assessment, treatment, and rehabilitation.
Topics: Alendronate; Analgesics, Opioid; Cyclooxygenase Inhibitors; Diagnosis, Differential; Humans; Osteopo | 2005 |
[Effects of teriparatide and alendronate on bone mineral density of osteoporotic rats].
Topics: Alendronate; Animals; Bone Density; Bone Remodeling; Drug Therapy, Combination; Female; Osteoporosis | 2005 |
Effects of trans-resveratrol from Polygonum cuspidatum on bone loss using the ovariectomized rat model.
Topics: Absorptiometry, Photon; Alendronate; Analysis of Variance; Animals; Bone and Bones; Bone Density; Ca | 2005 |
New help for old bones.
Topics: Age Distribution; Aged; Alendronate; Calcitonin; Estrogen Replacement Therapy; Humans; Mass Screenin | 2005 |
The effect of intravenous pamidronate versus oral alendronate on bone mineral density in patients with osteoporosis.
Topics: Absorptiometry, Photon; Administration, Oral; Aged; Aged, 80 and over; Alendronate; Anti-Inflammator | 2005 |
Absorption of the oral bisphosphonate alendronate in osteoporotic patients with Crohn's disease.
Topics: Absorption; Administration, Oral; Alendronate; Biological Availability; Biomarkers; Bone Density; Bo | 2005 |
Effectiveness of alendronate and etidronate in the treatment of osteoporosis in men: a prospective observational study.
Topics: Alendronate; Body Height; Body Weight; Bone Density; Bone Density Conservation Agents; Etidronic Aci | 2006 |
Osteonecrosis of the jaw and bisphosphonates.
Topics: Alendronate; Animals; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Osteonecrosis; Osteoporosis; | 2005 |
Alendronate (Fosamax) and risedronate (Actonel) revisited.
Topics: Alendronate; Etidronic Acid; Humans; Osteoporosis; Risedronic Acid | 2005 |
Acute granulomatous interstitial nephritis secondary to bisphosphonate alendronate sodium.
Topics: Acute Disease; Acute Kidney Injury; Aged; Alendronate; Biopsy, Needle; Female; Follow-Up Studies; Hu | 2005 |
Effects of alendronate and calcitonin on bone mineral density in postmenopausal osteoporotic women. An observational study.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Calcitonin; Costs and Cost Analys | 2005 |
Second hip fracture in elderly hip fracture patients: cost and effectiveness of fracture prevention treatment.
Topics: Aged; Alendronate; Calcium; Cholecalciferol; Costs and Cost Analysis; Hip Fractures; Humans; Osteopo | 2005 |
Effect of alendronate on bone mineral density in Puerto Rican males with osteoporosis.
Topics: Absorptiometry, Photon; Adult; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Hi | 2005 |
Modulation of bone turnover by alfacalcidol and/or alendronate does not prevent glucocorticoid-induced osteoporosis in growing minipigs.
Topics: Absorptiometry, Photon; Adjuvants, Immunologic; Alendronate; Animals; Body Weight; Bone and Bones; B | 2005 |
Effect of Korean oriental medicine extract on bone mass as compared with alendronate in ovariectomized rats.
Topics: Acid Phosphatase; Alendronate; Amino Acids; Animals; Biomechanical Phenomena; Bone Density; Bone Rem | 2005 |
Alendronate and vertebral fracture risk.
Topics: Alendronate; Bone Density; Female; Femur Neck; Humans; Osteoporosis; Risk Factors; Spinal Fractures | 2005 |
[Protocol for prevention and treatment of osteoporosis in patients with cystic fibrosis].
Topics: Adult; Alendronate; Bone Density; Calcium Compounds; Clinical Protocols; Cystic Fibrosis; Dietary Su | 2005 |
Enhancement of crude bone morphogenetic protein-induced new bone formation and normalization of endochondral ossification by bisphosphonate treatment in osteoprotegerin-deficient mice.
Topics: Alendronate; Alkaline Phosphatase; Animals; Bone Morphogenetic Proteins; Bone Resorption; Cattle; Ch | 2005 |
Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment.
Topics: Abscess; Alendronate; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breas | 2005 |
Are oral bisphosphonates effective in improving lumbar bone mineral density in breast cancer survivors with osteopenia or osteoporosis?
Topics: Aged; Alendronate; Analysis of Variance; Bone Density; Bone Density Conservation Agents; Bone Diseas | 2005 |
The patient's page. Bone health facts.
Topics: Alendronate; Bone and Bones; Bone Density; Bone Density Conservation Agents; Calcitonin; Dietary Sup | 2005 |
The use of micro-CT to evaluate cortical bone geometry and strength in nude rats: correlation with mechanical testing, pQCT and DXA.
Topics: Absorptiometry, Photon; Alendronate; Animals; Bone Density Conservation Agents; Femur; Humans; Male; | 2006 |
[Examination and treatment of orthopedic-surgery patients with osteoporosis-related fragility fractures].
Topics: Adult; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Calcium; Etidronic Acid; F | 2005 |
Alendronate for treatment of renal transplant patients with osteoporosis.
Topics: Alendronate; Bone Density Conservation Agents; Humans; Immunosuppressive Agents; Kidney Transplantat | 2005 |
[Cost effective osteoporosis therapy. Alendronate is also immediately available as a generic drug].
Topics: Alendronate; Bone Density Conservation Agents; Cost-Benefit Analysis; Drug Costs; Drugs, Generic; Ge | 2005 |
[Reliably combined to combat osteoporosis].
Topics: Aged; Alendronate; Bone Density Conservation Agents; Clinical Trials as Topic; Drug Administration S | 2005 |
Should bisphosphonates be continued indefinitely? An unusual fracture in a healthy woman on long-term alendronate.
Topics: Absorptiometry, Photon; Alendronate; Bone Density; Bone Density Conservation Agents; Drug Therapy, C | 2006 |
Evaluation of modal damping factor as a diagnostic tool for osteoporosis and its relation with serum osteocalcin and collagen I N-telopeptide for monitoring the efficacy of alendronate in ovariectomized rats.
Topics: Alendronate; Animals; Collagen Type I; Female; Osteocalcin; Osteoporosis; Ovariectomy; Peptides; Rat | 2006 |
Agreement and validity of pharmacy data versus self-report for use of osteoporosis medications among chronic glucocorticoid users.
Topics: Alendronate; Databases as Topic; Diphosphonates; Drug Prescriptions; Drug Utilization; Etidronic Aci | 2006 |
A study of codispensing with sodium alendronate in Australia.
Topics: Alendronate; Australia; Bone Density Conservation Agents; Calcitriol; Cohort Studies; Databases, Fac | 2006 |
Effect of alendronate on bone mineral density in adult patients with Laron syndrome (primary growth hormone insensitivity).
Topics: Absorptiometry, Photon; Adult; Alendronate; Alkaline Phosphatase; Amino Acids; Bone Density Conserva | 2006 |
Is the increase in osteoporosis prevention a result of the audit?
Topics: Adrenal Cortex Hormones; Alendronate; Bone Density Conservation Agents; Calcium; Clinical Trials as | 2006 |
[Skeletal biomechanical properties improvement in ovariectomized osteoporotic rats of teriparatide was retarded by alendronate].
Topics: Alendronate; Animals; Biomechanical Phenomena; Bone Density; Bone Density Conservation Agents; Drug | 2006 |
[New therapeutic approaches to osteoporosis].
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Female; Fractures, Bone; Humans; Male; Osteoporo | 2006 |
I was prescribed alendronate (Fosamax) for bone loss a year ago, when I was 55. I just got the results of my recent bone density scan and I'm puzzled by the results. Why would it show a good improvement in the spine but no so much on my hip? How long do I
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Humans; Middle Aged; Osteoporosis; Pelv | 2006 |
Synthesis and study of alendronate derivatives as potential prodrugs of alendronate sodium for the treatment of low bone density and osteoporosis.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Osteoporosis; Prodrugs; Rats; | 2006 |
Channeling and adherence with alendronate and risedronate among chronic glucocorticoid users.
Topics: Adult; Aged; Alendronate; Bone Density Conservation Agents; Etidronic Acid; Female; Glucocorticoids; | 2006 |
[Pregnancy-associated osteoporosis. A new case].
Topics: Adult; Alendronate; Bone Density; Bone Density Conservation Agents; Female; Follow-Up Studies; Fract | 2006 |
The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Cost-Benefit Analysis; Drug Therapy, Combinatio | 2006 |
Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Comorbidity; Etidronic Acid; Female; Humans; Ma | 2006 |
[Progress for patients with osteoporosis].
Topics: Alendronate; Awards and Prizes; Bone Density Conservation Agents; Cholecalciferol; Clinical Trials a | 2006 |
[Drug therapy for prevention of falls and fractures].
Topics: Accidental Falls; Alendronate; Bone Density Conservation Agents; Drug Therapy, Combination; Evidence | 2006 |
Severe skeletal complications in a child with acute lymphoblastic leukemia.
Topics: Alendronate; Bone Density; Child; Female; Femur Neck; Humans; Lumbar Vertebrae; Osteoporosis; Precur | 2006 |
Treatment of severe osteoporosis with alendronate in a patient with lysinuric protein intolerance.
Topics: Alendronate; Amino Acid Metabolism, Inborn Errors; Bone Density Conservation Agents; Humans; Lysine; | 2006 |
[FOSAVANCE -- alendronate plus vitamin D in a weekly tablet].
Topics: Alendronate; Bone Density Conservation Agents; Controlled Clinical Trials as Topic; Drug Combination | 2006 |
The problem of low levels of vitamin D and osteoporosis: use of combination therapy with alendronic acid and colecalciferol (vitamin D3).
Topics: Alendronate; Bone and Bones; Bone Density Conservation Agents; Calcium; Cholecalciferol; Drug Combin | 2006 |
Case-only analysis of treatment-covariate interactions in clinical trials.
Topics: Alendronate; Analysis of Variance; Bias; Biometry; Clinical Trials as Topic; Cohort Studies; Coronar | 2006 |
Fracture incidence and characterization in patients on osteoporosis treatment: the ICARO study.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Etidronic Acid; Female; Fractures, Bone; Humans | 2006 |
The outcome of pregnancy following pre-pregnancy or early pregnancy alendronate treatment.
Topics: Adult; Alendronate; Arthritis, Psoriatic; Arthritis, Rheumatoid; Asthma; Behcet Syndrome; Berylliosi | 2006 |
Use of generic alendronate in the treatment of osteoporosis.
Topics: Alendronate; Bone Density Conservation Agents; Drugs, Generic; Humans; Osteoporosis; South Africa | 2006 |
Prevalence of evaluation and treatment of glucocorticoid-induced osteoporosis in men.
Topics: Aged; Aged, 80 and over; Alendronate; Arthritis, Rheumatoid; Bone Density; Bone Density Conservation | 2006 |
NOFSA statement on generic bisphosphonates.
Topics: Alendronate; Bone Density Conservation Agents; Drugs, Generic; Humans; Osteoporosis; South Africa | 2006 |
Estrogen and alendronate therapies may prevent the influence of estrogen deficiency on the tooth-supporting alveolar bone: a histometric study in rats.
Topics: Alendronate; Alkaline Phosphatase; Alveolar Process; Animals; Bone Density; Bone Density Conservatio | 2006 |
Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis.
Topics: Adult; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Fractures, Bone | 2006 |
Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Glucocorticoids; Humans; Hydroxycholeca | 2006 |
Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Collagen Type I; Glucocorticoids; Human | 2006 |
Images in clinical medicine. Bisphosphonate-associated contact stomatitis.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Female; Humans; Osteoporosis; Stomatitis | 2006 |
Generic alendronate in the treatment of osteoporosis.
Topics: Alendronate; Bone Density Conservation Agents; Drugs, Generic; Humans; Osteoporosis; Therapeutic Equ | 2006 |
Differences in osteoclast formation between proximal and distal tibial osteoporosis in rats with adjuvant arthritis: inhibitory effects of bisphosphonates on osteoclasts.
Topics: Absorptiometry, Photon; Acid Phosphatase; Alendronate; Animals; Arthritis, Experimental; Bone Densit | 2006 |
NOFSA statement on generic bisphosphonates.
Topics: Alendronate; Diphosphonates; Drug Approval; Humans; Osteoporosis; South Africa; Therapeutic Equivale | 2006 |
Bone necrosis of the jaws associated with bisphosphonate treatment: a report of twenty-nine cases.
Topics: Aged; Aged, 80 and over; Alendronate; Anti-Bacterial Agents; Antifungal Agents; Bone Density Conserv | 2006 |
Is the current anti-osteoporotic therapy paradigm good enough?
Topics: Aged; Alendronate; Bone Density Conservation Agents; Cost-Benefit Analysis; Female; Humans; Male; Mi | 2006 |
NOFSA statement on generic bisphosphonates.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Humans; Osteoporosis; Societies, Medi | 2006 |
By the way, doctor. I'm 60 and have osteoporosis. My doctor is recommending Fosamax, but I'm concerned about jawbone problems. Are there any other drugs I can take?
Topics: Alendronate; Bone Density Conservation Agents; Estrogen Replacement Therapy; Exercise; Female; Human | 2006 |
Prevention and treatment of glucocorticoid-induced osteoporosis.
Topics: Alendronate; Bone Density Conservation Agents; Calcium; Cost-Benefit Analysis; Diphosphonates; Etidr | 2007 |
Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance.
Topics: Aged; Aged, 80 and over; Alendronate; Attitude to Health; Bone Density; Bone Density Conservation Ag | 2007 |
[Prevention of glucocorticoid induced osteoporosis with alendronate or alfacalcidol].
Topics: Alendronate; Bone Density Conservation Agents; Humans; Hydroxycholecalciferols; Osteoporosis | 2007 |
[Severe osteoporosis with vertebral crushes in juvenile dermatomyositis. Effect of oral alendronate therapy].
Topics: Adrenal Cortex Hormones; Alendronate; Body Height; Bone Density; Bone Density Conservation Agents; C | 2007 |
Bisphosphonates. A cornerstone of osteoporosis treatment.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Estrogen Replacement Therapy; Etidron | 2007 |
[Mouth ulcers].
Topics: Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Esophagitis; Humans; Male; Oral Ul | 2007 |
Simulation-based cost-utility analysis of population screening-based alendronate use in Switzerland.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cost | 2007 |
Effect of 17beta-estradiol and alendronate on the removal torque of osseointegrated titanium implants in ovariectomized rats.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Bone Regeneration; Dental Impl | 2007 |
Age-related changes in marmoset trabecular and cortical bone and response to alendronate therapy resemble human bone physiology and architecture.
Topics: Absorptiometry, Photon; Aging; Alendronate; Animals; Bone and Bones; Bone Density Conservation Agent | 2007 |
[Correlation between studies and general practice].
Topics: Aged; Alendronate; Bone Density Conservation Agents; Calcitonin; Etidronic Acid; Family Practice; Fe | 2006 |
Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cost | 2007 |
Factors affecting long-term compliance of osteoporotic patients with bisphosphonate treatment and QOL assessment in actual practice: alendronate and risedronate.
Topics: Aged; Aged, 80 and over; Alendronate; Diphosphonates; Etidronic Acid; Female; Humans; Logistic Model | 2007 |
Pelvic insufficiency fracture associated with severe suppression of bone turnover by alendronate therapy.
Topics: Aged; Alendronate; Bone and Bones; Female; Hip Fractures; Humans; Osteoporosis; Risk Factors | 2007 |
Patient compliance with alendronate, risedronate and raloxifene for the treatment of osteoporosis in postmenopausal women.
Topics: Alendronate; Drug Administration Schedule; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis | 2007 |
Adherence to alendronate in male veterans.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Hip Joint; Hum | 2008 |
Use of weekly alendronate to treat osteoporosis in boys with muscular dystrophy.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Calcium; Child; Diphosphonates; Humans; | 2008 |
[Osteoporosis treatment: choices and options].
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Clinical Trials as Topic; Etidronic Aci | 2007 |
Bone densitometry and treatment for osteoporosis in older men.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cost | 2007 |
Anabolic therapy in glucocorticoid-induced osteoporosis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Fractures, Bone; Gluco | 2007 |
The cost-effectiveness of alendronate in the management of osteoporosis.
Topics: Alendronate; Bone Density; Cost-Benefit Analysis; Female; Fractures, Bone; Humans; Osteoporosis; Ris | 2008 |
AAOMP case challenge: pain in the right posterior mandible.
Topics: Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Dental Fistula; Facial Pain; Femal | 2008 |
Persistence of weekly alendronate: a real-world study in Croatia.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Croatia; Female; Humans; Male; Middle Aged; Ost | 2008 |
Cost-effectiveness of a fixed dose combination of alendronate and cholecalciferol in the treatment and prevention of osteoporosis in the United Kingdom and The Netherlands.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cholecalciferol; Cost-Benefi | 2008 |
Influence of estrogen deficiency and its treatment with alendronate and estrogen on bone density around osseointegrated implants: radiographic study in female rats.
Topics: Absorptiometry, Photon; Alendronate; Alveolar Bone Loss; Analysis of Variance; Animals; Bone Density | 2008 |
Ask the doctor. I am 86 years old and have been taking Fosamax to strengthen my bones for nearly 10 years. A few months ago, I suddenly fainted and was later diagnosed with atrial fibrillation. Did that happen because I was taking Fosamax?
Topics: Aged, 80 and over; Alendronate; Atrial Fibrillation; Bone Density Conservation Agents; Humans; Osteo | 2007 |
Discontinuity and failures of therapy with bisphosphonates: joint assessment of predictors with multi-state models.
Topics: Age Factors; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cohort Studies; | 2008 |
Efficacy of intravenous alendronate for the treatment of glucocorticoid-induced osteoporosis in children with autoimmune diseases.
Topics: Alendronate; Antirheumatic Agents; Bone Density; Bone Density Conservation Agents; Bone Remodeling; | 2008 |
Latent hypoparathyroidism in an osteoporotic patient with multiple endocrinopathies and secondary hemochromatosis due to multiple blood transfusions, unmasked by alendronate and glucocorticoid at adrenal crisis.
Topics: Adrenal Glands; Adult; Alendronate; Bone Density Conservation Agents; Bone Resorption; Calcium; Diab | 2008 |
Teriparatide or alendronate in glucocorticoid-induced osteoporosis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Glucocorticoids; Humans; Osteoporosis; | 2008 |
Teriparatide or alendronate in glucocorticoid-induced osteoporosis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Drug Costs; Glucocorticoids; Humans; Os | 2008 |
Effect of preoperative combined treatment with alendronate and calcitriol on fixation of hydroxyapatite-coated implants in ovariectomized rats.
Topics: Absorptiometry, Photon; Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Calcit | 2008 |
Summaries for patients. Drug therapy for osteoporosis.
Topics: Administration, Inhalation; Administration, Oral; Aged; Alendronate; Bone Density Conservation Agent | 2008 |
Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture.
Topics: Administration, Inhalation; Administration, Oral; Aged; Alendronate; Bone Density Conservation Agent | 2008 |
Impact of noncompliance with alendronate and risedronate on the incidence of nonvertebral osteoporotic fractures in elderly women.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Epidemiologic Methods; Etidr | 2008 |
Increase in bone mass after correction of vitamin D insufficiency in bisphosphonate-treated patients.
Topics: Absorptiometry, Photon; Adult; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Cons | 2008 |
Acute effects of bisphosphonates on new and traditional markers of bone resorption.
Topics: Acid Phosphatase; Aged; Aged, 80 and over; Alendronate; Amino Acids; Biomarkers; Bone and Bones; Bon | 1995 |
Alendronate: some remaining paradoxes.
Topics: Alendronate; Animals; Bone Density; Bone Resorption; Diphosphonates; Female; Humans; Osteoporosis | 1993 |
Contradictory hormone studies renew debate over breast cancer link.
Topics: Adult; Age Factors; Alendronate; Breast Neoplasms; Case-Control Studies; Coronary Disease; Diphospho | 1995 |
Re: Osteoporosis as a complication of orchiectomy in 2 elderly men with prostatic cancer.
Topics: Aged; Alendronate; Animals; Antineoplastic Agents, Hormonal; Diphosphonates; Humans; Leuprolide; Mal | 1996 |
Intravenous administration of alendronate counteracts the in vivo effects of glucocorticoids on bone remodeling.
Topics: Adolescent; Alendronate; Bone Density; Bone Remodeling; Child; Female; Glucocorticoids; Humans; Inje | 1996 |
Esophageal ulceration due to alendronate.
Topics: Adult; Alendronate; Esophageal Diseases; Humans; Male; Osteoporosis; Ulcer | 1996 |
Bone densitometry.
Topics: Absorptiometry, Photon; Alendronate; Bone Density; Female; Humans; Middle Aged; Osteoporosis | 1996 |
Mineralization of cancellous bone after alendronate and sodium fluoride treatment: a quantitative backscattered electron imaging study on minipig ribs.
Topics: Alendronate; Animals; Biomechanical Phenomena; Bone Density; Bone Remodeling; Humans; Osteoporosis; | 1997 |
Osteoporosis 2000.
Topics: Alendronate; Calcitonin; Chemoprevention; Cost of Illness; Fractures, Bone; Health Education; Humans | 1996 |
Measurement of bone degradation products in serum using antibodies reactive with an isomerized form of an 8 amino acid sequence of the C-telopeptide of type I collagen.
Topics: Adult; Alendronate; Amino Acid Sequence; Antibodies; Biomarkers; Bone Resorption; Collagen; Collagen | 1997 |
[Drugs for osteoporosis].
Topics: Alendronate; Dose-Response Relationship, Drug; Female; Humans; Osteoporosis; Osteoporosis, Postmenop | 1997 |
Alendronate: preclinical studies.
Topics: Alendronate; Animals; Bone Density; Bone Remodeling; Bone Resorption; Disease Models, Animal; Female | 1997 |
Evolving toward a new paradigm for prevention of osteoporosis--the time is upon us.
Topics: Alendronate; Diphosphonates; Double-Blind Method; Endocrinology; Estrogens; Etidronic Acid; Humans; | 1997 |
Local delivery of an amino bisphosphonate prevents the resorptive phase of alveolar bone following mucoperiosteal flap surgery in rats.
Topics: Administration, Topical; Alendronate; Alveolar Bone Loss; Alveolar Process; Animals; Bone Diseases; | 1997 |
Prevention of corticosteroid-induced bone loss with alendronate.
Topics: Adrenal Cortex Hormones; Alendronate; Animals; Bone Density; Estradiol; Estrogens; Female; Femur; Ma | 1998 |
[Effects of synthetic salmon calcitonin and alendronate on bone quality in ovariectomized rats].
Topics: Alendronate; Analysis of Variance; Animals; Bone and Bones; Bone Density; Calcitonin; Crystallograph | 1997 |
[Fosamax--newest scientific information. Prague, 14 November 1997].
Topics: Alendronate; Bone Density; Fractures, Bone; Humans; Osteoporosis; Postmenopause | 1998 |
[Fracture of the femoral neck and osteoporosis].
Topics: Age Factors; Aged; Aged, 80 and over; Alendronate; Analgesics; Calcitonin; Calcium, Dietary; Femoral | 1997 |
Pharmaceuticals and osteoporosis.
Topics: Alendronate; Etidronic Acid; Humans; Osteoporosis | 1998 |
Research data on alendronate: biased opinions?
Topics: Alendronate; Evidence-Based Medicine; Female; Humans; Osteoporosis | 1998 |
[Alendronate].
Topics: Alendronate; Diphosphonates; Female; Humans; Osteoporosis; Osteoporosis, Postmenopausal | 1998 |
Combining herbal supplements with prescription drugs.
Topics: Alendronate; Calcium; Drug Interactions; Female; Humans; Middle Aged; Nurse Practitioners; Osteoporo | 1998 |
Alendronate-associated esophagitis: endoscopic and pathologic features.
Topics: Adult; Aged; Alendronate; Biopsy, Needle; Esophagitis; Esophagoscopy; Female; Follow-Up Studies; Hum | 1998 |
Biological basis of anti-resorptive therapies for osteoporosis.
Topics: Aged; Alendronate; Bone Resorption; Calcitonin; Estrogen Replacement Therapy; Female; Humans; Middle | 1998 |
United Kingdom experience with alendronate and oesophageal reactions.
Topics: Aged; Alendronate; Esophagitis; Female; Humans; Male; Middle Aged; Osteoporosis; Osteoporosis, Postm | 1998 |
Bisphosphonates and glucocorticoid-induced osteoporosis: implications for patients with respiratory diseases.
Topics: Adult; Alendronate; Clinical Trials as Topic; Diphosphonates; Etidronic Acid; Glucocorticoids; Human | 1998 |
Prevention of osteoporosis in women treated for hereditary breast and ovarian carcinoma: a need that is overlooked.
Topics: Adult; Alendronate; Breast Neoplasms; Calcitonin; Diet; Diphosphonates; Exercise Therapy; Female; Hu | 1998 |
Pre-emptive bone strikes in prevention of osteoporosis.
Topics: Alendronate; Bone and Bones; Bone Density; Bone Resorption; Estradiol Congeners; Female; Humans; Ost | 1998 |
Fosamax prevents fractures--for some.
Topics: Alendronate; Bone Density; Female; Fractures, Bone; Humans; Osteoporosis | 1999 |
Outcomes assessment in osteoporosis: strategies for improvement.
Topics: Administration, Intranasal; Alendronate; Calcitonin; Cost of Illness; Diphosphonates; Estrogen Repla | 1996 |
Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis.
Topics: Aged; Alendronate; California; Female; Gastroesophageal Reflux; Health Maintenance Organizations; Hu | 1998 |
A medication use evaluation of alendronate: compliance with administration guidelines.
Topics: Alendronate; Counseling; Drug Utilization Review; Forms and Records Control; Guidelines as Topic; Ho | 1999 |
Rebuilding strong bones. Treatment may help prevent millions of fractures.
Topics: Aged; Alendronate; Bone Density; Calcium; Fractures, Bone; Hormone Replacement Therapy; Humans; Long | 1999 |
Planning and analysis of repeated measures at key time-points in clinical trials sponsored by pharmaceutical companies.
Topics: Alendronate; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Data Collectio | 1999 |
Osteoporosis: protecting bone mass with fundamentals and drug therapy.
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density; Calcitonin; Calcium; Decision Trees; Dietar | 1999 |
Clinical usefulness of biochemical resorption markers in osteoporosis.
Topics: Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Resorption; Female; Humans; Immunoenzyme Tech | 1999 |
Severe oral ulcerations induced by alendronate.
Topics: Alendronate; Humans; Male; Middle Aged; Oral Ulcer; Osteoporosis | 1999 |
Postoperative hypocalcemic tetany caused by fleet phospho-soda preparation in a patient taking alendronate sodium: report of a case.
Topics: Adult; Alendronate; Cathartics; Colectomy; Colonoscopy; Crohn Disease; Drug Combinations; Enema; Fem | 1999 |
Iatrogenic osteoporosis.
Topics: Alendronate; Calcium Channel Blockers; Etidronic Acid; Female; Glucocorticoids; Humans; Osteoporosis | 1999 |
[Is osteoporosis a disease?].
Topics: Aged; Alendronate; Bone Density; Calcitonin; Female; Hormone Replacement Therapy; Humans; Incidence; | 1996 |
A 73-year-old woman with osteoporosis, 1 year later.
Topics: Aged; Alendronate; Diphosphonates; Female; Humans; Osteoporosis; Pamidronate | 2000 |
Caution monitoring bone mineral density.
Topics: Alendronate; Bone Density; Female; Humans; Osteoporosis | 2000 |
Vertebroplasty: an opportunity to do something really good for patients.
Topics: Alendronate; Bone Cements; Calcitonin; Humans; Osteoporosis; Raloxifene Hydrochloride; Selective Est | 2000 |
Bisphosphonates: safety and efficacy in the treatment and prevention of osteoporosis.
Topics: Alendronate; Bone Density; Diphosphonates; Female; Humans; Osteoporosis; Osteoporosis, Postmenopausa | 2000 |
Are biochemical markers for bone turnover clinically useful for monitoring therapy in individual osteoporotic patients?
Topics: Alendronate; Biomarkers; Bone Density; Bone Remodeling; Drug Monitoring; Female; Hormone Replacement | 2000 |
Monitoring individual response to hormone replacement therapy with bone markers.
Topics: Alendronate; Bone Density; Drug Monitoring; Female; Hormone Replacement Therapy; Humans; Osteoporosi | 2000 |
Coverage by the news media of the benefits and risks of medications.
Topics: Alendronate; Anticholesteremic Agents; Aspirin; Biomedical Research; Cardiovascular Diseases; Confli | 2000 |
Patterns of medication use before and after bone densitometry: factors associated with appropriate treatment.
Topics: Aged; Alendronate; Bone Density; Calcitonin; Densitometry; Endocrinology; Etidronic Acid; Female; Ho | 2000 |
A Canadian survey on the management of corticosteroid induced osteoporosis by rheumatologists.
Topics: Absorptiometry, Photon; Adrenal Cortex Hormones; Adult; Alendronate; Bone Density; Calcitonin; Canad | 2000 |
By the way, doctor. My doctor prescribed Fosamax to me for osteoporosis prevention, but it upsets my stomach. Are there any other proven medications for osteoporosis prevention?
Topics: Alendronate; Calcium; Diphosphonates; Estrogens; Humans; Osteoporosis; Vitamin D | 2000 |
[Most recent study results show: the bisphosphonate alendronate works more rapidly than previously assumed].
Topics: Alendronate; Evidence-Based Medicine; Fractures, Spontaneous; Hip Fractures; Humans; Osteoporosis; T | 2000 |
New developments in osteoporosis treatment.
Topics: Alendronate; Anticholesteremic Agents; Drug Administration Schedule; Etidronic Acid; Humans; Osteopo | 2000 |
Failure to diagnose and treat osteoporosis in elderly patients hospitalized with hip fracture.
Topics: Accidental Falls; Aged; Aged, 80 and over; Alendronate; Calcium Compounds; Comorbidity; Diagnosis, D | 2000 |
Alendronate administration and skeletal response during chronic alcohol intake in the adolescent male rat.
Topics: Alcoholism; Alendronate; Alkaline Phosphatase; Animals; Biomechanical Phenomena; Bone and Bones; Bon | 2000 |
Treatment with risedronate or alendronate prevents hind-limb immobilization-induced loss of bone density and strength in adult female rats.
Topics: Alendronate; Animals; Body Weight; Etidronic Acid; Female; Femur; Hindlimb Suspension; Osteoporosis; | 2000 |
Osteoporosis treatment for men.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Humans; Male; Middle Aged; Osteoporosis; Risk Factors | 2000 |
[Cost effectiveness analysis of alendronate versus placebo in the prevention of hip fractures].
Topics: Alendronate; Controlled Clinical Trials as Topic; Cost-Benefit Analysis; Female; Hip Fractures; Huma | 2000 |
Prevention of bone loss with alendronate in kidney transplant recipients.
Topics: Alendronate; Humans; Kidney Transplantation; Osteoporosis | 2000 |
Osteoporosis. Efficacy and safety of a bisphosphonate dosed once weekly.
Topics: Alendronate; Bone Remodeling; Female; Humans; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausa | 2001 |
Managing menopause after breast cancer: balancing risks and benefits.
Topics: Adult; Alendronate; Antidepressive Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Calcit | 2001 |
Alendronate and male osteoporosis.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Humans; Male; Middle Aged; Osteoporosis; Research Desig | 2001 |
Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption.
Topics: Alendronate; Animals; Aortic Diseases; Bone Resorption; Calcification, Physiologic; Calcinosis; Diph | 2001 |
Bones and Crohn's: should we treat Crohn's disease patients with alendronate?
Topics: Alendronate; Bone Density; Crohn Disease; Female; Humans; Male; Osteoporosis | 2001 |
Osteoporosis in men.
Topics: Alendronate; Calcium Channel Blockers; Etidronic Acid; Humans; Male; Osteoporosis; Risedronic Acid | 2001 |
Alendronate treatment for osteoporosis in patients infected with human immunodeficiency virus.
Topics: Alendronate; Antiretroviral Therapy, Highly Active; HIV Infections; Humans; Male; Middle Aged; Osteo | 2001 |
Prevalence and determinants of osteoporosis drug prescription among patients with high exposure to glucocorticoid drugs.
Topics: Adult; Aged; Alendronate; Calcitonin; California; Drug Prescriptions; Drug Utilization Review; Etidr | 2001 |
Alendronate influences bending force of femoral diaphysis after orchidectomy in rats.
Topics: Alendronate; Animals; Biomechanical Phenomena; Bone Density; Bone Remodeling; Diaphyses; Femur; Male | 2001 |
Male osteoporosis associated with longterm cyproterone treatment.
Topics: Alendronate; Androgen Antagonists; Bone Density; Cyproterone; Humans; Male; Middle Aged; Osteoporosi | 2001 |
Effect of 17beta-estradiol or alendronate on the bone densitometry, bone histomorphometry and bone metabolism of ovariectomized rats.
Topics: Alendronate; Animals; Bone and Bones; Bone Density; Densitometry; Disease Models, Animal; Estradiol; | 2001 |
Effect of alendronate on bone mineral density in male idiopathic osteoporosis.
Topics: Absorptiometry, Photon; Alendronate; Bone Density; Humans; Male; Middle Aged; Osteoporosis | 2001 |
[Osteoporosis and multiple pregnancy--a case report with positive outcome].
Topics: Adult; Alendronate; Bone Density; Calcium Channel Agonists; Calcium, Dietary; Cholecalciferol; Contr | 2001 |
Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women.
Topics: Alendronate; Biopsy; Bone and Bones; Calcification, Physiologic; Humans; Osteoporosis; Placebos; Sca | 2001 |
Vgamma2Vdelta2 T-cell receptor-mediated recognition of aminobisphosphonates.
Topics: Alendronate; Antigens; Cell Line, Transformed; Cytotoxicity, Immunologic; Diphosphonates; Etidronic | 2001 |
[Bisphosphonates once weekly. Osteoporosis therapy becomes more effective].
Topics: Aged; Alendronate; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Male; Mid | 2001 |
Fosamax for HIV-related bone problems?
Topics: Alendronate; Antiretroviral Therapy, Highly Active; HIV Infections; Humans; Osteoporosis | 2001 |
[Osteoporosis therapy with bisphosphonates. Once weekly is enough].
Topics: Alendronate; Clinical Trials as Topic; Humans; Osteoporosis; Time Factors | 2001 |
Alendronate increases bone density in chronic spinal cord injury: a case report.
Topics: Absorptiometry, Photon; Alendronate; Bone Density; Humans; Male; Middle Aged; Osteoporosis; Spinal C | 2002 |
[The treatment of osteoporosis and bone resorption of alveoli with alendronate in rat model].
Topics: Alendronate; Alveolar Process; Animals; Bone Density; Bone Resorption; Calcium; Disease Models, Anim | 2001 |
For osteoporosis, are two antiresorptive drugs better than one?
Topics: Alendronate; Drug Therapy, Combination; Humans; Osteoporosis; Raloxifene Hydrochloride | 2002 |
Use of a peripheral dexa measurement for osteoporosis screening.
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density; Female; Heel; Humans; Mass Screening; Middl | 2002 |
Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids.
Topics: Alendronate; Animals; Apoptosis; Bone Density; Bone Resorption; Cell Survival; Dexamethasone; Glucoc | 2002 |
Prevent corticosteroid-induced osteoporosis.
Topics: Adrenal Cortex Hormones; Alendronate; Bone Remodeling; Humans; Osteoporosis; Vitamin D | 2002 |
Lymphoplasmacytoid lymphoma presenting as severe osteoporosis.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Etidronic Acid; Humans; Leukemia, Lymphocytic, C | 2002 |
Weekly dose of osteoporosis drug.
Topics: Alendronate; Drug Administration Schedule; Humans; Osteoporosis; Patient Compliance; Time Factors | 2002 |
Alendronate-induced lichen planus.
Topics: Alendronate; Female; Humans; Lichen Planus; Middle Aged; Osteoporosis | 2002 |
Case 26-2001: scleroderma renal crisis and polymyositis.
Topics: Alendronate; Deglutition Disorders; Glucocorticoids; Humans; Osteoporosis; Polymyositis; Scleroderma | 2002 |